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Abstract
Phosphodiesterases (PDEs) are of central importance in the regulation of cyclic AMP 
(cAMP) signalling, since they mediate its degradation. Cyclic AMP and the downstream 
kinase, protein kinase A (PKA), are central to many cellular processes including cell 
proliferation, where they exert effects on the cell cycle machinery at a number of levels. 
The study of PDEs through the cell cycle in mammalian somatic cells has been sparse.
Here, an investigation into the activities of different PDE isoforms through the cell cycle 
was undertaken. Reproducible methods for arresting Rat-1 fibroblasts in different stages of 
the cell cycle were developed. These were used to determine the profiles of PDE activity in 
the different phases of the cycle. It was found that, in Rat-1 cells, there was an increase in 
total PDE activity during mitosis. This was found to be largely attributable to PDE4 
activity since it was sensitive to rolipram inhibition. Selective immunoprécipitation 
allowed the changes to be attributed to specific PDE4 subfamilies. In particular PDE4D3, 
when immunoprecipitated from mitotic lysates, exhibited the highest activity. This 
increased activity of PDE4D3 coincided with a fraction of the protein migrating as a 
double bandshift when analysed by SDS-PAGE and immunoblotting. Both the increased 
activity and the bandshifts occurring during mitosis were specific to mitosis and both 
disappeared within 2 h following a release from mitotic block. Both the increased activity 
and the bandshifts seen during mitosis were sensitive to the general kinase inhibitor, 
staurosporine, but insensitive to a range of other more specific inhibitors for kinases such 
as PKA, PKC, PI 3-kinase, ERK and Cdk2/ Cyclin B. They were also sensitive to 
treatment with alkaline phosphatase, and could be maintained following release from 
mitosis using concentrations of okadaic acid characteristic of protein phosphatase 1 
inhibition.
HPLC and mass spectrometric analysis of tryptically digested PDE4D3 phosphopeptides, 
four residues were identified as being highly phosphorylated by kinases that were active in 
mitotic lysate. Three of these residues Ser^\ Ser^  ^ and Ser^^  ^ are previously unknown 
phosphorylation sites. The fourth phosphorylated residue, Ser^^ ,^ has previously been 
shown to be phosphorylated by ERK.
When the activity of PKA in cell lysates was assayed, it was noted that in mitosis there was 
a fall in PKA activity that coincided with the increases in PDE4D3 activity. Upon 
rolipram-mediated inhibition of PDE4 in these mitotic cells a concomitant increase in PKA
activity was noted. Furthermore, this inhibition of PDE4 in mitotic cells caused an increase 
in the rate at which the cells left mitosis.
These observations suggest that the phosphorylation and activation of PDE4D3 in mitosis, 
by an as yet unidentified kinase, may lead to the decrease in PKA activity. The inhibition 
of PDE4 may cause an increase in the rate at which cells leave mitosis, suggesting a 
specific regulatory role for PDE4D3 in the control of the transition of cells through 
mitosis.
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Chapter 1
General Introduction
1.1. Cyclic nucleotide signaliing pathways 
7- 7.7. Cyclic nucleotide generation in ceils
The cyclic nucleotides cyclic 3’5’ guanosine monophosphate (cGMP) and cyclic 3 5 -  
adenosine monophosphate (cAMP) are intracellular second messengers ubiquitously 
generated in cells to mediate the physiological responses of a host to specific cellular 
stimuli. Cyclic nucleotides mediate a diverse range of effects. Since its discovery cAMP 
(Sutherland and Rail, 1958) has been found to mediate numerous biological responses 
(Sutherland and Rail, 1958; Shacter et al., 1988). Cyclic AMP can elicit acute, reversible 
changes in dynamically regulated processes such as neurotransmission, muscle contraction 
and regulate metabolic processes such as glycogenolysis (Verne et ah, 1973;Byus et ah, 
1976) and lipolysis (Pohl, 1981). Yet, in other contexts, cAMP can have long term effects 
on, for example, embryonic development, cell growth, proliferation and differentiation. 
Most of the cellular effects of modulation of cAMP concentrations are due to the 
stimulatory effect of cAMP on protein kinase A (PKA) activity (Walsh et ah, 1968). PKA 
then phosphorylates key target proteins ultimately leading to alterations in cell functioning 
(Scott, 1991).
1.1.1.1. G~Protein Coupled Receptors
Cyclic AMP is produced within cells, from ATP, by the action of adenylyl cyclase. This 
enzyme can be either directly activated by forskolin or indirectly activated through 
interaction of a G-protein coupled cell surface receptor (GPCR) with its cognate ligand. 
There are over 1000 members of the GPCR family identified to date, classed into groups 
based on their sequence homology. All GPCRs have common structural features; the N- 
terminus of the protein is extracellular, there are seven transmembrane helical domains, 
connected by short loops and the intracellular C-terminal (Milligan, 1998). GPCRs are 
activated by extracellular signals such as hormones, neurotransmitters, chemokines, 
odorants and light. Upon activation GPCRs undergo a conformational change and complex 
with and activate their cognate heterotrimeric G-proteins (Neer, 1995; Gether et ah, 1995). 
Modulation of the cAMP-signailing cascade, to elicit a regulated cellular response to a 
stimulant, is brought about through the ability of the GPCRs to couple to the C-terminus of 
one of the multiple Gotg isoforms, the specificity of which is determined by the third 
intracellular loop of the receptor (Neer, 1995; Gether, 2000). Gas, in its inactive state binds 
GDP and exists in a complex with cognate Py subunits. The ligand bound GPCR induces a 
Gas conformational change and the bound GDP is exchanged for GTP while the Py
subunits dissociate from the G-protein complex (Bimbaumer et ah, 1990). The active GOg- 
GTP binds to membrane associated adenylyl cyclase (AC) activating it, whereas the 
released py complex itself goes on to modulate other intracellular signalling cascades 
(reviewed in (Hamm, 1998), Fig. l.L ). Activation of AC persists until such time as the 
GTP bound to the G% is hydrolysed by the intrinsic GTPase activity of the Gas and the 
reassociation of the Py subunits (Neer, 1995).
Other intracellular mechanisms can also serve to attenuate the stimulated G-protein 
response at different levels of the signalling cascade. Phosphorylation of the receptor by a 
G-protein receptor specific kinase (GRK) increases the affinity of the GPCR for a class of 
binding proteins called arrestins (Lefkowitz, 1998). The binding of an arrestin to the 
carboxyl terminal region of the GPCR sterically inhibits receptor interaction with G- 
proteins, thereby causing desensitisation. The bound arrestin also leads to receptor 
internalisation by clathrin coated vesicles (Lefkowitz, 1998; Milligan, 1998). Other kinase 
mediated phosphorylations of the receptor, such as through PKC (Diviani et al., 1997) or 
PKA (Freedman et ah, 1995), inhibit the interaction between the receptor and the G- 
protein, so aid the desensitisation of the cAMP mediated signal (reviewed in Bunemann 
and Hosey, 1999). There exists a family of GPCRs, which when stimulated, interact with 
the inhibitory G protein, Gai. This G-protein, once stimulated, inactivates adenylyl cyclase 
by binding directly to it (Houslay, 1991).
1.1.1.2. Adenylyl cyclases
Adenylyl cyclases (ACs) belong to a multigene family of transmembrane proteins of which 
there are nine known mammalian isozymes (Patel et al., 2001). They are activated by the 
stimulation of Gas coupled receptor by hormones (Hawes et ah, 2000), cytokines 
(Tachibana et ah, 1998) or neurotransmitters (Spada et ah, 1997). All mammalian ACs are 
activated by Gag and their activities are differentially regulated by binding 
calcium/calmodulin, through phosphorylation by PKC or PKA and by the association of 
various G-protein subunits (Hurley, 1998). The ligand, which activates the cell-surface 
receptors, alters cAMP signalling in a way that depends on the family of AC the G-protein 
is co-localised with. AC enzymes are typically more than 1000 amino acids long with 
molecular weights of approximately 120 kDa (Taussig and Gilman, 1995). Members of the 
mammalian AC family all have a similar structure consisting of two sets of six 
transmembrane helices (Ml and M2) with relatively low sequence homology between AC 
species. Each transmembrane helix is separated by very short connecting loops except M l
and M2 which are separated by a large intracellular loop called C l {Fig. 1.2.). This loop is 
subdivided into the highly conserved C la catalytic domain and Clb, which acts as a 
specific regulatory site for the AC, that is poorly conserved between isoforms. The 
carboxyl terminal tail of the ACs, termed C2, is cytoplasmic and contains the well- 
conserved C2a region, which encodes the second part of the catalytic domain and the 
terminal C2b domain. C2b is found only within the type I, II, III and VIII AC isoforms 
(Hurley, 1999) for which it appears to act as a regulatory module. The cytoplasmic loops 
interact with one another to form a catalytic site for the enzyme {Fig. 1.2.).
All but type IX AC are activated by forskolin, a chemical which appears to promote the 
assembly of the catalytic region by binding to the hydrophobic pocket at one end of the 
central cleft between the catalytic dimers (Patel et al., 2001; Hurley, 1998). Divalent metal 
cations play an important role in directly regulating AC. They interact with C2 at the dimer 
interface so, like forskolin, exert their stimulatory effect by altering the conformation of 
the catalytic site (Houslay and Milligan, 1997). ACs are activated via a direct interaction 
between the Gsa and the C la and C2a domains (Patel et ah, 2001). However, the different 
AC forms often have contrasting modulating effectors (Houslay and Milligan, 1997). For 
example, the activity of the AC I, III and VIII isoforms can be stimulated by binding 
calcium/calmodulin whereas the AC V, VI and IX isoforms are inhibited by calcium 
(Taussig and Gilman, 1995; Cooper et ah, 1995, for summary of AC isoform modulation 
see table 1.1.). The different catalytic properties of the AC act in determining cAMP fluxes 
in the cell (Houslay and Milligan, 1997) and numerous physiological roles of the different 
isoforms have been identified (reviewed in Patel et ah, 2001).
1.1.2. Targets of cAMP generation
Cyclic AMP activates several downstream signalling mechanisms through direct 
interaction with proteins. It binds to and activates a class of cyclic nucleotide gated ion 
channels (Sanchez et ah, 2001; Viscomi et ah, 2001) as well as the guanine nucleotide 
exchange factors (cAMP-GEFs) for the small G-protein Rapl, also called Epacl and 
Epac2 (de Rooij et ah, 1998). However the best characterised cAMP receptor in 
mammalian cells with which the majority of biological effects of cAMP have been 
associated, is PKA.
1.1.2.1. Protein Kinase A
Protein kinase A was originally classed as a ‘third messenger’ which was activated by 
cAMP and conveyed a physiological signal through modulation of substrate activity by 
phosphorylating them (Walsh et ah, 1968). PKA is a heterotetrameric enzyme composed of 
two regulatory subunits (Riot, Rip, R lla  or Rllp) bound to two catalytic subunits (Ca, Cp 
or Cy). The RI regulatory subunits have high homology with one another, as do the RII 
subunits (Skalhegg and Tasken, 2000), and further diversification of R Ia is brought about 
by the existence of several splice variants (Solberg et al., 1997). R Ia and R lla  are 
expressed ubiquitously, whereas RIip is expressed predominantly in endocrine, brain, fat 
and reproductive cells (Taylor et ah, 1992).
Multiplicity of the PKA catalytic subunit occurs, with there being three distinct splice 
variants of C a  and several CP variants (Skalhegg and Tasken, 2000). The PKAII (RllazCz 
and RIIP2C2) holoenzymes are assembled preferentially over PKAI (RIa2C2 and RIP2C2) 
under physiological conditions (Francis and Corbin, 1994). However, complex 
mechanisms influenced by multiple factors govern to what extent PKA-I and PKA H 
assembly is preferred in vivo. The assembly of different catalytic and regulatory subunits 
gives rise to a number of PKA holoenzymes which posses different biological 
characteristics (Skalhegg and Tasken, 2000). The PKA type I complex is generally 
cytoplasmic and is activated transiently by weak cAMP signalling (Houslay and Milligan, 
1997). The type II complex, however, is associated with cell particulate fractions and 
responds only to high and persistent cAMP stimulation (Rubin et ah, 1979; Stein et ah, 
1987). The localisation of PKAII to specific subcellular compartments is mediated by 
interactions with anchoring proteins called AKAPs {see below).
Cyclic AMP binds co-operatively to two sites on each of the PKA regulatory subunits 
(reviewed in Doskeland et ah, 1993). The R subunits binding affinity for cAMP differs 
between isoforms. R Ia has a much higher affinity for cAMP relative to R lla  and RIIp 
(Taylor et ah, 1992). This interaction with cAMP causes a conformational change of the 
regulatory subunits which mediates their dissociation from the catalytic subunits, enabling 
the free catalytic subunits to target serine and threonine residues on substrate proteins for 
phosphorylation (Skalhegg and Tasken, 2000).
1.1.2.2. A Kinase-anchoring proteins (AKAPs)
AKAPs represent a functionally related family of regulatory proteins that contain a PKA 
binding domain and unique targeting sequences that direct the complex to specific 
subcellular structures (Murphy and Scott, 1998). AKAPs have diverse amino acid 
sequences but share certain structural features. AKAPs bind to the first 30 amino acids of 
the N-terminus of the PKA RII subunit, which is also crucial for the promotion of 
dimérisation of the RII subunits ((Li and Rubin, 1995), Fig. 1.3.). AKAPs appear to bind 
selectively with high affinity to RII dimers (Scott et ah, 1990). Recently, several AKAPs 
have also been shown to interact with RI, similarly targeting them to membranous regions 
of the cell (Feliciello et ah, 2001). The tissue specific expression of AKAPs, their 
localisation, role in cellular functions and R subunit binding specificities are reviewed in 
detail in (Feliciello et ah, 2001).
1.1.2.3. PKA independent mechanisms of cAMP dependent signalling
Cyclic AMP also acts in a fashion independent of PKA, notably through the exchange 
protein directly activated by cAMP (Epac). Epacs are guanine nucleotide exchange factors 
(GEFs) for the small GTPase Rapl, which are activated both in vitro and in vivo by the 
direct binding of cAMP in an N-terminal domain (de Rooij et ah, 1998). This domain 
contains a motif similar to that found in the cAMP binding pocket of PKA (Kawasaki et 
ah, 1998; de Rooij et ah, 1998). There are three known Epac family members, Epacl and 
Epac2, and Repac (related to Epac). Epacl binds cAMP at only one location, Epac2 has 
two binding sites for cAMP and Repac is constitutively active (de Rooij et ah, 2000). 
Epacs have a C-terminal catalytic region which contains the GEF domain that activates 
Rapl and Rap2 (de Rooij et ah, 2000) but not the other members of the small G-protein 
family Ras, Ral, or R-ras (Kawasaki et ah, 1998). In the absence of cAMP the catalytic 
ability of Epacl is constrained, by a direct interaction of the GEF domain with the high 
affinity cAMP binding domain (de Rooij et ah, 2000). Upon interaction with cAMP, a 
conformational change of Epac relieves this auto-inhibition and GEF activity is resumed. 
Epac is tightly associated with cell membranes via its DEP (common to Disheveled, Egl-10 
and pleckstrin) domain, a characteristic which is not regulated by cAMP (de Rooij et ah, 
2000).
t, 1.3. Cyclic nucleotide hydrolysis within cells
Termination of cAMP mediated intracellular signal is controlled by phosphodiesterases 
(PDE), which were first discovered shortly after the identification of cAMP (Butcher and 
Sutherland, 1962). PDEs act to hydrolyse the 3'-phosphoester bond of the 3', 5’-purine 
ribose cyclic monophosphate nucleotides leaving the residual 5'-monophosphate, thus 
terminating the cyclic nucleotide stimulated pathways in cells. This is important not only in 
the ablation of cellular signalling, but also in the maintenance of tight regulation of 
downstream effector activity. The isolation of PDEs from preparations of heart tissue were 
found, initially, to hydrolyse cAMP, however, with further investigation, the preparations 
were found to hydrolyse both cAMP and cGMP (Nair, 1966). Purification of the PDEs 
from the tissue homogenate, by ion exchange chromatography, identified several peaks of 
cAMP and cGMP hydrolytic activity. Each peak had different kinetics for its substrate and 
could be differentially inhibited or activated (Goren and Rosen, 1972). The peaks were 
characterised and correlated to different families of PDE (Butcher and Sutherland, 1962).
PDEs serve four major functions within cells: they act as effectors of signal transduction 
by interacting with receptors and G-proteins; they integrate cAMP signalling with other 
signalling transduction pathways; they play a role as homeostatic regulators, by acting as 
feedback regulators of cyclic nucleotide levels; and they act to control the diffusion of 
cyclic nucleotides and creating subcellular compartmentalisation of cyclic nucleotide 
signalling.
1.2. The phosphodiesterase superfamily
The PDE family is evolutionarily conserved, homology of the molecule exists in organisms 
ranging from Dictyostelium to human beings (Charbonneau, 1990). The 35 currently 
known PDEs are encoded for by 21 different genes and classed into 11 families determined 
by their genetic sequence and functionally by their substrate specificity and kinetic 
properties, inhibitory profiles and regulation by allosteric activators or inhibitors. From 
comparative, structural and functional studies PDEs are known to possess a modular 
architecture. The conserved catalytic domain, containing a sequence of approximately 275 
amino acids, which is common to all PDEs, is located proximal to the carboxyl terminus. 
The catalytic core contains common structural elements which are important for the 
hydrolysis of cyclic nucleotides which include a PDE-specific motif (H-D-[L/FV/M/F/Y]- 
X-H-X-[A/G]-X-X-N-X-[L/FV/M/F/Y]) and two consensus divalent cation (Zn^^ or
Mg '^*')- binding domains. Family specific regulatory domains or motifs are often found 
near the amino terminus of the enzyme {Figure 1.4.).
1.2.1. The PDE1 family of phosphodiesterases
PDEl was originally found as a calcium stimulated PDE activity from rat brain (Kakiuchi 
and Yamazaki, 1970). PDE Is act as one of the key enzymes involved in the complex 
interactions between cyclic nucleotide and Ca^ "*" second messenger systems. Three different 
genes code the CaM/Ca^"  ^stimulated PDEl family, and each gene has at least two different 
splice variants, which give rise to functionally different isozymes with distinct catalytic 
and regulatory properties. The PDEl isoforms have differing affinities for the CaM/ Ca^ "^  
complex, which binds within two regions of their N-terminal regulatory domains and 
determines subtle changes in their activity regulation (reviewed in Kakkar et al., 1999).
The stimulation of enzymatic activity of PDEl can also be differentially modulated by 
post-translational events. Phosphorylation of PDEl isoforms, by PKA and CaM dependent 
kinase, decreases PDEl affinity for Ca^VCaM, therefore decreasing the activity of the 
enzyme (summarised in Kakkar et ah, 1999). PDEls have Michaelis constant (Km) values 
of between 1 pM and 40 jxM for cAMP and between 1 |iM and 3 jiM for cGMP with 
different cyclic nucleotide specificity for each isoform (Yan et ah, 1996).
The CaM-dependent PDEs have been localised in the postsynaptic regions in several brain 
areas, including olfactory neurones. PDEIA has been localised to the cortex, PDEIB to the 
striated region of the dentate gyrus and PDEIC in the neuronal epithelia (Yan et ah, 1996). 
Inhibitors of PDEl isoforms include Ginsenoides that are used for the treatment of heart 
failure, and have antipsychotic, anticonvulsant and antifatigue actions. Amantadine and 
Deprenyl are both anti-parkinsonian agents that also inhibit PDEls possibly through 
disruption of the CaM/PDE interaction (reviewed in Kakkar et ah, 1999).
1.2.2. The PDE2 famiiy of phosphodiesterases
PDE2 activity was first identified in rat liver extracts (Beavo et ah, 1970). Cyclic AMP and 
cGMP are hydrolysed by this enzyme with Km values of 50 jiM for both substrates. The 
protein has an N-terminal non-catalytic binding site for cGMP which when bound causes 
an increased affinity of the catalytic site for cAMP (Manganiello et ah, 1990), providing a 
point of crosstalk between the cAMP and cGMP signalling pathways (reviewed in Beavo,
1995). One PDE2 gene has been identified to date and this has at least three different splice 
variants encoding PDE2A1, PDE2A2 and PDE2A3.
PDE2 is localised to the adrenal cortex and several areas of the brain, as well as in goblet 
cells, olfactory neurones and in capillary and endothelial cells (Sadhu et ah, 1999). PDE2 
activity has been implicated in cardiac Ca^^ channel control, catecholamine secretion in the 
central nervous system (Beavo, 1995) and in olfactory neurone signalling (Juilfs et ah, 
1997).
1.2.3. The PDB3 family of phosphodiesterases
Two different genes make up the PDE3 family and further diversification exists since at 
least two different splice variants of PDE3A are known. The members of the PDE3 family 
have a low for cAMP and can bind cGMP with high affinity (Km = 0.3 pM). However, 
they hydrolyse cGMP poorly so, in effect, the binding of cGMP inhibits enzymatic activity 
to cAMP (reviewed in Beavo, 1995). Phosphorylation of PDE3 by PKA has been shown to 
increase the activity of this enzyme (Smith et ah, 1991). PDE3A is found in smooth 
muscle, platelets and cardiac tissue (Liu and Maurice, 1998). PDE3B is abundant in 
adipocytes where it is activated upon insulin stimulation and where it participates in the 
regulation of glucose transport mechanisms and stimulates the antilipolytic and 
antiglycogenolytic actions of insulin (Degerman et ah, 1997; Sano et ah, 2001). To achieve 
this insulin activates PDE3 via an IRS-1, PI 3-kinase, PDK and PKB/Akt dependent 
mechanism (Ahmad et ah, 2000). PDE3 isoforms have also been associated with platelet 
aggregation, myocardial contractility, relaxation of smooth muscle, and inhibition of T cell 
and vascular smooth muscle cell proliferation (Manganiello et ah, 1995).
1.2.4. The PDE4 famiiy of phosphodiesterases
PDE4 enzymes currently provide the largest known PDE family. The PDE4A1 isozyme 
was the first PDE to be cloned, it was identified in a screen of a rat brain cDNA library 
using the product of the Drosophila melanogaster dunce gene as a probe (Davis et ah, 
1989). Four genes encode PDE4s, giving rise to at least 18 different splice variants. These 
cDNAs can be grouped into long, short and super-short categories {Fig. 1.5.). All PDE4s 
have a conserved catalytic region, located within a 360 amino acid domain. The ‘long’ 
isoforms have two of the conserved N-terminal regulatory domains, termed UCRl (for 
upstream conserved region 1) and UCR2 of 59 and 79 amino acids, respectively {Fig. 1.5.). 
A linker region (LRl) of 24 amino acids separates UCRl and UCR2, which is the site
spliced to produce truncated proteins lacking UCRl in the ‘short’ isoforms. The ‘super­
short’ PDE4 species have an N-terminal truncation within the UCR2 region of the protein 
and unique N-terminal sequences (structures of PDE4s are reviewed extensively in 
Houslay, 2001). PDE4 enzymes are specific for the hydrolysis of cAMP with values in 
the range of 1 to 5 |iM. Modulation of PDE4 activity is carried out by post-translational 
modifications such as phosphorylation, and through interaction with adapter proteins and 
phospholipids (reviewed in (Houslay, 2001) and see section 1.3.4. for more details). The 
various PDE4 species have heterogeneous patterns of expression in cells and specific 
isoform profiles of various cell types and tissues have been determined (reviewed in 
Houslay, 2001).
1.2.5. The PDE5 family of phosphodiesterases
There is one PDE5 gene that gives rise to 2 alternatively spliced variants, PDE5A1 and 
PDE5A2 (Loughney et al., 1998). These enzymes exist as a homodimers, which exhibit 
cGMP specific hydrolytic activity. Each subunit of the holoenzyme contains two high 
affinity cGMP non-catalytic binding sites (GAF domains) at their N- terminus. Once 
bound to cGMP phosphorylation of PDE5 by protein kinase-G (PKG) increases the affinity 
of the catalytic site for cGMP (Km = 1 jiM), and elevates cGMP hydrolysis (reviewed in 
Beavo, 1995). PDE5 mRNA is most highly expressed in aortic smooth muscle cells, heart, 
placenta, skeletal muscle and pancreas (Stacey et al., 1998). Sildenafil, the PDE5 selective 
inhibitor, is marketed by Pfizer as Viagra™ and functions as a treatment for penile erection 
dysfunction which implicates PDE5 in playing a pivotal role in controlling smooth muscle 
relaxation (reviewed in Cartledge and Eardley, 1999).
1.2.6. The PDES famiiy of phosphodiesterases
The PDE6  family constitutes the central effector enzyme in the phototransduction cascade 
of the rod and cone photoreceptor cells. The enzyme is regulated by direct interaction with 
the transducin heterotrimeric G-protein T a  subunit (Stryer et al., 1983). The PDE6  enzyme 
is cGMP specific (Km = 60 |LtM for cGMP and 2000 |^M for cAMP) and exists in a 
heterotetrameric complex containing one catalytic a  (PDE6 A), one catalytic |3 (PDE6 B) 
subunit and two small inhibitory y subunits. A ô subunit also co-purifies with PDE6  and is 
involved in the localisation of the complex to the membranous fraction of the cell (Florio 
et al., 1996). Both PDE6  catalytic subunits contain two high affinity, non-catalytic, cGMP- 
binding sites (GAF domains) and binding cGMP at these sites increases the aP affinity for
the Y subunits in the catalytic pocket of the enzyme (reviewed in Artemyev et ah, 1998). 
Upon light stimulation of the photoreceptor cell, rhodopsin activates the retinal G-protein, 
transducin, the Tot binds in the catalytic pocket of the otp complex, displacing the y subunit 
and stimulating enzymatic cGMP hydrolysis.
1.2.7. The PDE7 family of phosphodiesterases
The PDE7 protein was originally found by a genetic screening procedure developed in 
yeast to identify cDNA clones encoding functional, high-affinity cAMP specific PDEs 
(Michaeli et al., 1993). PDE7 was initially identified as the cAMP specific, IBMX- 
insensitive PDE isoform which had a Km value for cAMP of approximately 0.1 |iM. There 
are two PDE7 genes, PDE7A whose human gene locus has been mapped to chromosome 
8ql3 (Han et ah, 1998) and has at least three different splice variants (Sasaki et ah, 2000; 
Glavas et ah, 2001) and PDE7B (Hetman et ah, 2000). The PDE7 isofoiTns have different 
sub-cellular localisations determined by the nature of their N-terminal domain. The 
hydrophobic N-teiininus of PDE7A2, for example, interacts directly with membranous 
fractions of the cell (Bloom and Beavo, 1996). The main functional interest concerning 
PDE7 is due to its specific expression in activated T-lymphocytes, where it is seen to 
stimulate cell proliferation and induce expression of the interleukin-2 cytokine (Li et ah, 
1999).
1.2.8. The PDE8 family of phosphodiesterases
The PDE8  cDNA was identified by screening a database of expressed sequence tags 
(ESTs, Soderling et ah, 1998). The homology of the sequence to known PDE sequences 
identified this protein as belonging to a novel family of PDEs. Two genes encoding PDE8  
have now been identified, and the PDE8 A is thought to have 5 splice variants (Wang et ah, 
2001b). PDE8  is specific for the hydrolysis of cAMP, with a Km of 70 nM. PDE8  has a 
PAS/PAC (for Per, ARNT and Sim protein where this motif was originally identified) 
domain, located within the N-terminal regulatory region of the protein. This domain is 
found in many signal transduction proteins, and is thought to mediate specific homo- and 
heteromeric protein-protein interactions, although the function in PDE8  is not clear as yet. 
PDE8 A is most highly expressed in mouse testis, in the seminiferous epithelium (Soderling 
et ah, 1998) whereas PDE8 B is expressed in the thyroid gland (reviewed in Soderling and 
Beavo, 2000). Functional analysis of the enzymes has not yet been performed although up- 
regulation of PDE8 A protein levels have been observed upon activation of T cells (Glavas 
et ah, 2 0 0 1 ).
1.2.9. The PDE9 family of phosphodiesterases
The PDE9 cDNA was identified by screening a database ESTs, the homology of the 
sequence to known PDE sequences identified this protein as belonging to a novel family of 
PDEs. To date one gene encoding PDE9 has been identified which has four alternative 
splice variants (Guipponi et al., 1998). The PDE9 enzyme family specifically hydrolyses 
cGMP with very high affinity (Km=70 nM). It is insensitive to many known PDE inhibitors 
including rolipram, vinpocetine, sildenafil and IB MX, however, it is sensitive to the PDE5 
inhibitor zaprinast (IC5o= 3 5  pM, reviewed in Soderling and Beavo, 2000). Tissue 
distribution studies have identified mRNA of all PDE9 splice variants to be expressed in 
most tissues, except blood (Guipponi et al., 1998), although no physiological function of 
the enzymes have yet been identified.
1.2.10. The PDE 10 famiiy of phosphodiesterases
The PDEIO cDNA was also identified by screening a database of ESTs (Fujishige et al.,
1999). To date only one gene encoding PDEIO has been identified which has no known 
splice variants. PDEIO has the capacity to hydrolyse both cAMP and cGMP with Km 
values of 0.26 (xM and 7.2 (xM, respectively (Fujishige et al., 1999), and contains two N- 
terminally located GAF domains, which are likely to constitute a low-affinity binding site 
for cGMP. The kinetics of the protein have implicated this enzyme as a cAMP inhibited 
cGMP specific phosphodiesterase in vivo (reviewed in Soderling and Beavo, 2000). 
PDEIO is sensitive to inhibition by the general PDE inhibitor, IBMX (IC50 =2.6 juM). 
Tissue distribution studies have identified PDEIO mRNA to be expressed in the putamen 
and caudate nucleus regions of the brain (Fujishige et al., 1999), although no physiological 
functions of these enzymes have yet been reported.
1.2.11. The PDEl 1 famiiy of phosphodiesterases
The PD E ll family is the most recently characterised phosphodiesterase family, again 
identified by screening a database ESTs (Fawcett et al., 2000). There are potentially three 
members of the family all having a single N-terminal GAF domain, which constitutes a 
potential allosteric binding site for cGMP or another small ligand, and hydrolyse cAMP 
and cGMP with Km values of 1 pM and 0.5 |xM, respectively. The enzyme kinetics indicate 
that PD E ll A might regulate both cAMP and cGMP hydrolysis under physiological 
conditions. However, no studies of physiological functions of the isozymes have yet been
undertaken. Tissue distribution studies have determined PDEl 1 mRNA to be expressed in 
skeletal muscle, prostate kidney, liver, pituitary and salivary glands (Fawcett et al., 2000).
1.3. Biochemistry of the PDE4 cAMP-specific 
phosphodiesterases
The mammalian PDE4 family members are homologues of the Drosophila melanogaster 
dunce gene (Davis and Kiger, Jr., 1981). The importance of PDE4 within cells was initially 
demonstrated when flies deficient in PDE displayed impaired CNS and reproductive 
functions (Dudai et al., 1976). The disruption of the reproductive function in Drosophila 
was apparent in a defect in egg deposition due to impaired function of both egg and 
nursing cells (Byers et ah, 1981; Bellen et ah, 1987). There are currently 18 different 
mammalian PDE4 isoforms that have been identified. The are encoded by four distinct 
genes, each giving rise to multiple splice variants, and each gene represents a PDE4 
subfamily {Fig. 1.6.).
1.3.1. The PDE4A subfamily
The human PDE4A gene, which is located on chromosome 19pl3.1, has been cloned and 
well characterised (reviewed Houslay, 2001). It is currently thought that there are at least 
four different PDE4A splice variants {Fig. 1.7.), of which three are ‘long forms’. 
PDE4A4B was originally named ‘pde46’ (Huston et ah, 1996) and is a homologue of 
rodent PDE4A5 (McPhee et ah, 1995). These variants are localised to the cortical regions 
in a cell including membrane ruffles and also perinuclear regions (McPhee et ah, 1995) via 
interactions with adaptor proteins containing src homology 3 (SH3) domains (O'Connell et 
ah, 1996). PDE4A10 is also a ‘long-form’ PDE4 isoform, cloned from a rat olfactory 
library (Rena et ah, 2001). The ‘long-form’ rat PDE4A8 (also known as rpde39, Bolger et 
ah, 1996), was originally cloned from a rat testis cDNA library and using RNA protection 
studies has been shown to be exclusively expressed in the testes and in maturing 
spermatozoa (Naro et ah, 1996). A human homologue of PDE4A8 has not yet been 
identified. The membrane-associated (Shakur et ah, 1995; Pooley et ah, 1997) PDE4A1 
(also refeiTed to as RDI, Sullivan et ah, 1998) is a ‘super-short’ PDE4A isoform, which 
lacks UCRl and has an N-terminally truncated UCR2 {Fig. 7.7.), whose expression is 
confined to the brain (Shakur et ah, 1995).
Modulation of long-form PDE4A activity occurs via binding of phosphatidic acid (PA) and 
phosphatidylserine to a region proposed to be located within the UCRl domain (Nemoz et
al, 1997). Phosphorylation of PDE4A isoforms also affects the activity of the enzymes. 
For example, p70s6 kinase is believed to specifically phosphorylate and activate 
PDE4A4/5 isoforms via a PI 3-kinase dependent pathway in 3T3 F442A adipocytes 
(MacKenzie et al., 1998) and in U937 monocytic cells (MacKenzie and Houslay, 2000).
1.3.2. The PDE4B subfamily
The human PDE4B gene is located on chromosome 1 (reviewed by Houslay, 2001) and it 
encodes at least four different splice variants (Fig. 1.8.). There are three long isoforms, 
PDE4B1, PDE4B3 and PDE4B4, and one short isoform, PDE4B2, all of which have been 
found associated with both the soluble and particulate fractions of the cell (Huston et al., 
1997; Obemolte et al., 1993).
Phosphorylation plays a key role in modulating PDE4B isoform activities. The ‘short- 
form’ of PDE4B, PDE4B2, is phosphorylated at Ser"^ ^^  by ERK and this activates the 
enzyme. However, ERK phosphorylation of the long PDE4B1 form, at the equivalent 
residue, Ser^^ ,^ inhibits the enzymatic activity of this protein (Baillie et a l, 2000). The 
binding of the phosholipids, phosphatidic acid and phosphatidylserine, at an as yet 
unidentified site, up regulates PDE4B1 activity, whereas the short form PDE4B2 activity 
remains unaffected in the presence of these molecules (Nemoz et a l, 1997).
1.3.3. The PDE4C subfamily
The human PDE4C gene is located on chromosome 19pl3.2 (Sullivan et a l, 1999). There 
are at least three long forms of PDE4C (Obemolte et a l, 1997) and no ‘short’ or ‘super­
short’ PDE4C species have been identified thus far. Although these proteins have not been 
characterised in any detail, the PDE4C2 protein has been shown to be a substrate for ERK- 
mediated phosphorylation. The residue targeted for modification is Ser^^ ,^ the equivalent 
residue as that phosphorylated by ERK in the PDE4B isoforms. This ERK phosphorylation 
causes an inhibition of the PDE4C enzymatic activity (Baillie et a l, 2000).
1.3.4. The PDE4D subfamily
The human PDE4D gene is located on chromosome 5 (reviewed in Houslay, 2001). Of the 
five PDE4D splice variants identified to date, three are ‘long-forms’ (PDE4D3, PDE4D4 
and PDE4D5), PDE4D1 is a ‘short-form’ and PDE4D2 is a ‘super-short’ forni (Fig. 1.9.). 
PDE4D1-5 have molecular weights of 6 8 , 72, 95, 119 and 105 kDa, respectively. The in
vivo function of PDE4D has been investigated in knock-out mice models. PDE4D- 
deficient mice have reduced viability, diminished sensitivity of the granulosa cells to 
gonadotropins and reduced fertility (Jin et ah, 1999). The latter phenotype is caused by 
impaired ovulation and degeneration of oocytes due to disrupted metaphase (Jin et al.,
1999). Deficient mice also display impaired growth with lower than normal weight due to 
a proportional decrease in muscle and bone mass and internal organ weight. The airways of 
these transgenic mice are also no longer responsive to cholinergic stimulation due to 
defective receptor signalling and are no longer protected against allergen-induced airway 
hyper-reactivity, thus improving asthma symptoms (Hansen et al., 2000). These 
characteristics suggest that PDE4D plays a non-redundant role in cAMP signalling, with 
unique and non-overlapping functions.
1.3.4.1. ‘Short-form '  splice variants of PDE4D
PDE4D1 and PDE4D2 have Km values for cAMP of 5 (xM and are found predominantly in 
the cytoplasm (Jin et al., 1998; Bolger et al., 1997). PDE4D1 and PDE4D2 protein 
expression levels are up-regulated upon prolonged stimulation of the cAMP/PKA pathway 
in vascular smooth muscle cells (VSMC, Liu et ah, 2000a), L6  myoblasts (Kovala et ah, 
1994) and in Jurkat T cells (Erdogan and Houslay, 1997). However, simultaneous 
activation of the ERK signalling mechanism and cAMP elevation attenuates this cAMP 
induced expression of PDE4D1 and PDE4D2 (Liu et ah, 2000a). Expression of PDE4D1 
and PDE4D2 is apparent in the early stages of spermatogenesis, with transcript levels 
diminishing after day 15 of development (Salanova et ah, 1999). Up-regulation of both 
expression and activity of the ‘short-form’ PDE4D isoforms can also occur in a hormone 
dependent fashion, in Sertoli cells treated with follicular stimulating hormone (FSH) or 
thyroid cells treated with thyroid stimulating hormone (TSH, Vicini and Conti, 1997). 
Post-translational modifications of PDE4D1 also regulates its enzymatic activity, where 
the ERK mediated phosphorylation of Ser"^ ^^  on PDE4D1, the equivalent residue to Ser^^  ^
on PDE4D3, stimulates enzymatic activity (MacKenzie et ah, 2000).
1.3.4.2. ‘Long-form’ splice variants of PDE4D
PDE4D3 in over-expressed systems is found in both the cytosolic and particulate fractions 
of the cell, having Km values of 1.4 jxM and 0.6 jxM, respectively (Bolger et ah, 1997). The 
localisation of PDE4D3 within the cell to discrete sites is maintained by the formation of 
complexes with scaffolding/structural proteins (Dodge et ah, 2001; Tasken et ah, 2001; 
Verde et ah, 2001). The muscle-selective A-kinase anchoring protein (mAKAP) maintains
a signalling module with PKA and PDE4D3 in complex (Dodge et ah, 2001). In rat 
ventriculocytes, induction of mAKAP by treatment of the cells with hypertrophic stimuli 
induces a redistribution of PDE4D3, moving it from the cytosol to accumulate in the 
perinuclear region of the cell where mAKAP is localised (Dodge et ah, 2001). At the 
centrosome of Sertoli cells, PDE4D3 co-localises with PKA-RIIa and RIIp subunits, in a 
complex co-ordinated by binding to AKAP450 (Tasken et ah, 2001). Centrosomal, Golgi 
and sarcomeric localisation of PDE4D3 is also brought about by the formation of a 
complex with a novel structural protein called myomegalin (Verde et ah, 2001).
There are well-characterised mechanisms by which PDE4D3 activity is modulated by 
phosphorylation by kinases such as PKA and ERK, and through interactions with 
phospholipids (see below).
PDE4D4 is found mainly associated with the particulate fraction of cells (Jin et ah, 1998). 
This localisation may be due to the propensity of PDE4D4 to interact with SH3 containing 
adapter proteins, specifically of the src family of tyrosyl kinases, via the proline rich region 
in the unique N-terminus of PDE4D4 (Beard et ah, 1999). Modulation of activity of 
PDE4D4 by phosphorylation events is thought to be similar to that exhibited by PDE4D3 
as it is also a long isoform containing the equivalent Ser^  ^and Ser^^  ^residues for PKA and 
ERK phosphorylation, respectively.
PDE4D5 exists in both cytosolic and membrane associated pools of the cell (Bolger et ah, 
1997; Jin et ah, 1998). The interaction of PDE4D5 isoform with the scaffolding protein, 
receptor for activated Ç kinase (RACKl), via residues in the unique N-terminus of the 
PDE, determines the localisation of the PDE within the cell but does not effect enzymatic 
activity (Yarwood et ah, 1999). PDE4D5 is inhibited by ERK phosphorylation of the Ser^^’ 
residue, which is the equivalent residue of Ser^^  ^in PDE4D3 (Hoffmann et ah, 1999). It is 
also activated by phosphorylation of Ser^^  ^ by PKA (Sette and Conti, 1996; Hoffmann et 
ah, 1998), which is the equivalent of Ser^ "^  in PDE4D3.
1.3.4.3. Régula tion of PDE4D by PKA
Expression of ‘short-form’ PDE4D isoforms are tightly regulated by cAMP concentration 
and PKA activity in the cell (Erdogan and Houslay, 1997; Kovala et ah, 1994; Liu et ah, 
2 0 0 0 a), whereas the expression of the long isoforms appears to be influenced only to a 
minor degree (Liu et ah, 2000a). Although the absolute levels of protein are important in 
determining the cellular activity of the PDE4D enzymes, the main mechanism by which
PKA regulates PDE4D activity occurs through direct phosphorylation. As already 
mentioned, PKA phosphorylates PDE4D3 at Ser^  ^ residue in the unique N-terminus of the 
protein and at Ser^ "^  in the UCRl domain. Activation of recombinant enzyme depends 
specifically on the phosphorylation of the latter Ser^^ residue (Sette and Conti, 1996; 
Hoffmann et al., 1998). The structural changes, which occur upon PKA phosphorylation 
of PDE4D3, are such that when PDE4D3 is in its basal conformation a sub-domain in the 
carboxyl terminus of UCR2, interacts strongly with the catalytic domain, inhibiting the 
binding of cAMP. When Ser^ "^  is phosphorylated a conformational change is brought about 
and the affinity of the amino terminus of UCRl for UCR2 increases. This therefore 
relieves the auto-inhibitory action of UCR2 on the catalytic domain, thus increasing 
enzyme activity (Lim et al., 1999, Fig.1.10.).
1.3 A  A. Régula tion of PDE4D by ERK
An ERK consensus phosphorylation motif (P-X-S/T-P) has been identified in the carboxyl 
terminus of the catalytic domain of PDE4D isoforms. The kinase interaction motif (KIM) 
and an FQF domain, both of which act as docking motifs for ERK2 (MacKenzie et ah,
2000), flank this consensus motif, and are required for ERK2 binding and phosphorylation 
in the PDE4D enzymes (MacKenzie et ah, 2000). The Ser^^  ^ residue (PDE4D3 residue 
numbering system) is rapidly and specifically targeted for phosphorylation by ERK2 upon 
stimulation of the epidermal growth factor receptor (EGF-R, Hoffmann et ah, 1999). 
Depending on the nature of the PDE4D isoform, different effects on the regulation of the 
enzymatic activity by ERK phosphorylation are seen. There is an up-regulation of the 
‘short-form’ PDE4D1 activity, most probably due to the presence of the extreme N- 
terminal residues of UCR2 as the super-short PDE4D2 isoform, which lacks these residues, 
is mildly inhibited upon ERK activation (MacKenzie et ah, 2000). However, ERK 
phosphorylation of the same residue in the long PDE4D isoforms (PDE4D3, PDE4D4 and 
PDE4D5) causes a large reduction in activity. This effect is attributed to the presence of 
both the UCRl and UCR2 domains (MacKenzie et ah, 2000).
PMA stimulation of cells causes the inhibition of PDE4D5 in an ERK dependent fashion, 
which in human aortic smooth muscle cells induces the activation of PKA that 
subsequently leads to an increase in the activation of PDE4D5 (Baillie et ah, 2001). These 
observations exemplify the existence of a cross talk mechanism, which exists between 
PKA and ERK, that is regulated through the activity of PDE4D isozymes.
1.3.4.5. Regulation of PDE4D by phosphatidic acid
Phosphatidic acid (PA), a phospholipid which is generated in several cell types on 
stimulation by hormones and growth factors (Exton, 1994), has been implicated in the 
stimulation of proliferation of fibroblasts and increases the activity of recombinant 
PDE4D3 protein (Nemoz et ah, 1997). PA specifically binds to a region found between 
residues 31 and 64 in the N-terminus of PDE4D3. The site is rich in basic and hydrophobic 
residues and is located within the UCRl region which contains the Ser^ "^  residue, 
phosphorylated by PKA (Grange et ah, 2000).
1.4. Cyclic AMP Involvement In the cell cycle
The involvement of cAMP in the regulation of cell cycle control mechanisms has been 
apparent for decades (Pastan et ah, 1975). Elevation of intracellular cAMP in cells can 
stimulate some cell types to proliferate, whereas, in other cell lines it can cause the cells to 
quiesce. When thyroid cell lines are incubated with TSH the intracellular levels of cAMP 
are elevated, PKA is activated and redistribution of the catalytic subunits to the nucleus 
initiates the phosphorylation of transcription factors (Montminy, 1997). This induces the 
cells to exit GO and to re-enter the cell cycle, promoting proliferation (Tramontano et ah, 
1988). However, the general effect of the elevation of cAMP on cellular proliferation 
seems to be one of aiTesting cells at GO or at the G2/M transition (Pastan et ah, 1975). 
Elevation of intracellular cAMP, through the stimulation of adenylyl cyclase, using 
forskolin, by addition of non-hydrolysable cAMP derivatives, or by the addition of 
phosphodiesterase inhibitors, inhibits cell proliferation (Pastan et ah, 1975) in many cell 
lines including fibroblasts (L’Allemain et ah, 1997), smooth muscle cells (Koyama et ah, 
2001) and lymphocytes (Banner et ah, 2000). Indeed, it has been noted that in quiesced 
cells the levels of cAMP are naturally elevated, as is the activity of PKA (Grieco et ah,
1996). The initial observations of growth retardation, through the elevation of intracellular 
cAMP, were made in hamster kidney cells by Burk (Burk, 1963).
1.4.1. Cyclic AMP induced inhibition of cell cycle entry
Ordered progression through the cell cycle is governed by the formation of complexes in 
which cyclin dependent kinase (cdk) act as catalytic subunits and cyclins act as regulatory 
subunits of the complex (reviewed in Li and Blow, 2001). Cdks are expressed at similar 
levels throughout the cell cycle whereas the cyclins tend to be expressed and degraded in a 
cell cycle dependent fashion, therefore eliciting phase specific activation of the kinases.
Quiescent cells are stimulated to enter the cell cycle by the addition of mitogens which, 
through the activation of the mitogen signalling cascade, initiate the expression of cyclin D 
(cyclin D l, D2 and D3, Weber et ah, 1997). D-type cyclins form complexes with, and 
activate, cdk 4 and cdk 6  (SheiT, 1993), which phosphorylate the tumour suppressor 
Retinoblastoma protein, pRb. The phosphorylation of pRb disrupts its interaction with the 
E2F family of transcription factors thus allowing the co-ordinated transcription of genes 
whose activities are required for DNA synthesis (Weinberg, 1995, Fig. 1. IL).  Cyclin D is 
an unstable protein and when mitogens are removed from the cells levels of the protein are 
rapidly reduced, due to its ubiquitin mediated degradation by the proteasome (Sewing et 
al., 1993). If the cells have not passed the restriction point within G1 prior to mitogen 
withdrawal, quiescence is induced. If, however, mitogens are present until after the cells 
have passed the restriction point, the cells are committed to complete one full cell division 
under autonomous control (Pardee, 1989). Cyclin D therefore provides a link between 
extracellular mitogenic signals and the cell cycle machinery.
The E2F transcription factor initiates the transcription of the E-type cyclin which is 
periodically expressed later in G1 (Koff et al., 1992). Cyclin E has a high affinity for cdk2, 
to which it binds and forms an active complex required for S-phase entry in all mammalian 
cells (Ohtsubo et ah, 1995). After the cyclin D/cdk4 mediated initial phosphorylation of 
pRb the active cyclin E/cdk2 complex hyper-phosphorylates pRb, on additional sites 
providing sustained activity of E2F resulting in the expression of proteins required for the 
Gl/S transition (reviewed in Sherr, 1993). Attenuation of the cdk-mediated 
phosphorylation of pRb causes E2F to reassociate with it leading to a repression of the 
heterodimeric E2F transcription factor activity and subsequent down regulation of proteins 
required for the Gl/S transition (Stewart et ah, 1999).
The activity of the cdk complexes is not only controlled at the level of cyclin expression 
but is also regulated by association with the INK4 (inhibitors of cdk4) and cip/kip families 
of inhibitor proteins. The latent G1 phase inhibitor p27^^^ binds to both cyclin D/cdk4 and 
cyclin E/cdk 2 kinase complexes in a 1:1:1 stoichiometry (Blain et ah, 1997), but with a 
higher affinity for cyclin D/cdk4 than cyclin E/cdk2 (Polyak et ah, 1994a). The 
consequences of the interaction of p27^^^ with the cyclin D/cdk4 complex are contested. 
Some groups have shown that kinase activity is inhibited as p27^^^ prevents the cdk- 
activating kinase (CAK) from phosphorylating and activating cyclin D/cdk4 in vitro (Kato 
et ah, 1994). More recently, however, it has been shown that the p27^^^  ^ bound cyclin 
D/cdk4 complex maintains kinase activity in vivo (Blain et ah, 1997; Ravanko et ah, 2000) 
and that this interaction functions more as a sequestering mechanism for p27^^\ When
levels of exceed those of cyclin D/cdk4 the inhibitor binds to the cyclin E/cdk2
complex where it act as an effective antagonist of the kinase complex activity (Zerfass- 
Thome et ah, 1997; Ravanko et ah, 2000) thereby preventing cell cycle progression 
(Polyak et ah, 1994b). Once activated cyclin E/cdk2, is involved in a positive feedback 
loop, where it phosphorylates p27^^^\ targeting it for ubiquitin mediated degradation 
thereby facilitating its own activation (Sheaff et ah, 1997; Morisaki et ah, 1997, Fig.
1. 11.).
There are several mechanisms by which cAMP elevation and the activation of PKA 
influences cell cycle progression (LAllemain et ah, 1997). PKA causes an elevation in the 
levels of the G1 cyclin dependent kinase inhibitor p27^^^  ^ (Kato et ah, 1994) and the 
tumour supressor p53 (Hayashi et ah, 2000) and decreases the levels of the G1 cyclins D l 
and D3 (LAllemain et ah, 1997; Naderi et ah, 2000). Activation of PKA can also 
negatively regulate the mitogen signalling cascade, by preventing the activation of ERK 
(Graves et ah, 1993).
1.4.1.1. Cyclic AMP mediated elevation of protein levels
The amounts of p27^^^ mRNA remain constant throughout the cell cycle (Morisaki et ah,
1997). However, elevation of cAMP and subsequent activation of PKA causes a rapid 
increase in the levels of p27^^^ protein, through the initiation of translation and also 
through a reduction in protein degradation (Hengst and Reed, 1996; van Oirschot et ah, 
2001). The precise mechanism by which PKA increases p27^^^  ^ translation has not yet 
been elucidated. It has been postulated that PKA phosphorylation of the cAMP response 
element binding protein (CREB) initiates activation of the CRE promoter found upstream 
of the p27^^^  ^ gene that increases p27^^^ expression (Kwon et ah, 1996). PKA inhibits 
proteasome-mediated degradation of the p27^^^  ^ protein (LAllemain et ah, 1997; Boucher 
et ah, 2 0 0 1 ) by a mechanism that involves either direct phosphorylation of p27^^^ or 
phosphorylation of some component of the proteasome (Boucher et ah, 2001). In any case, 
the consequence of elevated p27^^^  ^ levels in the cell is that all cyclin D/cdk4 complexes 
become bound to the inhibitor. The excess p27^^^ then binds to cyclin E/cdk2, where it 
effectively blocks its kinase activity thus repressing pRb phosphorylation and consequently 
reducing the amount of cyclin E (reviewed in Sherr, 1993) and cyclin A (Weinberg, 1995; 
Zerfass-Thome et ah, 1997) protein expression. The net result is that cells arrest prior to 
their passage through the G1 restriction point (Kato et ah, 1994; LAllemain et ah, 1997).
1.4.1.2. Cyclic AMP mediated down regulation of D-type cyclins
Cellular levels of cyclin D are low during quiescence in the absence of growth factors but 
then rise upon mitogenic stimulation and remain elevated throughout the rest of the cell 
cycle (Weber et ah, 1997; Sewing et ah, 1993; Matsushime et ah, 1991). Elevation of 
cAMP in a cell reduces the protein levels of cyclins D l (LAllemain et ah, 1997) and D3 
(van Oirschot et ah, 2001; Naderi et ah, 2000), by increasing their proteasome dependent 
degradation (Diehl et ah, 1997); Stewart et ah, 1999). Elevation of cAMP also decreases 
levels of cyclin D by reducing the rates of cyclin D translation (Naderi et ah, 2000; Sewing 
et ah, 1993; LAllemain et ah, 1997). The decrease in active cyclin D/cdk4 correlates with 
a decrease in the phosphorylation of pRb (Boucher et ah, 2001) and therefore a decrease in 
the expression of the proteins required for the Gl/S transition (van Oirschot et ah, 2001; 
Naderi et ah, 2000). Low levels of the cyclin D/cdk4 complex increases the amount of free 
P2 7 KIP1 pj-otein, which can then redistribute, bind to and inhibit eyclin E/cdk2 (LAllemain 
et ah, 1997; Naderi et al., 2000).
1.4.1.3. Cyclic AMP mediated interference of the mitogen activated protein 
kinase cascade.
The activation of extracellular signal-regulated protein kinases (ERK) is central to 
mitogenic signalling in many cell types (Frye, 1992). The major pathway for ERK 
activation by ligands for receptor tyrosine kinases occurs via Ras dependent stimulation of 
Raf-1 and mitogen activated protein kinase kinase (MEK), a dual specificity kinase that 
specifically activates ERKs 1 and 2. Once ERK is activated it targets p90^^  ^ for 
phosphorylation and both proteins translocate to the nucleus where they activate early 
response transcription factors such as c-jun (Pulverer et ah, 1991), c-myc (Seth et ah, 1991) 
and Elk (reviewed in Davis, 1995). Sustained activation of ERKl is required for the 
continued expression of cyclin D l (Weber et ah, 1997), phosphorylation of pRb (Stewart et 
ah, 1999) and down regulation of p27^^^ (Greulich and Erikson, 1998) in G1 to enable S 
phase entry (Ramakrishnan et ah, 1998) and cellular proliferation (reviewed in Roovers 
and Assoian, 2000). Ras is a member of the small guanine 5’-triphosphate (GTP) binding 
protein superfamily. It is the product of an oncogene, found to be mutated in 15 % of 
tumour cell lines (Bos, 1989). Cells can be transformed by a point mutation of ras which 
leads to uncontrolled cell division due to continual activation of ERK (Bos, 1989). Non- 
hydrolysable cAMP analogues have been shown to induce growth inhibition of such 
transformed eells in a manner that is dependent on PKA activity (Noguchi et ah, 1998). 
The attenuation of mitogenic signalling by the activation of PKA occurs in a fashion that is
still not yet completely resolved. The effects of cAMP elevation on cell cycle progression 
is dependent on the isoforms of the Raf family expressed in the cell and on the growth 
factor used as a stimulus for proliferation (Cospedal et ah, 1999). PKA mediates the 
inhibition of Raf-1 via different mechanisms (Boucher et al., 2001). Firstly, it can 
phosphorylate Raf-1 directly (Ramstad et al., 2000), preventing it from binding to Ras and 
activating the MEK/ERK cascade (Cook and McCormick, 1993; Houslay and Kolch,
2000). Alternatively, Raf-1 activity can be modulated by another small G-protein of the 
Ras family, Rapl, whieh itself can be regulated by PKA. The mechanisms involving Rapl 
activation and inhibition of cell proliferation are still unclear and the downstream effects 
appear to be mechanistically and cellularly distinct (reviewed in Bos et al., 2001). Cyclic 
AMP binds directly to Epac and increases its guanine nucleotide exchange factor activity 
towards Rapl, thus activating it (Zwartkruis and Bos, 1999; de Rooij et al., 2000; 
Kawasaki et al., 1998). Rapl has also been shown to be directly regulated by cAMP in a 
PKA and Epac independent manner, whereby increases in cAMP inactivate Rapl, which 
causes the inhibition of ERK and PI3-kinase/PKB activity in glioma cell lines (Wang et al., 
2001a). The activation of Rapl increases its affinity for Raf-1 which might act to trap Raf- 
1 in an inactive complex (Bos, 1998) and hence antagonise the Ras/Raf-1 interaction in the 
Ras-Raf-MEK-ERK pathway (Schmitt and Stork, 2001; Koyama et ah, 2001). Although 
mutants of Rapl inhibit the ERK pathway, no studies have observed the absolute inhibition 
(or activation) of Rafl kinase upon extracellular Rapl aetivation, suggesting additional 
pathways are involved in the inactivation of the MEK/ERK signalling pathway (Bos et al.,
2001). Conversely, in some eells Rapl is implicated in activation of the ERK pathway in 
cells which express the Raf family member, B-raf (Vossler et al., 1997; Houslay and 
Kolch, 2000; Schmitt and Stork, 2000; Tsygankova et al., 2001).
1.4.1.4. P!3-kinase pathway
The phosphoinositide 3-kinase (PI 3-kinase) pathway is another signalling cascade within 
cells at which cAMP can elicit its inhibitory effects on cell cycle proliferation (reviewed in 
Ammit and Panettieri, Jr., 2001). Upon platelet derived growth factor interaction with its 
cognate GPCR PI 3-kinase is activated by the dissociated py complex (Walker et ah,
1998). PI 3-kinase can be equally activated by mitogens interacting with receptor tyrosine 
kinases (reviewed in Cantrell, 2001). PI 3-kinase then phosphorylates membrane 
phosphoinositides, in the 3’ position of the inositol ring, which function as second 
messengers and activate downstream effector molecules such as protein dependent kinase 
(PDKl), which in turn activates PKB, p70s6 kinase and the Rho family of GTPases 
(reviewed in Cantrell, 2001). PI 3-kinase activates the cyclin D l promoter and DNA
synthesis via an ERK independent mechanism (Page et ah, 2000) and p70s6 kinase 
activates the 40S ribosomal protein which up-regulates the translation of cyclin D l mRNA 
(Scott et ah, 1996). PI 3-kinase mediated signalling cascades also regulate the 
phosphorylation of the pRb causing the release of the E2F transcription factor and 
increasing the levels of expression of the G1 dependent eyclins (Brennan et ah, 1997; 
Krymskaya et ah, 1999). All these mechanisms are capable of initiating proliferation, 
although the activation of PI 3-kinase alone appears to be insufficient for the initiation of 
DNA synthesis in T cells (Brennan et ah, 1997). With the elevation of cAMP, through the 
addition of forskolin to cells, G1 progression is inhibited as cAMP interferes with the 
interaction of the p85 adapter subunit of PI 3-kinase with the tyrosine kinase receptor 
(Monfar et ah, 1995; Scott et ah, 1996; Frost et ah, 1995).
1.4.2. Cyclic-AMP involvement of M phase transition
Mitosis is the stage in the cell cycle during which cell division takes place. It can be 
separated into five distinct phases. In prophase the chromosomes condense and nuclear 
envelope breakdown occurs (Nigg, 2001). In prometaphase the mitotic spindles to which 
the chromosomes attach are formed. The alignment of chromosomes along the metaphase 
plate then takes plaee during metaphase (Leblond and El Alfy, 1998). At the onset of 
anaphase, the sister chromatid cohesion is reduced, they separate and migrate to the 
opposite poles of the cell and telophase determines the time at which the daughter cells 
physically separate by cytokinesis (Leblond and El Alfy, 1998). To maintain the ordered 
progression through mitosis there are highly regulated intrinsic mechanisms which depend 
on multiple feedback loops involving an increasing number of kinases and phosphatases. 
The entry of cells into mitosis is under the control of the maturation-promoting factor 
(MPF) which is a complex composed of the mitotically expressed cyclin B1 and the kinase 
subunit cdkl. MPF activity is tightly regulated by post-translational modifications, under 
the control of checkpoint phosphorylation and dephosphorylation mechanisms. The 
activation of MPF leads to alterations in spindle dynamics and the architeeture of the cell 
as well as initiating chromosome and centrosome duplieation (reviewed in Nigg, 2001; 
Smits and Medema, 2001; Ohi and Gould, 1999).
Mitotic exit requires chromatid separation, spindle disassembly and cytokinesis, the co­
ordination of which is dependent on the ubiquitin-dependent proteolysis of key regulatory 
proteins (King et al., 1996). The critical step in mitotic protein destruction is mediated by 
the anaphase promoting complex (APC), or the 20S cyclosome: a multi-subunit complex 
that functions as a cell cycle dependent ubiquitin ligase (King et ah, 1995). Once
ubiquitinylation of target proteins has occurred, they are then subjected to degradation by 
the 26S proteasome, which ensures unidirectional progression through mitosis (Morgan, 
1999). Cyclic AMP levels are usually elevated in cells in order to maintain an interphase 
state and antagonise mitotic entry (Lamb et ah, 1991). Cyclic AMP levels are reduced in 
mitosis (Grieco et ah, 1996) leading to activation of the MPF (Hohmann et ah, 1993) and 
the APC (Kotani et ah, 1999). The mechanisms by which cAMP levels are reduced and 
PKA is inactivated during mitosis have not yet been identified in vivo.
1.4.2.1. Cyclic AMP dependent modulation of MPF activity
The concentration of cAMP oscillates during the cell cycle, thus altering the levels of free 
PKA catalytic subunit and participating in the temporal regulation of the PKA mediated 
signalling cascade (Zeilig et ah, 1976; Grieco et ah, 1994). Cyclic AMP and PKA activity 
is elevated prior to the entry of cells into mitosis, with the activity then falling rapidly as 
cells enter mitosis (Kotani et ah, 1998; Zeilig et ah, 1976). The inactivation of PKA 
promotes the activation of the MPF at the onset of mitosis (Grieco et al., 1996; Fernandez 
et ah, 1995) as PKA antagonises the activation of MPF (Hohmann et al., 1993; Ohi and 
Gould, 1999; Grieeo et ah, 1994). Prolonged PKA activation using temperature sensitive 
mutants of PKA or cAMP elevating agents gives rise to abnormal mitotic spindle 
formation, blocks chromosome separation (Ishii et ah, 1996) and inhibits nuclear envelope 
breakdown (Lamb et ah, 1991), underlining the importance of this enzyme in these 
processes.
1.4.2.2. Cyclic AMP dependent modulation of the anaphase promoting complex 
activity
The activity of the anaphase-promoting complex (APC) is regulated by at least four 
distinet mechanisms: the phosphorylation and dephosphorylation of the ubiquitin ligase 
subunits and by the binding of positive and negative regulatory factors (reviewed Kotani et 
ah, 1999). However, the precise regulatory meehanism of substrate specific activation of 
mammalian APC remains to be elucidated.
Elevation of PKA activity prior to the metaphase /anaphase transition inhibits mitotic exit 
through negative regulation of the APC activity, at least in vitro (Kotani et ah, 1998; 
Yamashita et ah, 1996; Yanagida et ah, 1999). Saccharomyces cerevisiae (Anghileri et ah, 
1999) and Schizosaccharomyces pombe (Yamashita et ah, 1996; Yanagida et al., 1999) 
yeast species, in which temperature sensitive mutants of the APC subunits have been
generated, are being used to elucidate mechanisms involved in APC activation and mitotic 
progression. PKA phosphorylates the Cut4 (mammalian homologue APCl) and cut9 
(mammalian homologue APC6 ) subunits of the APC during interphase (Ishii et ah, 1996; 
Kotani et ah, 1998; Yamashita et ah, 1996) and this impairs the assembly of an active APC 
complex (Yamashita et ah, 1999; Yanagida et ah, 1999). The yeast Cut 20 and mammalian 
Cdc27 APC subunits have also been identified as targets for PKA phosphorylation 
(Yamashita et ah, 1996; Kotani et ah, 1998) and both could be involved in the negative 
regulation of the APC. Dephosphorylation of the PKA phosphorylated APC subunits by 
PPl at metaphase allows assembly of the APC subunits resulting in the formation of an 
active ubiquitin ligase complex (Ishii et ah, 1996).
The temporal control of PKA activity is not the only important mechanism by which it 
regulates mitotic progression, since the spatial regulation of active PKA is crucial in the 
determination of the targets for phosphorylation. PKA has been shown, in fibroblasts, to 
co-localise with MPF at the centrosome (Tournier et ah, 1991). The PKA regulatory 
subunit, R lla, is targeted for phosphorlyation by the MPF which causes its redistribution 
from the centrosome/Golgi, where it is held through an interaction with AKAP75, to the 
cytosol (Keryer et ah, 1998).
1.5. Phosphodiesterases and the cell cycle
Intracellulai' cAMP degradation, elicited by phosphodiesterases, has been studied in many 
cell types during the cell cycle. Maintaining a low level of cAMP within cells is associated 
with continual cell proliferation and is dependable on high PDE activities (Pan et ah, 1994; 
Leitman et ah, 1986; Drees et ah, 1993; Matousovic et ah, 1997). Many disease states that 
are characterised by excessive cellular proliferation have elevated PDE activity (Savini et 
ah, 1995). In proliferating cultured colon carcinoma cell lines levels of PDE activity are 
high, maintaining low concentrations of cAMP. As the cells reach confluency the PDE 
activity decreases, the concentration of cAMP increases and the proliferation rate markedly 
slows (Savini et ah, 1995). High levels of PDE activity have been observed in rat 
hepatomas (Tsou et ah, 1974) and endometrial cancer (Tsou et ah, 1986), where continual 
cellular proliferation is evident. In rat models of mesangialproliferative glomerulonephritis 
(MSGN), a disease hallmarked by excessive mesangial cell proliferation, nephron 
cellularity is decreased by treatment with the PDE3 selective inhibitors (Tsuboi et ah,
1996). Such treatment of these cells inhibits the mitogenic pathway and MAPK activity, 
leading to the reduction in cell proliferation (Tsuboi et ah, 1996). The PDE4 specific 
inhibitor, rolipram, however, has no effect on the activation of MAPK in these cells, even
though PDE4 is two times more abundant than PDE3 (Matousovic et ah, 1995) indicating 
the significance of compartmentali sation of the cAMP signalling cascades.
PDE inhibitors have been shown to inhibit the proliferation of endothelial cells (Leitman et 
ah, 1986), melanoma cell lines (Drees et ah, 1993) and epithelial cells (Matousovic et ah, 
1997), arresting them all at the Gl/S boundary, prior to the restriction point. Other studies 
have made implications of differential control of cAMP degradation by PDEs at other 
stages of the cell cycle. The general PDE inhibitor, IBMX, arrested Amphidiunium 
operculatum cells at G2/M transition as well as at the Gl/S boundary (Leighfield and Van 
Dolah, 2001). In Actinomyces, PDE activity has been shown to increase at G2 phase 
(Lefebvre et ah, 1980), and this high level of PDE activity is maintained during mitosis. 
Furthermore, the inhibition of PDE activity in both budding and fission yeast, through the 
generation of temperature sensitive mutants, has been shown to block mitotic exit 
(Yamashita et ah, 1996; Kishimoto and Yamashita, 2000).
There have also been studies on the fluctuations of PDE activity in different phases of the 
cell cycle. The initial observations were made during cell proliferation in the slime mould, 
Physarum polycephalum (Lovely and Threlfall, 1978; Lovely and Threlfall, 1979; Kupetz 
and Jeter, Jr., 1985). Later studies in actinomyces indicated that in the early stages of the 
cell cycle, during the first stage of protein synthesis and DNA replication, there was a 
decrease in the specific activity of PDEs. This increased aetivity post DNA replication as 
cells entered G2 and M (Lefebvre et ah, 1980). Fluctuations of PDE activity have also been 
noted in germ cell proliferation, in seminiferous epithelium, where rolipram sensitive 
activity was maximal at the early stages of sperm development (stages H-VI) and minimal 
at later stages (stages IX-XII, Morena et ah, 1995). As fluctuations of cAMP levels have 
been studied so extensively during the cell cycle and the mechanisms that they influence 
are now being elucidated and fully characterised.
1.5.1. Phosphodiesterases and T cell proliferation
The human T lymphotrophic virus (HTLV-1) is endemic in some Asian, Caribbean and 
African countries. It is capable of infecting and transforming mature T cells and has been 
implicated in the adult T cell leukaemia (ATL): a rapidly progressive, usually fatal, mature 
T cell leukaemia (Greene and Leonard, 1986). MJ cells, a HTLV-1 transformed T cell line, 
have elevated levels of PDE4 activity compared to untransformed cells (Ekholm et ah, 
1999), suggesting that cAMP hydrolysis maintains the proliferative ability of the cells.
Additionally, incubation of MJ cells with the PDE4 specific inhibitor, rolipram, reduces 
cell proliferation (Ekholm et al., 1999).
Inhibition of PDE3 (Giembycz et ah, 1996), PDE4 (Essayan et ah, 1997) and PDE7 (Li et 
ah, 1999; Mary et ah, 1987) have all been shown to attenuate the proliferation of T cell 
lines. However, the precise cellular mechanisms by which the inhibition of PDEs decrease 
proliferation are difficult to pinpoint as the full activation of T cells, which leads to their 
increased proliferation, requires the activation of multiple pathways.
T cells require two distinct extracellular signals in order to be activated, to proliferate and 
to induce an immune response. An antigen, bound to the major histocompatability complex 
(MHC) on the antigen-presenting cell, interacts with the CD3 T cell receptor complex on 
the surface of T cells (Geppert and Lipsky, 1986) inducing the expression of low levels of 
the cytokine interleukin 2 (IL-2) and causing cells to pass from quiescence to G I (Tsoukas 
et ah, 1985). IL-2 acts in an autocrine fashion when bound to its cognate receptor (Smith, 
1984), inducing further activation of the T cell by stimulating the protein tyrosine kinase- 
dependent pathways that activate Ras (reviewed in Izquierdo et ah, 1995), the transcription 
factors Stat3 and Stat5 (Johnston et ah, 1995) and PI 3-kinase (Brennan et ah, 1997). PI 3- 
kinase increases the transcriptional activation of E2F, which in turns increases the levels of 
cyclins D2, D3 and E and decreases the amount of p27^^^  ^ (Modiano et ah, 1994) in the T 
cell (Brennan et ah, 1997). Nevertheless, the stimulation of PI 3-kinase through the IL-2 
signalling pathway alone is not sufficient to induce DNA synthesis (Brennan et ah, 1997).
Expression of IL-2 in primed T cells is enhanced synergistically upon co-stimulation of 
CD28, an accessory molecule expressed on the surface of the T cell, that is stimulated non- 
specifically by the antigen-presenting cell (reviewed in Jenkins and Johnson, 1993). The 
cellular signalling events initiated upon CD3 and CD28 co-stimulation include an increase 
in PDE activity, leading to decreased levels of cAMP (Skalhegg et ah, 1994; Takemoto et 
ah, 1978; Epstein et ah, 1980). This decrease in cAMP inactivates PKA, enabling the 
activation of the MAPK pathway which causes primed T cells to increase their production 
of IL-2 (Mary et ah, 1987) and expression of IL-2 reeeptors (IL-2R, Toribio et ah, 1989; 
Krause and Deutsch, 1991). All these effects consequently elicit the full activation of the T 
cell. When T cells are fully activated, DNA synthesis is initiated, the cells make the 
transition into S phase (Smith, 1984) and clonal expansion of the cell population is 
prompted, generating an immune response (Giembycz et ah, 1996; Lingk et ah, 1990). In 
addition to inducing cell proliferation, the decrease in cAMP levels, upon CD3/CD28 
activation also increases the levels of cytokine expression and exocytosis (Shahinian et ah.
1993) from the activated T cells (Borger et al., 1996; Giembyez et al., 1996; Shichijo et al., 
1997).
Elevation of cAMP levels in T cells by the addition of catecholamines, prostaglandin 2 
(PGE2, Wacholtz et ah, 1991; Baker et ah, 1981), forskolin (Lingk et ah, 1990; Shiehijo et 
ah, 1997), cholera toxin (Wacholtz et ah, 1991) and PDE inhibitors (Ekholm et ah, 1999) 
attenuates mitogen stimulated T cell proliferation (Baker et ah, 1981; van Oirschot et ah,
2001) and IL-2-mediated DNA synthesis (Lingk et ah, 1990), suppressing the immune 
response.
1.5.1.1. PDE4 and T cell proliferation
T cell activation is associated with inflammatory diseases such as atopic dermatitis and 
asthma (reviewed in Kay, 2000). Mononuclear cells from patients with atopic dermatitis 
are found to be more sensitive to the anti-proliferative effects of PDE4 inhibitors than non- 
atopic subjects (Banner et ah, 1995), as they appear to express elevated levels of cAMP 
specific PDEs (Holden et ah, 1986). Human T lymphocytes and mononuclear cells, 
stimulated with the lectin phytohaemagglutinin (PHA), decrease their proliferation upon 
treatment with PDE4 and PDE3 specific inhibitors (Banner et ah, 2000; Banner et ah, 
1995; Robicsek et ah, 1991). This suggests that phosphodiesterases influence the control of 
cell cycle machinery at least to some extent.
PDE4 inhibition augments the proliferative responses of anti gen-driven T helper cell 
clones (Essayan et ah, 1997) and suppresses the production of several cytokines including 
IL-1 (Giembycz et ah, 1994), IL-2 (Giembycz et ah, 1996), EL-4 (Robicsek et ah, 1991) 
and EL-13 in human T cells (Shichijo et ah, 1997; Essayan et ah, 1997; Kanda and 
Watanabe, 2001), again underlying the importance of this class of enzyme in the regulation 
of T cell activation.
The effects of PDE inhibition on the modulation of the different T cell responses are not 
solely dependent on the net increase of cAMP levels in the cell but are also dependent on 
the localisation of the PDE isoforms. The Barnes group (Giembycz et ah, 1996) showed 
that inhibition of cytosolic PDE4 led to the attenuation of both EL-2 release and 
proliferation of PHA treated and CD3 induced CD4'*' and CD8  ^ T lymphocytes, whereas 
inhibition of the membrane associated PDE3 had no effect on any of these responses. 
Interestingly, however, inhibition of PDE3 potentiates the anti-proliferative effect of PDE4 
inhibitors (Giembycz et ah, 1994), indicating cross talk between the classes of
phosphodiesterases. Stimulation of T cells with different mitogens has been demonstrated 
to determine alternative modes of activation of the eell. When PMA and ionomycin are 
used as co-mitogens of the CD4^ and CD8  ^ lymphocytes inhibition of PDE4 does not 
affect proliferation, but does suppress IL-2 and interferon y (IFNy) release (Giembycz et 
al., 1996).
1.5.1.2. PDE7 and T cell proliferation
Following inhibition of both PDE4 and PDE3 in T lymphocytes it was noted that there was 
between 25 -  40 % residual cAMP specific activity in the cytosolic fraction of the T cell 
(Robicsek et al., 1991; Tenor et al., 1995; Giembycz et al., 1996). This has been attributed 
to PDE7 and referred to as the cAMP specific, rolipram-insensitive activity in these T cells 
(Ichimura and Kase, 1993), to which selective inhibitors have only recently being 
developed (Martinez et al., 2000; Barnes et al., 2001). Both CD4^ and CD8  ^T cells express 
PDE7 isoforms (Giembycz et al., 1996) at low levels in peripheral T lymphocytes. When 
the cells are activated by anti-CD3/CD28 stimulation, there is a rapid increase in PDE7A1 
and PDE7A3 mRNA and protein levels (Glavas et al., 2001). However, PHA stimulation 
of the same cells has no effect on PDE7 levels or activity (Kanda and Watanabe, 2001; 
Bloom and Beavo, 1996). PDE7 activity is associated with the signalling eascades that 
initiate full activation of the T cells inducing cell proliferation and IL-2 release from the 
cells (Giembycz et al., 1996). Down-regulation of PDE7 expression, using anti-sense 
oligonucleotides (Kanda and Watanabe, 2001), deereased the amount of EL-2 expression 
and inhibited proliferation of activated T cells by 70 - 80 % (Li et al., 1999). With PDE7 
contributing significantly to mechanisms involved in the full activation of T cells it could 
be a potential target for drug design, to inhibit EL-2 production and prevent excessive 
cellular proliferation without the toxicity associated with PDE4 inhibition (Barnes et ah, 
2001).
1.5.2. PDEs and smooth muscle cell proliferation
Increased airway smooth muscle mass, caused by increased hypertrophy and hyperplasia 
(Johnson et ah, 2001), is associated with airway hyper-responsiveness in type I, and to a 
lesser degree, in type II asthmatics (Ebina et ah, 1993), which leads to amplification of 
airway resistance. PI 3-kinase-dependent mechanisms are activated in the mitogenic 
signalling pathway in human airway smooth muscle cells (ASMCs), particularly acting 
through the stimulation of p70®*^ ,^ which increases protein and DNA synthesis and 
increases cell proliferation (Scott et ah, 1996). In cultured ASMCs, P2-adrenergic receptor
ou
agonists decrease the proliferative response in part by a cAMP-mediated mechanism 
(Tomlinson et ah, 1995; S te wait et ah, 1999). Smooth muscle cell proliferation can also be 
inhibited by other agents which cause the elevation of cAMP such as prostaglandin E l, 
which can be produced by endothelial cells (Loesberg et ah, 1985), forskolin and 
prostaglandin E2 (PGE2, Lee et ah, 2001; Stewart et ah, 1999; Florio et ah, 1994) and 
inhibition of PDEs with the general inhibitor IBMX or by the addition of the PDE3- 
selective inhibitor, siguazodan (Billington et ah, 1999). These cause cells to arrest within 
G1 phase, prior to the entry to S phase (Loesberg et ah, 1985; Florio et ah, 1994; 
Tomlinson et ah, 1995). However, the selective inhibition of PDE4, by the addition of 
rolipram to ASMCs, does not attenuate proliferation. This suggests that the 
compartmentalisation of cAMP elevation, at least in ASMCs, may be functionally relevant 
(Billington et ah, 1999).
A typical event in the pathogenesis of ishemic heart disease resulting from atherosclerosis 
is the proliferation of vascular smooth muscle cells (VSMCs). This can be treated using 
catheter-based techniques such as balloon angioplasty. However this damages the smooth 
muscle cells inducing the formation of neointima resulting in restenosis (Indolfi et ah, 
1997; Ip et ah, 1990). The proliferation of VSMC, caused by this mechanical damage, can 
be attenuated by the elevation of cAMP through the inhibition of PDEs (Indolfi et ah,
1997). Selective inhibitors of PDE3, such as cilostomide (Tsuchikane et ah, 1999), 
trequinsin (Osinski and Schror, 2000), amiinone (Indolfi et ah, 1997) and CI-930 
(Johnson-Mills et ah, 1998) have all been shown to attenuate proliferation of cultured 
VSMC (Johnson-Mills et ah, 1998; Pan et ah, 1994) and also VSMC from subjects which 
have undergone balloon angioplasty (Indolfi et ah, 1997; Tsuchikane et ah, 1999). The 
effect of selective inhibitors of PDE4, on the proliferation of vascular smooth muscle cells, 
on the other hand is debatable. Some studies have shown that, when used independently of 
PDE3 inhibitors, rolipram attenuates VSMC proliferation (Pan et ah, 1994). Whereas, 
others suggest there is no deerease in proliferation (Johnson-Mlls et ah, 1998; Souness et 
ah, 1992; Osinski and Schror, 2000). In either case it does seem clear that when PDE3 and 
PDE4 are inhibited simultaneously, a supra-inhibition of VSMC proliferation is observed 
(Johnson-Mills et ah, 1998; Pan et ah, 1994; Souness et ah, 1992). This has led to 
speculation concerning the compartmentalisation of PDE isoforms differentially regulating 
the cell cycle machinery. VSMC proliferation can also be attenuated by the PDE5 specific 
inhibitor, sildenafil, which interferes with the mitogenic signalling pathway (Osinski et ah, 
2001).
Elevated cAMP in VSMC reduces cyclin D1 protein levels (Lee et al., 2001) by increasing 
proteosome mediated degradation of the protein (Stewart et al., 1999). The reduction of 
cyclin D1 levels prevents the phosphorylation of the pRb, thereby attenuating cell cycle 
progression (Stewart et al., 1999). Increased cAMP concentrations also attenuate ERK 
stimulated activation of p90^^^ and c~Fos (Lee et al,, 2001). The phase of the cell cycle at 
which the elevation of cAMP causes inhibition of SMC proliferation is at the G 1/S 
transition (Loesberg et al., 1985), where PKA activation antagonises the mitogen signalling 
cascade (Osinski and Schror, 2000; Osinski et al., 2001). PKA phosphorylates the cAMP 
response element binding protein (CREB) which subsequently associates with the cAMP 
response element (CRE) in the cyclin D1 and cyclin A promoter sequence (Musa et al.,
1999), impairing the expression of cyclin D1 and cyclin A mRNA and protein (Kronemann 
et al., 1999).
Although changes in PDE activity have been noted during different phases of the cell cycle 
in germ cells (Morena et al., 1995) and in prokaryotes (Leighfield and Van Dolah, 2001; 
Lefebvre et al., 1980), no studies have been carried out to investigate the fluctuation of 
specific PDE isoform activities in the somatic cell cycle. A significant down regulation of 
PKA activity has been identified at the metaphase/anaphase transition (Grieco et al., 1996), 
and this has since been shown to be of fundamental importance in the progression through 
M phase in yeast (Yanagida et al., 1999). The relevance of the decreased PKA activity, in 
mammalian cell lines, is still not clear and the mechanisms by which cAMP levels are 
reduced at the metaphase/anaphase transition have not yet been elucidated. Given that the 
functions of PKA and PDE work antagonistically, it seemed likely that PDE isoforms 
might contribute to the control of cAMP regulation during the cell cycle. Therefore, the 
main aim of this thesis was to examine phosphodiesterase activities in mammalian somatic 
cells during the cell cycle.
The initial work, presented in chapter 3, deals with the optimisation of methods for 
arresting cells at the vaiious stages of the cell cycle. These methods were then used in an 
analysis of PDE and PKA activities throughout the cell cycle. This work uncovered the 
interesting observation that PDE4D3 activity was selectively and markedly increased 
during mitosis. A detailed study of this phenomenon was then undertaken, the results of 
which are presented in chapter 4. In addition, some preliminary work, investigating a 
poorly chai'acterised member of the PDE family, PDE7, was carried out and this is the 
focus of chapter 5.
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Figure 1.1. G-protein coupled receptor activation of protein kinase A.
Upon a ligand binding to its cognate Gs coupled receptor GDP/GTP 
exchange on the Ga subunit occurs and the heterotrimeric G protein 
dissociates such that the GPy complex activates downstream signalling 
cascades and the Ga-GTP interacts with the membrane associated adenylate 
cyclase. The active adenylate cyclase then converts intracellular ATP to 
cAMP, which diffuses away from the site of production and binds to the 
regulatory subunits of PKA. This induces a conformational change in the 
PKA subunits, causing the active catalytic subunits to disassociate and 
activate PKA regulated pathways. Picture taken from 
http://www.biocarta.com/pathfiles/gsPathway.asp.
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Figure 1,2. The topology of membrane bound adenylate cyclase. The
adenylate cyclase enzyme is composed of two sets of six transmembrane 
helices (M  ^ and Mj). These are separated by the first large intracellular 
loop which is composed of the catalytic C l a domain and the regulatory 
C lb domain. The long intracellular C-terminal domain is composed of the 
C2a catalytic domain and the terminal regulatory C2b domain. Divalent 
metal ions bind at the interface of the two catalytic motifs, holding the 
catalytic domain together. Both the N- and C- termini of the protein are 
intracellular. Picture adapted from Houslay & Milligan (1997).
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Figure 1.3. Interaction of AKAPs with PKA regulatory domains.
Panel A. AKAPs interact with the first 30 amino acids of the N-terminus 
of the PKA RII regulatory subunits. These residues also promote 
dimérisation of the RII subunits, which is a prerequisite for binding to 
AKA P. Each regulatory subunit of PKA interacts with a catalytic subunit. 
Upon binding two molecules of cAMP a conformational change of the 
regulatory subunit causes dissociation of the catalytic subunits. Panel B. 
The targeting domain of AKAPs determines the localisation at discrete 
subcellular compartments.
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Regulatory
Unique Regions Catalytic Domain Unique
NH2 COOH
PDE Family Regulatory Module Nucleotide Specificity
1 Ca^VCalmodulin cAMP/cGMP
2 cGMP/GAF cAMP/cGMP
3 cAMP
4 UCR1/UCR2 cAMP
5 cGMP/GAF cGMP
6 cGMP/GAF cGMP
7 cAMP
8 PAS/PAC cAMP
9 cGMP
10 GAF cAMP/cGMP
11 GAF cAMP/cGMP
Figure 1.4. Mammalian PDE isozyme families. The table summarises 
the current classification of PDEs into 11 isoenzyme families. This 
classification is based primarily on sequence homology however 
different enzyme families often display distinctive pharmacological and 
biochemical properties such as substrate preference and mode of 
regulation. The name of the regulatory module is indicated and binding 
to these areas determines catalytic domain affinity and enzymic activity 
of the isoform.
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Figure 1.5. Splice variation of PDE4 isoforms. The diversification of a 
PDE family is brought about by splice variation of the protein. All PDE4 
isoforms contain a catalytic domain: a region of approximately 360 amino 
acids (aa) near the C-terminus. In the ‘long-form’ PDE4 iso forms, this is 
joined to the 79 aa upstream conserved region 2 (UCR2) through the linker 
region 2 (LR2), which consists of 10-28 aa depending on the PDE4 family. 
The UCR2 is joined to the 59 aa of the upstream conserved region 1 
(UCRl) by the 24 aa linker region 1 (LRl). The ‘short form’ PDE4 
iso forms are spliced within the LRl region and therefore lack the UCRl. 
‘Super-short’ PDE4 iso forms are further truncated and lack the UCRl, LRl 
and the N-terminal portion of the UCR2 domain.
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Figure 1.6. Alignment of the deduced amino acid sequences of cDNAs 
for the human PDE4 families. The figure shows an alignment, made 
using the GCG PILEUP multiple alignment software, of the PDE4 
isoforms HSPDE4A4, HSPDE4B1, HSPDE4C1 and HSPDE4D3. The 
regions of sequence coloured in green are regions conserved between all 
PDE4 isoforms. These are UCRl (residues 141-200 in HSPDE4A4B), 
UCR2 (residues 224-302 in HSPDE4A4B) and the catalytic region 
(residues 332-688 in HSPDE4A4B). The positions of LRl (residues 
201-223 in HSPDE4A4B) and LR2 region (residues 303-331 in 
HSPDE4A4B) are also shown.
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Figure 1.7. Structure of mRNA transcripts from the rat PDE4A gene.
The numbers indicate the structure of the following PDE4A mRNA 
transcripts: 5, PDE4A5; 10, PDE4A10; 8 , PDE4A8; 1, PDE4A1. The red 
bar indicates the catalytic region, the green bar represents upstream 
conserved region 1 (UCRl) and the blue bar represents upstream 
conserved region 1 (UCR2) sequences. Regions of alternatively spliced 
sequence that are unique to each splice variant are shown as thin bars.
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Figure 1.8. Structure of mRNA transcripts from the PDE4B gene. The
numbers indicate the structure of the following PDE4B mRNA transcripts: 
1, PDE4B1; 2, PDE4B2; 3, PDE4B3; 4, PDE4B4. The red bar indicates the 
catalytic region, the green bar represents upstream conserved region 1 
(UCRl) and the blue bar represents upstream conserved region 1 (UCR2) 
sequences. Regions of alternatively spliced sequence that are unique to 
each splice variant are shown as thin bars.
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Figure 1.9. Structure of mRNA transcripts from the PDE4D gene. The
numbers indicate the structure of the following PDE4D mRNA transcripts: 
1, PDE4D1; 2, PDE4D2; 3, PDE4D3; 4, PDE4D4; 5, PDE4D5. The red bar 
indicates the catalytic region, the green bar represents upstream conserved 
region 1 (UCRl) and the blue bar represents UCR2. Regions of 
alternatively spliced sequence that are unique to each splice variant are 
shown as thin bars.
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Figure 1.10. Postulated mechanism of ^iong form* PDE activation 
upon PKA phosphorylation. Long form PDE4 isoforms impose 
inhibition of cAMP specific activity by the interaction of the N-terminus 
of the UCR2 domain forming weak interactions with the catalytic domain 
of the protein. Upon PKA phosphorylation of the Ser'^ and Ser^ '^  residues 
a conformational change of the PDE is induced through an increase in the 
affinity of the N-terminus of UCRl for the C-terminus of UCR2. This 
relieves the UCR2 mediated inhibition on the catalytic domain and PDE 
activity is increased.
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Figure 1.11. Regulation of G l/S transition. Mitogenic signals promote the 
assembly of the active cyclin D/cdk4 complexes, with p27‘^ ' '^ at the start of 
G1 phase. The sequestering of p27*^ ""' facilitates activation of the cyclin 
E/cdk2 complex later in G1 phase. Both active complexes phosphorylate 
pRb, repressing its ability to bind the E2F transcription factors and allowing 
the initiation of transcription of proteins required for entry into S phase. 
Cyclin E/cdk2 antagonises the p27'^"'' mediated inhibition of the complex 
by phosphorylating it which targets the inhibitor for proteasome mediated 
degradation in effect positively regulating its own activity.
Adenylate 
Cyclase Isoform
Activators Inhibitors
I G sa , forskolin, 
Ca^VCalmodulin
G ia , GPy, Adenine nucleoside 3 ’ 
polyphosphates
II G sa , forskolin, G^y, 
PKC
Adenine nucleoside 3 ’ 
polyphosphates
III G sa , forskolin, 
Ca^VCalmodulin
CaM kinase II, Adenine 
nucleoside 3 ’ polyphosphates
IV G sa , forskolin, Gpy Adenine nucleoside 3 ' 
polyphosphates
V G sa , forskolin, PKC 
& Ç
G ia, Ca^^, PKA, G^y, Adenine 
nucleoside 3 ' polyphosphates
VI G sa , forskolin G ia , Ca^+, PKA, PKC, Adenine 
nucleoside 3 ’ polyphosphates
VII G sa , forskolin, G^y, 
PKC
Adenine nucleoside 3 ’ 
polyphosphates
V III G sa , forskolin, 
Ca^VCalmodulin
Adenine nucleoside 3 ’ 
polyphosphates
IX G sa Calcineurin, Adenine nucleoside 
3 ’ polyphosphates
Table 1.1. Effectors which modulate adenylate cyclase isoform 
activity. The table summarises the modes of regulation of each adenylate 
cyclase isoform. The abréviations are PKA; cAMP dependent protein 
kinase; PKC, protein kinase C and Camkinase II, Calmodulin dependent 
kinase type II.
Chapter 2
Materials and methods
Except where stated biochemicals were obtained either from Fisons or from Sigma-Aldrich 
and were of analytical grade.
2.1. Mammalian cell culture
2.1.1. Maintenance of cel! lines
2.1.1.1. Rat-1 cell line
Rat-1 fibroblasts, a rat embryo fibroblast derived cell line, were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma) supplemented with 2 mM Glutamine, 10 % 
foetal bovine serum (PBS) and penicillin/streptomycin (100 units/ml) at 37 °C in an 
atmosphere of 5 % CO2 . Cells were passaged at 90 % confluency, where they were split 
1:5. This was done by rinsing the cells with pre-warmed phosphate buffered saline (PBS), 
to which 1 -2 ml 0.25 % trypsin/0.03 % EDTA solution was added. The flasks were 
incubated at room temperature until the cells detached. 1 0  ml fresh culture medium was 
added and the cells were collected by centrifugation at 1000 rpm for 3 min in the MSE 
Mistral 1000 swinging bucket centrifuge. The cells were then resuspended in fresh culture 
media and dispensed into new culture flasks at approximately 1 0  ^cells/ml final volume.
2.1.1.2. He la cell line
The HeLa cell line (ATCC CCL 2), a cervical carcinoma cell line with epithelial like 
morphology (Puck et al., 1972), was maintained in Minimum Essential Media (MEM, 
Sigma) supplemented with 10 % PBS at 37 °C in an atmosphere of 5 % CO2 . The Hela 
cells were passaged as the Rat-1 fibroblasts.
2.1.1.3. SK-N-SH cell line
The SK-N-SH cell line (ATCC HTB 11), a human neuroblastoma derived cell line, with 
neuroblast or epithelial morphology (Biedler et al., 1973), were maintained and passaged 
in the same manner as the Rat-1 fibroblasts.
2.1.1.4. COS-1 and COS- 7 cell lines
The COS-1 and COS-7 cells lines (ATCC CRL 1650 and CRE 1651 respectively, 
(Gluzman, 1981), are both African green monkey kidney derived cell lines, transformed
with the SV40 virus, which have a fibroblast morphology. The cells were maintained and 
passaged as the Rat-1 fibroblast cell line.
2.1.1.5. HuT-78, Molt-3 and Jurkat J6 cel! lines
The cutaneous lymphoma T-cell line, HuT-78 (ATCC TIB 161) and the human leukaemic 
T cell lines: Jurkat J6  (ATCC BS TCL 110, Kaplan et al., 1988) and Molt-3 (ECACC 
90021901, Minowada et al., 1972) were grown in suspension, maintained in RPMI 1640 
media, supplemented with 10 % FBS, 2 mM Glutamine and penicillin/streptomycin (100 
units/ml) at 37 °C in an atmosphere of 5 % CO2 . The T cell lines were maintained at a cell 
density between 1 x 10^ and 5 x 1 0  ^cells/ml. The cells were collected by centrifugation at 
1000 rpm for 3 min (MSE mistral 1000 swinging bucket centrifuge) and resuspended in 
fresh culture media. Cells at a concentration of 10  ^cells/ml were used to seed fresh culture 
flasks.
2.1.1.6 HEK-293, U118 MG, FTC113 and U937 cell lines
The human embryonic kidney cell line, HEK-293 (ATCC CRL 1573, Harrison et al., 
1977), which has an epithelial cell morphology and the U-118 MG cells (ATCC Number: 
HTB-15), which are a human glioblastoma cell line, were maintained and sub-cultured as 
the Rat-1 cells. The human follicular thyroid carcinoma cell lines FTC133 (Wright et al., 
1991) and the U937 human monocyte-like cells derived from a lymphoma (ATCC 
Number: CRL-1593.2, Sundstrom and Nilsson, 1976) were maintained and cultured in 
RPMI 1640 supplemented with 10 % FBS, 2 mM Glutamine and penicillin/streptomyces 
(100 units/ml), as the T cell lines (see section 2.1.1.5).
2 .1.2. DEAE-Dextran transient transfection
Cells were passaged the day prior to transfection and allowed to grow to 50 -70 % 
confluency. 10 pg plasmid DNA was diluted to 250 pi with sterile Tris-EDTA (TE) buffer 
(1 mM Ethylenediaminetetra-acetic acid (EDTA), 10 mM Tris/HCl, pH7.5) in a sterile 15 
ml centrifuge tube, to which 200 pi sterile DEAE Dextran (10 mg/ml in PBS) was added, 
mixed and incubated at room temperature for 15 min. 10 ml of DMEM cell culture media, 
supplemented with 10 % Newborn Calf Serum (NCS) and 2 mM Glutamine 
penicillin/streptomycin (100 units/ml) was added to the DNA along with 10 pi filter 
sterilised 100 mM chloroquine. The solution was mixed and added to the monolayer of 
cells which were then incubated at 37 °C in an atmosphere of 5 % CO2 for 3 -4 h before
the media was removed and replaced with 10 ml sterile PBS supplemented with 10 % 
DMSO. This was incubated on the cells at room temperature for 2 -3 min, the cells were 
then washed twice with PBS and fresh cell culture media was added back to the cells. The 
transfected cells were incubated at 37 °C in an atmosphere of 5 % CO2 for 24 -48 h prior 
to harvest of the expressed recombinant protein.
2.1.3. LipofectAMINE™ transfection of Heia ceiis
Transfection of Hela cells was carried out utilising lipofectAMINE™ reagent (GibcoBRL). 
Cells were passaged the day prior to transfection into 100 mm dishes, and grown to 
approximately 50 % confluency. 7.5 pg plasmid DNA was diluted to a total volume of 300 
pi with Optimem I media (Gibco BRL) in a sterile 15 ml centrifuge tube and mixed. Into a 
fresh 15 ml centrifuge tube 30 pi lipofectAMINE'^'^ was diluted with 270 pi Optimem I 
media and this solution was mixed and added, in a dropwise fashion, to the DNA solution 
whilst the tube was agitated. Once all the lipofectAMINE™ solution had been added to the 
DNA containing solution the tube was incubated at room temperature for 30 min. Prior to 
the addition of the DNA/lipofectAMINE'^'^ solution to the monolayer of cells they were 
washed twice in 5 ml Optimem I media. 3.4 ml Optimem I media was added to the 
DNA/lipofectAMINE'^^ solution, which was mixed and transferred to the washed cell 
monolayer. The cells were harvested 18 -24 h post-transfection.
2.1.4. Ceii cycie arrest
To isolate Rat-1 fibroblast cells at different specific phases of the cell cycle cells the cells 
were subject to several different treatments. The optimisation of isolation of cells in 
specific phases of the cell cycle is explained in detail in section 3.3.2,
2.1.4.1. Asynchronous cell isolation
Rat-1 cells were seeded into 100 mm dishes at a density of 10  ^ cells/ml and incubated 
overnight in 10 ml cell culture media (DMEM, 10 % FBS, 2 mM glutamine, 
penicillin/streptomycin (100 units/ml)) and maintained at 37 °C in an atmosphere of 5 % 
CO2 . The cells, after 24 h growth, were asynchronous and either manipulated further or 
hai'vested.
2.1.4.2. GO phase arrest
Cells were seeded and incubated overnight as in 2.1.4.1., and then washed twice in PBS. 
The cell culture media was replaced with 10 ml serum free media (DMEM, 2 % 
Glutamine, penicillin/streptomycin (100 units/ml)) and the cells were incubated at 37 °C in 
an atmosphere of 5 % CO2 for 48 h, prior to their harvest.
2.1.4.3. G l / S  phase arrest
Cells were seeded and incubated overnight as in 2.1.4.1., after which 2 mM thymidine, 
dissolved in DMSO, was added to the media for a 16 h incubation at 37 °C in an 
atmosphere of 5 % CO2 . The cells were then washed twice with PBS and fresh media 
without thymidine was added to the cells for 14 h incubation. A further thymidine block 
was then carried out by the addition of 2  mM thymidine to the cells for a 16 h incubation, 
prior to their harvest.
2.1.4.4. S / G2  phase arrest
Cells were seeded and incubated overnight as in 2.1.4.1., after which time 2.5 mg/ml 
aphidicolin, dissolved in DMSO, was added to the culture media for a 24 h incubation at 
37 °C in an atmosphere of 5 % CO2 . The cells were then either harvested after the 24 h to 
obtain cells isolated in early S phase or, alternatively, the S phase arrested cells were 
washed twice with pre-warmed PBS and fresh culture media added for a 4 h incubation at 
37 °C in an atmosphere of 5 % CO2 to isolate cells in early G2 phase.
2.1.4.5 Mitotic arrest
Cells were seeded and incubated overnight as in 2.1.4.1., after which time 50 ng/ml 
nocodazole, dissolved in DMSO, was added to the media for a 14 h incubation at 37 °C in 
an atmosphere of 5 % CO2 . The cells harvested after this time were isolated in M phase. 
Alternatively, after nocodazole incubation cells were washed twice with pre-warmed PBS 
and fresh cell culture media added for up to two hours to isolate cells moving through the 
latter phases of mitosis into Gl.
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2.2. Analysis of cells In the cell cycle
2.2.1. Propidium iodide (Pi) doubie stranded DNA staining
Cells, once isolated at specific cell cycle phases (section 2.1.4), were washed with 5 ml 
PBS and removed from the plate by incubation with 1 ml 0.2 % Trypsin / 0.03 % EDTA 
solution for 2 min. The plates were agitated to dislodge all cells, which were then 
suspended in 5 ml culture media prior to collection by centrifugation at 1000 g for 3 
minutes (MSE Mistral 1000 swinging bucket centrifuge). The cells were then washed with 
5 ml ice-cold PBS and after collection were re-suspended in 5 ml ice-cold 0.1 % Saponin / 
0.5 % BSA in PBS (Eyler et al., 1994), collected by centrifugation and drained before 
being re-suspended in 0.5 ml Propidium Iodide (100 pg/ml)/100 U/ml RNAse A (Gibco). 
The cells were transferred to 10 cm^ FACs analysis tube, wrapped in foil for protection 
against light and incubated at 37 °C for 30 minutes, after which time they were analysed by 
flow cytometry on the Becton Dickinson FACScan.
2.2.2. FACs anaiysis of Pi stained ceiis
The settings of the FACscan were controlled using the CELLQuest software package on 
the Apple Macintosh computer attached to the Becton Dickinson FACScan. Forward 
scatter (FSC) was left on the default setting (EOO), Side scatter (SSC) adjusted to 288 volts, 
FL2-H (Propidium iodide detection channel) set to about 535 volts, and all other settings 
left as default. 20000 cells were collected for analysis and analysis settings on the FL2-H 
channel altered to maintain a peak of G l cells at 200 -300 amps and G2/M peak at 400 - 
600 amps on a histogram of FL2-H vs counts (Fig. 2.1.).
2.2.3. Labeiiing ceiis for duai Pi and bromo-deoxyuridine (BrdU) DNA 
anaiysis
2.2.3.1. Incorpora ting BrdU to proliferating cells
Cells were seeded into 75 cm^ flasks at a density of 10  ^cells/ml in 15 ml cell culture media 
and grown for at least 24 h at 37 °C in an atmosphere of 5 % CO2 , to enable asynchronous 
cell populations to establish. The flasks were wrapped in silver foil to prevent light 
exposure to the cells prior to the addition of 15 pi of 10 mM bromo-deoxyuridine (BrdU) 
dissolved in DMSO. BrdU is photogenically unstable, causing mutations in the cellular 
DNA which leads to S phase arrest, therefore any manipulations of cells after BrdU
addition were carried out in reduced lighting conditions. The cells were incubated in the 
presence of BrdU at 37 °C in an atmosphere of 5 % CO2 for 30 min, they were then 
washed three times with pre-warmed PBS. Fresh cell culture media was added to the cells, 
which were treated as required prior to harvesting.
2.2.3.2. Fixing BrdU labelled cells
Cells, after the incorporation of BrdU as described in 2.2.3.1., were harvested by 
incubation with 0.25 % Trypsin/ 0.03 % EDTA until they detached from the flask. The 
cells were suspended in cell culture media and collected by centrifugation at 1 0 0 0  rpm for
3 min (MSE Mistral 1000 swinging bucket centrifuge), they were then washed once with 
ice-cold PBS and collected by centrifugation. The cells were fixed by resuspending the cell 
pellet in 100 pi PBS, to which 1 ml ice-cold 70 % ethanol was added in a dropwise 
fashion, whilst vortexing. The cells were kept on ice for at least 1 hour to fix or at 4 °C for 
longer periods prior to further staining.
2.2.3.3. Staining BrdU labelled cells with FITC conjugated antibody and 
propidium iodide
After fixing the BrdU labelled cells were collected by centrifugation at 1000 g for 3 min 
(MSE Mistral 1000 swinging bucket centrifuge) and the ethanol aspirated from them. The 
cells were resuspended in 500 pi 0.5 M NaCl, to which 500 pi 4 N HCl was added whilst 
vortexing. The cells were incubated at room temperature for 15 min, after which time the 
cells were collected by centrifugation, and then washed three times in 1 ml PBT (0.5 % 
BSA/ 0.1 % Tween-20 in PBS) to remove the acid. The cells were then resuspended in 100 
pi PBT, to which 20 pi anti-BrdU-FITC conjugated antibody (Becton Dickinson) was 
added and incubated for 30 min, protected from light, at room temperature. 1 ml PBT was 
added to the cells whilst vortexing and the cells were then collected by centrifugation, 
1000 rpm for 3 min. The cell pellet was resuspended in 500 pi 5 ng/ml PI and incubated at
4 °C for at least 30 min prior to FACs analysis.
2.2.4. FACs analysis of BrdU-FiTC and Pi stained ceiis
The Becton Dickinson FACScalibur was used for the analysis of the BrdU-FTTC/PI stained 
cells, using the CELLQuest software on the attached Apple Macintosh computer. FACs 
analysis enabled a quantitative measurement of the parameters of interest to be carried out. 
The PI which intercalated with the double stranded DNA was detected in the second
channel (FL2-H) at around 600 volts and cells labelled with the FITC conjugated anti- 
BrdU antibody were excited and detected in the first channel (FLl-H) at around 500 volts. 
2 0 0 0 0  cells were collected for analysis.
2.2.4.1. FA CScalibur acquisition settings
A histogram of FL2-H vs counts was drawn that gave a normal DNA distribution enabling 
the determination of GO/1, S and G2/M phase cells. The FL2 amps were balanced so the 
peak of GO cells was around 300 -400 on the linear scale for FL2-H (Fig. 2.1.). Doublet 
discrimination was carried out to verify that all the cells being analysed were single cells. 
This was done by gating out any aneuploid cells, which had increased or decreased 
fluorescence pulse width, which is measured as the length of time the cell breaks the laser 
beam as it passes through. On a density plot of FL2-H vs FL2-W the clumps of cells were 
those which fell outside the G2/M population, which was 600 -800 on the FL2-H channel. 
Similarly apoptotic cells and cell debris were removed from analysis on the same density 
plot by gating out particles with a small pulse width, typically those less than 300-400 on 
the FL2-H (Fig. 2.2.). A histogram of FLl-H vs counts enabled the FLl amps to be 
balanced to maintain a peak of cells at 10 \ which correspond to the G l peak of cells. A 
shoulder on this G l peak corresponded to cells in G2/M and the peak at 10  ^ related to S 
phase cells (Fig. 2.3.).
2.2.4.2. FACs data analysis
Once acquired the cell distribution data was analysed further using the MODfit™ analysis 
software package. This works by breaking down the acquisition plots and using 
compensation for over lapping peaks of cellular distribution in the phases of the cell cycle, 
detected by flow cytometry, enabling a better approximation of the number of cells in each 
phase of the cell cycle. To carry out this analysis in MODfit™ the plot of FL2-W vs FL2-H 
was gated around the diploid cell population. This gated population was then analysed on 
an FL2-H vs FLl-H  plot and the cells in S-phase gated (Fig. 2.4. Panel A). The computer 
then required the sample model of the cells being analysed to be stipulated (fresh, diploid 
cells with a distinct G2/M and no clumps of cells) and the peaks on the histogram relating 
to the G l and G2/M population estimated and highlighted (Fig. 2,4. Panel B). The 
MODfit™ package then calculates the number of cells in each phase of the cell cycle as a 
percentage of the total number of single cells detected.
2.2.5. Apoptotic anaiysis of ceiis
2.2.5.1. Labelling ceils for apoptotic analysis
Control cells were seeded into 2 flasks, one was maintained as asynchronous and one was 
treated with the apoptosis inducing agent, staurosporine, for 24 h (Fraker et al., 1995). All 
cells were harvested by the addition of 0.25 % trypsin/ 0.03 % EDTA solution and once 
detached from the cell culture flask they were suspended in 5 ml cell culture media and 
collected by centrifugation at 1000 rpm for 3 min (MSE Mistral 1000 swinging bucket 
centrifuge). The cells were washed twice in ice-cold PBS, drained well and resuspended in 
500 111 binding buffer (10 mM HEPES, pH7.4, 140 mM NaCl, 2.5 mM CaClz). 100 pi of 
the cell suspension was transferred to a 10 cm^ FACs tube wrapped in foil. The 
asynchronous control cells were treated in the following manner: To one tube 10 pi 50 
pg/ml PI was added, to one tube 5 pi fluorescein conjugated annexin V (annexin V-FTTC) 
antibody was added and to the final tube nothing was added. All cells for apoptotic 
analysis were doubled stained with 10 pi annexin V-FITC antibody and 10 pi 50 pg/ml PI, 
the staurosporine treated cells provided a positive control for apoptosis.
2.2.5.2. FA Cs analysis of apoptotic cells
The settings of the FLl-H  and FL2-H channels were determined in each experiment by 
analysing the distribution of the control cells on an acquisition FL2-H vs FLl-H dot-plot. 
2 0 0 0 0  cells were collected in each analysis and the cells should fall in the following 
quadrants of the dot blot:
FLl-H
UL UR
LL LR
FL2-H
For the control cells the unstained cells were found only in the lower left (LL) quadrant 
and the PI only stained cells were found in the LL & lower right (LR) quadrants. The FL2- 
H amps were altered to isolate cells exclusively in these areas with LR representing the 
apoptotic cells. The annexin V-FITC conjugated stained cells were found in the LL and 
upper left (UL) quadrants, with the FLl-H  amps altered to isolate cells exclusively in these 
areas, the cells in the UL were apoptotic. The staurosporine treated dual labelled cells were 
isolated in the upper right (UR) quadrant, by alterations in FLl-H  and FL2-H amps, as all 
these cells are apoptotic. All cells analysed for apoptosis were found within LL and UR
quadrants, determining the proportion of cells that are non-apoptotic and apoptotic in the 
population.
2.3. Protein analysis
2.3.1. Harvesting ceii iysate
2.3.1.1. Whole cell lysate production
Cells were harvested at reduced temperatures to minimise the effect of protein degradation 
and enzyme inactivation caused by the disruption of the cell. The cell culture dishes were 
maintained on ice and all buffers used in the procedures were chilled. The cell culture 
media was removed from cells, which were washed twice with 5 ml ice-cold PBS. The 
cells were then drained thoroughly and 200 pi/100 mm dish 3T3-lysis buffer (20 mM N-2- 
Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), pH7.4, 50 mM NaCl, 50 mM 
NaF, 10 % glycerol, 1 % triton X-100, 10 mM Ethyleneglycol-bis(P-aminoethylether)- 
N,N,N’,N’“Tetra-acetic acid (EOTA), 30 mM sodium pyrophosphate, proteases inhibitor 
cocktail) was added. The cells were scraped from the plate, placed into a 1.5 ml eppendorf 
and subjected to a 20 min incubation at 4 °C with end-over-end rotation. The cell lysate 
was clarified by centrifugation at 10000 g at 4 °C (Heraeus bench-top centrifuge) for 5 
min, the supernatant was removed, aliquoted and snap frozen and stored at -80 °C until 
required.
2.3.1.2. Crude sub-cellular fractionation by differential centrifugation
Cells were harvested at reduced temperatures to minimise the effect of protein degradation 
and inactivation caused by the disruption of the cell. The cell culture dishes were 
maintained on ice and all buffers used in the procedures were chilled. The cell culture 
media was removed from cells which were washed once with 5 ml ice-cold PBS and then 
drained well. The cells were then incubated with 500 pi/100 mm dish ice-cold cKHEM (50 
mM HEPES KOH, pH7.4, 50 mM KCl, 10 mM EGTA, 1.92 mM MgCl^ supplemented 
with 1 mM diothiotrietol (DTT) and protease inhibitors) on ice for 5 min. The cells were 
drained thoroughly and scraped into a 1.5 ml eppendorf and diluted to a known volume 
with cKHEM. The cells were drawn through a 13 gauge needle 30 times whilst on ice and 
the unbroken cells and nuclei removed (PI fraction) by centrifugation at 2000 g, 4 °C for 7 
minutes (Heraeus refrigerated bench-top centrifuge). The supernatant was maintained and 
the resultant pellet was washed twice in cKHEM and resuspended in the same volume of
cKHEM as the supernatant. The supernatant was centrifuged at 75000 g, 4 °C for 45 min 
(Beckman TL-100 ultracentrifuge) producing the supernatant fraction (S fraction), 
enriched in cytosolic proteins, and the remaining pellet (P2 fraction), enriched in plasma 
membrane, vesicles formed from the Golgi apparatus and the endoplasmic reticulum, 
lysosomes and endosomes. The P2 was washed with cKHEM to remove any contaminating 
cytosolic proteins and resuspended in the same volume of cKHEM as the PI and S 
fraction. Each fraction was aliquoted, snap frozen and stored at -80 °C for later use.
2.2.1.3. Refined sub-cellular fractionation by differential centrifugation
Cells were harvested after appropriate treatment at reduced temperatures to minimise the 
effect of protein degradation and inactivation caused by the disruption of the cell. The cell 
culture dishes were maintained on ice and all buffers used in the procedures were chilled. 
The cell culture media was removed from cells that were washed twice with 5 ml ice-cold 
sucrose solution (250 mM Sucrose, 10 mM triethanolamine-acetic acid, pH7.6, 1 mM 
EDTA, supplemented with protease inhibitors) and then drained well. The cells were 
scraped from the plate and transfeiTed to a tight fitting douce homogeniser and the pestle 
raised and lowered 10 times. The unbroken cells, large sheets of plasma membrane and 
nuclei were collected by centrifugation at 1000 rpm at 4 °C for 10 min (Heraeus 
refrigerated bench-top centrifuge, N fraction). The pellet was washed twice in the sucrose 
buffer and the supernatant retained. The supernatant was subject to centrifugation at 13000 
rpm at 4 °C for 15 min (Heraeus refrigerated bench-top centrifuge) in order to isolate the 
membranous fractions containing large cell organelles (M fraction) from the homogenate. 
The M fraction pellet was washed twice with the sucrose buffer and the supernatant 
retained for isolation of the microsomes- small vesicles and fragments of organelles. The 
supernatant was centrifuged at 75000 rpm at 4 °C for 60 min (Beckman TL-100 
ultracentrifuge). The resultant microsome pellet was washed twice with the sucrose buffer 
and the supernatant enriched in cytosolic proteins was retained. Each fraction was 
aliquoted, snap frozen and stored at -80 °C until further use
2.3.2. Quantification of protein (Bradford assay)
Protein assays were carried out in 96 well microtitre plates. A spectrophotometric standard 
curve of protein concentration was produced using 0-5 |ig bovine serum albumin (BSA), 
which was dissolved in 50 \i\ distilled water. The protein quantification of cell lysate was 
carried out by taking 10 |il of diluted lysate sample and placing in wells on the 96 well
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microtitre plate to which 40 p,l distilled water was added, each sample was analysed in 
triplicate. Bio-Rad Bradford Assay reagent was diluted 1/5 with distilled water and 200 |il 
added to each well occupied with protein samples. The 96 -well plate was then analysed 
using the Revelation package on the computer, connected to an MRX microtitre plate 
reader, which read absorbance at a wavelength of 590 nm. Protein concentrations were 
determined by plotting the standard curve and using least squared regression analysis to 
obtain the line of best fit. The equation of the line was used to determine the protein 
concentration of the samples.
2.3.3. Enzyme~linked immunosorbent assay
Concentration of specific protein within a cell lysate sample was quantified using enzyme- 
linked immunosorbent assay (ELISA) carried out in a 96 well microtitre plate (Huston et 
ah, 1996). Lysates taken from cells were quantified for total protein concentration and 
between 0.4 and 50 |Ag protein loaded into wells, in triplicate for each lysate. The samples 
were diluted to 100 p.1 with bicarbonate buffer, pH 9.6 and incubated overnight at 4 °C. 
The wells were washed 3 times with TBS-tween20 (137 mM NaCl, 20 mM Tris/HCl 
pH7.4, 0.05 % Tween20) and blocked at room temperature for 2 h with 200 [i\ 5 % 
skimmed milk powder/TBS-tween20. The wells were washed 3 times with TBS-tween20 
and all residual solution removed, the primary antibody was diluted 1 : 2 0 0 0  in 0 . 1  % 
skimmed milk powder /TBS-tween20 and 100 |li1 added to each sample containing well for 
a 2 h incubation at room temperature. The plate was washed 3 times in TBS-tween20 and 
all residual solution removed. The secondary alkaline phosphatase conjugated anti­
immunoglobulin (IgG) antibody raised against the primary antibody was diluted 1:30000 
in 0.1 % skimmed milk powder/TBS-tween20 and 100 |il added to each sample containing 
well for a 1 h incubation at room temperature. The wells were then washed a further 6  
times in TBS-tween20 before the addition of substrate solution. Equal volumes of solution 
A and B of the BCIP Microwell phosphatase substrate system (Kirkegaard & Perry 
Laboratories) solutions were mixed and 100 jiil of the solution added to each well for a 30 - 
60 min incubation at room temperature. To arrest the alkaline phosphatase catalysed 
reaction 100 p,l 2 % EDTA solution was added to each well and the absorbances of the 
solutions at a wavelength of 620 nm were measured by the Revelation software on the 
computer, connected to an MRX microtitre plate reader. The absorbances were then 
compared for each sample to determine changes in expression levels of the protein 
between them.
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2.3.4. Lactate Dehydrogenase (LDH) assays
Sub-cellular fractionations were assayed for the lactate dehydrogenase (LDH) activity by 
the reverse reaction; Pyruvate + NADH —> Lactate + NAD. This kinetic enzymatic assay 
was carried out in 96 well microtitre plates and the conversion of NADH to NAD was 
measured spectrophotometrically using the MRX microtiter plate reader (Dynex 
Technologies), set at a wavelength of 340 nm. For each sample two sets of wells were set 
up in triplicate, the first set, measuring the free LDH, contained 186 p,l 150 mM Tris/HCl, 
pH7.4, 7 juil 10 mM Na pyruvate and 7 |Ltl sample. To the second set of wells, used to 
measure occluded LDH, was added 172 jxl 150 mM Tris/HCl, pH7.4, 7 |Lil 10 mM Na 
pyruvate, 14 jxl 30 % triton and 7 p,l sample. The reaction was started by the addition of 10 
p,l 2 mM (3-NADH and readings of the absorbance were taken at 20 sec intervals for 10 
min. The initial rate of decrease in the absorbance at 340 nm was taken to be directly 
proportional to the LDH activity present in the sample.
2.3.5. SDS-poly^acrylamide gel electrophoresis (SDS-PAGE)
2.3.5.1. Sample preparation
Lysate obtained from cells were assayed for protein concentration and 25 -100 jig protein 
diluted 1/5 with 5 x laemmli sample buffer (260 mM Tris/HCl (pH6.7), 55.5 % Glycerol, 
8 . 8  % SDS, 0.007 % Bromophenol blue, 11,1 % 2-mercaptopethanol, Laemmli et al., 
1970), which was made up to 150 [Û with Ix laemmli’s sample buffer. The sample was 
boiled for 5-10 min to allow dénaturation and reduction of the protein
2.3.5.2. Casting and running a tris-glycine gel
All gels were run on Bio-Rad Protean II xi cell unless otherwise stated. The apparatus was 
assembled according to the manufacturer’s instructions. A resolving gel containing the 
appropriate percentage of acrylamide (determined by the molecular weight of the protein 
of interest), usually 8  % unless otherwise stated, was cast between the two plates of the gel 
apparatus ( 8  % 29:1 acrylamide:N,N’-methylenebisacrylamide mix, 375 mM Tris/HCl 
(pH8 .8 ), 0.1 % SDS, 0.1 % Ammonium persulphate, 0.06 % N,N,N’,N’,-
tetramethylethylenediamine (TEMED)). This was overlaid with 1 ml water and allowed to 
polymerise at room temperature, the water was then removed, a comb placed between the 
plates and the resolving gel overlaid with stacking gel (5 % 29 :1 acrylamide:N,N’- 
methylenebisacrylamide mix, 125 mM Tris/HCl (pH6 .8 ), 0.1 % SDS, 0.1 % Ammonium
persulphate, 0.1 % TEMED). The gel was left for 30 min to polymerise, the comb was 
removed and the wells were washed out with tris-glycine mnning buffer (192 mM Glycine, 
25 mM Tris, 0.15 % SDS) to remove un-polymerised acrylamide. The gels were then 
assembled onto the central running stand according to the manufacturer’s instructions and 
placed into the running tank containing tris-glycine running buffer. The pre-boiled samples 
were loaded into each well and a standard lane was loaded with 10 |^ 1 Bio-Rad prestained 
broad range precision protein markers to determined protein migration weight by gel 
electrophoresis. The top reservoir of the gel running tank was filled with running buffer 
and run for approximately 5 h at 35 milliamps per gel or 16 h at 8  milliamps per gel, until 
the dye front reached the bottom of the gel.
2.3.6. Visualising protein by coomassie staining
Proteins were separated by gel electrophoresis as in 2.3.5., the gel was removed from the 
plates and washed with distilled water. The gel was placed in Coomassie stain (0.025 % 
Coomassie Brilliant Blue R250, 40 % methanol, 7 % acetic acid) with gentle shaking at 
room temperature for 30 min and then placed in destain (40 % methanol, 7 % acetic acid) 
overnight, to remove all background staining of the gel. The Coomassie stain remained 
bound to proteins to enable visualisation.
2.3.7. Visualising protein by silver staining
Greater sensitivity of detection of proteins on acrylamide gels than Coomassie staining was 
achieved by silver staining, the detection limit for which is 2-5 ng protein. The silver stain 
plus kit from Bio-Rad was used according to the manufacturer’s instructions, briefly: The 
fixative enhancer solution (50 % methanol, 10 % acetic acid, 10 % fixative enhancer 
concentrate, 30 % dH2 0 ) was added to the gel and incubated for 20 min at room 
temperature with agitation. The gel was washed in dHiO and then added to staining 
solution (10 % Silver complex solution, 10 % Reduction Moderator solution, 10 % image 
development reagent in water. Prior to addition to gel an equal volume of development 
Accelerator Solution was added for a 20 min incubation at room temperature with 
agitation. After the desired staining was reached the gel was transferred to 5 % acetic acid 
solution to stop the reaction.
2.3.8. Western îmmuno-blottîng
Proteins were separated by gel electrophoresis as in 2.3.5., after which the protein was 
transferred to nitrocellulose before being detected with specific antibody.
2.3.8.1. Transfer of protein from acrylamide gel to nitrocellulose
Under transfer buffer (192 mM Glycine, 25 mM Tris, 20 % Methanol) in a transfer cassette 
a piece of foam soaked in transfer buffer, was overlaid with a piece of Whatmann 3 MM 
paper. Onto this was placed the SDS gel and overlaid with a piece of nitrocellulose paper 
(Schleicher & Schuell), ensuring that all air bubbles were excluded from between all 
layers. The nitrocellulose was in turn covered by another piece of Whatmann 3 MM paper 
and a piece of foam. The outer cassette was used to close and hold the apparatus which was 
placed with the nitrocellulose to the positive electrode in the Hoefer TE series transphor 
electrophoresis unit, filled with transfer buffer. The proteins were transferred with an 
applied current of 0.7 amps for 90-120 min or 0.05 amps overnight.
2.3.5.2. Immunoblotting nitrocellulose
Once the proteins had been transferred onto the nitrocellulose as in section 2.3.8 .3. it was 
washed with distilled water followed by visualisation of the transfeiTed proteins with 
ponceau S stain (0.1 % Ponceau S, 3 % Trichloroaceatic acid). The ponceau S stain was 
added to the nitrocellulose for a few minutes until the protein became stained, the 
nitrocellulose membrane was then washed with 30 ml Tris-buffered saline (TBS-tween 20) 
(137 mM NaCl, 20 mM Tris/HCl (pH7.6), 0.1 % tween20) before immunological detection 
of protein. The unoccupied protein binding sites on the nitrocellulose were blocked with 5 
% skimmed milk powder in TBS-tween20 for 1 h at room temperature with agitation. After 
blocking the membrane was washed several times in TBS-tween20 and the appropriate 
primary antibody added to the membrane diluted 1 : 1 0 0 0 0  in 1 % skimmed milk powder in 
TBS-tween20. This incubation was carried out for 2 h with vigorous agitation, after which 
time the nitrocellulose was washed several times in TBS-tween20 before having the 
secondary antibody added to the membrane. The secondary antibody was a horse-radish 
peroxidase (HRP) conjugated anti-immunoglobulin (IgG) antibody, directed against the 
primary antibody, diluted 1:5000 in 1 % skimmed milk powder in TBS-tween20. This was 
incubated with the nitrocellulose membrane for 1 h with vigorous agitation, after which the 
nitrocellulose was washed several times in TBS-tween20 and then incubated with ECL 
reagents (Amersham), according to the manufacturers instructions. A piece of x-ray film
(Kodak) was exposed to the membrane in a darkroom for several minutes and then 
developed using a Kodak X-omat.
2.3.9. Phosphodiesterase-4 activity assay
Phosphodiesterase activity was measured in a cAMP hydrolysis assay. This used a 
modification of the two step procedure of Thomson and Appleman (Thompson and 
Appleman, 1971), as described previously by Marchmont and Houslay (Marchmont and 
Houslay, 1980). ^H-cyclic nucleotide ( 8  position of the adenine or guanine ring) was 
hydrolysed to form labelled nucleotide mono-phosphate. The nucleotide mono-phosphate 
ring was converted to the corresponding labelled nucleoside by incubation with snake 
venom, which has 5 -nucleotidase activity. The conditions were such that complete 
conversion takes place within the incubation time. Unhydrolysed cyclic nucleotide was 
separated from the nucleoside by batch binding of the mixture to Dowex-1 -chloride. This 
removes the charged nucleotides but not the uncharged nucleosides.
2.3.9.1. Activation of dowex 1X8-400 anion exchange resin
To activate the Dowex 1 X 8  -400, 4 1 of 1 M NaOH was added to 400 g of the resin, the 
mixture was incubated for 15 min at room temperature with gentle mixing. The resin was 
allowed to settle by gravity and the supernatant removed. The resin was then extensively 
washed with 4 1 distilled water (30 washes). After its last wash the resin was resuspended 
in 4 1 1 M HCl and incubated for 15 min at room temperature with gentle mixing before 
being allowed to settle by gravity. The resin was then washed 3 times with 4 1 distilled 
water, until the supernatant had a pH of 3. The activated resin was stored at 4 °C as a 1:1 
slurry with distilled water until required.
2.3.9.2. Assay tube preparation
Into 1.5 ml eppendorf tubes an appropriate amount of cell lysate was placed (0.1 -50 |Ltg 
protein depending on the activity of the sample) and made up to a volume of 25 \i\ with 
PDE assay diluting buffer (20 mM Tris/HCl, pH7.4), each sample tube was repeated in 
triplicate. All tubes were set up on ice, and remained on ice until all components for the 
assay had been added. To every tube 50 |il 2 pM cAMP containing 3 pCi [^HJcAMP in 20 
mM Tris/HCl /lO mM MgClz pH7.4 was added, the tubes vortexed and incubated at 30 °C 
for 10 min. After this time the tubes were boiled for 2 min to inactivate any PDE present 
and then cooled on ice. 25 pg snake venom (either Ophiophagus Hannah or Crotalus atrox
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venom) in 25 pi 20 mM Tris/HCl, pH 7.4 was added to each tube, mixed by vortexing and 
incubated at 30 °C for 10 min. The tubes were then held on ice and 400 pi 
Dowex/ethanol/water, in a 1 :1 :1 ratio was added to the tubes, mixed and incubated on ice 
for at least 20 min. The tubes were vortexed, the dowex removed by centrifugation at 
13000 rpm for 2 min (Heraeus bench top centrifuge) and 150 pi of the clear supernatant 
added to 1 ml Opti-scint scintillation fluid and counted on a Wallac 1409 liquid 
scintillation counter.
2.3.9.3. Determination of PDE3 and PDE4 activity
The PDE3 family is specifically inhibited by the drug cilostamide (Hidaka et ah, 1979) and 
the PDE4 family by rolipram (Wachtel, 1982). PDE inhibitors were dissolved in 100 % 
DMSO as 10 mM stocks and diluted in PDE assay dilution buffer for use in assay. The 
residual levels of DMSO do not affect PDE activity at the concentrations used (Spence et 
ah, 1995). Measurement of PDE activity with and without cilostamide (10 pM) and with 
and without rolipram (10 pM) present gave the contribution of PDE3 and PDE4 
respectively.
2.3.10. immunoprécipitation
2.3.10.1. Pre-clearing agarose beads
Protein G beads were used when the target protein was immuno-precipitated with a 
monoclonal antibody or a polyclonal antibody raised in a sheep and protein A beads were 
used when the target protein was immuno-precipitated with any other polyclonal 
antibodies. 25 pi of the appropriate beads were washed in 200 pi 3T3-Lysis buffer and 
recovered by centrifugation at 13000 rpm for 2  min at 4 °C in a refrigerated bench-top 
centrifuge. 300 pg of protein from cell lysate, diluted to a total of 500 pi with lysis buffer 
supplemented with protease inhibitors, was added to the washed beads and incubated with 
end-over-end rotation at 4 °C, for 30 min.
2.3.10.2. Binding target protein to antibody
After pre-clearing the beads were collected by centrifugation at 13000 rpm at 4 °C for 2 
min (Heraeus refrigerated bench-top centrifuge), the supernatant was removed and placed 
into a fresh eppendorf tube. To this fresh tube 7 pi of the polyclonal antibody or 3 pi 
monoclonal antibody was added and the tube rotated end-over-end at 4 °C for at least 2 h.
to enable the protein and antibody to bind. The solution was then transferred into a tube 
containing 60 pi pre-washed protein beads (A or G as required) and rotated end-over-end 
for at least one hour at 4 °C. The beads were isolated from solution by centrifugation at 
13000 rpm at 4 °C for 2 min (Heraeus refrigerated bench-top centrifuge) and washed to 
remove any non-specifically bound protein. The beads were washed firstly in lysis buffer 
supplemented with 500 mM NaCl, secondly with lysis buffer supplemented with 0.1 % 
SDS and then washed with 0.1 % NP-40 in 10 mM Tris pH 7.4. A final wash of the beads 
was carried out with PBS if the isolated protein was to be used in SDS-PAGE. Otherwise 
the final wash was carried out in 20 mM Tris (pH 7.4), when the protein was used in a 
PDE assay, or in kinase assay buffer if the protein was to be subject to in vitro 
phosphorylation.
2.4. Kinase assays
2.4.7. PKA assay
2.4.1.1. Cell lysa te extraction for PKA assay
Mammalian cells were grown and treated as required, after which time the cell media was 
removed, the cells washed with PBS and drained thoroughly. The monolayer of cells were 
scraped into 500 pi extraction buffer (5 mM EDTA, 50 mM Tris, pH 7.5) and 
homogenized by drawing through a 13 gauge needle 10 times. The cell debris was then 
removed by centrifugation for 2 mins at 13000 rpm at 4 °C (Heraeus refrigerated bench- 
top centrifuge) and the supernatant was used for a PKA assay.
2.4.1.2. PKA assay tube pre-incuba tion
For each cell lysate the following were set up on ice in 1.5 ml eppendorf tubes, adding the 
cell extract last and incubating on ice for 20 min, to allow the inhibitor to bind PKA. N.B- 
due to time restrictions during the assay a maximum of 9 different lysates can be analysed 
at any one time:
Tube Cell Extract Diluent 4x PKA Inhibitor 4x PKA Activator
A lOul 2 0 ul Oui Oui
B lOul lOpl lOul Oui
C lOul lOul Oui lOul
D lOul Oui lOul lOul
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Diluent -  50 mM Tris, pH7.5.
4 xPKA Inhibitor- 4 pM PKI( 6  -22) amide, 50 mM Tris, pH7.5.
4 xPKA Activator- 40 pM cAMP, 50 mM Tris, pH7.5).
2.4.1.3. PKA assay reaction
To 1 ml of the 4 X PKA substrate (200 pM Kemptide, 400 pM ATP, 40 mM MgCE, 1 
mg/ml BSA, 50 mM Tris, pH7.5) 6000 pCi/mmol of [y-^^PJATP was added whilst 
maintained on ice. To the first assay tube (lA) 10 pi of radioactive 4 x PKA substrate 
solution was added, the contents were mixed gently before being placed in a rack within a 
waterbath at 30 °C for 10 min. 15 seconds after substrate addition to the first tube 10 pi of 
the radioactive substrate was added to the next tube (IB), which was then mixed and 
incubated. This method of addition of substrate to tubes every 15 seconds continued until 
all the tubes with substrate were incubating at 30 °C. After the 10 min incubation of the 
first tube 2 0  pi of the reaction mix was removed and spotted onto a pre-marked piece of 
ion exchange phosphocellulose paper P81 (Whatman). This was carried out for each tube 
after they had each undergone the 10 min incubation with the substrate. The 
phosphocellulose pieces were then placed into a large beaker containing 1 %(v/v) 
phosphoric acid (H3PO4) and washed for 3 min with slight agitation. The waste acid was 
removed and the acid wash repeated. The phosphocellulose was then washed twice in 
dHzO before being placed in 1.5 ml eppendorf tubes, to which 1 ml scintillation fluid was 
added. The ^^P incorporated into the peptide bound to the phosphocellulose was counted on 
the Wallac 1409 liquid scintillation counter. To two separate vials 10 pi of the radioactive 
4 X PKA substrate was added to scintillation fluid, to enable the determination of the total 
counts from the substrate solution.
2.4.1.4. Calcula tions for PKA assay da ta
Step 1.
Total counts Inmol , , ,
---------------------------X------------------------ =  cpm/pmol phosphate
AnmolATP 1000pmol
D O
Step 2.
(cpm/phosphocellulose)x2 , , . . .   ^ ^\ jr tr c ------------- i—  _ pjfiQi peptide — incorporated phosphate
STEPl
Step 3.
STEP 2 . . . .  ,-----------= pmol/ mm /assay tube
1 0  min
Step 4.
STEP 3 u  ‘ f 1= pm ol/m m /m l
0.01ml extract
Step 5.
Tube A -  Tube B = pmol/rmn activated PKA 
Tube C - Tube D = pmol/min total PKA 
Step 6 .
p m o V ^ n  activated PKA ^  PKA
pm ol/m m  total PKA
2.4.2. Alkaline phosphatase treatment of protein
Protein was immunoprecipitated from cell lysate as described in 2.3.10. with the final wash 
of the protein bound beads earned out in 10 mM Tris, pH8 , plus protease inhibitors (PI). 
The isolated beads were resuspended in 70 pi 10 mM Tris, pH8 , plus PI, to which 10 pi 10 
X Calf intestinal alkaline phosphatase (CIAP) buffer (Promega) was added. This reaction 
mix was split into two fresh eppendorfs, to one 10 pi CIAP (10 units) was added, to the 
other 10 pi 10 mM Tris, pH8  was added. The tubes were incubated at 30 °C for 30 min, 
after which time to the CIAP containing tube another 10 units of CIAP was added, and a 
further incubation for 30 min at 30 °C was carried out. The beads were then isolated by 
centrifugation at 13000 ipm for 2 min at 4 °C (Heraeus refrigerated bench-top centrifuge)
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and either boiled in 35 pi 2 x laemmlis sample buffer to be separated by SDS-PAGE or 
else washed in 20 mM Tris prior to a PDE assay.
2.4.3. MBP fusion protein production
2.4.3.1. Induction of E .C o li  cells transformed with a recombinant protein- 
containing construct
A  50 ml sterile centrifuge tube containing 25 ml rich growth media (170 mM NaCl, 0.5 % 
(w/v) BactoYeast Extract, 1 % (w/v) Bacto-Tryptone pH7.5, 0.2 % glucose) supplemented 
with 100 mg/ml ampicillin was seeded with E.Coli (JM109) transformed with a 
recombinant protein construct, fused to maltose binding protein (MBP), and incubated at 
37 °C with agitation overnight. The cells from the overnight culture were used to inoculate 
a 2 1 flask containing 400 ml rich growth media, supplemented with 100 mg/ml ampicillin 
which was incubated at 37 °C with agitation until the absorbance of the culture at 600 nm 
was between 0.6 -1. Once growth of the cultures to the desired density had occuiTed 
addition of 400 pi of 100 mM isopropyl-P-D-thiogalactopyranoside (IPTG, Boehringer 
Mannheim) to induce fusion protein expression was carried out and the culture incubated 
at 30 °C with agitation for a further 3.5 h. Samples of cells before and after induction of 
recombinant protein expression were taken, separated by gel electrophoresis and visualised 
by Coomassie stain of the gel to ensure of protein expression. The induced cells were 
harvested by centrifugation at 5000 rpm for 10 min at 4 in the Beckman centrifuge, and 
frozen at -80 °C until required.
2.4.3.2. Isolation of recombinant MBP fusion protein from E .C o li  cells
The frozen E.Coli cells (2.4.3.1.) were defrosted on ice and resuspended in 10 ml ice-cold 
PBS, per original 400 ml culture, supplemented with ImM DTT and protease inhibitors. 
The cell suspension was separated into 2x 6 ml bijou bottles and sonicated on ice at 40 volts 
for 3x 1 min periods with 1 min intervals. The cell debris was removed by centrifugation at 
9000 g for 30 min at 4 °C and the supernatant containing the recombinant protein retained. 
Amylose resin (1 ml) was washed twice in 20 ml PBS and a final wash in PBS 
supplemented with 1 mM DTT and protease inhibitors in a 50 ml centrifuge tube. The 
supernatant containing the recombinant protein was then added to the resin, which was 
rotated at 4 °C for 1 h to enable binding of the protein, the resin was then collected by 
centrifugation at 3000 ipm for 1 min and the supernatant discarded. The resin was washed
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twice for 15 min at 4 °C, with rotation, with 20 ml PBS supplemented with 1 mM DTT and 
protease inhibitors and then once for 15 min at 4 °C with PBS alone. The protein could 
then be used bound directly to the resin or could be eluted from it.
2.4.3.3. Elution of recombinant MBP fusion protein from amylose resin
After the recombinant protein bound to the amylose resin had been washed it was 
resuspended in 1 ml PBS and transferred to 2 eppendorf tubes, the resin was collected by 
pulse spinning (Heraeus refrigerated bench-top centrifuge) and the supernatant was 
discarded. 500 p,l of 10 mM maltose was added to each eppendorf and incubated at 4 °C 
with rotation for 30 min. The eluate was retained and 500 p,l of 10 mM maltose was added 
for another incubation at 4 °C with rotation for 30 min, the eluates were pooled and protein 
concentration measured.
2.4.3.4. TEV cleavage of MBP fused recombinant protein from amylose resin
The amylose resin bound to the recombinant protein prepared as in 2.4.3.3, was washed in 
20 X rTEV Buffer (1 M Tris/HCl, pH8 , 10 mM EDTA). The resin was collected and 
resuspended in 15 |il 20 x rTEV Buffer, 3 |li1 100 mM DTT, 20 units of recombinant TEV 
Protease and 100 |xl dHiO. The reaction mix was incubated at 16 °C for 16 hr, the digested 
protein was then isolated in the supernatant.
2.4.4. In vivo phosphorylation of protein
Cells were seeded at a concentration of 10  ^cells/ml into 100 mm dishes the day prior to 
incubation of the cells with phosphate free media for whole cell labelling. Cells were 
washed twice with pre-warmed phosphate free media (Sigma) and then incubated for Ih 
with 5 ml phosphate free media at 37 °C in an atmosphere of 5 % CO2 prior to the addition 
of ^^P orthophosphate. 300 jitCi/ml ^^P orthophosphate or ^^P orthophosphate was added to 
the cells for a 2-4 h incubation at 37 °C in an atmosphere of 5 % CO2 . The cells were then 
washed in PBS and lysed in 3T3-lysis buffer as described in 2.3.1.1. The target protein was 
isolated by immunoprécipitation from the lysate as described in 2.3.10., sepaiated from 
other proteins by gel electrophoresis and transferred onto nitrocellulose as described in 
2.3.8.1.. The radiolabelled isolated protein was visualised by exposing the nitrocellulose to 
a phosphorimage plate (Kodak) for up to one week. The phosphorimage was detected
using the Bio-Rad Molecular Imager® FX phosphorimager on the Quantity One software 
(BIO-Rad).
2,4.5. In vitro phosphorylation of protein
2.4.5.1. Phosphorylation of a target protein from mammalian cells using a 
purified kinase
The protein for phosphorylation by a purified kinase was immunoprecipitate from 
mammalian cell lysate as described in 2.3.10., the final wash of the protein beads was in 
kinase assay buffer (KAB) (80 mM |3-glycerophosphate, pH7.2, 40 mM NaF, 0.2 mM 
MgCla.b H2O). The beads were then resuspended in 100 p.1 full KAB (KAB + 10 |LiM 
okadaic acid 1 mM ATP, 1 |iCi [y-^^PjATP). 1 ]il (1 unit) of recombinant kinase was 
added to all tubes except one, which serves as a negative control for the experiment. One 
of the kinase containing tubes also had 0.4 |xM of the kinase inhibitor added to it to block 
the phosphorylation event, again acting as a control for the experiment. The solutions were 
mixed and incubated for 30 min at 30 °C, shaking occasionally to mix the settling protein 
beads. After incubation the beads were isolated by centrifugation for 2 min at 13000 rpm at 
4 °C (Heraeus refrigerated bench-top centrifuge) and the supernatant removed. The beads 
were washed twice in KAB to remove any residual [y-^^PJATP and then boiled for 10 min 
in 70 p.12 X laemmli sample buffer.
2.4.5.2. Phosphorylation of recombinant target protein from E .C o li. using cellular 
lysate
Recombinant protein overexpressed in bacterial cell systems can be subject to 
phosphorylation by kinases present in cellular lysate. Recombinant protein from bacterial 
cells was purified as described in 2.4.3. and, once bound to the amylose resin, the final 
wash of the resin was in KAB. Two 1000 mm dishes of asynchronous cells or cells 
arrested in mitosis (as described in 2.1.4.5.) were washed twice with 5 ml breaking buffer 
(BBS) (100 mM Sucrose, 80 mM 2 -glycerophosphate, pH7.2, 20 mM EOT A, 15 mM 
MgCl2 .6  H2O, before use add 1 mM DTT, 2 mM ATP and 1 mM PMSF and 1 |LiM okadaic 
acid with mitotic lysate). The cells were then drained well and scraped into 2 x 1.5 ml 
eppendorf tubes. The cells were disrupted by passing them through a 13 gauge needle 10 - 
30 times and the lysate isolated by centrifugation of the homogenate for 15 min at 13000 
rpm at 4 °C (Heraeus refrigerated bench-top centrifuge). To increase the concentration of
proteins within the isolated cellular lysate 1 ml of the lysate was centrifuged in a centricon 
YMIO devise (Millipore) at 5000 rpm in a Beckman fixed angle centrifuge rotor at 4 °C 
for 45 minutes. The concentrated lysate was collected from the centricon devise by 
inverting the concentrating column and placing the opening in a collection tube. The 
apparatus was then centrifuged for 10 min at 1000 rpm at 4 °C in the Beckman fixed angle 
centrifuge.
100 p,l amylose resin bound recombinant protein was placed in a fresh 1.5 ml eppendorf 
tube to which 1 0 0  jxl concentrated cell lysate was added, which was supplemented with 1 
mM ATP and 1 juCi of [y-^^P] ATP. The tubes were mixed and incubated at 30 °C for 30 
min to enable phosphorylation of the protein. The resin was washed twice in KAB to 
remove any residual ATP and then boiled for 10 min in 70 jil 2 x laemmli sample
buffer.
2A.5.3. Phosphorylation using an isolated kinase
Cells isolated in mitosis or interphase were harvested as described in 2.4.5.2., in EBS 
buffer. The kinase of interest was immunoprecipitated from the lysate using a specific 
monoclonal antibody as described in 2.3.10. The beads were washed finally in KAB and 
placed in a fresh 1.5ml eppendorf tube, to which 100 p.1 eluted recombinant protein from 
E.Coli was added, produced as described in 2.4.3. Each tube was also supplemented with 1 
mM ATP and 1 p.Ci of [y-^^P]ATP and incubated at 30 °C for 30 min to enable 
phosphorylation of the protein. To the tube 15 |0.1 5 x laemmli sample buffer was added and 
the tube boiled for 1 0  min to reduce and denature the proteins.
2.4.5.4. Radiolabelled analysis of protein
An 8  % tris-glycine gel was produced as described in 2.3.5. and the labelled proteins 
loaded into the wells of the gel a standard lane was loaded with 8  |0.1 of Rainbow 
methylated protein molecular weight markers (Amersham Pharmacia Biotech). The 
molecular weights of the protein standards were: Myosin, 220 kDa, Phosphorylase b 97 
kDa and 6 6  kDa, Ovalbumin 45 kDa, Carbonic anhydrase 30 kDa, trypsin inhibitor 20.1 
kDa and lysozyme 14.3 kDa. The gel was allowed to run as described in 2.3.5. after which 
the proteins were transferred onto nitrocellulose as described in 2.3.8.1. The nitrocellulose 
was then placed into a phosphor-imagining cassette with a pre-blanked phosphorimaging 
plate (Kodak). The radiolabelled proteins were visualised using the Quantity One software
(BIO-Rad) on the computer connected to the Bio-Rad Molecular Imager ® FX 
phosphorimaging system.
2.4.5.5. ‘Cold’ i n  vit ro  phosphoryla tion of proteins
Proteins phosphorylated for the analysis of activity changes were treated in the same 
manner as the reactions described in 2.4.5.1. omitting the [y-^^PJATP from the reaction 
mix. Activity changes of the protein were analysed via the PDE assay as described in 2.3.9. 
with the protein bound to beads being washed in 20 mM Tris, pH7.4, prior to the assay. 
Visualisation of the cold phosphorylated protein was carried out by immunoblotting as 
described in 2.3.8..
2.4.6. Tryptically digested phosphopeptide analysis by 2D TLC
Recombinantly expressed target protein was isolated from E.Coli cells as described in
2.4.3. The protein was then subject to a hot phosphorylation reaction in the presence of 
either mitotic or interphase isolated concentrated cell lysate, as described in 2.4.5.2. The 
phosphorylated protein bound to the amylose resin was washed twice in Tev cleavage 
buffer and was then subject to Tev cleavage as described in 2.4.3.4. The phosphorylated 
proteins were separated by gel electrophoresis, transferred to nitrocellulose and visualised 
as described in 2.4.5.4.
2.4.6.1. Tryptic cleavage of phosphorylated protein
The area of nitrocellulose to which the radiolabelled protein of interest bound was cut out 
and placed into a 1.5 m l eppendorf. The nitrocellulose was blocked with 0.5 % PVP-40 in 
100 mM acetic acid incubated at 37 °C for 30 min and was then washed 5 times in dHzO 
and twice in 50 mM NH4HCO3 . 200 |nl fresh 50 mM NH4HCO3 was added to the 
nitrocellulose to which 10 p,g sequencing grade trypsin (Promega) was added. This was 
incubated for 2 h at 37 °C, then another 10 p,g sequencing grade trypsin was added for an 8  
h incubation at 37 °C. 300 |Lil dH2 0  was added to the digest, the supernatant removed and 
placed in a fresh 1.5 ml eppendorf, with a pierced lid. The solution was snap frozen and 
dried under vacuum.
2.4.6.2. Isolation of tryptically clea ved peptides
Fresh performic acid (1 volume 30 % H2O2 added to 9 volume formic acid incubated at 
room temperature for 1 h) was cooled on ice and 50 jal added to the dried down peptides. 
The resuspended peptides were incubated on ice for 2 h then 1 ml dH2 0  added and the 
solution snap frozen and dried under vacuum.
2.4.6.3. Loading plates for 2D TLC separation of phosphopeptides
An electrophoresis buffer with a pH of 1.9, composed of 50 ml formic acid ( 8 8  % w/v), 
156 ml glacial acetic acid and 1794 ml deionised water was used for the first dimension 
separation of the phophopeptides. The electrophoresis buffer of pHl.9 was used as at this 
pH value most peptides are soluble and streak maps are obtained less often (Van Der Geer 
et al., 1993). The phosphopeptides were dissolved in 20 p.1 electrophoresis buffer, the tubes 
containing the peptides were Çerenkov counted to ensure all of the radiolabelled 
phosphopeptide had been removed. The samples were loaded 1 p,l at a time to the TLC 
plate (Fig. 2.5.), with air-drying between applications to ensure minimal dispersal of the 
sample. The 10 |Lil of the marker dye mixture, e-dinitrophenyLlysine- which migrates with 
a charge of 0 at pH 1.9 - and xylene cyanol blue FF- which migrates with a charge of -1 at 
pH 1.9 (Hardie et al., 1993), was loaded at the indicated position (Fig. 2.5.), in the same 
manner as the sample.
2.4.6.4. First dimension thin-layer electrophoresis
The TLC plate was soaked with electrophoresis buffer, using blotting paper placed over the 
plates with holes cut out where the sample and marker loading points were. The buffer was 
brushed onto the blotting paper and was allowed to absorb into the sample and marker 
wells to concentrate the samples at these points. The plate was not wetted excessively and 
any pools of buffer were removed with blotting paper. The plate was then placed in the 
electrophoresis tank and two wicks measuring 20 xlO cm were wetted with the 
electrophoresis buffer and placed on the edges of the TLC plate into the buffer containing 
wells of the tank. The water cooling system on the running tank was engaged and a current 
of 1000 V applied to the plate until there is good separation of the marker dyes. The time 
for electrophoresis was variable for each plate but was usually carried out for 35 min in the 
first instance. The plate was then removed from the electrophoresis appaiatus and allowed 
to air-dry for 2  h.
2.4.6.5. Second dimension thin-layer chromatography
The buffer used for chromatography was composed of 750 ml n-butanol, 500 ml pyridine, 
150 ml glacial acetic acid and 600 ml deionized water. This buffer was selected as it is 
hydrophilic so would separate out the phosphopeptides, preventing them from binding to 
the stationary phase (Van Der Geer et al., 1993). A piece of blotting paper soaked in the 
chromatography buffer was used to line the chromatography tank, enough chromatography 
buffer to fill the first centimetre of the tank was added and the lid placed on the tank about 
1 h prior to adding the TLC plate. This enabled equilibration of the solvents in the tank, to 
allow uniform migration of the phosphopeptides. The TLC plates were placed in the tank 
and chromatography was carried out until the solvent front was 2  cm from the top of the 
TLC plate.
2.4.6.6. Identification radiolabelled phosphopeptides
The TLC plate, once chromatography had been carried out was air-dried for 2 h, to enable 
evaporation of the solvents, and was then subject to a week long exposure to a 
phosphorimage plate. The phosphopeptides were detected from the phosphorimage plate 
using the BioRad Quantity One package (see section 2.4.5.4.).
2.4.7. Tryptically digested phosphopeptide analysis by HPLC
Protein was subjected to in vitro phosphorylation using concentrated asynchronous or 
mitotic lysate. The reaction was stopped by rinsing the beads twice with kinase assay 
buffer and then adding 80 |il of 10 mM DTT and 1 % SDS solution. The samples were 
boiled for 5 min and then cooled prior to the addition of 0.5 % (v/v) 4-vinylpyridine. The 
samples were then shaken at 30 °C for 30 min, then 20 [xl 4 x novex sample buffer was 
added and the proteins that were consequently separated by gel electrophoresis on a 4-12 
% gradient gel (Novex). The gel was then sealed in plastic and exposed to high 
performance autoradiography film (amersham pharmacia biotech) for 10 min. The 
phosphorylated protein was cut from the gel and the gel pieces subjected to scintillation 
counting on the Wallac 1409 liquid scintillation counter to calculate levels of 
incorporated into the protein.
2.4.7.1. In gel tryptic digest of phosphorylated protein
The gel preparation for tryptic digestion was caiTied out in a keratin free environment in a 
laminar flow hood. The gel, from 2.4.7., was washed sequentially in 1 ml H2O for 15 min, 
1 ml 50 % acetonitrile for 15 min, 1 ml 0.1 M ammonium bicarbonate for 15 min and 
finally 0.1 M in 50 % acetonitrile for 15 min. The solution was removed and the pieces of 
gel were crushed into fine pieces with a small spatula. The gel pieces were then washed 
with 1 0 0  % acetonitrile for 1 0  min, after which time the acetonitrile was removed and the 
gel pieces were dried by rotary evapouration for 10 -20 min. To the dried gel pieces 2 |Xg 
trypsin, diluted in 200 |xl 50 mM ammonium bicarbonate and 0.05 % (w/v) zwittergent 3 - 
16, was added and incubated at room temperature for 30 min. After the initial incubation a 
further 200 |l i 1 50 mM ammonium bicarbonate and 0.05 % (w/v) zwittergent 3 -16 was 
added and left to incubate with shaking at 30 °C overnight. The supernatant from the digest 
was removed and 0.2 % trifluoroaceatic acid (TFA, by volume) added and the samples 
were loaded analysed by HPLC.
2.4.7.2. HPLC analysis of phosphopeptides
The tryptically digested protein samples from 2.4.7.1. were loaded onto a Vydac Cig 
(Separation group) column which had been equilibriated in 0.1 % (v/v) TFA in H2O. The 
column was developed with a linear acetonitrile gradient at a flow rate of 0 . 8  ml/min and 
0.4 ml eluates were collected. The levels of ^^P incorporated into peptides were then 
measured on a Wallac scintillation counter. The eluates containing high levels of 
incorporated ^^P were dried down and subjected to either mass spectrometric analysis and 
cycle burst Edman degradation sequencing or retained for phosphoamino acid analysis.
2.4.7. Protein binding assay
Protein labelled with was synthesised using the TNT® Quick Coupled Transcription/ 
Translation Systems (Promega), according to the manufacturer’s instructions. Briefly, 40 
|Lil TNT® T7 Quick master mix, 2 |xl lOmCi/ml [^^S] methionine, 1 |xl T7 TNT® PCR and 
5 |xl purified vector DNA were mixed in a 0.5 |xl eppendorf and incubated at 30 °C for 90 
min. 5 |xl of this synthesised protein was diluted in 500 |Lil cKHEM, to which 10 |Lig of the 
E. Coli expressed protein GST fusion protein of interest was added. This was placed on an 
end over end rotor at 4 °C for 2 h after which time 60 |xl of pre-washed Glutathione (GSH) 
beads were added and rotated for 30 min at 4 °C. The GSH beads were isolated by
centrifugation 13000 rpm for 1 min at 4 °C and washed 3 times with cKHEM. The beads 
were boiled for 10 min in 1 x laemillis sample buffer before being run on an 8  % Tris- 
Glycine SDS-PAGE gel. The proteins were then transferred onto nitrocellulose and 
exposed to a phosphorimage plate overnight, the proteins were visualised using the BioRad 
Quantity one package (see section 2.4.5.4.).
2.5. Molecular Biology
All molecular biology techniques were carried out with sterilised equipment and buffers, to 
prevent contamination of solutions used.
2.5.1. Large scale production of piasmid DNA
500 ml LB growth media (170 mM NaCl, 0.5 % (w/v) BactoYeast Extract, 1 % (w/v) 
Bacto-Tryptone pH7.5) supplemented with 100 mg/ml ampicillin in a 2 1 flask was spiked 
with a pipette tip from a glycerol stock of transformed cells containing the DNA of 
interest. The culture was incubated at 37 °C overnight with agitation and harvested the next 
day by centrifugation at 6000 g for 15 min using the JA-14 rotor in the Beckman 
refrigerated centrifuge. The DNA was extracted from the cell pellet using the Qiagen 
Maxiprep kit, according to the manufacturer’s instructions, briefly: The bacterial pellet was 
resuspended in 10 ml Buffer PI (resuspension buffer), to which 10 ml Buffer P2 (lysis 
buffer) was added, the solutions were mixed and incubated at room temperature for 5 min. 
10ml of chilled buffer P3 (neutralisation buffer) was then mixed with the lysed cells which 
was incubated on ice for 20 min. The cell lysate was clarified by centrifugation of the 
solution at 10000 g for 30 min at 4 °C. Meanwhile the QIAGEN-tip 500 was equilibrated 
with 10 ml Buffer QBT which was allowed to flow through by gravity. The supernatant 
from the lysed cells was passed through muslin into the equilibrated column, which was 
then washed twice with 30 ml Buffer QC. The DNA, which had bound to the resin in the 
QIAGEN-tip 500, was eluted by the addition of 15 ml buffer QF.
2.5.1.1. Ethanol precipitation of DNA
DNA was precipitated from the eluted solution (section 2.5.1.) by the addition of 0.7 
volumes room temperature isopropanol. The solutions were mixed and centrifuged at 
15000 g for 30 min at 4 °C. The DNA pellet was washed with 5 ml room temperature 70 % 
ethanol and air-dried for 5-10 min before being resuspended in 500 |Jil dH^O.
2.5.1.2. Quantification of DNA
DNA was quantified spectrophotometricly; 5 |jl1 DNA was diluted to 1 ml with distilled 
water and absorbance measurements were taken at 260 nM and 280 nM using a Shimadzu 
UV-1201 UV-VS spectrophotometer blanked with distilled water. The concentration of 
nucleic acid was then calculated using the following approximations:
An absorbance reading of 1 at 260 nM corresponds to;
50 /xg/ml double stranded DNA 
37 /xg/ml single stranded DNA
The ratio between the absorbance measurements at 260 nM and 280 nM provided an 
indication of the purity of the nucleic acid. In solution, pure DNA typically has A260 :A2go 
ratios of 1.8. If the absorbance ratio is significantly less than this it indicates that the 
nucleic acid may be contaminated.
2.5.2. Small scale production of plasmid DNA
5 ml LB growth media supplemented with 100 mg/ml ampicillin in a sterile 25 ml 
universal tube was spiked with a pipette tip from a glycerol stock of transformed cells 
containing the DNA of interest. The culture was incubated at 37 °C overnight with 
agitation and the cells harvested the next day by centrifugation at 3000 rpm for 5 min 
(Heraeus bench-top refrigerated centrifuge). The DNA was extracted from the cells using 
the QIAprep spin miniprep kit according to the manufacturer’s instructions, briefly: The 
bacterial pellet was resuspended in 250 |l i 1 Buffer PI (resuspension buffer), to which 250 |xl 
Buffer P2 (lysis buffer) was added, the solutions were mixed and incubated at room 
temperature for 5 min. 350 |xl of Buffer N3 (neutralisation buffer) was then mixed with the 
lysed cells and the solution was centrifuged for 10 min at 13000 rpm. The supernatant was 
added to the QIAprep spin column, which was centrifuged at 13000 rpm for 1 min, the 
flow through was discarded and the column washed with 750 |xl Buffer PE. The column 
was centrifuged for 1 min prior to the elution of the bound DNA. 50 jxl dH2 0  was placed 
onto the resin in the column and incubated for 1 min, the DNA was eluted from the column 
by centrifugation for 1 min at 13000 rpm (Heraeus bench-top refrigerated centrifuge).
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2.5.3. Analysis of piasmid DNA
2.5.3.1. DNA restriction digest
The restriction enzyme and the optimum restriction buffer used in the reaction depended 
on the site of digestion of the DNA for subsequent manipulations. If two restriction 
enzymes were used and the optimum restriction buffers were not compatible ethanol 
precipitation of the DNA between restriction digests was carried out. Each digest was 
carried out on 300 ng DNA in a total volume of 10 jxl per restriction enzyme used in the 
reaction. 1 unit of restriction enzyme was used and the appropriate volume of 1 0  x 
restriction added to the mix. The digests were cai'ried out for 1-2 h at the optimal 
temperature for the enzyme, usually 37 °C.
2.5.3.2. Agarose gel analysis of DNA
DNA was visualised using agarose gel electrophoresis, the percentage of agarose used in 
the gel was dependent on the size of DNA fragment to be identified. For a 1 % agarose gel 
1 % agarose was dissolved in 1 x TAE (40 mM Tris/HCl, 1 mM EDTA, 0.114 % glacial 
acetic acid) by heating until the agarose dissolved. To this 0.01 % ethidium bromide was 
added, which enabled visualisation of the DNA under a UV light source. The molten agar 
was poured into the gel apparatus, set up according to the manufacturer’s instructions and 
allowed to set completely. The comb and end stoppers were removed, the gel tank filled 
with Ix TAE and the samples loaded into the lanes. All DNA samples were diluted 6:1 in 
6 x sample buffer (0.25 % Bromophenol Blue, 0.25 % xylene cyanol blue, 30 % glycerol in 
H2O). In one lane 5 |xl standard 1 kb DNA ladder markers (Roche) were add to enable 
prediction of the size of DNA fragments run on the gel. The gel was run at 50 V until the 
dye front had migrated along the gel and the fragments of DNA were separated, the gel 
was removed from the tank and the DNA observed under UV light. The range of 
separation of linear DNA molecules according to agarose concentration;
Percentage Gel Size of Fragment (kb)
0.9 0.5 -7
1 . 2 0.4 - 6
1.5 0.2 -3
2 0 . 1  - 2
2.5.3.3. Gel purification of digested DNA
The DNA once isolated by agarose gel electrophoresis was cleaved from the agarose gel 
and purified using the QIAquick Gel Extraction kit according to the manufacturer’s 
instructions for using the spin columns, briefly: The gel slice containing the target DNA 
was weighed in an eppendorf tube and 3 volumes of buffer QG was added per one volume 
of gel. This was incubated at 50 °C for 10 min until the gel had dissolved. One gel volume 
of isopropanol was then added to the sample and mixed, the solution was then added to a 
QIAquick column and centrifuged for 1 min at 13000 rpm (Heraeus benchtop centrifuge). 
The column was washed with 750 jxl Buffer PE, which was centrifuged through the 
column at 13000 rpm for 1 min, a further centrifugation for 1 min at 13000 rpm was 
carried out to remove excess solution prior to elution of the DNA. The DNA was eluted 
from the column by the addition of 50 |l i1 dHiO to the resin of the column which was 
incubated for 1 min and the DNA was then collected by centrifugation for 1 min at 13000 
rpm.
2.5.4. Ligation of dsDNA
For the ligation of DNA 100 ng of restriction digested vector DNA was added to a 0.5 ml 
eppendorf, to which 50 ng of dsDNA with cohesive ends was added. 1 jxl 10 x ligase buffer 
(30 mM Tris/HCl, pH7.8, 100 mM MgClz, 100 mM DTT, 10 mM ATP) and 1 |xl T4 DNA- 
ligase (Promega) was added to the DNA mix and the volume made up to 10 |xl with sterile 
distilled water. The contents of the tube were mixed thoroughly and incubated at 22 °C for 
3h.
2.5.5. Production of Competent Ceiis
For Competent cell production aseptic techniques were used at all times. Either DH5a or 
XLl-Blue cells were spiked from a glycerol stock into 5 ml LB media and incubated 
overnight at 37 °C with agitation. 500 |xl of the overnight culture was used to seed 50 ml 
LB growth medium which was incubated at 37 °C with agitation until the ODeoo = 0 .2 . The 
cells were harvested by centrifugation at 4000 rpm for 10 min at 4 °C (Beckman 
refrigerated centrifuge) and resuspended in 25 mis ice-cold 100 mM CaCL. Incubation of 
the cell suspension on ice was carried out for 2 0  min and the cells were then collected by 
centrifugation, 4000 rpm for 10 min at 4 °C. The cell pellet was resuspended in 2.5 ml ice-
cold 100 mM CaClz and glycerol was added to a final concentration of 10 %, the cells were 
then aliquotted and snap frozen in liquid Na and stored at -80 °C until required.
2.5.6. Transformation of Competent Ceiis with Target DNA
Transformation of competent cells was carried out with either lOng of purified plasmid 
DNA, or 1 |xl ligation product produced in 2.5.4. The DNA was placed in the bottom of a 
pre-chilled transformation tube (Falcon) to which 50 (xl competent cells produced in 2.5.5. 
were added. The DNA and cells were incubated for 30 min on ice and then heat shocked at 
42 °C for 45 sec. To the transformed cells 1 ml LB media was added and the cells were 
recovered at 37 for 1 h with agitation. 50 -100 |xl of cell suspension was plated onto 
LB-amp agai* plates (170 mM NaCl, 0.5 % (w/v) BactoYeast Extract, 1 % (w/v) Bacto- 
Tryptone pH7.5, 1 % agar, supplemented with 100 mg/ml ampicillin) using aseptic 
techniques, which were allowed to dry for 1 0  min before being inverted and incubated at 
37 °C overnight.
2.5.7. Giyceroi Stock Production
A  500 jxl sample from an overnight culture of transformed cells was taken aseptically and 
placed into a sterile screw top cryovial to which 500 \i\ sterile 80 % glycerol was added. 
The sample was mixed well and stored at -80 °C for further use.
2.5.8. DNA Sequencing
The DNA sequencing reaction was carried out using the BigDye termination kit and the 
resulting PCR product was sequenced by the University Sequencing Service. In a sterile 
0.5 ml PCR tube the reaction mix for the PCR reaction was set up as follows: 500 ng DNA, 
3.2 pmol primer, 8  jxl Big Dye Sequencing mix, dHzO, to a final volume of 20 jxl. The 
tubes were then mixed and subject to the following PCR reaction cycles:
96 °C 30 seconds
50 °C (variable depending on Tm) 15 seconds
60 °C 4 minutes
4 °C Hold
 ^ 25 cycles
The DNA product was precipitated from the reaction mix by the addition of 2 |xl 3 M 
NaOAc, pH4.8 and 50 jixl EtOH to the solution, this was mixed and incubated on ice for 10
min. The precipitated DNA was isolated by centrifugation at 13000 rpm for 30 min at 4 
°C. The pellet was washed once with 70 % ethanol and dried completely by heating in the 
PCR machine for 3 min at 80 °C.
2.5.9. Site directed mutagenesis of DNA using the QuickChange^^ kit
Site directed mutagenesis of DNA was performed using the QuickChange™ site directed 
mutagenesis kit (Stratagene) using primers designed to incorporated the mutation of the 
DNA required, flanked by unmodified nucleotide sequence. The mutagenesis was carried 
out according to the manufacturer’s instructions, briefly; The reaction was set up in a 0.5 
ml sterile PCR tube with 5-50 ng dsDNA template, 125 ng primer 1, 125 ng primer 2, 5 |xl 
10 X reaction buffer (100 mM KCl, 100 mM (NH4)2S0 4 , 200 mM Tris/HCl, pH8 .8 , 20 mM 
MgS0 4 , 1 % Triton X-100, 1 mg/ml BSA), 1 pil dNTP mix and ddH2 0  to a final volume of 
50 [xl. To this 2.5 units PfuTurboDNA polymerase was added, mixed and subject to the 
following PCR reaction cycles:
95 °C 30 seconds
96 °C 30 seconds
55 °C 1 minute
6 8  °C 2 minutes/kb plasmid length
4 °C Hold
12-18 cycles depending on type 
of mutation
2.5.9.1. Isolation and transformation of mutated DNA
To each amplification reaction from 2.5.9. 10 units of Dpnl restriction enzyme was added 
and incubated at 37 °C for 1 h. E.Coli XL-1 Blue supercompetent cells were thawed on ice 
and 50 jxl added to a chilled transformation tube (falcon) to which 1 |xl of the Dpnl treated 
DNA was added. The DNA and cells were mixed and incubated on ice for 30 min then 
heat pulsed for 45 sec at 42 °C. The cells were left on ice for 2 min before the addition of 
500 |xl pre-warmed NZY"  ^broth (1 % (w/v) NZ amine (casein hydrolysate), 0.5 % (w/v) 
NaCl, pH7.5, 12.5 mM MgCl2, 12.5 mM MgS0 4  and 20 mM glucose). The cells were 
incubated at 37 °C with shaking for 1 h and then plated into LB-amp agar plates. The 
plates were inverted and incubated overnight at 37 °C.
2.5.10. Reverse transcription PCR (RT-PCR)
2.5.10.1 RNA isolation
Total RNA was isolated from cells using the RNAeasy kit from Promega, according to the 
manufacturers instructions. Briefly, cells were aspirated of all growth media and the cells 
were lysed into 600 |xl buffer RLT, the cells were scraped into an eppendorf tube and 
homogenised by passing the supernatant 5 times through a 20 gauge needle connected to a 
syringe. 600 jxl 70 % ethanol was added to the homogenate and mixed by pipetting. The 
sample was applied to an RNeasy minispin column which was centrifuged for 15 sec at 
8000 g (Hereaus benchtop centrifuge). The RNA bound to the column was washed 
initially with 700 jxl buffer RW l, which was incubated for 5 min at room temperature and 
then centrifuged at 8000 g for 15 sec. The column was washed a further two times by the 
addition of 500 jxl buffer RPE, this was removed by centrifugation for 15 sec at 8000 g 
initially with a final drying centrifugation at 13000 g for 2 min. The RNA was eluted from 
the column in 30 |xl RNase-free water by centrifugation at 8000 g for 1 min.
2.5.10.2. First strand complementary DNA (cDNA) synthesis
First strand cDNA was synthesised using the Pharmacia First-strand cDNA Synthesis Kit 
according the manufacturers instructions. Briefly 5 jug of total RNA was made up to 20 jal 
with DEPC treated distilled water. This was heated to 65 °C in a thermal cycler for 10 min 
then immediately chilled on ice. The "Bulk 1st strand cDNA mix" (supplied with the kit) was 
gently mixed by being pipetted up and down several times and was then collected with a brief 
centrifugation. The cDNA synthesis reaction mixture was assembled in a sterile 0.5 ml 
Eppendorf tube that was chilled on ice. The cDNA synthesis reaction was then incubated at 
37 °C for 1 h.
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Figure 2.1. FL2-H distribution of ceils labeled with propidium iodide.
Rat-1 cells were arrested at specific phases of the cell cycle (see section 
2.1.4.1. - 2.1.4.5.), hai'vested and stained with propidium iodide (as 
described in section 2.2.1.). 2 0 0 0 0  cells were acquired for analysis by flow 
cytometry and utilising the acquisition setting on the CELLQuest package 
the amps of the FL2 channel were adjusted to place the peaks of GO/1 cells 
between 300-400 and the G2/M cells between 600-800, as indicated on the 
diagram.
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Figure 2.2. Doublet discrimination of a Rat-1 cell population. Rat-1 cells 
when arrested at specific stages of the cell cycle (as described in section 
2.1 A .I. - 2.1.4.5.) were then harvested and labeled with BrdU-FITC and 
propidium iodide (as described in section 2.2.3.3.). 2 0 0 0 0  labeled cells were 
then collected and analysed by flow cytometry, using the CELLQuest 
acquisition package., A density plot of FL2-H vs FL2-W from these collected 
cells was produced (the cells are represented by the black dots on the density 
plot) and the cells were gated (thin black line) to remove clumps of cells, 
apoptotic cells and cell debris, leaving the single diploid cells (Rl) for further 
analysis.
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Figure 2.3. Normal FLl-H distribution of cells from an asynchronous 
population. Asynchronous Rat-1 cells were harvested and stained with 
BrdU-HTC and propidium iodide {as described in section 2.2.3.3.). 20000 
labeled cells were collected by FACs and analysed using the CELLQuest 
acquisition package. A histogram of FLl-H vs counts was generated and the 
amps in the FLl channel were adjusted to place the G1 peak of cells at <10\ 
the G2/M peak as a shoulder on the G1 peak and the S cells peak at 10 ,^ as 
indicated on the diagram.
84
GO/Gl .
G2/M
FL2-H
B
GO-Gl
G2-M
Channels
DIPLOID; 100.00% 
Dip GO-Gi: 57.65%  
at 82.70 
DipG2-M: 18.10% at 
150.46
DipS: 24.25%  
G2/G1: 1.82 
Dip %CV: 5.06
Total S-Phase: 24.25 %
Extra Pop: %
Debris: 0.78 % 
Aggregates: 0.00 % 
Modeled Events: 9259 
RCS: 1.666
Diploid B A D.: 0.77 % 
no aggs
Figure 2.4. analysis of BrdU-FITC and propidium iodide
labelled cells. Rat-1 cells which had been stained with BrdU-FITC and 
propidium iodide {as described in section 2.2.J.3.) were acquired by FACs 
using the CELLQuest package (as described in section 2.2.4.1.) and then 
quantified using the MODfit ™ analysis package. Panel A. The 
distribution of the labelled population of cells was acquired on a FL2-H vs 
FLl-H density plot and the cells within the GO/Gl, S and G2/M phases of 
the cell cycle, as indicated on the diagram, were identified. The S phase 
cells were gated and quantified as a proportion of the total cell distribution 
Panel B. Quantification of the cells distributed within GO/Gl, S and G2/M 
phase by the MODfit™ analysis package displayed the number of cells in 
each phase as a percentage of the number of diploid cells analysed. The 
analysis also displays the percentage debris in the population, the 
percentage aggregated cells and the number of cells analysed (Modelled 
Events).
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Figure 2.5. Locations of sample and dye origins for two-dimensional 
separation of phosphopeptides on 20 x 20 TLC plates. The figure indicates 
the locations of the application points for the sample and dye for 
electrophoresis at pH 1.9 on a TLC plate, as described in section 2.4.6.3. 
Also indicated are the orientations of the charges that are applied to the TLC 
plate upon first dimension separation of peptides.
Chapter 3
Phosphodiesterases and the cell cycle
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3.1. Introduction
3-1.1. The cell cycle; a brief overview
The identification of the cell cycle began with the discovery of the mechanisms which lead 
to cell division, where the generation of two cells from one was teimed mitosis. With the 
invention of high powered microscopes the observation was made that DNA replicated in a 
restricted part of interphase and this part of the cell cycle was termed S phase (Howard and 
Pelc, 1953). Mitosis and S phase are separated by two gap phases, G1 occmxing between 
M and S phase and G2 occurring between S and M phase (Mitchinson, 1971, Fig. 3.1.). 
During G1 phase cells are under the influence of extra-cellular mitogenic stimuli. If 
deprived of these mitogens the cells enter GO phase, or quiescence (Ammit and Panettieri, 
Jr., 2001; Lee et al., 2001). Mitogens have to be present until the cells have passed the 
restriction point within G l, after which time the cell is committed to complete one full cell 
division under autonomous control (Paidee, 1989). The cell cycle is a complicated process 
and S and M phases are rigorously ordered to allow correct duplication of the cell. 
Checkpoint mechanisms exist during the cell cycle, which are regulated by the coordinated 
action of proteases and cyclin dependent kinases (cdk). The control mechanisms are 
specifically activated at the Gl/S boundary, during S phase and during the G2/M transition 
(Nurse, 2000) and enable analysis of DNA damage and incomplete DNA replication as 
well as the misalignment of chromosomes on spindle bodies (Ford and Pardee, 1998). 
Mitosis is a complex cell cycle phase, which is separated into distinct stages. In prophase, 
spindle formation occurs and the chromosomes condense. In prometaphase they then attach 
to the spindles by their centromere, and during metaphase, they start aligning on the 
spindle fibres. During anaphase the chromatids segregate and migrate to the opposite poles 
of the cell. Cytokinesis then takes place during telophase, resulting in the production of 
two identical daughter cells (Fig. 3.2., Leblond and El Alfy, 1998).
3.1.2. Cyclic AMP control of the cell cycle
The involvement of cAMP in the regulation of cell cycle control mechanisms has been 
apparent for decades (Pastan et al., 1975). Initial observations of the retardation of 
proliferation by the elevation of intracellular cAMP were made in hamster kidney cells by 
Burk (Burk, 1968). It has since been exemplified in many cell lines, through increasing 
intracellular cAMP, by either forskolin-stimulation of adenylyl cyclase, by the addition of 
non-hydrolysable cAMP derivatives, or by addition of phosphodiesterase inhibitors. All 
methods seemingly serve to inhibit cell proliferation (Pastan et al., 1975). It has been
oo
noted, however, that the elevation of intracellular cAMP can actually stimulate cell 
division in certain cell types, specifically the thyroid and pituitary (Feliciello et ah, 2000). 
However, these appear to be distinct cases and thus the inhibitory effect of cAMP on 
proliferation will be primarily considered here.
3.1.2.1, Elevated cAMP induces cell quiescence
Elevation of cAMP activates the cAMP dependent protein kinase (PKA), which blocks 
proliferation of cells through an array of different intracellular signalling mechanisms. 
PKA causes the down regulation in expression of the G l specific cdk regulatory subunit 
proteins, cyclin D1 (L’Allemain et al., 1997; Koyama et ah, 2001) and cyclin D3 (Naderi et 
ah, 2000; van Oirschot et ah, 2001) at the level of transcription and translation, 
respectively (Musa et ah, 1999). The decrease in cyclin D1 protein levels, and its 
associated activity, cause dephosphorylation of the tumour suppressor. Retinoblastoma 
(Rb) protein which, in turn, binds to and inactivates the E2F transcription factor. This 
prevents DNA synthesis and Gl/S phase transition (Tomlinson et ah, 1995; Naderi et ah, 
2000; Christoffersen et ah, 1994; Blomhoff et ah, 1988). High levels of cAMP also 
increase the levels of expression of the G l specific cdk inhibitor, p27^^^\ This inhibitor 
binds to active cdk complexes causing their inactivation, blocking the cell cycle prior to 
passage through the G l restriction point (Kato et ah, 1994; L ’Allemain et ah, 1997). A rise 
in cAMP concentration causes a respective inhibition of the Mitogen Activated Protein 
Kinase (MAPK) signalling cascade required for Gl/S progression through the activation of 
PKA which antagonises the Ras/Raf-1 interaction in the Ras-Raf-MEK-ERK pathway 
(Koyama et ah, 2001; Schmitt and Stork, 2001, Fig.3.3.).
3.1.2.2. Cyclic AMP controls cells in interphase and mitosis
Cyclic AMP-mediated control of the cell cycle is evident during the transition of cells from 
S to G2. Elevated levels of cAMP decrease the stability of the mitosis-specific cdk 
complex, MPF, which causes a decrease in the rate of passage of cells into and through G2 
phase, thus acting as a checkpoint mechanism (Kato et ah, 1994; Kurokawa and Kato,
1998). A decrease in cAMP levels is crucial for the passage of cells into mitosis, as 
inhibition of PKA is required in order to allow formation and activation of the mitotically- 
regulated ubiquitin ligase, the anaphase promoting complex (APC) (Grieco et ah, 1996; 
Yamashita et ah, 1996; Kotani et ah, 1998; Kishimoto and Yamashita, 2000). High levels 
of cAMP during mitosis have been seen to give abnormal mitotic spindle formation, block 
chromosome separation and prevent telophase exit (Anghileri et ah, 1999).
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3.1.3. Phosphodiesterases inhibit cell cycle progression
Phosphodiesterase (PDE) elicited intracellular cAMP degradation, during the cell cycle has 
been studied in many cell types and fluctuations in PDE activity have been observed 
during cell proliferation in the slime mould, Physarum polycephalum (Kupetz and Jeter, 
Jr., 1985). Indeed, high levels of PDE activity have been associated with the proliferation 
of colon carcinoma cells, with a consequently decrease in PDE activity as the cells reached 
confluency (Savini et al., 1995). The effect of PDE inhibition on the cell cycle has been 
extensively studied in T cell proliferation, as cellular proliferation is fundamental to 
progression of diseases such as asthma (reviewed in Kay, 2000). In virally-transformed T 
cells PDE4 dependent cAMP-specific PDE activity has been shown to be functionally up- 
regulated and such T cells appear to arrest in Gl phase upon the addition of the PDE4 
selective inhibitor rolipram (Ekholm et al., 1999). PDE4 inhibitors specifically down- 
regulate antigen driven proliferation of T helper cell clones (Essayan et al., 1997) and 
PHA-stimulated mononuclear cell division (Banner et al., 2000; Banner et al., 1995). Non- 
selective PDE inhibitors have also been shown to inhibit proliferation of smooth muscle 
cells (Pan et al., 1994; Souness et al., 1992), endothelial cells (Leitman et al., 1986), 
melanoma cell lines (Drees et al., 1993) and epithelial cells (Matousovic et al., 1997), 
arresting them all on Gl/S boundary, prior to passing the restriction point. Other studies 
have implied that differential control of cAMP degradation by PDEs is important at other 
stages of the cell cycle. The non-selective PDE inhibitor, IBMX arrests Amphidiunium 
operculatum cells at G2/M transition as well as at the Gl/S boundary (Leighfield and Van 
Dolah, 2001). In actinomycetes PDE activity has been shown to increase at G2 phase and 
is maintained during mitosis (Lefebvre et al., 1980). The inhibition of PDE activity in both 
budding and fission yeast, through the generation of temperature sensitive mutants, has 
been shown to block mitotic exit (Yamashita et al., 1996; Kishimoto and Yamashita, 
2000).
I have undertaken a study to investigate the involvement of PDEs in the control of the cell 
cycle so as to establish whether specific PDE isoforms are implicated in the cell cycle 
checkpoint regulatory mechanisms that are under the control of intracellular cAMP. An 
endogenous cellular system was used for observing changes in PDE activity profiles during 
phases of the cell cycle. The model cell line of choice was the Rat-1 fibroblasts which were 
originally isolated from rat embryos (for details see Materials and methods 2.1.1.1.). Rat-1 
fibroblasts were used for initial cell cycle isolation work and in the elucidation of the PDE 
profiles and intracellular signalling mechanisms at different phases of the cell cycle. 
Signalling mechanisms of Rat-1 cell lines have been well characterised and they have
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previously been used extensively in studies of the cell cycle (Prouty et al., 1993; Crossen et 
al., 1986; Knudsen et al., 1998).
Results
3.2. Characterisation of Rat-1 fibrobiast PDE4 profiie
In order to define the profile of PDE4 isoforms expressed in the Rat-1 cells a western blot 
analysis approach, as described in section 2.3.8., was undertaken using rat PDE4A, PDE4B 
PDE4C and PDE4D caihoxy-terminal specific antibodies to probe cellular lysate from 
asynchronous cells.
3.2.1. Western blot analysis of PDE4A splice variants
Immunoblots (Materials and methods 2.3.8.) of whole cell lysate from asynchronous Rat-1 
cells identified no PDE4A species that co-mi grated specifically with any of the 
recombinant protein PDE4A standards. This suggested that either there was no PDE4A 
expression or that the level of expression of the PDE4A isoforms in the Rat-1 cells was too 
low to be detected by immunoblotting whole cell lysates with the PDE4A specific 
antibody. Thus, in order to concentrate PDE4A for blotting 1 set out to immunoprecipitate 
PDE4A (Materials and methods 2.3.10) using the Genosys ‘270’ polyclonal antibody, 
raised in rabbits against a GST fusion protein containing the TPGRWGSGGDPA peptide, 
corresponding to the extreme C-terminal residues present in all rat PDE4A isoforms. The 
immunoprecipitated PDE4A protein was then immunoblotted with the same antibody. 
Using these a single PDE4A isoform was identified in the Rat-1 cells. This appeared to be 
the 109 kDa PDE4A5 protein (Genbank accession L27057, Fig. 3.4., Panel A). However, 
the PDE4A5 appeared to run with a higher mobility than the standard recombinant protein, 
an observation made repeatedly in the laboratory (personal communication, E. Huston). 
Therefore the immunoprecipitated protein was immunoblotted with the PDE4A5 N- 
terminal specific ‘24’ antibody. This antibody was raised in rabbit to a GST fused peptide 
that corresponded to the unique sequence within the N-terminus of PDE4A5, This clearly 
identified a PDE4A5 species which had a slightly lower apparent molecular weight than 
the standard PDE4A5 proteins {Fig 3.4., Panel B).
3.2.1.1. RT~PCR analysis of PDE4A isoforms found in Rat-1 fibroblast
To confirm by a further independent means that the PDE4A protein expressed in Rat-1 
cells was the PDE4A5 isoform RT-PCR analysis was carried out on total RNA isolated 
from the cells (Materials and methods 2.5.10.). The primers used for the RT-PCR were 
confirmed as being unique to particular isoforms by analysis using the BLASTn program
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(Altschuler et al, 1991), against the non-redundant database {Fig. 3.5.). RT-PCR analysis 
of total cellular RNA extracted from Rat-1 cells, using generic PDE4A primers confirmed 
expression of the PDE4A gene in these cells (Fig. 3.6.). However, the expression of the 
PDE4A5 isoform could not be specifically shown in this way.
3.2.2. Western blot analysis of PDE4B splice variants
To determine whether PDE4B isoforms were expressed in Rat-1 fibroblasts, cell lysate 
from an asynchronous population of cells were immunoblotted with a polyclonal antibody 
(Materials and methods 2.3.8.) raised against a GST protein fused to the sequence 
DPENRDSLGETDIDIATED, which corresponds to the extreme C-termini of all known 
rat PDE4B isoforms. This detected a single PDE4B splice variant that co-migrated with 
PDE4B2 (Genbank accession L27058) standard recombinant protein, at 80 kDa, on an 
SDS-PAGE gel (Fig. 3.7.).
3.2.2.1. RT-PCR analysis of PDE4B isoforms found in Rat-1 fibroblasts
As the PDE4B2 protein appeared to migrate with a slightly different molecular weight to 
the recombinant protein standards by SDS-PAGE further confirmation that the PDE4B 
protein expressed in Rat-1 cells was the PDE4B2 isoform was carried out using RT-PCR 
analysis of total RNA isolated from the cells (see section 2.5.10.). The primers used for the 
RT-PCR were again designed to unique nucleotide sequences within the individual 
isoforms, which were confirmed as being unique using the BLASTn program against the 
non-redundant database (Fig. 3.8.). The RT-PCR analysis of total cellular RNA extracted 
from Rat-1 cells confirmed the expression of the PDE4B2 isoform (Fig. 3.9.).
3.2.3. Western blot analysis of PDE4C isoforms
Asynchronous cellular lysate from the Rat-1 fibroblasts was probed with the Genosys 
‘232’ C-terminal PDE4C specific polyclonal antibody (Materials and methods 2.3.8.). This 
had been raised in rabbits against the a GST protein fused to the peptide sequence 
KEALELPDTELLSPEAGPDPGD, which corresponds to a peptide located in the extreme 
C-termini of all known PDE4C isoforms. The expression levels of the PDE4C protein were 
too low to be detected directly from cellular lysate, therefore immunoprécipitation of the 
PDE4C protein with the same polyclonal antibody was carried out to concentrate the 
protein (Materials and methods 2.3.10.). The isolated PDE4C species were then 
immunoblotted with the same antibody and a protein that co-migrated with recombinant
PDE4C2 at 80 kDa was identified (Fig. 3.10., Genbank accession L27061, M25347 and 
M28410, all of which are partial sequences).
3.2.4. Western blot analysis of PDE4D Isoforms
To assess whether PDE4D isofoims were expressed in Rat-1 cells, immunoblot analysis 
(Materials and methods 2.3.8.) was performed using a SAPU PDE4D specific polyclonal 
antibody, which was raised in sheep to a peptide corresponding to the sequence 
QVEEDTSCSDSKTLCTQDSESTEPLDEQVEEEAVGEEEESQPEACVIDDRSPDT, 
located at the extreme C-termini of all rat PDE4D isoforms. This revealed the only major 
PDE4D splice variant expressed endogenously within the cells was the 95 kDa, PDE4D3 
(Fig. 3.11., Panel A, Genbank accession U09457). Immunoprécipitation of the Rat-1 cell 
lysate (Materials and methods 2.3.10.) was carried out using the same PDE4D specific 
antibody and immunoprobing of the isolated protein was done with the ICOS PDE4D 
monoclonal antibody (Bolger et al., 1997). This mouse monoclonal antibody was raised 
against the TDQSESTEPLDEQVEE peptide, also present near the extreme C-termini of 
PDE4D isoforms and revealed no PDE4D isoforms were expressed in the Rat-1 cells in 
addition to the PDE4D3 (Fig. 3.11., Panel B).
3.3. Cell cycle analysis In Rat-1 fibroblasts
In order to study the changes in PDE isozyme activities during the cell cycle it was 
necessary, initially, to characterise the distribution of an asynchronous population of Rat-1 
cells through the cell cycle. Then determination of rates at which the cells pass through the 
different cell cycle phases was made. Once these observations had been made populations 
of cells were isolated at specific phases of the cell cycle in order to ascertain whether there 
were alterations in specific PDE activities during the cell cycle.
3.3.1. Determination of the rates of proliferation of Rat^l fibroblasts
Asynchronous Rat-1 cells were analysed by flow cytometry (Materials and methods
2.2.4.), indicating a mixed distribution of the population through the cell cycle, with 
approximately 57 % of the cells in G l, 18 % in S and 25 % in G2/M (Fig. 3,12.).
To decipher the length of time it took Rat-1 cells to move through phases of the cell cycle, 
and the time it took the cells to complete one cell division, BrdU-labelled cells (see section
2.2.3.) were analysed by FACs (see section 2.2.4.). The time taken by the cells to move
from the start of one S phase to the beginning of the next consecutive S phase was 
determined as the duration of one complete cell cycle. For Rat-1 cells this was found to be 
approximately 16 h (Fig. 3.13.).
In an attempt to isolate a large population of cells at different phases of the cell cycle, cells 
were deprived of serum for 48 h. The re-addition of serum to the cells caused them to re­
enter the cell cycle, although synchrony was lost within 6  h (data not shown). Therefore 
alternative methods of isolation of synchronous populations of cells within distinct phases 
of the cell cycle were required.
3.3.2. Method development for the isolation of Rat-1 cells in specific phases 
of the cell cycle
Highly synchronous cell populations were required for the analysis of PDE activities in 
specific cell cycle phases, thus a strategy for isolating cells at checkpoints within the cell 
cycle by chemical means was utilised. Although well described, these methods have been 
previously employed for cell types other than Rat-1 cells (Zeilig et al., 1976; Cordeiro- 
Stone and Kaufman, 1985; Crossen et al., 1986; Jordan et al., 1992; Keryer et al., 1998). 
These 1 had to optimise to achieve cell cycle arrest in Rat-1 cells.
3.3.3. Arresting Cells in GO phase
As evidenced by FACs analysis cells were completely arrested in GO phase of the cell 
cycle through serum deprivation for 48 h (Fig. 3.14.). Some cells lines undergo apoptosis 
after such prolonged serum withdrawal (Helbing et al., 1998). However, clear cell 
synchrony was only obtained in the Rat-1 fibroblasts after such extensive periods of serum 
starvation. Furthermore, only a small proportion of these cells appeared to have entered 
apoptosis after this time (data not shown).
3.3.4. Arresting Cells in Gl/S
To inhibit cells at Gl/S, the double thymidine block method was utilised (Materials and 
methods 2.I.4.3. Cho et al., 2001). As evidenced by FACs analysis, the thymidine 
feedback inhibition of DNA synthesis blocked cells already undergoing S-phase (Fig. 
3.15.) so it was necessary to carry out a double blocking mechanism to collect all cells at 
the Gl/S boundary. Several thymidine block release times were investigated, including 8  h, 
14 h and 20 h. A 14 h release was found to be sufficient to almost completely synchronise
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cells at the G l /S checkpoint upon the re-application of 2.5 mM thymidine for 16 h, post 
release {Fig. 3.15.), whereas other release times arrested too many cells in S phase.
3.3.4.1. Alterna five means of G1 arrest
Another means of Gl/S synchronisation was investigated utilising the cyclin-dependent 
kinase inhibitor, olomucine (Abraham et al., 1995). However, as evidenced by FACs 
analysis, it was found that cells were being blocked at both the Gl/S checkpoint and the 
S/G2 checkpoint, utilising olomucine. This method of cell cycle inhibition was not 
efficient enough for isolation of individual populations of cells (Fig. 3.16.).
3.3.5. Inhibition of cells in S-phase
Aphidicolin is a tetracyclin diterpene antibiotic that acts as an inhibitor of DNA 
polymerase a  and ô, causing cell cycle arrest at S-phase (Spadari et al., 1985). In previous 
studies for the isolation of cells at S phase prior synchronisation of cells using the double 
thymidine block has been implemented (Keryer et al., 1998). I undertook an investigation 
to assess whether prior synchronisation of Rat-1 cells was required for optimal S phase 
isolation of the cells. 1 found that the addition of aphidicolin to an asynchronous population 
of Rat-1 cells caused their arrest directly in S phase without the need for prior treatment 
(Fig. 3.17. Panel A). Release of the cells from an aphidicolin induced block, by washing 
them twice with PBS and incubating with fresh media for 3 h prior to cell harvest, allowed 
the isolation of 88 % of cells in S/G2 (Fig. 3.17. Panel B).
3.3.5.1. Alternative means of S phase arrest
The plant amino acid L-mimosine, which inhibits the eIF5-A transcription factor 
(Hanauske-Abel et al., 1994; Frost et al., 1995), has been reported to arrest cells in S phase 
(Krude, 1999). However, it was found to be ineffective at amesting Rat-1 fibroblasts in S 
phase as many cells proceeded to enter G2/M following incubation with the cells (Fig. 
3.18.).
3.3.6. Inhibition of cells in M-phase
Mitotic arrest can be brought about through several different mechanisms, one method is 
through the inhibition of cells in S-phase, by the addition of hydroxyurea, which is then 
removed and cells are released and harvested once they have moved into M phase. This
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method of isolating requires exact knowledge of the length of time it takes the cells to pass 
from S phase, through G2 phase and into mitosis. A more precise mechanism of M-phase 
arrest uses nocodazole which has a highly specific antimicrotubular activity, promoting 
tubulin depolymerisation (Mikhailov and Gundersen, 1998; Jordan et al., 1992; Verdoodt 
et al., 1999). This prevents the cell from establishing a bipolarised state and blocks cell 
division midway through mitosis at the metaphase/anaphase transition point.
3.3.6.1. Microtubule disruption agents and M-phase arrest
The inhibition of mitosis in the Rat-1 cells, as evidenced by FACs analysis (see section
2.2.4.), was apparent upon addition of nocodazole for 14 h {Fig. 3.19.). However, 
nocodazole has also been shown to induce apoptosis in certain cells, including thymocytes 
(Bumbasirevic et al., 1995), lymphocytes (Verdoodt et al., 1999) and Rat-1 (Kook et al., 
2000) cells. Nevertheless, at the concentration of nocodazole used here to achieve mitotic 
arrest (50 ng/ml), in Rat-1 cells, it was shown not to induce apoptosis {Table 3.1.), as 
evidenced by FACs analysis (Materials and methods 2.2.5.). Nocodazole-induced mitotic 
aiTest was reversible as upon removal of nocodazole from Rat-1 cells re-entry into the next 
cell cycle was observed {Fig. 3.20.).
3.3.6.2. Alternative antimicrotubular agents for M-phase arrest
Studies using a different antimicrotubular agent, colcemid, were carried out to confirm the 
action of nocodazole in causing M-phase arrest. Colcemid also induced mitotic arrest in the 
Rat-1 fibroblasts. However, nocodazole is used widely as a mitotic inhibitor (Hayne et al., 
2000; Mikhailov and Gundersen, 1998; Tsuiki et al., 2001) and was the preferred means of 
to inducing mitotic arrest.
3.3.7. Expression of marker proteins to determine the isolation of Rat-1 cells 
in cell cycle phases
1 wished to provide independent conformation of the observations obtained by FACs 
analysis on the isolation of the Rat-1 cells in the various phases of the cell cycle, using the 
different cell cycle inhibitors (see section 2.1.4.). To do this 1 analysed the presence of cell 
cycle markers in lysates from the treated cells.
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3.3.7.1. Detection of Cyclin E in celis isolated at different phases of the cell 
cycle
Cyclin E during the cell cycle exhibits differential levels of expression and is required for 
the transition of cells from G l to S phase (Ohtsubo et ah, 1995; Koff et ah, 1992; 
Nakayama et ah, 2001; Sheaff et ah, 1997). I thus used cyclin E as a marker to confirm the 
FACs analysis data. Cell lysates isolated from Rat-1 fibroblasts arrested at different phases 
of the cell cycle (Materials and methods 2.1.4.) were immunoblotted, as outlined in section 
2.3.8., with a cyclin E antibody (Santa Cruz Laboratories). The antibody was raised in 
rabbit against an epitope mapping to the carboxy terminus of cyclin E of rat origin. The 
levels of cyclin E were elevated in cells isolated at the Gl/S point upon treatment with the 
double thymidine block (Materials and methods 2.1.4.3.), decreasing in the cells subjected 
to the aphidicolin treatments (S phase) and reaching a minimal level in cells incubated with 
nocodazole (Fig. 3.21., Panel A.).
3.3.7.2. Detection of Cyclin B in cells isolated at different phases of the cell 
cycle
Cyclin B1-dependent activation of cdkl is required for the transition of cells from G2 to 
mitosis (Nigg, 2001; Ito, 2000; Grieco et ah, 1996) and cyclin B1 exhibits differential 
levels of expression during the cell cycle (Piaggio et ah, 1995; Pines and Hunter, 1989; 
Smits and Medema, 2001). I thus used cyclin B1 as a further marker to confirm the FACs 
analysis data, for determination of stage specific isolation of cells upon inhibitor addition 
(Materials and methods 2.1.4.). Cell lysates isolated from Rat-1 fibroblasts arrested at 
different phases of the cell cycle (Materials and methods 2.1.4.) were immunoprobed, as 
outlined in section 2.3.8., with a cyclin B antibody (Pharmingen). There were no detectable 
levels of cyclin B expressed in cells isolated in GO or Gl/S. However, in cells isolated after 
either aphidicolin block and release (Materials and methods 2.1.4.4.) or upon nocodazole 
treatment (Materials and methods 2.1.4.5.) then cyclin B immunoreactivity was evidenced 
(Fig. 3.21., Panel B.). This confirms these treatments arrested cells within G2 and mitosis, 
as in agreement with the FACs analysis data (see Figs. 3.17. & 3.19.).
3.3.7.3. Detection of phospho-ERK in cells isolated at different phases of the 
cell cycle
ERK has been shown to exhibit different levels of activation during the cell cycle (Roovers 
and Assoian, 2000; Wright et al., 1999; Black et al., 2000; Hayne et al., 2000; Laird et al.,
1999). I thus also used this as a marker to confirm the FACs analysis data, for 
determination of stage specific isolation of cells upon inhibitor addition (Materials and 
methods 2.1.4.). The activation status of ERK was determined by analysis of the 
phosphorylation of the TEY motif, detected using a phospho-ERK antibody. Cell lysates 
isolated from Rat-1 fibroblasts, arrested at different phases of the cell cycle (Materials and 
methods 2.1.4.), were immunoprobed, as outlined in section 2.3.8., with a phospho-ERK 
antibody (Upstate Biotechnology). The antibody was raised in mouse against a 
phosphopeptide specific for dually-phosphorylated ERKl and ERK2. There were high 
levels of immunoreactive phospho-ERK detected during serum deprivation, the levels 
decreased in thymidine treated cells (Materials and methods 2.1.4.3.), recovering again in 
cells subjected to aphidicolin treatments (Materials and methods 2.1.4.4.). The levels of 
phosphorylated ERK were reduced in cells isolated in mitosis, upon incubation with 
nocodazole. (Fig. 3.21., Panel C.).
3.3.7.4. Detection of phospho-MEK in cells isolated at different phases of the 
cell cycle
MEK directly activates ERK by phosphorylation of the TEY motif (Crews and Erikson, 
1992; Crews et al., 1992). MEK also exhibits differential activation during the cell cycle, 
paralleling the activity profile of ERK (Roovers and Assoian, 2000; Wright et al., 1999; 
Hayne et al., 2000; Laird et al., 1999). MEK was therefore also used as a marker to 
confirm the FACs analysis and phospho-ERK data, for determination of stage specific 
isolation of cells upon inhibitor addition (Materials and methods 2.1.4). Activation of 
MEK was determined by analysis of the phosphorylation status of residues Ser^^  ^ and 
Ser^^ ,^ as detected using a phospho-MEK antibody. Cell lysates isolated from Rat-1 
fibroblasts arrested at different phases of the cell cycle (Materials and methods 2.1.4.) were 
immunoprobed, as outlined in section 2.3.8., with the phospho-MEK antibody (Upstate 
Biotechnology). The antibody was raised in goat against a phosphopeptide specific for 
dually-phosphorylated MEKl of human origin. There were high levels of immunoreactive 
phospho-MEK detected after serum deprivation, the levels were decreased in double 
thymidine-blocked cells, isolated at the Gl/S transition and increased again in cells
subjected to aphidicolin treatment. The levels of phosphorylated MEK were also low in 
cells isolated in mitosis, upon incubation with nocodazole (Fig. 3.21., Panel D).
3.4. Analysing the changes in cAMP phosphodiesterase activity 
in the ceii cycle
Once I established that populations of Rat-1 cells could be isolated at specific phases of the 
cell cycle in sufficient amounts to perform biochemical analysis. I thus set out to see if 
alterations in PDE isozyme activities occurred on the progression of the cells through the 
cell cycle.
3.4.1. Determination of cAMP PDE activity in Rat-1 cells isolated at different 
stages of the cell cycle
The profile of total PDE enzymatic activity (Materials and methods 2.3.9.) changed in 
lysates obtained from Rat-1 cells arrested at specific stages of the cell cycle (Fig. 3.22., 
Panel A). There appeared to be a general increase in the total PDE activity of cells that had 
been serum starved for 48 h. This activity then decreased in cells arrested at the Gl/S 
transition and then decreased further as cells passed through S phase and entered G2. 
However, when cells were arrested within mitosis an elevated total PDE activity was seen, 
which decreased as the cells were released into the latter phases of mitosis and the next cell 
cycle.
Cyclic AMP hydrolysis in cells can be achieved through the action of various different 
PDE isozymes. Thus the activities of the major cAMP hydrolytic enzymes, PDE3 and 
PDE4, were examined in the Rat-1 cells in order to assess their relative contributions.
3.4.1.1. PDE4 activity in Rat-1 cells isolated at different stages of the cell 
cycle
In order to monitor cAMP specific hydrolysis catalysed by PDE4, PDE enzymatic activity 
of cell lysates was assayed in the presence of 10 pM of the PDE4-specific inhibitor, 
rolipram (Materials and methods 2.3.9.). It was found that the rolipram-sensitive PDE4 
activity provided a major fraction of the total cAMP-specific hydrolytic activity in these 
cells when the were left asynchronous (~ 75 %, Fig 3.22., Panel B). Whilst little change in 
the profile of PDE4 activity occurred during different stages of the cell cycle, a slight 
increase in PDE4 activity was seen in cells arrested in mitosis. This elevation in PDE4
activity decreased as cells passed through mitosis, reaching ‘basal’ levels as the cells 
entered the next Gl.
3.4.1.2. PDE3 activity in Rat-1 cells isolated at different stages of the cell 
cycle
In order to elucidate possible changes in PDE3 activity in cells arrested at specific phases 
of the cell cycle, PDE assays were done in the presence of 10 pM of the PDE3-specific 
inhibitor, cilostomide. Almost all of the residual cAMP-specific PDE activity, after PDE4 
inhibition, was found to be attributable to PDE3 (Fig. 3.22.), The profile of PDE3 activity 
did not appear to change through the cell cycle and thus further studies were focused on the 
cell cycle dependent changes in PDE4 activity.
3.4.2. Analysis of PDE4 Isoform activity changes in celis Isolated at different 
stages of the cell cycle
With PDE4 identified as the most active class of cAMP hydrolysing PDE within Rat-1 
fibroblasts a more detailed analysis of the enzymatic activity of the individual PDE4 
isoforms in lysates isolated at different phases of cell cycle was carried out. Specific PDE4 
isoforms were immunoprecipitated from the cell lysates using PDE4 sub-family specific 
antiserum (see section 3.2.). It has previously been confirmed that antibody binding to the 
PDE4 isoforms during immunoprécipitation does not affect their activity (Baillie et al.,
2000). This provides an effective means of assessing individual PDE4 isoform activity. 
Indeed, it is the only way currently available because, as yet, there are no PDE4 isoform- 
specific inhibitors.
3.4.2.1. Changes in PDE4A and PDE4C isoform activity in cells isolated at 
different stages of the ceii cycle
PDE4A and PDE4C proteins from Rat-1 cell lysates were successfully immunoprecipitated 
(for examples see Figs. 3.4. & 3.10.). However, the activities they exhibited showed little 
discernible change when isolated from Rat-1 cells arrested in specific phases of the cell 
cycle {Fig. 3.23., Panels A and C).
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3A.2.2. Changes in PDB4B activity in cells isolated at different stages of the
cell cycle
Depending on which particular stage of the cell cycle the cells had been arrested, between 
15-40 % of the total PDE4 activity in Rat-1 cells was attributable to the PDE4B isoform 
(Fig. 3.23.). The PDE4B specific activity was constant in lysates from cells isolated at all 
phases of the cell cycle apart from those cells subjected to aphidicolin block release. This 
arrested cells at S/G2, where PDE4B activity was increased by 0.5-fold. However, 
isolation of cells in mitosis showed no such increase in PDE4B activity (Fig. 3.23., Panel 
B).
3.4.2.3. Changes in PDE4D activity in cells isolated at different stages of the
cell cycle
PDE4D was the most active species of the PDE4 subfamilies contributing to the cAMP 
hydrolytic activity in the Rat-1 cells (Fig. 3.23.). From immunoblotting studies of the Rat- 
1 cell lysates it was evident that the only species of PDE4D present was PDE4D3 (see Fig. 
3.11.). There was very little change in activity of PDE4D observed in lysates isolated in the 
GO, G l, S and early G2 cell cycle phases. However, in cells arrested in mitosis there was a 
1.7-fold increase in PDE4D activity (Fig, 3.23., Panel D).
3.4.2.4. Changes in PDE4D protein expression in cells isolated at different 
stages of the cell cycle
I set out to determine whether the increase in PDE4D cAMP-specific hydrolytic activity 
seen in cells arrested in mitosis was due to an activity change or whether it was the result 
of an increase in PDE4D3 protein expression. I thus analysed the expression levels of 
PDE4D3 in cell lysates isolated at different stages of the cell cycle. This was carried out by 
enzyme linked immuno-absorbent assay (ELISA, Materials and methods 2.3.3.), using the 
C-terminal PDE4D specific antibody. In mitotically extracted lysates the level of PDE4D 
protein expression was similar to that found in cells lysates from all other phases of the cell 
cycle (Table 3.2.). Thus suggesting that the increase in PDE4D activity in mitosis was not 
caused by up regulation of PDE4D3 protein or the up-regulation of any other PDE4D 
isoform, but was due to a change in the specific activity of PDE4D3.
3.4.3. Subceüuiar localisation of PDE4D protein in cells Isolated at different 
stages of the cell cycle
Changes in the subcellular distribution of PKA R lla  subunit has been noted in during 
mitosis (Keryer et ah, 1998). Therefore I set out to determine whether there was a change 
in the subcellular localisation of PDE4D3 in cells isolated at different phases of the cell 
cycle. When cells isolated in different phases of the cell cycle (Materials and methods
2.1.4.) were fractionated by differential centrifugation (Materials and methods 2.I.3.2.) it 
was found that there was no change in the distribution of PDE4D protein between the 
subcellular fractions (Figures 3.24a & 3.24b.).
3.5. Analysis of the changes in PKA activity In the cell cycle
The changes observed in PDE4 activity during the cell cycle in Rat-1 cells may provide an 
important contribution in determining the intracellular concentrations of cAMP by 
mediating its degradation. If increased cAMP hydrolysis should lead to lower the cAMP 
concentration in the cells this, in turn, may lead to the inactivation of PKA, so terminating 
the PKA signalling cascade activation. In order to determine the importance of the 
variation in PDE4 activities in Rat-1 cells, and any relationship it has to the changes in 
PKA activity, I set out to observe if alterations in PKA activity occurred in cells isolated at 
different stages of the cell cycle.
3.5.1. Determination of PKA activity in ceiis isoiated at different stages of 
the cell cycle
Work has been carried out by several groups on the activity of PKA during the cell cycle in 
cell types as diverse as Xenopus oocytes and Saccharomyces cerevisae (Feliciello et al., 
2000; Grieco et al., 1996; Anghileri et al., 1999). In order to establish the fluctuations of 
PKA activity in Rat-1 fibroblasts, cells were isolated at specific stages of the cell cycle and 
then analysed for PKA activity (Materials and methods 2.4.1.).
3.5.1.1. Changes in PKA activity in the cell cycle
PKA activity peaked in lysates isolated at GO phase of the cell cycle (Fig. 3.25.). However, 
the activity of PKA was lower in lysates obtained from cells isolated at other phases of the 
cell cycle, with the lowest activity observed during nocodazole-induced, metaphase aixest.
PKA activity increased again as the cells were released from the mitotic block and passed 
through the end of mitosis into G l of the next cell cycle {Fig. 3.25.).
3.5.1.2. Detection of phosptio-CREB in cell lysates isolated at different 
phases of the cell cycle
In addition to measuring PKA activity directly, as above, the phosphorylation of the cyclic- 
AMP response element binding protein (CREB) was used as a marker of PKA activity. 
Rat-1 cell lysates were immunoprobed with a phospho-CREB antibody (Upstate 
biotechnology). The antibody has been raised in rabbits to a synthetic phosphopeptide 
corresponding to residues KRREILSRRPpSYRK, which specifically detects PKA 
phosphorylated CREB (Bito et ah, 1996). In agreement with the PKA activity data, the cell 
lysates isolated at specific phases of the cell cycle indicated that CREB was highly 
phosphorylated in cells arrested in GO and the levels of CREB phosphorylation decreased 
in cells isolated at different stages of S phase, reaching a minimum in cells isolated in 
mitosis {Fig. 3.26.).
3.5.1.3. Levels of PKA activity controlled specifically by PDE4 dependent 
mechanisms in Rat-1 cells
To assess the contribution of PDE4 enzymes in the control of intracellular PKA activation, 
Rat-1 cells arrested in different phases of the cell cycle were treated with the PDE4 
specific inhibitor rolipram for 15 min prior to harvesting for the PKA activity assay. It was 
observed that, upon the addition of rolipram to asynchronous cells and cells isolated in 
quiescence, there was no change in PKA activity. However, in cells isolated during S 
phase and mitosis the rolipram-mediated inhibition of PDE4 induced an elevation in PKA 
activity, increasing the percentage of active PKA in the cells back to basal levels observed 
in cells deprived of serum for 48 h {Fig. 3.27.).
3.6. The effects of the inhibition of PDE isoforms on ceii 
proilferation
In order to study the significance of PDE activity on the control of cell cycle transition, the 
inhibition of the various cAMP-specific PDE isoforms, within the Rat-1 cells, was carried 
out. It has previously been shown that growing bovine aortic endothelial cells in the 
presence of the non-selective PDE inhibitor, IBMX, inhibits growth of the cells by 60 - 80 
% (Leitman et al., 1986). The inhibition of PDE4 specifically has been demonstrated to
inhibit the proliferation of such cells as umbilical cord blood mononuclear cells (Banner et 
al., 2000), vascular smooth muscle cells (Pan et al., 1994) and in MJ cells, an HTLV-1 
transformed T cell line (Ekholm et al., 1999).
3.6.1. Inhibition of PDE4 reduces Rat-1 cell proliferation
I set out to examine the effect of PDE4 inhibition on the rate of cell cycle phase transition 
and proliferation. I analysed the distribution of Rat-1 cells, within the cell cycle, in the 
presence and absence of the PDE4 spécifié inhibitor, rolipram, by FACs analysis (see 
section 2.2.4.). Sub-confluent, proliferating Rat-1 cells were pulse-labelled with BrdU for 
30 min, then incubated with 10 pM rolipram for up to 18 h. Cells were removed at 3 h 
intervals during this treatment and their distribution within the cell cycle were determined.
3.6.1.1. Inhibition of PDE4 alters the distribution of Rat-1 cells within the cell 
cycle
Upon inhibition of PDE4 in Rat-1 cells there was a decrease in the proportion of cells 
isolated in S phase when the distribution of the cells within the cell cycle was compared to 
untreated cells. This change in cell cycle phase distribution was due, within the first 9 h of 
cell isolation, to an increase in the proportion of cells entering G2 /M (Fig. 3.28.). In the 
later stages of the study, from 12 h to 18 h, there was also a decrease in the amount of cells 
isolated in S phase. This was due to the elevation of cells in the G l / GO phases of the cell 
cycle. Thus the rolipram-mediated inhibition of PDE4 presumably increased cAMP 
concentration in these cells and reduced the rate of Gl/S transition.
3.6.2. Inhibition of PDE3 does not alter the rate of Rat-1 cell proliferation
To examine the effect of PDE3 inhibition on the rate of cell cycle phase transition and 
proliferation cell cycle, the distribution of Rat-1 cells was determined by FACs analysis 
(see section 2.2.4.), in the presence and absence of the PDE3 specific inhibitor, 
cilostomide. Sub-confluent proliferating Rat-1 cells were pulse-labelled with BrdU for 30 
min, then incubated with 10 pM cilostomide for up to 18 h. Cells were removed at 3 h 
intervals during this treatment and their distribution within the cell cycle was determined.
3.6.2.1. Inhibition of PDE3 does not alter the distribution of Rat-1 cells within 
the cell cycle
Upon incubation of cells with cilostomide the distribution of cells through the phases of the 
cell cycle did not alter throughout the 18 h analysis period when compared cells treated 
with vehicle only. There was a slight initial decrease in the proportion of cells in S phase, 
with 3 h cilostomide treatment, which was concurrent with an increase in the proportion of 
cells detected in G2 /M phase (Fig. 3.29.). Unlike rolipram treatment of the Rat-1 
fibroblasts there was no accumulation of cells within the G l /GO phases after a 12 -18 h 
incubation with cilostomide.
3.7. Discussion and conclusions
Every cell type appears to expresses a unique profile of PDE isoforms (for some examples 
see Conti et al., 1998; Juilfs et al., 1997; Bloom and Beavo, 1996; Erdogan and Houslay, 
1997). These presumably enable differential control of hydrolysis of cyclic nucleotides so 
as to elicit specific functional consequences within the cell. The major cyclic nucleotide 
phosphodiesterases that specifically hydrolysed cAMP in Rat-1 fibroblasts were shown to 
be of the PDE3 and PDE4 families. The PDE4 isozymes contributed the majority (-72 %) 
of the total cAMP specific enzymatic activity within these cells, assessed at 2 ijlM cAMP. 
The elucidation of the PDE4 isoform profile showed conclusively that the PDE4B2, 
PDE4C2 and PDE4D3 isoforms were expressed. Although the profile of expressed PDE4A 
isoforms was not conclusively established it was presumed, from observations made in this 
study and from those made previously by other lab members (personal communication, E. 
Huston) that the PDE4A5 isoform was also expressed.
Increased PDE activity is associated with cells that have elevated proliferation rates (Tsou 
et al., 1974; Tsou et al., 1986). This, presumably, acts to reduce levels of cAMP and 
maintain low levels of the G1 cyclin dependent kinase (cdk) inhibitor, p27^^^ (Hengst and 
Reed, 1996; van Oirschot et al., 2001). As high levels of the active cdk complexes, 
cdk4/cyclin D and cdk2/cyclin E, are required for Gl/S transition (L’Allemain et al., 1997; 
van Oirschot et al., 2001; Naderi et al., 2000) this may provide a major means whereby 
cAMP regulates the cell cycle. During progression through the cell cycle changes in the 
profiles of activities of PDE families have been noted within Actinomyces (Lefebvre et al., 
1980) and Physarum polycephalum (Lovely and Threlfall, 1978; Lovely and Threlfall, 
1979; Kupetz and Jeter, Jr., 1985). Similarly, alterations in the activities of specific PDE 
isoforms during the cell cycle have been observed within germ cells (Morena et al., 1995). 
However, no attempts have been made to identify changes in specific PDE isoform 
activities in somatic cell lines.
In order to study activities of PDE isoforms at specific phases of the cell cycle in a somatic 
cell line it is necessary to isolate sufficiently large populations of cells at these phases to 
allow for biochemical analysis. Although many studies have been able to maintain an 
asynchronous population of cells by the re-addition of growth factors to serum deprived 
cells, this was found not to be a means by which Rat-1 cells retained synchrony.
There are well-characterised methods for the isolation of various cell types at different 
phases of the cell cycle, using chemical means (Fantes and Brooks, 1993). In this study
these methods were optimised for Rat-1 fibroblasts and cell cycle distribution was 
determined utilising FACs analysis. These observations were confirmed by immunoblot 
analysis of cell lysate for cyclins that undergo differential expression (Sauer and Lehner, 
1995; Nakayama et al., 2001; Piaggio et al., 1995; Pines and Hunter, 1989; Smits and 
Medema, 2001) and enzymes which are subjected to differential activation (Roovers and 
Assoian, 2000; Wright et al., 1999; Black et al., 2000; Hayne et al., 2000; Laird et al., 
1999) through the cell cycle.
Once methods of isolation of Rat-1 cell populations at specific stages of the cell cycle were 
established I undertook investigations into the fluctuation of cAMP-specific PDE activity 
in these cells. No clear alterations in total PDE activity in Rat-1 cells was evident in cells 
isolated at different stages of the cell cycle. However, a slight elevation in total PDE 
activity was noted in cells isolated in both GO and mitosis {Fig. 3.22., Panel A). As both 
PDE3 and PDE4 represent the major fraction of the total cAMP PDE activity, in cells 
assayed at 2 jiiM cAMP, I then analysed the rolipram-inhibited PDE4 activity. This allowed 
me to identify a slight increase in PDE4 activity in cells arrested in mitosis. Similarly, 
PDE4 activity represents the action of multiple isoforms. I thus determine that in the 
mitotic cell population the activity of PDE4D3 contributed to approximately 67 % of the 
PDE4 activity, PDE4B2 contributed to approximately 17 %, PDE4C2 approximately 8 % 
and PDE4A5 approximately 7 %. Meanwhile, cilostomide-inhibited, PDE3 activity 
showed no change in activity between lysates isolated at any stage of the cell cycle.
This study of the changes of PDE4 isoform activity profiles in the cell cycle made evident 
the fact that there was a 1.7 fold elevation in the levels of PDE4D3 activity within cell 
lysates isolated during mitosis {Fig. 3.23, Panel D), whereas no other isoforms 
demonstrated any major fluctuations in activity. Given that the absolute levels of PDE4D3 
protein appeared unchanged throughout the cell cycle a likely explanation for this 
increased activity was that PDE4D3 was being modified in some way, so as to activate it. 
One possibility is that this modification and activation occurs through phosphorylation, 
another is that an inhibitory protein could be released from the phosphodiesterase when the 
cells are arrested in mitosis, again elevating activity. However, phosphorylation of 
PDE4D3 by PKA and ERK is known to regulate its enzymatic activity (Sette and Conti, 
1996; Hoffmann et al., 1999), as is the binding of phospholipids (Grange et al., 2000; 
Nemoz et al., 1997). Of the phosphorylation processes, PKA phosphorylation of Ser '^^  in 
UCRl of PDE4D3 causes it to be activated (Lim et al., 1999) and in contrast ERK 
phosphorylation of Ser^^  ^in the catalytic unit causes its inhibition (Hoffmann et al., 1999).
As I observed activation of PDE4D3 in mitosis I set out to see if PKA was activated during 
mitosis.
Fluctuations in the levels of active PKA during the cell cycle have been shown in oocytes 
(Grieco et al., 1996) and cells from budding and fission yeast (Yamashita et al., 1996; 
Grieco et al., 1996; Kotani et al., 1998). The proportion of active PKA in Rat-1 fibroblasts 
was shown to be maximal in quiesced cells, which had been deprived of serum for 48 h, 
confirming previously documented observations of the increase in active PKA in quiesced 
cells (Pastan et ah, 1975; Grieco et ah, 1996). Cells aiTested through the stages of S phase 
had a decreasing proportion of active PKA, and those cells arrested in mitosis contained 
the lowest detected proportion of active PKA. These alterations in PKA activity were 
confirmed by immunoblot analysis of the amount of CREB in the cell that had been 
phosphorylated by PKA.
A decrease in PKA activity can be brought about either by the inactivation of adenylate 
cyclases or by the activation of phosphodiesterases (Houslay and Milligan, 1997). A 
decrease in PKA activity during mitosis has been noted before by others in xenopus 
oocytes (Grieco et ah, 1996; Fernandez et ah, 1995), budding yeast (Anghileri et ah, 1999), 
in fission yeast (Yamashita et ah, 1996; Yanagida et ah, 1999), in lymphoid precursor Reh 
cells (Blomhoff et ah, 1988; Christoffersen et al., 1994) and in fibroblasts (Lamb et ah, 
1991; Hohmann et ah, 1993; Kotani et ah, 1998; Kotani et ah, 1999; Oh et ah, 1996; Zeilig 
et ah, 1976). However, the underlying mechanism of PKA inactivation at mitotic onset has 
not been elucidated, although in yeast the deletion of phosphodiesterases prevents mitotic 
exit (Anghileri et ah, 1999; Yanagida et ah, 1999). The mitotic elevation of PDE4, and 
more specifically the increase in PDE4D3 activity, coincides with this observed down- 
regulation in PKA activity. This raises the intriguing possibility that the elevated PDE4D3 
activity in mitotic cells decreases the levels of cAMP, causing the inactivation of PKA. To 
investigate the involvement of PDE4 isoforms in the control of PKA activity in cells 
isolated at different phases of the cell cycle I thus set out to specifically inhibit PDE4 
activity, using rolipram, in order to define the consequential changes in PKA activity. This 
showed that rolipram inhibition of PDE4 activity appeared to cause an increase in PKA 
activity in cells isolated in S phase and mitosis. This is consistent with the suggestion that 
PDE4 is playing a role in the control of PKA activity during mitosis.
Studies by other groups have suggested that PDE4 inhibition causes a reduction in the rates 
of proliferation in several cell types, including umbilical cord and peripheral blood 
mononuclear cells (Banner et al., 2000; Banner et al., 1995), T helper cell clones (Essayan
et al., 1997), aortic endothelial cells (Leitman et al., 1986), melanoma and mammary 
carcinoma cells (Drees et al., 1993). Indeed, inhibition of PDE4 has also been shown to 
specifically inhibit cell cycle progression at the Gl/S transition (Matousovic et al., 1997 
133 /id; Drees et al., 1993). However, negligible alterations in proliferation of Rat-1 cells 
were seen here upon the incubation of Rat-1 cells with rolipram (Fig. 3.28.), Indeed, there 
appeared only to be a small proportion of the cells arresting prior to the Gl/S transition. 
However, there was a slight redistribution of the Rat-1 cells within the cell cycle upon 
incubation with rolipram, presumably due to a reduction of cells in S phase. This coincided 
with an increase in the amount of cells in G2/M and a decrease in the number of cells 
moving from G1 {Fig. 3.28.). Although the incubation of Rat-1 cells with rolipram 
appeared only to give a slight change in cell cycle distribution there was no change in the 
distribution of Rat-1 cells incubated with the PDE3 inhibitor cilostomide. The 
simultaneous inhibition of PDE3 and PDE4 might be an interesting area to look into here, 
as it has been shown that simultaneous inhibition of the phosphodiesterases potentiates the 
inhibition of smooth muscle cell proliferation (Johnson-Mills et al., 1998; Pan et al., 1994; 
Souness et al., 1992).
In this chapter I have presented work showing the optimisation of conditions for accurately 
arresting Rat-1 fibroblasts at various stages of the cell cycle. This was then used for 
analysis of PKA and PDE activities in these various phases. Such studies uncovered the 
novel and particularly interesting observation that PDE4D3 enzymatic activity was 
increased during mitosis, a phase where PKA is least active. Rolipram mediated inhibition 
of PDE4 activity was shown to activate PKA at Gl/S, S, G2 and M phases of the cell 
cycle. There is also a suggestion that there is a slight redistribution of cells from S phase to 
the G2/M and G1 phases of the cell cycle upon incubation with rolipram. The next chapter 
aims to build on these observations and in particular to focus on and further characterise 
the cell cycle-dependent alterations in PDE4D3 activity.
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Figure 3.1. Stages of the cell cycle. A schematic representation of the 
phases of the cell cycle indicates that mitogen stimulation of cells in G1 
induces the expression of protein required for Gl/S transition. If mitogens 
are removed prior to the passage of cell through the restriction point (R) 
they leave the cell cycle and quiess (GO). Once passed R, however, cells 
are committed to complete one cell cycle under autonomous control. DNA 
is replicated during S phase and checkpoint mechanisms allow cyclin 
degradation and allow progression into the second gap phase (G2). Mitotic 
progression (M) is under strict control mechanisms which rely on the 
degradation of cyclins to enable cell division to take place.
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Figure 3.2. The changes in chromosome morphology during the 
different phases of mitosis. Upon transition of the cells from interphase 
(A) to prophase (B) the chromosomes condense and become visible. 
Chromosomes then attach to the mitotic spindles, which are generated 
between the centrioles, during metaphase (C). The chromatids segregate 
and migrate to opposite poles of the cell in anaphase (D) and the cells 
finally divide by cytokinesis during telophase (E). Pictures taken from 
http://www.bioweb.uncc.edu/bioll 110/Stages.htm
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Figure 3.3. Effects of cAMP elevation and PKA activation on G l/S  
arrest. Cyclic AMP elevation acts on several signalling mechanisms in 
order to bring about arrest of cells prior to the Gl/S transition. Activation 
of PKA, by cAMP, leads to down regulation of the expression of the 01 
dependent D-type cyclins. PKA increases the expression of p27'^"^', the 
cdk inhibitor molecule which binds to the active cdk complexes, cyclin 
D/cdk4 and cyclin E/cdk2. By decreasing the levels of active cyclin 
complexes the phosphorylation of the tumour suppressor retinoblastoma 
protein (pRb) is blocked. This then sequesters the E2F transcription 
factor and prevents expression of proteins required for Gl/S transition. 
PKA activation interferes with the activation of the ERK signalling 
cascade as PKA phosphorylation of Raf-1 prevents it from forming an 
active complex with Ras and thus interferes with the activation of MEK. 
Cyclic AMP can also activate Epac, which causes activation of Rap-1. 
The affinity of Rap-1 for Raf-1 increases which in turn inactivates the 
MEK-ERK mediated mitogen signalling cascade.
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Figure 3.4. Western blot analysis of PDE4A isoforms expressed in Rat- 
1 cells. Panel A, Rat-1 cells were harvested in 3T3 lysis buffer and PDE4A 
was isolated from 1 mg of Rat-1 lysate using a specific antibody directed 
against the C-terminus of PDE4A, as described in section 3.2.1.. The 
isolated protein (Rat-1) was subjected to SDS-PAGE on an 8 % gel 
alongside 25 /xg recombinant protein of PDE4A splice variants 
PDE4Amet26 (met26, an N-terminally truncated species of PDE4A1, 76 
kDa), PDE4A1 (4A1, 79 kDa), PDE4A8 (4A8, 98 kDa), rpde66 ( ‘66’, a rat 
PDE4A splice variant that has since been found to be an artefact) and 
PDE4A5 (4A5, 109 kDa), as indicated. The proteins were transferred to 
nitrocellulose which was then immunoblotted with the same PDE4A 
specific antibody. The positions of molecular weight markers are indicated. 
Panel B, The same immunoprecipitated protein and protein standards were 
immunoprobed with a PDE4A5 specific antibody directed against the N- 
terminus of PDE4A5, as described in section 3.2.1., the molecular weight 
markers are indicated.
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57 °C 
2 m in
72 °C 
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p G e n A  A S
CAGGGTGAGTCCACATCGTGG
PDE4A1
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p A l  S
TTCTTCTGCGAGACCTGCTCCAAG
C
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72 °C 
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C
PDE4A5
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P A 8  S
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1 min
62 °C 
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72 °C 
1 min
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CAGGCCCCATTTGCTCAAGTTCTC
C
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p A 6
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215 94 °C 
1 min
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Figure 3.5. Annealing positions of primers and primer sequences for 
RT-PCR analysis of rat PDE4A splice variants. Panel A, a schematic 
representation of the annealing positions for the RT-PCR primers on 
mRNA transcripts of rat PDE4A splice variants, RNPDE4A1A, 
RNPDE4A5A and RNPDE4A8. The primer pairs used in each reaction are 
highlighted in the same colours, with all sense primers indicated by arrows 
to the right and antisense primers indicated by arrows to the left. Panel 5, a 
table defining specificity of each primer, the primer nomenclature, the 
primer sequence, the expected size of each amplified fragment and the 
PCR cycling conditions. Each RT-PCR reaction was subjected to an initial 
15 min incubation at 95 ”C followed by 40 cycles, specified for each primer 
pair.
Plasmid Standards Rat-1 RNA
Gen.4A 4A1 4A8 4A5 Gen.4A 4A1 4A8 4A5
Size
(bp)
1018
517
396
220
Figure 3.6. RT-PCR analysis of Rat-1 cell total RNA using PDE4A 
specific primers. RNA isolated from Rat-1 cells was subjected to first 
strand cDNA synthesis followed by RT-PCR {see section 2.5.10.), using 
primers designed specifically to regions found within the generic PDE4A 
sequence (Gen 4A), to PDE4A1 specific sequence (4A1), PDE4A5 
specific sequence (4A5) and PDE4A8 specific sequence (4A8) {see Fig. 
3.5.). As controls plasmids encoding the relevant PDE4A isoform, as 
indicated, were subjected to the same PCR reactions. The PCR products 
were separated on a 2 % agarose gel and the PDE4A products from the 
Rat-1 RNA (right hand panel) were compared to the produces from PCR 
of the plasmid standards (left hand panel, for product sizes see Fig. 3.5.). 
The size of the standard DNA markers are indicated in base pairs (bp).
Standards
-150  kDa
-  100 kDa
-  75 kDa
Figure 3.7. Western blot analysis of PDE4B isoforms expressed in Rat- 
1 cells. Rat-1 cells were harvested in 3T3 lysis buffer and 100 /xg protein 
from the cell lysate (Rat-1) was subjected to SDS-PAGE on an 8 % gel 
alongside 25 pg recombinant PDE4B isoform standards of PDE4B1 (Bl, 
104 kDa), PDE4B2 (B2, 80 kDa), PDE4B3 (B3, 103 kDa) and PDE4B4 
(B4, 90kDa). The proteins were transferred to nitrocellulose and 
immunoblotted with a polyclonal PDE4B specific antibody, as described in 
section 3.2.2.. The positions and sizes of molecular weight markers are 
indicated on the right hand side.
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Figure 3.8. Annealing positions of primers and primer sequences for 
RT-PCR analysis of rat PDE4B splice variants. Panel A, a schematic 
representation of the annealing positions for the RT-PCR primers on 
mRNA transcripts of rat PDE4B splice variants, PDE4B1, PDE4B2 and 
PDE4B3. The primer pairs used in each reaction are highlighted in the 
same colours, with all sense primers indicated by arrows to the right and 
anti sense primers indicated by arrows to the left. Panel B, a table defining 
specificity of each primer, the primer nomenclature, the primer sequence, 
the expected size of each amplified fragment and the PCR cycling 
conditions. Each RT-PCR reaction was subjected to an initial 15 min 
incubation at 95”C followed by 40 cycles, specified for each primer pair.
Gen 4B 4B1 4B2 4B3 Markers
Size
(bp)
2036
1636
1018
517
396
Figure 3.9. RT-PCR analysis of Rat-1 cell total RNA using PDE4B 
specific primers. RNA isolated from Rat-1 cells was subjected to first 
strand cDNA synthesis followed by PCR {see section 2.5.10.), using 
primers designed specifically to regions found within the generic PDE4B 
sequence (Gen 4B, expected product size 786 bp), to PDE4B1 specific 
sequence (4B1, expected product size 929 bp), PDE4B2 specific sequence 
(4B2, expected product size 667 bp) and PDE4B3 specific sequence (4B3, 
expected product size 598 bp) {as shown in figure 3.8.). The PCR products 
were separated on a 2 % agarose gel the positions and sizes (in base pairs) 
of the standard DNA markers are shown on the right hand side.
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Figure 3.10. Western blot analysis of PDE4C isoforms expressed in 
Rat-1 cells. Rat-1 cells were harvested in 3T3 lysis buffer and PDE4C 
isoforms were isolated by immunoprécipitation using the PDE4C specific 
antibody, as described in section 3.2.3., from 1 mg cell lysate. The isolated 
protein (Rat-1) was subjected to SDS-PAGE on an 8 % gel alongside 25 
(ig recombinant PDE4C2 protein standard (4C2 Std., 80 kDa). The proteins 
were transferred to nitrocellulose and immunoprobed with the PDE4C 
specific antibody. The positions and sizes of molecular weight markers are 
indicated on the right.
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Figure 3.11. Western blot analysis of PDE4D isoforms expressed in 
Rat-1 cells. Panel A, 25 pg recombinant protein of the PDE4D splice 
variants (lane 2) were subjected to SDS-PAGE on an 8 % gel alongside 
100 |ig of Rat-1 lysate, harvested in 3T3 lysis buffer. The proteins were 
transferred to nitrocellulose and immunoblotted using a PDE4D specific 
polyclonal antibody directed against the C-terminus of PDE4D, as 
described in sections 3.2.4 and 2.3.8.. The recombinant PDE4D protein 
species of PDE4D1 (68 kDa), PDE4D2 (67 kDa), PDE4D3 (95 kDa) and 
PDE4D5 (105 kDa) and the positions of molecular weight markers are 
indicated. Panel B, PDE4D was immunoprecipitated from 1 mg Rat-1 cell 
lysate, using the PDE4D specific polyclonal antibody, as described in 
materials and methods. The isolated proteins (PDE4D IP) were subjected 
to SDS-PAGE on an 8 % gel and were transferred to nitrocellulose which 
was immunoblotted using a PDE4D specific monoclonal antibody (see 
section 3.2.4.). The isolated PDE4D isoform (-95 kDa) and the position of 
the molecular weight markers are indicated.
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Figure 3.12. Analysis of cell cycle distribution in an asynchronous 
population of Rat-1 cells. An asynchronous population of Rat-1 cells was 
dual labelled with BrdU-FITC and propidium iodide {see section 2.2.3.), 
harvested and the distribution of 20000 cells in the phases of the cell cycle 
was analysed by flow cytometry {see section 2.2.4.). The cell cycle 
distribution acquired by the CELLQuest acquisition programme is 
indicated on the histogram, with the peaks of cells laying in GO/Gl, S and 
G2/M phases indicated. Quantification of the cell cycle distribution was 
carried out using the MODrit"^*  ^ analysis package. Calculations of the 
distribution of cells within the phases of the cell cycle are displayed as a 
percentage of the analysed events in the accompanying table.
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Figure 3.13. Determination of the duration of a complete cell cycle in 
Rat-1 cells. Asynchronous Rat-1 cells were harvested at 3 h intervals, as 
indicated, and dual labelled with BrdU-FITC/PI {see section 2.2.3.). The 
distribution of 20000 of the sampled cells within the phases of the cell 
cycle was determined by flow cytometry {see section 2.2.4.). The 
distribution of cells within G I (O ) , S (O )  and G2/M (O ) are expressed as a 
percentage of all the cells analysed at that time point. The shown data are 
the means ± S.E. of 5 independent experiments.
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Figure 3.14. Arrest of Rat-1 cells in GO upon 48 h serum starvation.
Rat-1 cells were incubated in serum-free cell culture media for a period of 
48 h. Cells were harvested, dual labeled with BrdU-FITC and propidium 
iodide, and 20000 were analysed by flow cytometry (see sections 2.2.3. 
and 2.2.4.). The histogram denoting cellular DNA content of the sampled 
population was generated by the CELLQuest acquisition programme, and 
quantification was carried out using the MODfif^^ analysis package. The 
calculation of cell cycle phase distribution of the population is displayed 
as a percentage of the analysed events in the accompanying table. These 
figures are representative of three independent experiments.
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Figure 3.15, Arrest of Rat-1 cells at G l/S upon a double thymidine 
block. Rat-1 cells were treated with 2.5 mM thymidine for 16 h {top panel), 
or with 2.5 mM thymidine for 16 h, released for 8 h prior to re addition of 
2.5 mM thymidine overnight {middle panel) or with 2.5 mM thymidine for 
16 h then released for 14 h prior to readdition of 2.5 mM thymidine 
overnight {bottom panel), prior to cell harvest. The cells were dual labeled 
with BrdU-FITC/PI {see section 2.2.3.) and the distribution of 20000 of the 
treated cells within the cell cycle was analysed by flow cytometry {see 
section 2.2.4.). The histograms showing the cellular DNA content of the 
population were generated by the CELLQuest acquisition program, and 
quantification of the distribution of cells within the phases of cell cycle was 
carried out using the MODfit™ analysis package. The results are displayed 
in the accompanying tables as a percentage of the total cells analysed. 
These figures are representative of three independent experiments.
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Figure 3.16. Treatment of Rat-1 cells with olomucine. Rat-1 cells 
were treated with the 10 /iM cyclin dependent kinase inhibitor 
olomucine for 24 h. The cells were then harvested and dual labeled with 
BrdU-FITC/PI {see section 2.2.3.) and 20000 cells were analysed by 
flow cytometry {see section 2.2.4.). The histogram denoting cellular 
DNA content was generated by the CELLQuest acquisition programme, 
and quantification of the distribution of the population within the phases 
of the cell cycle was carried out using the MODfit™ analysis package. 
The distribution of cells within the phases of the cell cycle are displayed 
as a percentage of the total events analysed in the accompanying table. 
These figures are representative of two independent experiments.
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Figure 3.17. Arrest of Rat-1 cells in S and S/G2 upon incubation with 
aphidicolin. Aphidicolin was added cell culture media (2.5 mg/ml) which 
was incubated on Rat-1 cells for a 24 h prior to cells being harvested 
{Panel A) or for 24 h with a 3 h release from the block prior to the cells 
being harvested {Panel B). Cells were dual labeled with BrdU-FITC/PI 
{see section 2.2.3.) and 20000 cells were analysed by flow cytometry {see 
section 2.2.4.). The histogram denoting cellular DNA content was 
generated by the CellQuest acquisition programme, and quantification was 
carried out using the MODfit^^ analysis package. The calculation of cell 
cycle phase distribution is displayed as a percentage of the analysed events 
in the accompanying table. These figures are representative of three 
independent experiments.
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Figure 3.18. Treatment of Rat-1 cells with L-mimosine for 24 h. L-
mimosine was added to Rat-1 cells for 24 h. The cells were harvested and 
then dual labeled with BrdU-FITC/PI {see section 2.2.3.). 20000 cells were 
then analysed by flow cytometry (see section 2.2.4.). The histogram 
denoting cellular DNA content was generated by the CELLQuest 
acquisition programme, and quantification of the cell cycle distribution 
was carried out using the MODfit™ analysis package. The distribution of 
cells within the phases of the cell cycle are displayed in the accompanying 
table as a percentage of the total events analysed. These figures are 
representative of three independent experiments.
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Figure 3.19. Arrest of Rat-1 cells in M phase upon 14 h incubation 
with nocodazole. Nocodazole was added to the cell culture media (50 
ng/ml) which was incubated on Rat-1 cells for a period of 14 h. Cells were 
harvested and dual labeled with BrdU-FITC/PI (see section 2.2.3,) and 
20000 cells were analysed by flow cytometry (see section 2.2.4.), The 
histogram denoting cellular DNA content was generated by the 
CELLQuest acquisition programme, and quantification was carried out 
using the MODfit™ analysis package. The distribution of the sampled 
population within the phases of the cell cycle is displayed as a percentage 
of the analysed events in the accompanying table. These figures are 
representative of two independent experiments.
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Figure 3.20. Redistribution of Rat-1 cells within the cell cycle upon 
release of nocodazole block. Rat-1 cells were released from the 14 h 
incubation with 50 ng/ml media nocodazole (A) for 1 h (5), 2 h (C), 3 h (D) 
and 4 h (E) prior to harvesting. Cells were dual labeled with BrdU-FITC/PI 
{see section 2.2.3.) and 20000 cells were analysed by flow cytometry {see 
section 2.2.4.). The histogram denoting cellular DNA content was generated 
by the CELLQuest acquisition programme, and quantification was carried 
out using the MODfit' '^M analysis package. The calculation the distribution 
of the sampled population within the phases of the cell cycle is displayed as 
a percentage of the analysed events in the accompanying table. These 
figures are representative of three independent experiments.
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Figure 3.21. Differential expression and phosphorylation of marker 
proteins in Rat-1 cells isolated at different phases of the cell cycle.
Rat-1 cells were arrested in the indicated stages of the cell cycle (see 
sections 2.1.4.1. -  2.1.4.5.). The cells were harvested in 3T3 lysis buffer 
and 100 pg of protein from these cell lysates were subjected to SDS- 
PAGE on an 8 % gel. Proteins were then transferred to nitrocellulose and 
immunoblotted with specific antibodies raised against cyclin E (Panel A, 
52 kDa), cyclin Bl (Panel B, 58 kDa), phospho-ERK (Panel C, 42 and 
44 kDa) and phosphoMEK (Panel D, 45 and 46 kDa), as described in 
section 3.4.7.. The migratory positions of the proteins are indicated.
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Figure 3.22. Change in cAMP specific PDF activities in Rat-1 cell lysates 
isolated at different stages of the cell cycle. Rat-1 cells were isolated at specific 
stages of the cell cycle, as indicated (see sections 2.1.4.1 -  2.1.4.5.). The cells 
were harvested in 3T3 lysis buffer and the lysates were assayed for; Panel A total 
cAMP-specific PDE activity ( ■ ), Panel B PDE4 enzymatic activity ( □ ), 
determined as the rolipram-sensitive fraction of the cell lysate and Panel C PDE3 
(□) enzymatic activity, determined as the cilostomide-sensitive fraction of the cell 
lysate (see section 2.3.9.). These activities are compared directly to one another in 
Panel D. The changes in enzymatic activities of the different cell cycle phases are 
shown as the means ± S.E. of between four and eleven independent experiments.
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Figure 3.23. Change in specific PDE4 isoform activities in Rat-1 cell lysates 
isolated at different stages of the cell cycle. Rat-1 cells were isolated at specific 
stages of the cell cycle, as indicated, {see sections 2.1.4.1 -  2.1.4.5.) and harvested 
in 3T3 lysis buffer. The PDE isoforms were immunoprecipitated from 300 pg of 
these cell lysates, using specific antibodies raised to the C-termini of the 
individual PDE4 subfamilies, PDE4A (■, Panel A), PDE4B (□ , Panel B), PDE4C 
(■ , Panel C) and PDE4D (□ , Panel D) {see section 2.3.10.). The enzymatic 
activities of the isolated proteins were monitored by PDE assay {see section 
2.3.9.). The changes in activities of the isoforms in the different phases of the cell 
cycle are shown as the means ± S.E. of between three and seven independent 
experiments.
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Figure 3.24b. Quantification of changes in subcellular localisation of 
PDE4D protein in Rat-1 cells isolated at different phases of the cell 
cycle. Rat-1 cells were arrested at specified phases of the cell cycle and the 
lysates were subjected to crude fractionation by differential centrifugation. 
100 pi of the PI (□), P2 (■) and S (■) fraction were separated by SDS- 
PAGE the proteins were transferred to nitrocellulose and then 
immunoblotted using a PDE4D specific antiserum {see Fig. 3.24a.). The 
protein was then quantified by densitometric scanning of the immunoblots. 
The amount of PDE4D3 protein in each fraction is expressed as a 
percentage of the total PDE4D3 protein in the cell, the results are shown as 
the mean ± S.E. of four independent experiments.
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Figure 3.25. Analysis of PKA activity in Rat-1 cell lysates isolated at 
different phases of the cell cycle. Rat-1 cells were arrested at specific 
phases of the cell cycle, as indicated {see sections 2.1.4.1. -  2.1.4.5.), and 
harvested in extraction buffer {see section 2.4.1.1.). The lysates were 
assayed for active PKA as outlined in section 2.4.1. and the results are 
expressed as a percentage of the total PKA present in the cell lysate that 
could stimulated by exogenously added excess cAMP. The values are 
shown as the means ± S.E. of between three and five independent 
experiments assayed for active PKA.
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Figure 3.26. Analysis of CREB phosphorylation in Rat-1 cell lysates 
isolated at different phases of the cell cycle. Rat-1 cells were arrested in 
the indicated stages of the cell cycle {see sections 2.1.4.1.- 2.4.1.5.) and 
harvested in 3T3 lysis buffer. 100 pg of protein from the cell lysates were 
subjected to SDS-PAGE on an 10 % gel, transferred to nitrocellulose and 
immunoblotted with a specific antibody raised against PKA 
phosphorylated CREB. The migration of phospho-CREB (43 kDa) is 
indicated.
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Figure 3.27. The effect of PDE4 inhibition on the percentage active 
PKA in Rat-1 cells isolated at different phases of the cell cycle. Panel 
A Rat-1 cells were arrested at specific phases of the cell cycle, as 
indicated {see sections 2.1.4.1.- 2.4.1.5.), in the presence (■) or absence 
(□) of 10 pM of the PDE4 specific inhibitor, rolipram. The cells were 
harvested in extraction buffer {see section 2.4.1.1.) and the lysates were 
assayed for active PKA {see section 2.4.1.). The results are expressed as a 
percentage of the total PKA present in the cell lysate that could stimulated 
by exogenously added cAMP. The values are shown as the means ± S.E. 
of between three and five independent experiments. Panel B. A graph 
which highlights the approximate differences between the amount of 
active PKA in cells with and without treatment with 10 pM rolipram.
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Figure 3.28. Changes in cell cycle distribution of Rat-1 cells upon 
incubation with rolipram. Rat-1 cells incubated with (O ) and without ( o )  
10 |iM of the PDE4 specific inhibitor, rolipram were removed at 3 h time 
intervals over an 18 h period. The cells were dual labelled with BrdU- 
FITC/PI {see section 2.2.3.). The distribution of 20000 cells within G1 
{Panel ^), S {Panel B) and G2/M {Panel C) were measured by flow 
cytometry {see section 2.2.4.). The distribution of the cells in each phase is 
expressed as a percentage of all cells analysed at that time point. These 
data are shown as the mean ± S.E. of five independent experiments.
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Figure 3.29. Changes in cell cycle distribution of Rat-1 cells upon 
incubation with cilostomide. Rat-1 cells incubated with (o) and without (□) 
10 |iM of the PDE3 specific inhibitor, cilostomide were removed at 3 h time 
intervals over an 18 h period. The cells were dual labelled with BrdU/PI 
{see section 2.2.3.) and the distribution of 20000 cells within G1 {Panel A), 
S {Panel B) and G2/M {Panel C) were measured by flow cytometry {see 
section 2.2.4.). The distribution of the cells in each phase is expressed as a 
percentage of all cells analysed at that time point. These data are 
representative of four independent experiments.
Quadrant location Cell No.
(percentage of total cells 
analysed)
Asynchronous Mitotic
Lower Left (LL) 63 % 73 %
Lower Right (LR) 4% 5%
Upper Left (UL) 3 % 8 %
Upper Right (UR) 29% 14%
Table 3.1. Quantification of the proportion of apoptotic Rat-1 cells on an 
FLl-H vs FL2-H density plot when treated with nocodazole. Rat-1 cells 
were subjected to nocodazole-induced mitotic arrest (see section 2.1.4.5.) and 
were then harvested and stained with Annexin V-HTC and propidium iodide 
{see section 2.2.5.1.). The labelled cells were collected by FACs and analysed 
using the CELLQuest acquisition package, on a density plot of FLl-H  vs 
FL2-H (see section 2.2.5.2.). The distribution of cells within the four 
quadrants of the density plot are indicated, which corresponds to the amount 
of dual labelled apoptotic cells (UR) and intact cells (LL) and the single 
labelled popullation (LR and UL).
Celll Cycle Phase Fold change in PDE4D3 
expression (per 25 pg cell 
lysate)
Asynchronous 1 + 0
GO 0.8 ± 0.25
Gl/S 0.93+0.16
S 1.02 + 0.06
S/G2 0.9 + 0.01
M 1.05 + 0.05
Table 3.2. Assesment of PDE4D3 protein expression in Rat-1 cells 
isolated at different phases of the cell cycle. Rat-1 cells were arrested at 
different phases of the cell cycle {see sections 2.1.4.1 -  2.1.4.5., as 
indicated) and the concentration of PDE4D protein within 25 jttg cell lysate 
were determined by ELISA {see section 2.3.3.). The changes in PDE4D 
protein concentrations are expressed as the fold change in comparison to 
levels expressed in asynchronously isolated cells. The results are shown as 
mean ± S.E. of three independent experiments.
Chapter 4
Investigation of PDE4D3 in mitosis
1 4 0
4.1. Introduction
Mitosis is the stage in the cell cycle at which cell division takes place. It can be separated 
into five distinct phases. In prophase the chromosomes condense and nuclear envelope 
breakdown occurs (Nigg, 2001). In prometaphase the mitotic spindles are formed to which 
the chromosomes attach, and the alignment of chromosomes along the metaphase plate 
then takes place during metaphase (Leblond and El Alfy, 1998). At the onset of anaphase 
the sister chromatid cohesion is reduced, they separate and migrate to the opposite poles of 
the cell and telophase determines the time at which the cell physically separates by 
cytokinesis, producing two daughter cells (Leblond and El Alfy, 1998, see Fig. 3.2.). To 
maintain the ordered progression through mitosis, highly regulated intrinsic mechanisms, 
which depend on multiple feedback loops, have evolved. Our understanding of the control 
of mitotic progression is a rapidly evolving, with an increasing number of kinases and 
phosphatases being identified in achieving the regulation of mitosis.
4.1.1. PKA and mitotic regulation
The onset of mitosis, which involves the condensation of chromosomes and the breakdown 
of the nuclear envelope, is controlled by the formation and activation of the maturation- 
promoting factor (MPF). The MPF is an active kinase complex formed between the cyclin 
expressed in mitosis, cyclin B, and the kinase unit, cdkl (also known as p34 cdc2). Exit 
from mitosis requires the activation of the anaphase promoting complex (APC) or 20S 
cyclosome, a multi-subunit complex that functions as a cell cycle dependent ubiquitin 
ligase, targeting cyclins for proteolysis by the 26S proteasome (Morgan, 1999).
Down-regulation of PKA activity appears to be essential for the induction of mitosis 
(Lamb et al., 1991) as it regulates the mechanisms that lead to mitotic spindle formation 
(Browne et al., 1990) and nuclear envelope breakdown (Lamb et al., 1991). Elevation of 
cAMP prior to metaphase inhibits mitotic progression as active PKA compromises the 
activity of the MPF (Fernandez et al., 1995; Hohmann et al., 1993; Oh et al., 1996) and 
thus the nuclear envelope persists (Lamb et ah, 1991). Cellular PKA activity is minimal at 
metaphase (Zeilig et ah, 1976), but increases as the cells pass from metaphase through to 
anaphase and reaches a peak at the M/Gl transition (Grieco et ah, 1996). This reactivation 
of PKA is required for the reformation of the nuclear envelope at M /Gl transition (Steen et 
ah, 2000). Thus elevating levels of cAMP after metaphase increases the rate of cells 
transition through mitosis (Zeilig et ah, 1976).
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The spatial regulation of PKA-mediated signalling cascades during the cell cycle appears 
to be very important. PKA, in fibroblasts, co-localises with MPF at the centrosome 
(Toumier et al., 1991) where it is held through an interaction with AKAP75 (Keryer et al., 
1998). The PKA regulatory subunit, R lla, is targeted for phosphorylation by the active 
MPF, during the early stages of mitosis, which causes its redistribution from the 
centrosome/golgi to the cytosol (Keryer et al., 1998).
Formation of the active APC, at the onset of anaphase, is regulated by several mechanisms 
including cell cycle specific phosphorylation and dephosphorylation of its component 
subunits (Yanagida et al., 1999; Ishii et al., 1996). The specificity of the targets for APC- 
dependent ubiquitinylation is determined by the interaction of the APC with WD-repeat 
proteins (Anghileri et al., 1999). The formation and activation of the APC complex is 
inhibited at the onset of mitosis by dominant PKA phosphorylations of the Cut4, Cut9 
(mammalian homologue, Cdc7) and Cut20 (mammalian homologue, Tsg24) subunits 
(Kotani et al., 1998; Yamashita et al., 1996). Only when PKA activity is down-regulated at 
metaphase (Kotani et al., 1998) by an as yet unidentified mechanism and only when these 
subunits are dephosphorylated by protein phosphatse-1 (Yanagida et al., 1999) is the APC 
formed and activated (Fig. 4.1.). Once activated, mitotic cyclins are targeted for 
degradation and the cells progress through the M/Gl transition.
4,1.2. PDE4D3 function, localisation and modification
In order to establish spatio-temporal signalling cascades within cells, defined cAMP 
concentration gradients exist. PDE4 isoforms have specific subcellular localisations, due to 
their ability to interact with membranes and scaffolding proteins (Shakur et al., 1995; 
Dodge et al., 2001). As such their reactivities may underpin the creation, stabilisation and 
shaping of such gradients of cAMP and hence PKA activity in cells. PDE4D3 maintains 
specific subcellular localisations through its ability to complexes with the 
scaffolding/structural A-kinase anchoring proteins (AKAPs) (Dodge et al., 2001; Tasken et 
al., 2001; Verde et al., 2001). The muscle selective AKAP (mAKAP) co-ordinates the 
formation of a complex between PKA and PDE4D3 which maintains a cAMP signalling 
module that establishes a negative feedback loop to maintain basal cAMP levels (Dodge et 
al., 2001). PDE4D3 can also co-localise with the PKA R lla  and RIip regulatory subunits 
at the centrosome of Sertoli cells in a complex co-ordinated by AKAP450 (Tasken et al., 
2001). Centrosomal and Golgi localisation of PDE4D3 has also been associated with its 
ability to form a complex with a novel structural protein called myomegalin (Verde et al., 
2001).
PDE4D3 activity is modified post-translationally by phosphorylations mediated by both 
PKA and ERK (Sette and Conti, 1996; Hoffmann et al., 1999). PKA phosphorylates 
PDE4D3 at Ser^  ^ and Ser^ "^  residues. The phosphorylation of Ser^ induces a 
conformational change that disrupts the interaction between UCR2 and the catalytic region 
of the protein causing an increase in the Vmax of the enzyme (Sette and Conti, 1996) 
(Hoffmann et al., 1998; Lim et al., 1999). It is unclear what the physiological relevance of 
the Ser phosphorylation might be.
Phosphorylation of PDE4D3 by ERK occurs at Ser^^  ^ within the catalytic unit and this 
leads to a marked reduction of PDE4D3 activity (Hoffmann et al., 1999; MacKenzie et al.,
2000). This inhibitory effect of ERK phosphorylation is orchestrated by the regulatory 
UCRl and UCR2 domains found in PDE4D3, as ERK phosphorylation of the ‘naked’ 
PDE4D catalytic unit has little effect on activity (Baillie et al., 2000). ERK inhibition of 
PDE4D3 can be expected to increase cAMP levels and activate PKA. Indeed, this provides 
a unique feedback system as the activated PKA can phosphorylate PDE4D3 on Ser^ "^ . This 
serves to negate the inhibitory effect of ERK phosphorylation (Baillie et al., 2001).
Phosphatidic acid, a phospholipid which has been implicated in the stimulation of 
proliferation of fibroblasts, can also increase the activity of recombinant PDE4D3 protein 
(Nemoz et al., 1997). Phosphatidic acid has been shown to interact directly with PDE4D3 
at a site which has been mapped to the N-terminus of the UCRl domain, within the same 
region as the Ser^'^PKA phosphorylation motif (Grange et al., 2000).
In this chapter I set out to characterise the modification which led to the activation of 
PDE4D3 during mitosis, as shown previously in chapter 3. This was done in an attempt to 
identify the control mechanisms that could link the activation of PDE4D3 to the decrease 
in PKA activity that also takes place upon entry of cells into mitosis.
Results 
4.2 Characterisation of PDE4D3 in nocodazole-induced mitosis
In Chapter 3, I showed the specific activity of PDE4D markedly increased in Rat-1 cells 
isolated in mitosis, when compared to the PDE4D activity in asynchronous cells. The Rat- 
1 fibroblasts only express the long PDE4D3 isoform, so this isoform was further studied 
during mitosis with a view to understanding the nature of the modification responsible for 
its increased activity.
4.2.1. Changes in PDE4D electrophoretic mobility during mitosis
To determine whether the increase in PDE4D3 activity coincided with a change in the 
electrophoretic mobility of PDE4D3, Rat-1 cell lysates from cells arrested at different 
stages of the cell cycle (Materials and methods 2.1.4) were immunoblotted with the 
PDE4D C-terminal specific antiserum. The lysate from the Rat-1 cells isolated in mitosis 
showed a change in electrophoretic mobility of PDE4D3, with about 35 % of the PDE4D3 
protein migrating with a reduced electrophoretic mobility compared to the native PDE4D3 
protein (Fig 4.2.). The PDE4D3 migrated as two electrophoretically shifted species, with a 
lower and hyper-shifted band, now referred to as stage 1 (which migrates with an apparent 
molecular weight of approximately 100 kDa) and stage 2 (which migrates with an apparent 
molecular weight of 102 kDa) respectively (Fig. 4.2.).
4.2.1.1. Identification of electrophoretically retarded PDE4D species in Rat-1 
cells
To confirm that the proteins migrating at stage 1 and stage 2 in mitosis were in fact 
modified PDE4D3 protein and not PDE4D5, a long form PDE4D that migrates with a 
higher molecular weight of 105 kDa, lysates from Rat-1 cells arrested in mitosis were 
immunoblotted with the Genosys ‘224’ antibody. This is a PDE4D5 specific antibody that 
has been raised in sheep to the peptide MAQQTSPDTLTVPEVDNPHC, which 
corresponds to residues within the unique N-terminal region of PDE4D5. No PDE4D5 
immunoreactivity was detected in either the asynchronous or mitotic Rat-1 cell lysates 
(Fig. 4.3.).
4.2.2. Subcellular distribution of PDE4D3 protein in mitosis
PDE4D3 is associated with the both the cytosolic and particulate fraction of the cell, with 
approximately 17 % of the protein present in the 100000 g pellet upon subcellular 
fractionation of VSMCs (Bolger et al., 1997). A similar amount of particulate associated 
PDE4D3 was seen in Rat-1 cells and the majority of the PDE4D3 was found to remain 
within the cytosol at all phases of the cell cycle (see Figures 3.24a. & 3.24b.). To 
determine in which subcellular fraction the modified PDE4D3 was associated in mitotic 
cells, fractionation of Rat-1 cells was done by two methods of differential centrifugation 
were carried out (Materials and methods 2.3.1.2. and 2.3.1.3.). The resulting subcellular 
fractions were then immunoblotted using the PDE4D specific antiserum. The 
electrophoretically shifted species of the PDE4D3 were found to be predominantly 
associated with the cytosolic fraction of the cells. There was also a very small amount of 
the stage 1 shifted PDE4D3 protein associated with the P2, microsome fraction (Figs. 4.4a. 
& 4.4b.).
4.2.3. Modification of PDE4D3 as cells accumulate in mitosis
In order to investigate the increase in PDE4D activity, and the coincidental decrease in the 
PDE4D3 electrophoretic mobility in cells isolated in mitosis, the addition of nocodazole to 
asynchronous Rat-1 cells over a 24 h period was carried out. The accumulation of cells in 
mitosis and the alterations in PDE4D3 activity and electrophoretic mobility were then 
analysed.
4.2.3.1. Nocodazole induced modification of PDE4D3 is not brought about by 
disruption of microtubule dynamics
High concentrations of nocodazole (200 nM-10 jiiM) cause the disruption of microtubular 
dynamics (Mikhailov and Gundersen, 1998). This disruption is a rapid process with the 
microtubules showing disorder within 1-2 h of nocodazole treatment. At lower 
concentrations (1 nM), and over longer time-courses, nocodazole induces cell cycle arrest 
at mitosis by interfering with the microtubule dynamics (Jordan et al., 1992). To ascertain 
whether the modification(s) of PDE4D3, which caused a decrease in its electrophoretic 
mobility, were specifically due to a mitotic event or as a cause of microtubule disruption 
per se, asynchronous cells were treated with a range of concentrations of nocodazole, from 
50 ng/ml to 5 |Lig/ml, for 2 h (Fig. 4.5.). There was no change in the electrophoretic
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mobility or activity of PDE4D3 with the incubation of the various concentrations of 
nocodazole on cells over this 2 h time course.
4.2.3.2. Accumulation of Rat-1 cells in mitosis with nocodazole treatment
To determine the rate of accumulation of Rat-1 cells in mitosis asynchronous cells were 
incubated with 50 ng/ml nocodazole over 7 h and samples removed at 1 h time intervals. 
The distribution of each sample of cells within the phases of the cell cycle was then 
analysed by flow cytometry (Materials and methods 2.2.). After a 4 h incubation of the 
cells with nocodazole approximately 54 % cells were isolated in the G2/M-phases of the 
cell cycle and by 6 -7 h, 90 -95 % of the labelled cells in the analysed population were in 
the G2/M-phases (Fig. 4.6.).
4.2.3.3. Electrophoretic mobility of PDE4D3 is reduced as cells accumulate in 
mitosis
I set out to determine the time-course of generation of the electrophoretic ally shifted 
species of PDE4D3. This was detected by immunoblot analysis over a 14 h time course, 
subsequent to incubation of the asynchronous cells with 50 ng/ml nocodazole. PDE4D3 
species with reduced electrophoretic mobilities were detected after 4 h incubation of cells 
with nocodazole (Fig. 4.7.). The amount of PDE4D3 protein, migrating at stage 1 and 
stage 2, increased over the time course of nocodazole incubation, reaching a maximal level 
after 14 h.
4.2.3.4. Activity of PDE4D increases as cells accumulate in mitosis
I then set out to analyse the time-course for the increase in PDE4D3 specific activity in 
Rat-1 cells upon nocodazole-induced mitosis. Thus, asynchronous cells were treated with 
50 ng/ml nocodazole and collected every 1 h or 2 h over a 24 h time course for PDE assay 
(Materials and methods 2.3.9.). The enzymatic activity of PDE4D increased steadily over 
the first 7 h of nocodazole addition and then declined slightly after 8 h, only to increase 
again, reaching a peak at 14 h after the start of incubation with nocodazole (Fig. 4.8.). 
After a 14 h nocodazole incubation the activity of PDE4D decreased slightly, then 
plateaued and remained constant after 16 h.
4.2.4. Modification of PDE4D3 as cells leave mitosis
In order to investigate the inactivation of PDE4D3 and the increase in electrophoretic 
mobility of PDE4D3 as cells leave mitosis, characterisation of PDE4D3 when cells were 
released from nocodazole-induced mitotic arrest was carried out.
4.2.4.1. Cell cycle analysis of Rat-1 cells released from nocodazole block
Rat-1 cells were released from nocodazole-induced mitosis and harvested at 30 min 
intervals for analysis of the distribution of the cells within the cell cycle by flow cytometry 
(Materials and methods 2.2.). It was found that after a 30 min release no cells had started to 
moved into G1 phase (Fig. 4.9.). After 1 h release there was an increase in the population 
of cells in G1 and after 2 h some 62 % of cells had moved from mitosis and into the next 
cell cycle.
4.2.4.2. Electrophoretic mobility of PDE4D3 is increased as Rat-1 cells leave 
mitosis
To ascertain when the increase in the electrophoretic mobility of PDE4D3 occurs as cells 
leave mitosis, Rat-1 cells were released from nocodazole-induced mitosis and harvested at 
30 min intervals post-release. The electrophoretic mobility of PDE4D3 was analysed by 
SDS-PAGE and immunoblotting (Materials and methods, 2.3.8.). It was found that as the 
cells were released from the mitotic block then the electrophoretic mobility of the PDE4D3 
increased (Fig. 4.10.). After 30 min release, there was a 4 % decrease in the amount of 
protein migrating in stage 2. The amount of protein migrating in stage 1 only decreased 
after 1.5 -  2 h after release from mitosis, when all PDE4D3 protein migrated at the same 
mobility as the native species.
4.2.4.3. Activity of PDE4D decreases as Rat-1 cells leave mitosis
To determine whether there was a change in the activity of PDE4D as cells were released 
from the mitotic block, Rat-1 cells were arrested in mitosis by incubation with nocodazole, 
then released and harvested at 30 min intervals. The PDE4D3 protein was isolated from 
cells by selective immunoprécipitation, and the enzymatic activity was determined by PDE 
assay (Materials and methods 2.3.10.). There was an almost 2-fold decrease in PDE4D3 
activity 30 min after cells were released from the mitotic block (Fig. 4.11.). After 1 h
release the activity of PDE4D3 increased slightly and subsequently decreased again after 
1.5 -2 h until it returned to the level of activity observed in asynchronous cells.
4.3. Identification of the PDE4D3 mitotic modification
Modifications of PDE4 isoforms, which have led to alterations in the activity of the 
enzymes include the direct phosphorylation by PKA (Sette and Conti, 1996), the direct 
phosphorylation by ERK (Hoffmann et al., 1999) and phosphorylation via a PI 3-kinase 
dependent mechanism, possibly acting through p70s6 kinase (MacKenzie et al., 1998). 
Interaction with lipids, such as phosphatidic acid (Grange et al., 2000), and interactions 
with AKAPs (Dodge et al., 2001) also modulated the activity of PDE4 enzymes. I 
undertook studies to identify the cause of the modification of PDE4D3 in mitotically 
isolated Rat-1 cells, which lead to the increase in the enzymatic activity and coincided with 
the shift in the electrophoretic migration of the protein by SDS-PAGE.
4.3.1. Mitotically Isolated PDE4D3 Is not ubiquitinylated
Ubiquitinylation of a protein occurs through the recognition of phosphorylated PEST 
motifs or phosphorylated destruction box motifs (R-(A/T)-(A)-L-(G)-X-(I/V)-(G/T)-(N)) 
found on cell cycle regulatory proteins (Ciechanover et al., 2000). Many proteins are 
targeted for ubiquitinylation during mitosis and such a modification could decrease the 
electrophoretic mobility of a protein. There are two potential PEST motifs located within 
the extreme C-terminus of PDE4D3, from residues 569-590 and 633-668. To investigate 
whether ubiquitination modifies PDE4D3 during mitosis, PDE4D3 was isolated by 
immunoprécipitation from mitotic cells and immuno-probed with an anti-ubiquitin 
antibody, raised in rabbit to ubiquitin conjugated to keyhole limpet haemocyanin using 
glutaraldehyde (Haas and Bright, 1985). No ubiquitinylation of PDE4D3 was observed 
(Fig. 4.12.).
4.3.2. In vivo phosphorylation of PDE4D3 with ^^ P orthophosphate
To determine whether the mitotic modification of PDE4D3 was due to a phosphorylation 
event, cells were arrested in mitosis, by treatment with 50 ng/ml nocodazole, prior to being 
labelled in vivo with [^^P]-orthophosphate (Materials and methods 2.4.4.). Once the cells 
were labelled PDE4D3 was isolated by immunopurification (Materials and methods 
2.3.10) and analysed for incorporated ^^P by phosphorimage analysis (Materials and 
methods 2.4.4.). The immuno-isolated PDE4D3 protein was found to be phosphorylated in
asynchronous cells, and when analysed by densitometry 1.3 -fold more was 
incorporated in PDE4D3 in the mitotic cells {Fig. 4.13.). However, the electrophoretically 
retarded stage 1 and stage 2 species of PDE4D3, observed by immunoblotting whole cell 
lysate from mitotic cells {Fig. 4.13.), was not detected on the phosphorimage of the ^^ P 
labelled PDE4D3.
4.3.3. The mitotic modifications of PDE4D can be maintained by 
phosphatase inhibition
Although the shifted species of PDE4D3 could not be detected by in vivo phosphorylation, 
the phosphorylation the protein was subjected to further investigations. Firstly, an attempt 
was made to maintain the activated and shifted species of PDE4D3, by inhibiting 
phosphatases, as the cells were released from the mitotic block.
4.3.3.1 Electrophoretically shifted species of PDE4D3 are maintained upon 
addition of okadaic acid to mitotically released cells
Okadaic acid (OA) inhibits of protein phosphatase 1 (PPl) at concentrations of 10 -15 nM 
but can selectively inhibit protein phosphatase 2 A (PP2A) at the much lower 
concentrations of 0.1 nM (Cohen et al., 1990). To investigate whether phosphatase 
inhibition could facilitate an increase in the electrophoretic mobility of PDE4D3 as cells 
leave mitosis, Rat-1 cells were released from nocodazole-induced mitotic arrest for 2 h in 
the presence of a range of OA concentrations. The loss of the PDE4D3 forms of reduced 
electrophoretic mobility (stage 1 and stage 2) seen as Rat-1 cells leave mitosis (Fig. 4. 10.) 
was inhibited by OA in a concentration dependent fashion (Fig. 4.14.). With 19 % of 
PDE4D3 migrating as a shifted species at 200 nM OA, 33 % of PDE4D3 migrating with 
the shifted PDE4D3 species at 500 nM OA and 37 % PDE4D3 migrating with the shifted 
species at 1000 nM.
4.3.3.2. Elevated PDE4D activity is maintained with Okadaic acid addition to 
mitotically released cells
As the shifted stage 1 and stage 2 species of PDE4D3 were maintained with OA 
incubation on cells released from mitosis (see section 4.3.3.1.) the effect that this same 
incubation with OA had on the activity of PDE4D3 was assessed. Rat-1 cells were thus 
released from nocodazole-induced mitotic arrest over a period of 2 h in the presence of a 
range of OA concentrations. As above, PDE4D3 was immunopurified from the lysate and
its activity determined. The decrease in PDE4D3 activity observed over a 2 h release 
period from mitosis was blocked by OA in a concentration dependent fashion {Fig. 4.15.). 
With PDE4D3 maintaining a 1.1 -fold increase in activity in the presence of 100 -  200 nM 
OA, a 1.3 -fold increase with 500 nM OA and a 1.8 -fold increase in the presence of 1000 
nM OA.
4.3.4. Phosphatase treatment of mitotic PDE4D3
I further investigated the phosphorylation-state of PDE4D3 during mitosis by treating 
mitotic PDE4D3 with phosphatase to determine the effect of dephosphorylation of the 
protein on its activity and electrophoretic mobility. Lysate extracted from Rat-1 cells 
arrested in mitosis was treated with calf intestinal alkaline phosphatase (CIAP) to remove 
all phosphate groups from the protein (Materials and methods 2.4.2.). Such phosphatase 
treatment of PDE4D3 caused the stage 1 and stage 2 forms seen in mitosis, to disappear 
and a single form migrated at the same molecular weight as the native form of the protein 
(-95 kDa), when analysed by SDS-PAGE (Fig. 4.16.).
The activity of the PDE4D3, after CIAP treatment of mitotic lysate, was also analysed. 
This showed that the removal of phosphate by CIAP caused a 3 -fold decrease in the 
activity of the protein thus activity of mitotic PDE4D3 returned to levels found in 
asynchronous cells {Fig. 4.17.).
4.3.5. Utiiisation of staurosporine to identify the nature of the mitotic 
modification of PDE4D3
The elevation of PDE4D3 activity and the change in the electrophoretic migration of 
PDE4D3 protein in Rat-1 cells arrested in mitosis appeared to be due to a phosphorylation 
event. Indeed, phosphatase inhibition by OA served to maintain the activity and the shifted 
species of PDE4D3 and the treatment of PDE4D3 with CIAP reduced activity and 
removed the stage 1 and stage 2 species of PDE4D3 with lowered electrophoretic mobility. 
A study was therefore undertaken to try to identify the kinase that was targeting PDE4D3 
for phosphorylation during mitosis.
The general kinase inhibitor staurosporine has specificity for PKA (IC50 = 7 nM), PKC 
(IC50 = 0.7 nM), CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 =1.3 nM), 
PKG (IC50 = 8.5 nM), cdk2 (IC50 = 0.07 nM), Chkl (IC50 = 20 nM) and Janus kinase 
(JAK2, IC50 = 100 nM). Staurosporine is also known to inhibit many kinases at higher
concentrations due to the similarities of its structure to the adenosine group on ATP 
(Toledo and Lydon, 1997). This was used initially to decrease the activity of a number of 
kinases that could be active in the mitotic cells, in an attempt to eliminate the bandshift and 
activity increase of PDE4D3.
4.3.5.1. Staurosporine increases the electrophoretic mobility of mitotically 
modified PDE4D3
A range of staurosporine concentrations were incubated on Rat-1 cells arrested in mitosis 
for 2 h in an attempt to identify potential kinases and eliminate other candidate kinases that 
could be targeting PDE4D3 during mitosis. The electrophoretic mobility of PDE4D3 from 
mitotic cells treated with staurosporine was analysed by SDS-PAGE an immunoblotting 
{Fig. 4.18.) and it was determined that migration of the shifted species of PDE4D3 protein 
was ablated when staurosporine at concentrations above 10 nM were incubated with the 
mitotic cells {Fig. 4.18.). However, at lower staurosporine concentrations, no alteration in 
PDE4D3 electrophoretic mobility were observed {Fig. 4.18.).
To ascertain the rate at which staurosporine ablates the PDE4D3 modification a time 
course of staurosporine incubation on mitotic cells was carried out. Staurosporine (100 
nM) was incubated with mitotically arrested cells for up to 2 h and cells were harvested at 
various time points. The electrophoretic mobility of the PDE4D3 protein was analysed by 
SDS-PAGE and it was found that 100 nM staurosporine inhibited the phosphorylation of 
PDE4D3 in a time dependent fashion {Fig. 4.19.). All of the stage 2 migrating species of 
PDE4D3 was lost after 10 min incubation with staurosporine, increasing the amount of 
immunoreactive protein that migrated at stage 1. There was a 6 % decrease in the amount 
of PDE4D3 migrating with the stage 1 species of PDE4D3 after 20 min and all of the 
PDE4D3 protein migrated the same as the native, unmodified PDE4D3 (-95 kDa) after a 
60 min incubation of mitotic cells with staurosporine {Fig. 4.19.).
4.3.5.2. Staurosporine decreases the activity of mitotically modified PDE4D
As incubation of mitotic cells with staurosporine led to loss of the stage 1 and stage 2 
forms of PDE4D3, an investigation as to whether there was an accompanying down 
regulation of PDE4D3 activity was undertaken. Rat-1 cells were arrested in mitosis and 
then incubated with 100 nM staurosporine over a 2 h time course. During this time cells 
were removed at intervals and PDE4D3 isolated by immunopurific ati on so that its cAMP- 
PDE activity could be determined. After a 10 min period with 100 nM staurosporine there
was no change in PDE4D3 activity (Fig. 4.20.). After 20 min there was a 0.25 -fold 
decrease in PDE4D3 activity, after 30 min there was a 0.35 -fold decrease in activity and 
after 60 min staurosporine incubation with mitotic cells there was a 0.5 fold decrease in 
PDE4D3 activity. After 60 mins no further decrease in the PDE4D3 activity was observed,
4.3.5.3. Staurosporine does not induce premature exit of Rat-1 cells from 
mitosis
Staurosporine has been shown to induce premature exit of cells from mitosis, by by­
passing cytokinesis to produce hyperploid cells in yeast and glioma cell lines (Tsuiki et al.,
2001). Staurosporine also increases the rate at which cells leave mitosis when added to 
mitotically-released HeLa cell lines (Ling et al., 1998). To check that the changes in 
activity and electrophoretic migration of PDE4D3 upon staurosporine incubation on the 
mitotic Rat-1 cells was not due to their premature exit from mitosis, cells were analysed by 
flow cytometry for their distribution within the cell cycle (Materials and methods 2.2.). 
There was no premature exit of the cells from mitosis and there was no increase in 
hyperploid cells upon staurosporine treatment (Fig. 4,21.).
4.3.6. Use of specific kinase inhibitors to identify the kinase which
targets PDE4D3 in mitosis
Kinase inhibitors act by binding to the ATP site of the enzyme, as in the case of the cyclin 
dependent kinase inhibitor, olomucine (Abraham et al., 1995), or by binding competitively 
to the same site of the kinase as the target protein, as occurs with the PKC selective 
inhibitor chelerythrine chloride (Herbert et al., 1990). Both mechanisms prevent the 
transfer of the phosphate group of ATP to the target protein. Specific kinase inhibitors 
were utilised as a tool in a study to attempt to identify the kinase that modifies PDE4D3 in 
cells arrested in mitosis by nocodazole.
4.3.6.1. Protein kinase C inhibitors do not affect the mitotic modification of
PDE4D3
Staurosporine was initially recognised as a PKC specific inhibitor (Tamaoki et al., 1986). 
Therefore, as the mitotic modification of PDE4D3 was inhibited by staurosporine more 
selective PKC inhibitors were investigated to determine whether they too ablated the stage 
1 and stage 2 mobility shifted forms of PDE4D3 and decreased the activity of PDE4D3 in 
mitosis. Bisindolylmaleimide II and chelerythrine chloride, both highly specific inhibitors
of PKC were incubated on mitotic Rat-1 cells for up to 2 h. The electrophoretic shift and 
the change in PDE4D activity seen in Rat-1 cells arrested in mitosis was not affected by 
these inhibitors {The ejfects o f Bisindolylmaleimide are shown in Figs. 4.22. & 4.23. and 
the data for chelrythrine chloride are not shown).
4.3.6.2. Many commercially available specific kinase inhibitors do not affect
the mitotic modification of PDE4D3
With the PKC inhibitors having no effect on the modifications of PDE4D3 which occur in 
nocodazole induced mitosis, a panel of specific kinase inhibitors were incubated with 
mitotic cells for time courses up to 2 h. The inhibitors used included U0126 (10 jaM), H89 
(10 |LiM), genistein (10 juiM), 5,6-Dichloro-l-(3-D-ribofuranosylbenzimidazole (DRB, 10 
jliM), Wortmannin (1 mM), LY294002 (10 ^M), Olomucine (20 p,M), PD98059 (10 jiM), 
ML-7 (5 jliM). They target multiple intracellular signalling cascades, full details of which 
are shown in Table 4.1. The activity of PDE4D3 and the electrophoretic mobility of the 
PDE4D3 protein by gel electrophoresis after incubation of inhibitors on cells arrested in 
mitosis was analysed, none of these inhibitors decreased PDE4D3 activity or ablated the 
formation of stagel and stage 2 forms of PDE4D3 (Figs. 4.22. & 4.23.).
4.4. The effect of PKA activation on PDE4D3 in mitotic cells
The PKA inhibitor H89 had no effect on decreasing the activity of PDE4D or ablating the 
bandshifted species of PDE4D3 when incubated on Rat-1 cells isolated in mitosis 
(4.3.6.2.). However, PKA is a kinase which targets PDE4D3 for phosphorylation, a 
modification which increases the activity of the protein (Lim et al., 1999) and inhibits 
PDE4D3 electrophoretic migration by SDS-PAGE (Sette and Conti, 1996). A study was 
therefore undertaken to investigate the effect of activating PKA in mitotic cells on the 
modifications of PDE4D3, to determine whether it could enhance activation or increase the 
amount of PDE4D3 protein migrating with decreased electrophoretic mobility.
4.4.1. Forskolin increases the amount of 'mitotic' PDE4D3 showing retarded 
electrophoretic migration
Forskolin is an agonist for adenylate cyclase and, when incubated with cells, increases the 
concentration of cAMP enough to stimulate the PKA mediated phosphorylation of 
PDE4D3 (Liu and Maurice, 1999; Lim et al., 1999; Liu et al., 2000a; Sette and Conti, 
1996). Asynchronous cells and cells in nocodazole-induced mitosis were treated with 100
|0.M forskolin for 15 min and the electrophoretic mobility of PDE4D3 on SDS-PAGE was 
analysed. In the mitotic population there was an increase of 17 % in the proportion of 
PDE4D3 that migrated with the stage 1 and an increase of 14 % in the proportion of 
PDE4D3 that migrated with the stage 2 form of PDE4D3 which was accompanied by a 31 
% loss of the faster migrating ‘native’ PDE4D3. In fact, virtually all the PDE4D3 protein 
was migrating as the bandshifted stage 1 and stage 2 species (~70 % immunoreactive 
PDE4D3). In the asynchronous population of cells, treated with forskolin, there was also 
about 70 % of PDE4D3 that migrated with a reduced electrophoretic mobility, however it 
only migrated as a single shifted species {Fig. 4.24.).
4.4.1.1. Forskolin retarded PDE4D3 is insensitive to H89
H89 was initially identified as a specific inhibitor for PKA (Chijiwa et al., 1990; Geilen et 
al., 1992) although, subsequently, it has been found to inhibit other kinases at higher 
concentrations. The IC50 values of H89 for known kinases are; PKA (48 nM), Calmodulin 
kinase II (29.7 p,M), casein kinase I (38.3 pM), myosin light chain kinase (28.3 |xM), PKC 
(31.7 pM) (Calbiochem catalogue). H89, at a concentration of 10 jtiM, has been shown to 
ablate the PKA mediated phosphorylation of Ser^ "^  on PDE4D3 (Liu and Maurice, 1999). 
An investigation to see whether the forskolin-mediated increase in the proportion of 
PDE4D3 migrating with the retarded electrophoretic mobility was due to a PKA-specific 
phosphorylation event was carried out. Asynchronous and nocodazole arrested mitotic 
cells were pre-treated with 10 pM H89 for 10 min prior to the addition of 100 pM 
forskolin for 15 min. The electrophoretic mobility of PDE4D3 was then analysed by SDS- 
PAGE and immunoblotting. The pre-incubation of asynchronous cells with H89 ablated 
the forskolin-stimulated formation of the ‘bandshifted’ species of PDE4D3 {Fig. 4.24.). 
The pre-incubation of mitotic cells with H89 did not, however, completely abolish the 
forskolin-stimulated modification of PDE4D3 {Fig. 4.25.). There was a 10 % decrease in 
the amount of protein that comigrated with the stage 1 shifted PDE4D3 protein. However, 
there seemed to be only a 2 % decrease in the amount of PDE4D3 that migrated with the 
stage 2 form of PDE4D3 {Fig. 4.24.).
4.4.2. Forskolin increases the activity of mitotic PDE4D
Forskolin is known to activate PKA, which targets PDE4D3 for phosphorylation and leads 
to an increase in the activity of the protein (Sette and Conti, 1996). In order to ascertain 
whether stimulation of PKA could further enhance the activity of PDE4D3 in mitotic cells,
the effects of forskolin-treatment on PDE4D3 in both asynchronous and mitotic cells was 
studied. Nocodazole-treated mitotic cells and asynchronous cells were thus treated with 
100 |xM forskolin for 15 min and PDE4D3 was isolated by immunopurification. The 
enzymatic activity of the isolated PDE4D3 protein was analysed and found to have 
increased approximately 2.5-fold in asynchronous cells stimulated with forskolin. 
However, the activity of PDE4D3 in forskolin-stimulated mitotic cells was only increased 
by approximately 33%, when compared to the unstimulated cells. The forskolin-stimulated 
activation of PDE4D3 in mitotic cells did not increase to levels any higher than those in the 
forskolin-treated asynchronous cells (Fig. 4.25.).
4.4.2.1. Forskolin-stimulated PDE4D3 activity is insensitive to H89
To determine whether the forskolin stimulated increase in PDE4D3 activity from 
asynchronous and mitotic cells was brought about by a PKA mediated phosphorylation the 
PKA inhibitor H89 was incubated with asynchronous and mitotic cells for 20 min prior to 
forskolin stimulation. The enzymatic activity of isolated PDE4D3 was analysed and it was 
found that the forskolin-induced increase of PDE4D3 activity seen in asynchronous cells 
was reduced by 35 % when the cells were pre-treated with H89 (Fig. 4.25.). In contrast, the 
forskolin-induced increase of PDE4D3 aetivity seen in nocodazole-induced mitotic cells 
did not appear to decrease when the cells were pre-incubated with H89.
4.5. Identification of the potentiai phosphoryiation sites in 
PDE4D3
The kinase(s) responsible for the modifications of PDE4D3 during mitosis, causing 
increases in PDE4D enzymatic activity and causing the PDE4D3 protein to decrease its 
electrophoretic mobility, could not be identified by inhibition of kinases using several 
commercially available inhibitors. An alternative approach to identify the kinase(s) was 
therefore taken to try to ascertain the residues or peptide fragments of PDE4D3 that were 
being phosphorylated during mitosis and thus to use the motifs within these as a starting 
point for identifying the candidate kinase(s). Several analysis packages were used to 
investigate the potential phosphorylation motifs in PDE4D3 and then mutational analysis 
of potentially phosphorylated residues was carried out.
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4.5.1. Analysis packages used for identification of target sequence motifs in 
PDE4D3
There are several packages accessible over the Internet that can be utilised to predict the 
sites on a protein that could be phosphorylated by commonly studied kinases. NetPhos 2.0 
Prediction Server, at the Center for Biological Sequence Analysis, produces neural 
network predictions for serine, threonine and tyrosine phosphorylation sites in eukaryotic 
proteins with a sensitivity in the range from 69 to 96 %. PhosphoBase v2.0, a database of 
phosphorylation sites provided by the Center for Biological Sequence Analysis (Kreegipuu 
et al., 1999) is a service which implements a prediction algorithm based on substrate 
consensus sequences of some more common protein kinases. The results for these 
predicted protein phosphorylation sequence sites have to be interpreted with caution 
however, as many sequences that do not correspond to a consensus sequence can be 
phosphorylated and not all consensus phosphorylation sequences are indeed 
phosphorylated in vivo. The sites identified by these services were therefore only used as a 
guideline for the potential phosphorylation sites of the protein.
4.5.1.1. Predicted serine, threonine and tyrosine phosphorylation sites of 
PDE4D3
The amino acid sequence for the rat PDE4D3 isoform (Fig. 4.26.) was submitted for 
phosphorylation sequence prediction via the web at either the NetPhos prediction server 
(http://www.cbs.dtu.dk/services/NetPhos/I or at the PhosphoBase prediction server 
rhttp://www«cbd.dtu.dk/database/Phosphobase/predict/predform.htmn. The residues 
predicted to be phosphorylated and their calculated probabilities are shown in Tables 4.2 
and 4.3..
4.6. Mutational analysis of the modification of PDE4D3 during 
mitosis in alternative cell lines
PDE4D3 (accession number U50159.1) is a ‘long’ PDE4D isoform, which has a unique 15 
amino acid sequence at the extreme N-terminus, all other residues of the protein , are 
common to other long-form PDE4D isoforms (Bolger et al., 1997). In an attempt to 
identify the residue(s) of PDE4D3 targeted for modification during mitosis, truncated 
PDE4D constructs and PDE4D constructs containing mutants of specific serine and 
threonine residue were studied.
l O »
Rat-1 cells do not have a high transfection efficiency (personal observations and Bonfoco 
et al., 2001). Therefore an alternative cell line, HeLa cells (Materials and methods
2.1.1.2.), which have a high level of transfection efficiency, were utilised to enable the 
study of modifications of the mutated PDE4D3 constructs.
4.6.1. Endogenous PDE4D3/5 in HeLa ceils arrested in mitosis have reduced 
eiectrophoretic mobiiities
HeLa cells have been extensively characterised and used as a model for cell cycle studies 
by many different groups (for examples see Stephen et al., 1990; Molinari, 2000) and was 
a suitable cell line in which to study heterologously expressed mutant PDE4D3 constructs.
HeLa cells endogenously express both PDE4D3 and PDE4D5 isoforms at similar levels 
(Fig. 4.27.) and when the cells were blocked in mitosis a change in the electrophoretic 
mobility of both the PDE4D3 and PDE4D5 isoforms was observed when analysed by 
SDS-PAGE and immunoblotting with a PDE4D specific antiserum (Fig. 4.27.). The 
PDE4D3 protein from cells aiTested in mitosis appeared to migrate as a single shifted 
species, although a second shifted species could have co-migrate with the native PDE4D5 
protein. The PDE4D5 protein from HeLa cells arrested in mitosis appeared to migrate as 
two shifted species, similar to the pattern of migration observed for the PDE4D3 protein in 
mitotic lysates of Rat-1 cells (Fig. 4.27.).
4.6.2. Serine and threonine mutants of PDE4D3 are modified during mitosis
Mutant constructs of human PDE4D3, previously engineered in this laboratory (Hoffmann 
et al., 1998), were employed in an attempt to identify the residues phosphorylated by 
kinases in mitotic cell lysates.
4.6.2.1. Electrophoretic mobility of mutants of the PKA phosphorylated sites 
in PDE4D3 during mitosis
PDE4D3 and PDE4D5 both appear to undergo the same modification in cells arrested in 
mitosis as evidenced by bandshifts (Fig. 4.27.). Therefore, it might be concluded that a 
similar modification occurs in both proteins during mitosis so the sites modified might well 
be within the common PDE4D ‘long-form’ sequence.
I set out firstly to analyse whether Ser^ ,^ the PKA phosphorylation site located in the 
unique N-terminal 15 amino acids of PDE4D3, was responsible for the changes in motility 
and activity seen in PDE4D3 to occur in mitosis. The construct used encoded PDE4D3 
with the Ser^  ^residue mutated to alanine, it also had a VSV epitope tag at the C-terminus 
so that it could be selectively isolated from the endogenous PDE4D3 (Hoffmann et al., 
1998). The S13A-PDE4D3-VSV construct was transfected into HeLa cells (Materials and 
methods 2.1.3.) and the cells arrested in mitosis through incubation with nocodazole 
(Materials and methods 2.1.4.5). Under these conditions the SerlSAla mutant migrated at 
the same molecular weight as PDE4D3 on an SDS-PAGE gel and crucially, both the stage 
1 and stage 2 species of PDE4D3 were apparent {Figs. 4.28 and 4.29.). Furthermore, the 
stage 1 and stage 2 forms of PDE4D3 were no longer apparent after a 2 h incubation of the 
mitotic cells with 100 nM staurosporine {Fig. 4.28.), as was the case with wild-type 
PDE4D3, seen previously.
4.6.2.2. Analysis of the activity of Ser13Aia and Ser54Aia PDE4D3 mutants 
in mitosis
PKA phosphorylates PDE4D3 at both Ser^  ^ and Ser^ "^ . However, activation is attributable 
to phosphorylation of Ser^ "^  in UCRl (Sette and Conti, 1996). Given that the mitotic 
modification of PDE4D3 coincided with an increase in the enzymatic activity it was 
decided to analyse whether the two known PKA phosphorylation sites, Ser^  ^ and Ser^ "^  
were involved in this activation event. To analyse this VSV-tagged mutants of PDE4D3, in 
which either Ser^  ^ or Ser^ "^  had been mutated to alanine, were expressed in HeLa cells. 
These transfected cells were aiTested in mitosis and the PDE activities of the cells lysates 
were measured. There was a slight increase in the activity of wild-type PDE4D3, but no 
conclusive change in the activity of the mutant proteins was observed {shown within Fig. 4. 
30.).
4.6.2.3. The eiectrophoretic mobility of truncated PDE4D mutants in mitosis
A mutant PDE4D ‘long-form’ construct has previously been engineered which is truncated 
at the common splice junction of the PDE4D3, PDE4D5 and PDE4D4 ‘long’ isoforms. It, 
therefore, lacks the unique N-terminal regions of each of these species {Fig. 4.31.). A  
shorter truncated mutant of PDE4D, which lacks the UCRl and the LRl domains, has also 
been generated {Fig. 4.31.). Both mutants were transfected into HeLa cells (Materials and 
methods 2.1.3.), which were subsequently arrested in mitosis or left asynchronous 
(Materials and methods 2.1.4.5), and the electrophoretic mobilities of the N-terminally
truncated PDE4D proteins determined by SDS-PAGE and immunoblotting. The PDE4D 
protein truncated at the common ‘long form’ splice region behaved as the wild-type 
species, with decreased electrophoretic mobility observed when the cells were arrested in 
mitosis {Fig. 4.29.). The shorter truncate lacking the UCRl and LRl regions, however, 
showed no change in electrophoretic mobility when the HeLa cells were arrested in mitosis 
{Fig. 4.29.).
4.6.2.4. Analysis of the activity and electrophoretic mobiiity of other PDE4D3
mutants in mitosis
In an attempt to identify the involvement of putative phosphorylation targets in the 
residues between the PDE4D common ‘long-form’ splice junction and the beginning of 
UCRl these serine and threonine residues were mutated to alanine {Fig. 4.31.). All these 
mutants of PDE4D3 had altered electrophoretic mobility when the transfected cells were 
arrested in mitosis {Fig. 4.29.). However, when the activities of these PDE4D3 mutants 
were examined, from asynchronous or mitotic cells, there was no conclusive change in 
enzymatic activity of the protein {Fig. 4.30.).
4.7. I n  v i t r o  phosphorylation of PDE4D3
4.7.1. UCRl is phosphoryiated In vitro by mitotic kinases
In order to establish whether the UCRl region of PDE4D3 is targeted for phosphorylation 
by mitotic kinases, recombinant GST fusion proteins containing the UCRl region alone, 
the UCR2 region alone or the combined UCRl and UCR2 regions {Fig. 4.32.) were 
subjected to an in vitro phosphorylation with mitotic lysate from Rat-1 cells (Material and 
methods 2.4.5.2.). As a control for the reaction, the purified PKA catalytic subunit was 
used to try and phosphorylate the same recombinant proteins, as PKA is known to 
phosphorylate Ser '^^  in UCRl (Sette and Conti, 1996). The UCRl domain and the 
combined UCRl and UCR2 domains were shown to become phosphorylated by kinases 
present in mitotic lysates, whereas the UCR2 domain, when subjected to the same reaction 
conditions, remained unphosphorylated {Fig. 4.33.). The UCRl domain was 
phosphorylated by the isolated PKA catalytic subunit, as expected, whilst the UCR2 
domain remained unphosphorylated when subjected to the same reaction conditions {Fig 
4.33.).
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4.7.2. Phosphoryiation of PDE4D3 by mitotic kinases is within a different 
peptide to that targeted by PKA
It has previously been reported that when recombinant PDE4D3 protein that has been 
phosphorylated by the purified PKA catalytic subunit is then cleaved by cyanogen bromide 
it gives two peptides that incorporate ^^P. These peptides were found to contain either the 
Ser^  ^ or Ser^ "^  residue (Sette and Conti, 1996). In an attempt to identify the PDE4D3 
peptide phosphorylated by kinases present in mitotic or asynchronous cell lysate, a similar 
strategy of cyanogen bromide cleavage was employed, using full-length PDE4D3 
phosphorylated with either cell lysates or PKA catalytic subunit.
4.7.2.1. Cyanogen bromide cleavage of phosphopeptides
Cyanogen bromide (CnBr) reacts specifically with methionine residues in proteins and, 
under acidic conditions, leads to the cleavage of the peptide bond at the carboxy terminus 
of the amino acid. Methionine residues are generally in low abundance in proteins and 
cyanogen bromide cleavage, therefore, generally generates large peptides that can be 
analysed by SDS-PAGE (Van Der Geer et al., 1993). The peptides generated by cyanogen 
bromide cleavage of PDE4D3 {Table 4.4), which had been phosphorylated by kinases from 
either asynchronous or mitotic lysate from Rat-1 cells or purified PKA, were separated by 
SDS-PAGE. I identified two peptides of PDE4D3 phosphorylated by PKA and these 
migrated at molecular weights of 3.5 kDa and 6 kDa (Sette and Conti, 1996, Fig. 4.34.). 
The kinases present in asynchronous and mitotic lysates appeared to phosphorylate several 
PDE4D3 peptides. These species migrated with molecular weights of between 3 .5 -6  kDa, 
14 kDa, around 20 kDa and a large peptide that migrated at approximately 27 kDa. These 
four peptides appeared to be distinct from the two peptides phosphorylated by PICA. The 
kinases present in mitotic lysate from Rat-1 cells appears to phosphorylate PDE4D3 to a 
greater extent than the kinases in the asynchronous lysate as indicated by densitometric 
analysis {Fig. 4.34.).
4.7.3. 2D analysis of PDE4D3 peptides phosphorylated with mitotic lysate
To further analyse PDE4D3 phosphopeptides phosphorylated by kinases in mitotic cell 
lysate E. Coli expressed recombinant PDE4D3 protein was subjected to in vitro 
phosphorylation, using either lysate from asynchronous cells or cells isolated in mitosis. 
Isolated PDE4D3 was then digested, using trypsin, to generate peptides for 2D separation.
Trypsin hydrolyses peptide bonds at the carboxy terminal side of arginine (Arg) and lysine 
(Lys) residues (Cunningham, 1954), so might be expected to generate more peptides from 
PDE4D3 than cyanogen bromide mediated cleavage (section 4.7.2.).
The trypsin-generated peptides were separated by 2D electrophoresis on thin layer 
cellulose plates (materials and methods 2.4.6.). In four independent experiments three 
phospho-peptides from PDE4D3 appeared to be phosphorylated to a higher degree by 
kinases present in the mitotic lysate compared to the same peptides phosphorylated by 
kinases in the asynchronous lysate (Fig 4.35.).
4.7.4. HPLC identification of PDE4D3 peptides phosphoryiated with mitotic 
iysate
It was initially intended to extract the PDE4D3 phosphopeptides from the cellulose plates 
and to sequence them. However, cellulose plates contain contaminants that interfere with 
sequencing (Tavare and Issad, 2001) and to purify the peptides away from these 
contaminants would result in further loss of phosphorylated protein. As approximately 1 
picomole of peptide is required for sequencing, high performance liquid chromatography 
(HPLC) was employed in order to try and isolate PDE4D3 peptides phosphorylated during 
mitosis.
E.Coli expressed recombinant PDE4D3 protein was phosphorylated in vitro using lysate 
from asynchronous and mitotic cells in the presence of ^^P-ATP. The PDE4D3 protein was 
then digested, using trypsin, and the phosphorylated peptides isolated by HPLC (Materials 
and methods 2.4.7.). There were four peaks of radioactivity eluted that had been 
phosphorylated by kinases from asynchronous cell lysate and eleven radioactive peaks 
from PDE4D3 phosphorylated using mitotic cell lysate (Fig. 4.36.). The four radioactive 
peaks produced using asynchronous lysate were also present in the peptides 
phosphorylated by mitotic kinases. However, approximately 4-5 fold higher amounts of ^^P 
were incorporated into these peptides when subjected to mitotic lysate phosphorylation. 
Having isolated the PDE4D3 peptides associated with the radioactive peaks (Materials and 
methods 2.4.7.2.), their identification could then be carried out by mass spectrometry 
analysis.
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4.7.4.1. Mass spectrometry identification of PDE4D3 peptides 
phosphorylated by mitotic kinases
The four PDE4D3 peptides, referred to as A, B, C and D, that appeared to be highly 
phosphorylated by kinases from mitotic cells were submitted to the TingerPrints’ 
proteomics facility at the University of Dundee, where identification and sequencing of the 
peptides was carried out. The smallest peptide phosphorylated by kinases in mitotic lysate, 
peptide A, corresponded to residues 59-68 and mapped to a region within the N terminus 
of the UCRl domain of PDE4D3 {Fig. 4.37.). Another larger peptide from UCRl, peptide 
C, which corresponded to residues 73-98 of PDE4D3 was also phosphorylated by the 
mitotic kinases. There was one peptide, peptide B, from PDE4D3 that mapped to residues 
232/233 to 246 that was located to a region within the N terminal portion of the catalytic 
domain and another, very large peptide, peptide D, that mapped to residues 534 to 591 in 
the C terminal portion of the catalytic domain. This large peptide from the catalytic domain 
was hydrolysed further by the proteomics facility to enable sequencing and identification 
of the phosphorylated residue within.
4.7.4.2. Cycle burst identification of residues phosphoryiated in mitosis
The PDE4D3 peptides phosphorylated to a high level by kinases in mitotic lysate were 
sequenced using Cycle Burst and Edman degradation (TingerPrints’ Proteomics Facility, 
University of Dundee). This enabled the phosphorylated residues within the PDE4D3 
phosphopeptides to be identified. The results from this analysis are summarised in Figures 
4.38a. - 4.38d.
4.7.5. The activity of PDE4D3 is increased by in vitro phosphoryiation using 
kinases present in mitotic iysates
To determine whether the in vitro phosphorylation of PDE4D3 led to a similar increase in 
enzyme activity as that seen in vivo, PDE4D3 protein, immunopurified from a HEK-293 
cell line over-expressing PDE4D3, was subjected to ‘cold’ in vitro phosphorylation using 
kinases in both asynchronous and mitotic cell lysates (Materials and methods 2.4.5.5.). The 
enzymatic activity of PDE4D3 was then assayed. I found that PDE4D3 treated with the 
mitotic lysate under phosphorylating conditions had a higher level of activity compared to 
PDE4D3 treated under similar conditions with asynchronous lysate (Fig. 4.39.).
4.8. The effects of the mitotic increase in PDE4D activity on 
mitotic processes
I set out to determine whether the increase in PDE4D3 activity could influence processes 
related to mitosis. To do this, cells subjected to nocodazole-induced mitotic arrest were 
analysed for changes in PKA activity and mitotic progression upon the inhibition of PDE4 
activity, using the PDE4 selective inhibitor, rolipram,
4.8.1. Rolipram causes an elevation of PKA activity in mitotic ceils
Rat-1 cells that had been arrested in mitosis, where PDE4D3 is activated, were treated with 
10 \xM rolipram for up to 2 h. Cells were then harvested at set intervals, lysed and the PKA 
activity of these samples determined using the standard PKA assay (materials and methods 
2.4.1). The activity of PKA in mitotic cells increased 1.5 fold after a 10 min incubation 
with rolipram (Fig. 4.40.). This increase of PKA activity was maintained throughout the 2 
h time course of rolipram incubation. Note that I have shown previously (Chapter 3) that 
rolipram exerts but a small stimulatory effect on PKA activity in asynchronous cells but a 
profound effect in mitotic cells, where PDE4D3 activity is high.
4.8.2. Rolipram increases the rate of M/G1 transition
PKA activity is down-regulated in cells as they enter mitosis, enabling the activation of the 
maturation promoting factor (MPF, Fernandez et al., 1995; Oh et al., 1996) and nuclear 
envelope disassembly (Lamb et al., 1991). Inactivation of PKA prevents cells from 
completing mitosis by blocking them at metaphase (Grieeo et al., 1996). Reactivation of 
PKA at the metaphase/anaphase transition (Zeilig et al., 1976) is required for the 
reformation of the nuclear envelope (Steen et al., 2000) and the exit of cells from mitosis 
(Grieeo et al., 1996). I therefore undertook a study to investigate the effects of the 
inhibition of PDE4 activity on both mitotic progression and on the rate at which cells leave 
mitosis. Rat-1 cells arrested in nocodazole-induced mitosis were released from this block 
in the presence of 10 pM rolipram and the progression of the cells into the next G1 phase 
was monitored by FACs analysis. The Rat-1 cells incubated with rolipram progressed into 
the next G1 stage of the cell cycle at a quicker rate than the Rat-1 cells released from the 
mitotic block in the absence of a PDE inhibitor (Fig. 4.41.).
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4.9. Discussion
The PDE4D3 isoform is modified in Rat-1 cells and HeLa cells that are subjected to 
nocodazole-induced mitosis. This modification causes the 1.7 fold activation of PDE4D3. 
In addition, up to 35 % of PDE4D3 appears to be converted into species that migrate with 
reduced electrophoretic mobilities when analysed by SDS-PAGE. One of the ‘bandshifted’ 
PDE4D3 species has been called here stage 1, which has a slightly reduced electrophoretic 
mobility compared to the native PDE4D3 and appears to migrate with a molecular weight 
of approximately 100 kDa. The second was called stage 2, which exhibits a further 
reduction in electrophoretic mobility and appears to migrate with a molecular weight of 
approximately 102 kDa.
It is unclear as to the basis of the observation that only a proportion of PDE4D3 has an 
altered electrophoretic mobility. It could be, for example, that mitosis brings about a 
‘redistribution’ of only a small proportion of PDE4D3 to a subcellular location where it 
can be targeted for modification. However, in Rat-1 cells, the bandshifted PDE4D3 protein 
is found primarily in the cytosolic fraction, with a small amount associated with the 
microsomal and nuclear fractions. There was no apparent translocation of PDE4D3 in cells 
isolated at different phases of the cell cycle, thus the cytosolic distribution of PDE4D3 
suggests that if there are factors which limit accessibility of the protein to the modifying 
enzyme(s) they might be due to the formation of complexes with cytosolic proteins. 
Alternatively, modification of only a fraction of PDE4D3 could reflect a steady state level 
of modification by specific kinases and phosphatases whose balance is altered in the 
mitotic cells, compared to the asynchronous ones.
The modifications of PDE4D3, which led to its altered electrophoretic mobility and 
activity, appear to be specifically related to mitosis. It is only when Rat-1 cells treated with 
nocodazole accumulate in mitosis that the immunoreactive stage 1 and stage 2 forms of 
PDE4D3 were detected. The accumulation of cells in mitosis also led to a time dependent 
increase in PDE4D3 enzymatic activity. Incubating cells with nocodazole causes inhibition 
of microtubule assembly (Thyberg and Moskalewski, 1989). However, it does not appear 
to be the disregulation of microtubule dynamics per se that causes modification of 
PDE4D3 since short-term incubation with this drug did not affect the electrophoretic 
mobility or activity of PDE4D3, whilst it did cause disruption of microtubular 
cytoskeleton.
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Confirmation that the ‘bandshifts’ and the increase in PDE4D3 activity were due to a 
reversible mitotic event(s) was also indicated using Rat-1 cells released from nocodazole- 
induced mitosis. Cells rapidly leave mitosis when they are released from a nocodazole 
block (Hamilton and Snyder, 1982) and, as they pass through the latter phases of mitosis 
they enter G l. In doing this the species of PDE4D3 with reduced electrophoretic mobilities 
disappeared and the total PDE4D3 activity progressively decreased back to levels seen in 
asynchronous cells. These effects were inhibited by incubation of cells released from the 
mitotic block with high concentrations of the phosphatase inhibitor okadaic acid (OA, 
>200 nM). This suggests that the dephosphorylation of PDE4D3 leads both to a loss of 
species with lowered electrophoretic mobility and a restoration of lowered PDE4D3 
activity. The identification of the candidate phosphatase for this dephosphorylation of 
PDE4D3 upon mitotic exit was not ultimately proved. However, it was unlikely to be 
protein phosphatase 2A, as this species is sensitive to sub-nanomolar concentrations of OA 
(Cohen et al., 1990), as are the less common protein phosphatases (PP) such as PP3 
(Honkanen et al., 1991), PP4 (Brewis et al., 1993) and PP5 (Chen et al., 1994). Other 
potential candidate protein phosphatases, such as PP2B (Klee and Kiinks, 1978) and 
Cdc25, the cell cycle-dependent phosphatase which has been shown to have high activity 
during mitosis (Kishimoto and Yamashita, 2000; Honda et al., 1993; Gordon, 1991) are 
both insensitive to OA. It is thus possible that PPl may serve to dephosphorylate PDE4D3 
upon mitotic exit. However, further studies are needed to confirm this and to exclude any 
role of PP2B, Cdc25 and any other less common phosphatases, such as PP7, in 
dephosphorylating PDE4D3 upon mitotic exit. Indeed, further conformation that PPl 
specifically dephosphorylated PDE4D3 is also required.
Dephosphorylation of PDE4D3, by treatment of mitotic lysate with calf intestinal alkaline 
phosphatase, also led to both the disappearance of the stage 1 and stage 2 forms of 
PDE4D3 and to reduce, by 2.5-fold, PDE4D3 activity. Upon inhibition of kinase activities 
in mitotic cells it was shown that the general kinase inhibitor staurosporine ablated the 
appearance of the bandshifted species of PDE4D3. It also caused an approximate 2-fold 
reduction in the activity of PDE4D3 in mitotic cells, lowering it to a level comparable to 
that seen in asynchronous cells. Collectively, these results provide more evidence that 
PDE4D3 was specifically phosphorylated during mitosis and that such events served to 
both retard the electrophoretic mobility of a portion of total PDE4D3 and to increase 
PDE4D3 activity aproximately 2-fold in mitosis.
I was, however, seemingly unable to detect the stage 1 and stage 2 forms of PDE4D3 by in 
vivo labelling of the mitotic cells with ^^P orthophosphate, despite these species being
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evident on the immunoblot of the same nitrocellulose. This may be due to the fact that only 
-30 % of total PDE4D3 had such a reduced electrophoretic mobility in mitotic cells. Thus, 
if proteins had been exposed to the phosphorimage screen for a longer period the stage 1 
and stage 2 forms of PDE4D3 might have been detected. Neverthless, the incorporation of 
higher levels of ^^P into PDE4D3 migrating with the ‘native’ protein in mitotic cells 
suggests that the phosphorylation inducing the 'bandshift' and that increasing PDE4D3 
activity are two independent events.
Stimulation of mitotic cells with forskolin highlights the fact that the phosphorylation that 
causes activation of PDE4D3 occurs independently of the phosphorylation which alters the 
electrophoretic mobility of PDE4D3. When adenylate cyclase was activated; by forskolin, 
there was a 2-fold increase in the proportion of PDE4D3 protein that migrated with the 
stage 1 and stage 2 forms on SDS-PAGE, which coincided with only a 1.2-fold increase in 
PDE4D3 activity. If these two events were linked by the same phosphorylation then a 
proportional increase in activation of PDE4D3 would be expected to accompany the 
decrease in PDE4D3 electrophoretic mobility. Intriguingly, the increase in the proportion 
of PDE4D3 which migrated at the stage 2 position was insensitive to H89, as was the 
increase in activity of PDE4D3 in the forskolin stimulated mitotic cells. These 
observations suggest that the enzyme(s) modifying PDE4D3 in this situation was not PKA, 
but was activated in a cAMP-dependent fashion. This might suggest that either Epac or 
Rapl stimulate unidentified kinases to achieve this. Thus multiple phosphorylations of 
PDE4D3 in mitotic cells might be mediated by the action of multiple proteins.
PDE4 enzymes are known to be phosphorylated in cells by PKA (Sette and Conti, 1996) 
and ERK (MacKenzie et al., 2000). In an attempt to identify the specific kinase targeting 
PDE4D3 for modification in nocodazole-induced mitosis, several commercially available 
kinase inhibitors were incubated with mitotic cells. Unlike staurosporine, none of the 
specific kinase inhibitors employed either decreased the amount of protein migrating with 
the stage 1 and stage 2 shifted species of PDE4D3 or reduced the activity of PDE4D3. The 
fact that specific inhibitors of PKA and ERK were among these implies that the kinase 
targeting PDE4D3 in mitotic cells is one that has not been shown previously to 
phosphorylate PDE4 Isoforms.
There are multiple mitotic kinases for which there are yet no known commercially 
available inhibitors. These include the members of the Polo-like kinase (Plk) family (Clay 
et al., 1993), the Aurora kinases (Adams et al., 2001) and mammalian homologues of 
NIMA (never in mitosis A) family of kinases (Kandli et al., 2000). All of these kinases are
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activated at the onset or during mitosis, so may serve as potential candidates for 
phosphorylating PDE4D3 at the metaphase/anaphase transition. Plk isoforms, for instance, 
are activated during mitosis (Kotani et al., 1998; Gallant et al., 1995) and are known to 
target multiple substrates required for spindle formation (Lane and Nigg, 1996), ordered 
mitotic progression (Nigg et al., 1996) and cell division (reviewed in Donaldson et al., 
2001). Aurora kinases are activated in mitosis and are associated with the segregation of 
chromosomes (Kimura et al., 1997; Hannak et al., 2001). Potential targets for this kinase 
are continually being discovered and no details regarding the phosphorylation motif are 
known, so Aurora family of kinases may provide yet more candidate kinases that could 
target PDE4D3 during mitosis. The NIMA related kinases are thought to regulate multiple 
events associated with mitosis, such as assembly and maintenance of the centrosome and 
displays dynamic behaviour within cell localisations through the different stages of 
interphase and mitosis (Ha et al., 2002). As there are no inhibitors for these kinases, studies 
will have to be carried out using purified recombinant kinases in an attempt to determine 
whether they have the potential to phosphorylate PDE4D3 in mitosis and if they do 
phosphorylate PDE4D3 which sites they target.
Since the identification of the kinase(s) that modifies PDE4D3 during mitosis was not 
possible through treatment of cells with kinase inhibitors, analysis of potential 
phosphorylation motifs within the PDE4D3 protein sequence was performed. Some 
identified sites within the unique ‘long-form’ N-terminal region of PDE4D isoforms were 
then mutated in an attempt to ablate the bandshift of PDE4D3 and the concomitant increase 
in its activity in mitotic cells. Whilst no changes in these properties were observed with a 
range of point mutations in this region, a truncated mutant of PDE4D3 that lacked the 
UCRl and LRl domains did not ‘bandshift’ when the cells were arrested in mitosis. This 
suggests that residues phosphorylated during mitosis might lie within UCRl. It is known 
that modifications of the UCRl domain, either through phosphorylation by PKA (Sette and 
Conti, 1996; Hoffmann et al., 1998) or by interaction with phosphatidic acid (Grange et al., 
2000) can increase the activity of PDE4D3. These various data suggest that a 
phosphorylation of UCRl might be key to activation of PDE4D3 in mitosis. Further 
studies, using the isolated UCRl domain of PDE4D3, established that UCRl was indeed 
phosphorylated by kinases in mitotic cell lysates, whereas the UCR2 was not. These 
observations are entirely consistent with the model of activation of PDE4D3 proposed by 
both Lim et al. (1999) and Beard et al. (2000) using independent methods. These envisage 
that phosphorylation of UCRl induces a conformational change of the protein, thus 
relieving an inhibitory interaction between the UCR2 and the catalytic domain.
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Phosphorylation of full-length PDE4D3 protein and phosphopeptide mapping by 2D 
electrophoresis identified at least three peptides that were more highly phosphorylated by 
mitotic than asynchronous lysate. Separation of these peptides by reverse phase HPLC 
identified four peptides that were more highly phosphorylated by kinases present in mitotic 
lysate. Two of the identified peptides mapped to the UCRl domain, both of these 
incorporated approximately 1 pmole ^^P in the in vitro kinase reaction using mitotic lysate. 
One of these peptides mapped to the N-terminus of UCRl and was phosphorylated at 
Ser^\ another longer peptide, at the C-terminus of UCRl, was phosphorylated at Ser^ .^ 
Both of these reflect novel phosphorylations of the UCRl domain. Ser^  ^ is proximal to 
residues 31-59, which have been identified as being crucial for the interaction with 
phosphatidic acid (Grange et al., 2000) and also to the PKA target residue Ser^ "^  (Sette and 
Conti, 1996). In the PhosphoBase prediction Se/^ had the potential to be phosphorylated 
by Calmodulin dependent kinase II (CaMII) and PKA. It has been shown in this study that 
PKA is unlikely to play a role in the activation of PDE4D3 or alteration in PDE4D3 
electrophoretic mobility, when analysed by SDS-PAGE. Additionally, mutational analysis 
(Sette and Conti, 1996) have shown PKA only phosphorylates Ser^^ and Ser^ "^  in PDE4D3. 
However, calcium oscillations appear to be a property of mitotic progression (reviewed in 
Whitaker, 1997). CaMII has been shown to be required for metaphase/anaphase transition 
in HeLa and endothelial cells (Petzelt et al., 2001), and is thought to facilitate activation of 
Cdc25, the phosphatase activated upon mitotic onset (Patel et al., 1999). Therefore, CaMII 
could potentially be the kinase phosphorylating Ser^  ^ in mitosis.
The Ser^  ^ residue was predicted to have the potential of being phosphorylated by casein 
kinase I (CKI). As the CKl inhibitor, DRB, showed no effect on either the activity or the 
‘bandshift’ of PDE4D3 it is unlikely that CKI is the candidate kinase phosphorylating the 
Ser^  ^ site. However, to confirm this observation the efficacy of the DRB inhibitor 
compound, on CKI activity would need to be determined. However, Ser^  ^does lie within a 
consensus motif for the checkpoint dependent protein kinase (Chkl) (cp-X-P-X-X-(S/T), 
where (p is hydrophobic (M>I>L>V) and |3 is a basic amino acid (R>K) and X is any 
residue Hutchins et al., 2000). Chkl is a kinase expressed and activated in cells in response 
to DNA damage (Walworth, 2001). Chkl then phosphorylates the Cdc25 protein 
phosphatase which causes Cdc25 to bind to 14-3-3 proteins and prevents its translocation 
to the nucleus to activate the Cdc2/cyclinB 1 kinase. These effects lead to G2/M checkpoint 
aiTest (Yang et al., 1999). Chkl activity is detectable in cells subjected to nocodazole- 
induced mitotic anest (Liu et al., 2000b) and, as the Ser^  ^ residue lies within a Chkl site 
this suggests that Chkl could be a candidate kinase for PDE4D3 phosphorylation at Ser^ .^
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Two further phosphopeptides aiising in PDE4D3 during mitosis that were identified by 
HPLC/mass spectrometry analysis, were phosphorylated at Ser^^  ^ and Ser^^ .^ These sites 
incorporate between 2 -3 pmol more than the previously detailed serine residues, 
phosphorylated by kinases active in mitosis. The Ser^^  ^ and Ser^^  ^ residues map to the 
catalytic domain of PDE4D3.
Phosphorylation of the Ser^^  ^ residue is potentially interesting as not only is it located 
within the catalytic domain but it is also found within the N-terminus of the catalytic 
domain, a region that has been proposed to interact with the inhibitory sub-domain of 
UCR2 (Lim et al., 1999). With the PhosphoBase prediction glycogen synthase kinase -3  
(GSK-3) was identified as a kinase which could phosphorylate this site. However, GSK-3 
requires that the serine/threonine four residues upstream of the phosphorylated site is 
phosphorylated, to act as a priming phosphorylation. The Ser^ "^  ^ in the PDE4D3 was not 
shown to be phosphorylated, therefore, it is unlikely that GSK-3 phosphorylates this site in 
mitosis.
Phosphorylation of Ser^’  ^ has already been shown by our laboratory to be mediated by 
ERK (Hoffmann et al., 1999). However, this leads to inhibition rather than activation of 
PDE4D3. The question raised here, however, is why PDE4D3 is phosphorylated by ERK 
during mitosis as this is the stage in the cell cycle at which the levels of ERK activity and 
phospho-ERK are lowest (Wright et al., 1999; Hayne et al., 2000, see section 3.3.7.3.). It 
could be that the small proportion of active ERK in the cells at this time is co-localised 
with PDE4D3 and therefore able to target it for phosphorylation. However, further studies 
are required to confirm an interaction between PDE4D3 and ERK during mitosis. Why 
should Ser^^  ^ be phosphorylated during mitosis when ERK phosphorylation of this site 
inhibits the enzymatic activity of long-form PDE4 isoforms (Baillie et al., 2000)? 
However, it has been shown that the increase in PDE4D3 enzymatic activity caused by 
PKA phosphorylation is a dominant effect over inhibitory ERK phosphorylation of 
PDE4D3 (Baillie et al., 2000). A similar relationship could exist between the novel mitotic 
phosphorylations of PDE4D3 and the ERK phosphorylation. Consistent with this, 
inhibition of ERK in mitotic cells did not affect the activity of PDE4D3 (see section
4.3.6.2.). Nevertheless, further studies should be carried out to investigate the significance 
of the ERK phosphorylation of PDE4D3 in mitotic cells.
Further studies with recombinant kinases are required for absolute identification of the 
candidate mitotic kinase(s) that phosphorylate PDE4D3 during mitosis. The novel 
phosphorylation sites should also be mutated individually and in combination and the
resulting PDE4D3 mutants analysed for bandshifts, PDE activity and also for their effects 
on PKA activity and cell cycle progression. Current speculation of how phosphorylation of 
the Ser*’^ Ser^ ,^ Ser^^  ^and Ser^^  ^residues of PDE4D3 might be linked to its activation and 
how they might also alter the electrophoretic mobility of PDE4D3 when observed by SDS- 
PAGE are discussed further in Chapter 6.
The effect of PDE4 inhibition on processes that occur during mitotic progression indicate 
that down-regulation of PKA activity in cells entering mitosis, which continues until the 
metaphase/ anaphase transition (Fernandez et al., 1995; Kotani et al., 1998), is caused by 
PDE4 dependent hydrolysis of cAMP. It is also clear that release of cells from the mitotic 
arrest in the presence of rolipram causes cells to progress into the next G l stage at a 
quicker rate than untreated cells. These findings confirm observations by other groups that 
PKA activation is required for mitotic exit (Grieeo et al., 1996).
In summary, by relating the changes of PDE4D3 activity to the control of mitotic 
progression, the results within this chapter suggest that the elevation of PDE4D3 activity 
upon mitotic entry, is caused by phosphorylation of the enzyme by a staurosporine- 
sensitive kinase. This phosphorylation occurs at any one or more of the four target residues 
and serves to increase cAMP hydrolysis and inhibit PKA. The inactivation of PKA is 
required to allow nuclear envelope breakdown (Lamb et a l, 1991), MPF activation (Oh et 
a l, 1996) and chromatin condensation (Fernandez et a l, 1995). When the 
metaphase/anaphase transition is made, PDE4D3 is inactivated by dephosphorylation of 
the target residues through the action of a phosphatase that is sensitive to high levels of 
okadaic acid. This initiates the reactivation of PKA, which causes chromatin to décondense 
(Fernandez et a l, 1995) and allows the nuclear envelope to reform (Steen et a l, 2000; 
Lamb et a l, 1991). Further studies need to be carried so we can determine conclusively 
what direct effect PDE4D3 has on PKA activity and the breakdown and formation of the 
nuclear envelope and chromatin condensation during mitotic progression.
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Figure 4.1. PKA activity and mitotic transition. The transition of cells 
through mitosis is a highly regulated mechanism, entry into mitosis brings 
about a down regulation of PKA activity. The inhibitory phosphorylation 
of the maturation promoting factor (MPF) that PKA catalyses, is removed 
by the Cdc25 phosphatase and the MPF is activated. Down regulation of 
PKA activity also enables the inhibitory phosphorylations on the anaphase 
promoting complex (APC) subunits to be removed by protein phosphatase 
1 (PPl). This allows assembly of the active APC that acts as a ubiquitin 
ligase, targeting multiple proteins for ubiquitinylation (ubq.), which marks 
them for proteolysis by the 26S proteasome. MPF phosphorylates PKA 
reactivating it after the metaphase/ anaphase transition enabling the exit of 
cells from mitosis.
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Figure 4.2. Change of PDE4D3 electrophoretic mobility during mitosis.
Rat-1 cells were arrested in specific stages of the cell cycle as indicated {see 
sections 2.1.4.1. - 2.1.4.5., Asyn - M) and harvested in 3T3 lysis buffer. 100 pg 
of protein from each cell lysate and 20 pg recombinant protein standards (Stds) 
were separated by SDS-PAGE on an 8 % gel. The proteins were transferred to 
nitrocellulose and immunoblotted with PDE4D C-terminal specific antiserum. 
The migration of PDE4D3 (95 kDa) and PDE4D5 (109 kDa) proteins are 
indicated. Cells arrested in mitosis (M) had species of PDE4D3 with reduced 
electrophoretic mobilities. The enlarged image of PDE4D3 proteins in mitosis is 
denoted with the nomenclature used for the different species of PDE4D3 
{explained in section 4.2.1.). The stage 1 form of of PDE4D3 migrates with and 
apparent molecular weight of 100 kDa and stage 2 form migrates with and 
apparent molecular weight of 102 kDa, both are calculated by plotting the Rf 
values of markers run on the same gel.
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Figure 4.3. PDE4D5 is not expressed in Rat-1 cells. Asynchronous Rat-1 
cells (Asyn.) or Rat-1 cells arrested in mitosis (Mit.) were harvested in 
3T3 lysis buffer and 100 fig of proteins from these lysates as well as 20 fig 
PDE4D5 recombinant protein (4D5 std., 109 kDa) were separated by SDS- 
PAGE on an 8 % gel. The proteins were transferred to nitrocellulose and 
were immunoblotted with a PDE4D5 N-terminal specific antibody (see 
section 4.2.L L ). The molecular weights of the protein standards are 
indicated.
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Figure 4.4a. Sub-cellular localisation of PDE4D3 in asynchronous Rat- 
1 cells and cells isolated in mitosis, determined by crude fractionation.
Asynchronous Rat-1 cells or cells arrested in mitosis were homogenised in 
cKHEM and subject to crude subcellular fractionation (see section
2.2.1.2.). The low speed cell fraction (PI) was collected at 2000 g for 10 
min in a fixed rotor centrifuge. The high speed fraction (P2) was collected 
at 75000 g for 30 min in an ultracentrifuge, leaving the residual cytosolic 
fraction (S). 100 /xl of the proteins from each fraction were separated by 
SDS-PAGE on an 8 % gel, transferred to nitrocellulose and
immunoblotted with a PDE4D specific antibody. The migration of all 
species of PDE4D3 protein is indicated. The stage 1 migrates at -100 kDa, 
stage 2 migrates at -102 kDa and native PDE4D3 migrates at 95 kDa 
when calculated by plotting the Rf values of markers run on the same gel.
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Figure 4.4b. Subcellular localisation of PDE4D3 in Rat-1 cells 
isolated in mitosis, determind by refined fractionation. Rat-1 cells 
arrested in mitosis were homogenised in sucrose buffer and subjected to 
a refined subcellular fractionation (see section 2.2.1.3.). The nuclear 
pellet (N) was collected at 1000 g for 10 min in a fixed angle centrifuge. 
The membranous fraction (M) was collected at 13000 g for 15 min in a 
fixed angle centrifuge and the microsomes (Micr.) were collected at 
75000 g for 60 min in an ultracentrifuge, leaving the residual cytosolic 
fraction (C). 100 pi proteins from each fraction were separated by SDS- 
PAGE on an 8 % gel, transferred to nitrocellulose and immunoblotted 
with a PDE4D specific antibody. The migration of all species of 
PDE4D3 protein are indicated.
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Fig 4.5. The effect of short-term incubation of increasing 
concentrations of on PDE4D3 modifîcation. Increasing concentrations 
of nocodazole (0.05 pg-500 pg per ml of growth media, as indicated) 
were added to asynchronous Rat-1 cells for 2 h, cells were then lysed in 
3T3 lysis buffer and 100 pg protein separated by SDS-PAGE on an 8 % 
gel. The proteins were transferred to nitrocellulose and immunoprobed 
with a PDE4D specific anti serum. The migration of the PDE4D3 protein 
(95 kDa) from each cell lysate is indicated.
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Figure 4.6. Change in Rat-1 cell cycle distribution with the addition of 
nocodazole. Asynchronous Rat-1 cells were treated with 50 ng/ml media 
nocodazole for up to 7 h, as indicated. Cells were harvested at 1 h intervals 
{see section 2.2.1.), as indicated, labelled with propidium iodide and 20000 
cells were analysed by flow cytometry for distribution within the cell cycle 
{see section 2.2.2.). The histograms determine the DNA content of these 
cells over this time course.
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Figure 4.7. Changes in electrophoretic mobility of PDE4D3 in Rat-1 
cells incubated with nocodazole for various times. Rat-1 cells were 
incubated with nocodazole (50 ng/ml media) over a 14 h time course and 
and harvested in 3T3 lysis buffer, at intervals as shown. 100 ixg protein 
from each cell lysate was subjected to SDS-PAGE on an 8 % gel, 
transferred to nitrocellulose and immunoprobed with the PDE4D specific 
antiserum. The migration of the species of PDE4D3 protein is indicated.
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Figure 4.8. The increase in PDE4D activity as cells accumulate in 
mitosis. Asynchronous Rat-1 cells were incubated with nocodazole (50 
ng/ml media) over a 24 h time course and harvested at the times indicated. 
PDE4D was isolated by immunoprécipitation from 300 pg cell lysate using 
the PDE4D specific antibody {see section 2.3.10.) and the enzymatic 
activity of PDE4D was measured (see section 2.3.9.). The results are 
expressed as the means ± SE of five independent experiments.
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Figure 4.9. Redistribution of Rat-1 cells through the cell cycle upon 
release of the nocodazole- induced mitotic block. Rat-1 cells subjected 
to nocodazole-induced mitotic arrest (see section 2.1.4.5.) were released 
from the block and harvested at half hour intervals as indicated (see 
section 2.2.1,). The distribution of a sample of 20000 cells through the 
cell cycle were determined by FACs analysis (see section 2.2.2.). The 
histograms represent the amount of DNA in the sampled population of 
cells and the proportion of cells in the phases of the cell cycle is indicated 
in the accompanying table.
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Figure 4.10. Increase in electrophoretic mobility of PDE4D3 protein as 
Rat-1 cells exit nocodazole-induced mitosis. Rat-1 cells arrested in 
mitosis, by the addition of nocodazole (50 ng/ml) for 14 h, were released 
into the next cell cycle and cells harvested at half hour intervals in 3T3 
lysis buffer, as indicated. 100 jig of cell lysates were separated by SDS- 
PAGE on an 8 % gel, transferred to nitrocellulose and immunoblotted with 
the PDE4D specific antibody. The electrophoretic mobility of the different 
species of PDE4D3 protein are indicated.
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Figure 4,11. Decrease in PDE4D activity in cells released from 
nocodazole - induced mitotic arrest. Rat-1 cells aiTested in mitosis by 
incubation with nocodazole (50 ng/ml media), were released from the 
mitotic block and harvested at 30 min intervals in 3T3 lysis buffer. The 
PDE4D protein was isolated by immunoprécipitation from 300 /rg cell 
lysate {see section 2.3.10.) and the enzymatic activity of the protein 
determined {see section 2.3.9.). The results are expressed at the mean ± 
SE of 4 independent experiments.
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Figure 4.12. PDE4D3 is not ubiquitinylated during mitosis. PDE4D3 
protein was isolated by immunoprécipitation from 1 mg cell lysate from 
Rat-1 cells arrested in mitosis, using PDE4D specific anti serum {see section 
4,3.10.). The immunoprecipitated protein (IP) and 100 fig Rat-1 cell lysate 
were separated by SDS-PAGE on an 8 % gel, transferred to nitrocellulose 
and the proteins were immunoblotted with an anti ubiquitin-protein 
conjugate antibody. The molecular weights of the protein standards are 
indicated, as it the expected position of PDE4D3 migration (95 kDa).
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Figure 4.13. In vivo phosphorylation of PDE4D3 in asynchronous and 
mitotic cells. Rat-1 cells were left asynchronous (Asyn.) or incubated with 
50 ng/ml media nocodazole for 14 h to arrest the cells in mitosis (Mit.). The 
cells were then incubated in phosphate free media, supplemented with 300 
pCi/ml orthophosphate, for 2 h. The cells were lysed and PDE4D 
protein isolated by immunoprécipitation using the PDE4D specific antisera. 
The protein was separated by SDS-PAGE on an 8 % gel, transferred to 
nitrocellulose and visualised by exposing the nitrocellulose to a 
phosphorimage screen for 24 h (left-hand panel). The molecular weights of 
the standard proteins (Stds.) and the migration of the ^^ P labelled PDE4D3 
(95 kDa) are indicated. The blot was then probed with PDE4D specific anti 
serum (right-hand panel). In this figure the migration of the stage 1, stage 2 
and native forms of PDE4D3 are indicated, as is the migration of the 
molecular weight standards.
Okadaic acid concentration
0 200 500 1000 nM
PDE4D3
Figure 4.14. Okadaic acid maintains bandshifted PDE4D3 
modification after release of cells from mitotic block. Rat-1 cells 
arrested in mitosis by incubation with nocodazole (50 ng/ml) were 
released from the mitotic block for 2 h in the presence of increasing 
concentrations of okadaic acid, as indicated. The cells were harvested in 
3T3 lysis buffer and 100 fig of protein from the cell lysates were 
separated by SDS-PAGE on an 8 % gel. The proteins were transferred 
to nitrocellulose and immunoblotted with a PDE4D specific antibody. 
The migration of the species of PDE4D3 are indicated.
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Figure 4.15. Okadaic acid maintains the elevated PDE4D activity 
after release of cells from mitotic block. Rat-1 cells arrested in mitosis 
by incubation with nocodazole (50 ng/ml media) were released from the 
mitotic block for 2 h in the presence of increasing concentration of 
okadaic acid, as indicated. PDE4D was isolated from 300 jxg of the cell 
lysates by immunoprécipitation {see section 2.3.10.), using the PDE4D 
specific antibody, the enzymatic activity of the protein was then 
determined {see section 2.3.9.). Results are shown as the means ± SE of 
four independent experiments.
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Figure 4.16. CIAP ablates the bandshifted species of PDE4D3 from 
nocodazole-induced mitotic lysate. Rat-1 cells arrested in mitosis 
were harvested and 100 /xg of the lysate were incubated with (4-) or 
without (-) 10 units calf intestinal alkaline phosphatase (CIAP) for 1 h 
(see section 2.4.2.). The protein was then subjected to SDS-PAGE on 
an 8 % gel, transferred to nitrocellulose and immunoblotted with the 
PDE4D specific antibody. The migration of the different species of 
PDE4D3 protein is indicated.
3 0 0 0 0
a
1
CL
20000 -
I
Q 10000-
I
+ CIAP-CIAP -C IA P
Mitotic Asynchronous
Treatment
Figure 4.17. CIAP reduces the activity of PDE4D in nocodazole- 
induced mitotic ceils. Lysate from Rat-1 cells arrested in mitosis was 
incubated in the absence or presence of 10 units calf intestinal alkaline 
phosphatase (CIAP) for 1 h (see section 2.4.2.). The PDE4D was then 
isolated from 300 jag of the treated mitotic lysates or from asynchronous 
lysate by immunoprécipitation, using the PDE4D specific antibody and 
the enzymatic activity of the protein was determined (see section 2.3.9). 
The results are shown as the means ± SE of three independent 
experiments.
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Figure 4.18. Staurosporine ablates the bandshifted species of PDE4D3 
in Rat-1 cells isolated in mitosis. Rat-1 cells arrested in mitosis by 
incubation with nocodazole (50 ng/ml) for 14 h, were incubated with 
increasing concentrations of staurosporine for 2 h, as indicated. The cells 
were harvested in 3T3-lysis buffer and 100 jag protein from the cell lysates 
were separated by SDS-PAGE on an 8 % gel, transferred to nitrocellulose 
and immunoprobed with a PDE4D specific antibody, the positions of the 
different species of PDE4D3 are indicated.
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Fig 4.19. Staurosporine ablates the nocodazole-induced mitotic 
bandshift of PDE4D3 in a time dependent fashion Rat-1 cells 
arrested in a nocodazole-induced mitosis were released from the block 
in the presence of 100 nM staurosporine for up to 2 h. Cells were 
harvested in 3T3 lysis buffer, at intervals as shown, and 100 pg protein 
from of the cell lysates were subjected to SDS-PAGE on an 8 % gel. 
The proteins were transferred to nitrocellulose and PDE4D3 was 
detected by immunoblot analysis using a PDE4D specific antibody. The 
positions of the different PDE4D3 species are indicated.
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Figure 4.20. Staurosporine reduces the activity of PDE4D in 
nocodazole-induced mitotic cells. Rat-1 cells in nocodazole-induced 
mitosis were incubated with 100 nM staurosporine for up to 2 h. Cells 
were harvested in 3T3 lysis buffere at the time points indicated and 
PDE4D was isolated by immunoprécipitation from 300 /xg of cell lysate 
{see section 2.3.10.). The enzymatic activity of PDE4D was measured 
{see section 2.3.9.) and the results expressed as the fold differences in 
activity of PDE4D compared to 0 min staurosporine incubation. The 
results are represented as the means ± SE of four independent 
experiments.
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Figure 4.21. FACs analysis of Rat-1 cells arrested in mitosis and 
subjected to a further incubation with staurosporine. Rat-1 cells were 
subjected to nocodazole-induced mitosis (see section 2.1.4.5.) and were then 
incubated with 100 nM staurosporine for 2 h. The cells were harvested and 
stained with BrdU-FITC and propidium iodide (PI, see section 2.2.3.) prior to 
the collection and analysis of 20000 cells by FACs using the CELLQuest 
acquisition package (see section 2.2.4.). Panel A, analysis of multinucleated 
cells, cell clumps and cell debris was measured on a density plot of the PI 
labelled cells in the FL2-H vs FL2-W channels. The single cell population 
are indicated. Panel B, the distribution of the 20000 cells within the cell 
cycle was analysed on a histogram of PI incorporation in FL2-H vs counts, 
the G2/mitotic population are indicated.
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Figure 4.22. Commercially available specific kinase inhibitors do not 
ablate the PDE4D3 bandshift in nocodazole induce mitotic cells. Rat-1 
cells incubated with nocodazole (50 ng/ml) for 14 h to arrest them in 
mitosis {lane 1) were subsequently incubated with 10 fxM H89 {lane 2), 10 
/xM genistein {lane 3), 10 /xM 5,6-Dichloro-l-P-D-
ribofuranosylbenzimidazole (DRB) {lane 4), 1 mM Wortmannin {lane 5), 
10 LY294002 {lane 6), 10 /xM U0126 {lane 7), 20 /xM Olomucine
{lane 8), 10 (iM PD98059 {lane 9) and 10 /xM Bisindolylmaleimide II 
{lane 10) for 2 h prior to cell harvest. The cells were lysed in 3T3 lysis 
buffer and 100 /xg of protein from each cell lysate was separated by SDS- 
PAGE on an 8 % gel, transferred to nitrocellulose and immunoblotted with 
a PDE4D specific antibody. The migration of the PDE4D3 species are 
indicated.
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Figure 4.23. The increased activity of PDE4D in nocodazole-induced 
mitotic cells is insensitive to many commercially available specific 
kinase inhibitors. Nocodazole-induced mitotic Rat-1 cells were incubated 
with commercially available kinase inhibitors, as indicated (for details o f 
concentrations o f inhibitors used see section 43,6.2.), for 2 h prior to 
harvest in 3T3 lysis buffer. The PDE4D protein was isolated from 300 jiLg 
cell lysates by immunoprécipitation (see section 2.3.10.) using the PDE4D 
specific anti serum and the enzymatic activity of the protein analysed (see 
section 2.3.9.). The results are expressed as the means ± SE of between 3-5 
independent experiments.
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Figure 4.24. Change in electrophoretic mobility of PDE4D3 in mitotic 
and asynchronous cells upon stimulation or inhibition of PKA 
activity. Asynchronous Rat-1 cells or cells arrested in mitosis with 
nocodazole were incubated with 100 |iM forskolin with or without a 
preincubation with H89, as indicated. 100 fig of protein from the cell 
lysates were separated by SDS-PAGE, on an 8 % gel, transferred to 
nitrocellulose and immunoprobed with the PDE4D specific antibody. The 
migration of the different species of PDE4D3 are indicated.
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Figure 4.25. Changes in PDE4D activity upon treatment with forskolin 
and H89. Asynchronous or mitotically arrested Rat-1 cells were pre­
incubated in the presence or absence of 10 jttM H89 for 20 min, prior to a 
subsequent 15 min incubation in the presence or absence of 100 fxM 
forskolin, as indicated. The PDE4D3 protein was then isolated from 300 
jLtg cell lysate by immunoprécipitation {see section 2,3,10.) using the 
PDE4D specific antiserum and the enzymatic activity of the protein 
assayed {see section 2.3.9.). The results are means ± SE of between 3-5 
independent experiments.
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Figure 4.26. The amino acid sequence of rat PDE4D3. The sequence of rat PDE4D3 
cDNA (accession number U09457), with the location of the UCRl, UCR2 and catalytic 
domain indicated. The numbers correspond to the amino acid residues.
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Figure 4.27. A proportion of endogenous PDE4D3/PDE4D5 in 
nocodazole induced mitotic HeLa cells has reduced electrophoretic 
mobilities. Asynchronous HeLa cells (Asyn.) and cells isolated in mitosis 
(Mitotic) with nocodazole incubation (50 ng/ml media for 14 h) were 
harvested in 3T3 lysis buffer and 100 /xg proteins from the cell lysate 
were separated by SDS-PAGE on an 8 % gel. The proteins were 
transferred to nitrocellulose which was immunoprobed with the PDE4D 
specific antiserum. The migration of the species of PDE4D3 and 
PDE4D5 are indicated.
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Figure 4.28. PDE4D3 Ser^VAIa mutant behaves as wild-type in 
nocodazole-induced mitosis. HeLa cells transfected with a construct 
encoding Ser’VAla mutant PDE4D3 were either left asynchronous (Asyn.) 
or arrested in mitosis by incubation with nocodazole (50 ng/ml media for 
14 h). The mitotic arrested cells were subjected to a further incubation 
with nocodazole for 2 h in the presence (+) or absence (-) of 100 nM 
staurosporine for 2 h. The cells were harvested in 3T3 lysis buffer and 100 
/xg protein from these lysates were separated by SDS-PAGE on an 8 % gel. 
The proteins were transferred to nitrocellulose which was immunoblotted 
with the anti-VSV polyclonal antibody. The migration of the PDE4D3 
species are indicated.
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Figure 4.29. Analysis of electrophoretic mobilities of PDE4D mutants in 
mitosis. Mutant forms of PDE4D3 were expressed in HeLa cells, as indicated 
{described in section 4.6.2.3.). The cells were left asynchronous (A) or were 
arrested in mitosis 24 h after transfection, by incubation with 50 ng/ml media 
nocodazole (M). The cells were harvested in 3T3 lysis buffer and 100 /xg protein 
from these lysates were separated by SDS-PAGE on an 8 % gel. The proteins were 
transferred to nitrocellulose and then probed using the anti-VSV polyclonal 
antibody. The positions of the different species of PDE4D3 are indicated.
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Figure 4.30. Mutant PDE4D3 protein activity in asynchronous and 
mitotic cells. Mutant constructs of PDE4D3 (See figure 4.31.) were 
transfected into HeLa cells {see section 2.1.3.), and the cells were 
subsequently left asynchronous (A) or subjected to nocodazole-induced 
mitotic aiTcst (M). The cells were harvested in 3T3 lysis buffer and the PDE 
activities of the cell lysates were measured {see section 2.3.9,). The results 
are representative of three independent experiments.
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Figure 4.33. Phosphorylation of recombinant UCR1/UCR2 
constructs by mitotic lysate and PKA. Recombinant proteins encoding 
UCRl (Ul) or UCR2 (U2) alone or both together (U1+U2) were 
expressed as GST fusions (see section 2.4.3.), purified and 100 [i\ was 
subjected to an in vitro phosphorylation reaction, in the presence of ^^P- 
ATP. The reactions were carried out with lysate from cells isolated in 
mitosis (mitotic) or with purified PKA catalytic subunit (PKA, see 
sections 2.4.5.1 and 2.4.5.2) as indicated. The proteins were separated 
by SDS-PAGE on a 10 % gel and the proteins transferred to 
nitrocellulose. Panel A, the nitrocellulose was stained with Ponceau-S 
(see section 2.3.8.2.) to detect the recombinant protein. Panel B, the ^^ P 
labelled proteins were detected by exposing the nitrocellulose to 
phosphorimage plate for 24 h (see section 2.4.5.2.).
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Figure 4.34. Peptides generated from in vitro phophorylated PDE4D3 
cleaved with cyanogen bromide. Full length recombinant PDE4D3 was 
phosphorylated in vitro with asynchronous (Asyn.) or mitotic lysate 
extracted from Rat-1 cells (see section 2.5.4.2.), or with purified PKA 
catalytic subunit (PKA, see section 2.5.4.1.), in the presence of y[^^P]- 
ATP. The protein was then subjected to a cyanogen bromide peptide 
cleavage for 24 h and the peptides were separated by SDS-PAGE on a 16 
% gel. The peptides were transferred to nitrocellulose and visualised by 
exposing the nitrocellulose to a phosphorimage plate for 48 h. The 
molecular weights of the protein standards (Stds.) are indicated.
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Figure 4.35. Separation of tryptically digested PDE4D3 
phosphopeptides by 2D tbin layer cbromatograpby. Recombinant 
PDE4D3 protein was phosphorylated in vitro by kinases isolated from 
asynchronous or mitotic cell lysate (see section 2.4.5.2.), then digested 
with trypsin (see section 2.4.6.). The peptides generated were separated 
in the 1st dimension by electrophoresis and in the 2nd dimension by 
chromatography (see section 2.4.6.). The TLC plates were then exposed 
to a phosphorimage plate and the phosphopeptides that were consistently 
more highly phosphorylated by kinases in mitotic lysate are indicated 
with arrows. These results are representative of 4 independent 
experiments.
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Figure 4.36. Separation of tryptically digested PDE4D3 
phosphopeptides by HPLC. Recombinant PDE4D3 protein was 
phosphorylated with kinases isolated from asynchronous (Asyn. red trace) 
or mitotic cell lysate (Mit., blue trace) (see section 2.4.5.2.) and then 
digested with trypsin (see section 2.4.7.1.). The peptides were isolated 
from the tryptic digest (see section 2.4.7.1.) and separated by reverse phase 
HPLC (see section 2.4.7.2.) and eluted from the column with increasing 
concentrations of acetonitrile. The elution times and amounts of ^^ P 
incorporated into each peptide are shown, the peptides used for further 
analysis are labelled A, B, C and D.
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Figure 4.37. Peptides of PDE4D3 phosphorylated in vitro by 
kinases from mitotic lysate. The phosphopeptides generated by the 
phosphorylation of recombinant PDE4D3 with kinases isolated from 
mitotic cell lysate, once purified by HPLC, were identified by mass 
spectrometry and mapped to PDE4D3 sequence (see section 4.7.4.). 
The phosphopeptides are highlighted in red, and the arrow letter 
associated with each peptide refers to the peptide isolated on the 
HPLC trace (see Fig. 4.36.). The UCRl domain is indicated in light 
green, UCR2 in dark green and the catalytic domain in blue. The 
remaining residues are within the unique, LRl,  LR2 and C-terminal 
domains of PDE4D3. The numbers relate to the residue number in the 
PDE4D3 protein.
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Figure 4.38a. Cycle burst amino acid analysis of residues 
phosphorylated in peptide A, found at the N-terminal of UCRl. The
peptide of PDE4D3 phosphorylated by kinases present in lysate from 
cells arrested in mitosis, (see section 4.8.4.) once identified by mass 
spectrometry analysis (see section 4.8.4.1.), was sequenced by Edman 
degradation and the levels of incorporated into each residue was 
measured. The amino acids are represented by their single letter 
nomenclature and the level of ^^P incorporated into each residue and 
Ser^  ^is indicated.
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Figure 4.38b. Cycle burst amino acid analysis of residues 
phosphorylated in peptide C, found at the C-terminal of U C R l. The
peptide of PDE4D3 phosphorylated by kinases present in lysate from 
cells arrested in mitosis, {see section 4.8.4.) once identified by mass 
spectrometry analysis {see section 4.8.4.I.), was sequenced by Edman 
degradation and the levels of incorporated into each residue was 
measured. The amino acids are represented by their single letter 
nomenclature and the level of incorporated into each residue is 
indicated, and the Ser^  ^ residue is numbered.
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Figure 4.38c. Cycle burst amino acid analysis of residues 
phosphorylated in peptide B, found at the N-terminal of the catalytic 
domain. The peptide of PDE4D3 phosphorylated by kinases present in 
lysate from cells arrested in mitosis, {see section 4.8.4.) once identified by 
mass spectrometry analysis {see section 4.8.4.L), was sequenced by 
Edman degradation and the levels of incorporated into each residue 
was measured. The amino acids are represented by their single letter 
nomenclature and the level of ^^P incorporated into each residue is 
indicated. The two sequences of amino acids are shown as there are two 
lysine residues located next to one another and some of the peptides 
generated by tryptic digest contain this residue, whereas other lack it. Two 
peaks of radiolabelled serines (Ser^^^) are therefore detected, however, 
both map to the final serine residue in the triplet within the sequence.
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Figure 4.38d. Cycle burst amino acid analysis of residues 
phosphorylated in peptide D found at the C-terminal of the catalytic 
domain. The peptide of PDE4D3 phosphorylated by kinases present in 
lysate from cells arrested in mitosis, {see section 4.8.4.) once identified 
by mass spectrometry analysis {see section 4.8.4.1.), was sequenced by 
Edman degradation and the levels of incorporated into each residue 
was measured. The amino acids are represented by their single letter 
nomenclature and the level of ^^ P incorporated into each residue and 
Ser^ '^  ^are indicated.
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Figure 4.39. Changes in PDE4D activity after in vitro phosphorylation 
with kinases isolated from asynchronous and mitotic lysate. 50 fig PDE4D3 
protein expressed in HEK-293 cells was isolated by immunoprécipitation 
using the VSV polyclonal antibody (see section 2.3.10.) and was subjected to 
‘cold’ in vitro phosphorylation using asynchronous (Asyn.) or mitotic lysates, 
(see section 2.4.S.2.). The activity of the PDE4D3 protein after 
phosphorylation was determined.
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Figure 4.40. Increase in proportion of active PKA in cells arrested 
In mitosis after incubation vyith rolipram. Rat-1 cells arrested in 
mitosis, through incubation with 50 ng/ml nocodazole for 14 h, were 
incubated with 10 /xM rolipram for up to 60 mins. Cells were harvested 
in extraction buffer {see section 2.4.l .L )  at the time points indicated 
and the proportion of active PKA in these cell extracts were determined 
{see section 2.4.1.). The PKA activity is shown as a percentage of total 
PKA which can be activated in the cells and is the means ± SE of four 
independent experiments.
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Figure 4.41. The effect of rolipram on cell cycle distribution after the 
release of cells from nocodazole-induced mitosis. Rat-1 cells were 
released from a nocodazole induced mitotic arrest (see section 2.1.4.5.) in 
the presence (filled, purple histogram) or absence (unfilled, green 
histogram) of 10 pM rolipram. Cells were harvested at 30 min intervals 
post release and their DNA content determined by FACs analysis (see 
sections 2.2.1. and 2.2.2.). The histograms were produced using the 
CELLQuest acquisition package and represent the DNA content of a 
population of 20000 cells analysed.
Inhibitor Specificity
Genistein Protein Tyrosine Kinases
5,6-Dichloro-l-P- D- 
ribofuranosylbenzimidazole
Casein kinase II
Wortmannin Phosphatidylinositol 3- 
Kinase
LY294002 Phosphatidylinositol 3- 
Kinase
U0129 MAPK
Olomucine Cdkl/cyclinB,
Cdk2/CyclinA,
Cdk2/CyclinE
Roscovitine Cdkl/CyclinB, 
Cdk2/Cyclin A, 
Cdk2/Cyclin E
Chelerythrine chloride Protein kinase C
Bisindolylmaleimide Protein kinase C
ML7 Myosin light chain Kinase
PD98059 Map kinase kinase (MEK)
Table 4.1. Panel of kinase inhibitors. A series of commercially 
available kinase inhibitors were incubated on Rat-1 cells isoalted in 
mitosis in an attempt to block the phosphorylation of PDE4D3 (see 
section 4.3.6.2.). The specific inhibitors used and their target kinases 
are laid out above.
ZI y
Residue Position and
phosphorylation
motif
Probability Residue Position and
phosphorylation
motif
Probability
Serine 13 FRRHSWICF 0.997 Threonine 181 NRELTHLSE 0.871
24 DNGTSAGRS 0.669 213 PSPTQKEK 0.938
28 SAGRSPLDP 0.996 252 FGVKTEQED 0.665
35 DPMTSPGSG 0.778 455 TMVETKKVT 0.965
49 NFVHSQRRE 0.991 499 YRQWTDRIM 0.710
54 QRRESFLYR 0.981 603 QFELTLEED 0.874
59 FLYRSDSDY 0.992 611 GESDTEKDS 0.954
61 YRSDSDYDL 0.997 624 VEEDTSCSD 0.966
66 DYDLSPKSM 0.981 640 DSESTEEPL 0.682
69 LSPKSMSRN 0.992 Tyrosine 63 SDSDYDLSP 0.973
70 PKSMSRNSS 0.809 137 TEEAYQKLA 0.970
74 MSRNSSIAS 0.996 196 QVSEYISNT 0.761
75 SRNSSIASD 0.957 319 LEDHYHADV 0.551
78 SSIASDIHG 0.518 325 ADVAYHNNI 0.745
116 DRAPSKRSP 0.992
119 PSKRSPMCN 0.929
142 QKLASETLE 0.585
163 QTRHSVSEM 0.997
164 RHSVSEMAS 0.824
169 SEMASNKFK 0.617
212 VEIPSPTQK 0.781
226 KRPMSQISG 0.997
279 lAELSGNRP 0.550
343 HVLLSTPAL 0.654
393 YNDSSVLEN 0.920
425 KQRQSLRKM 0.991
460 KKVTSSGVL 0.931
521 GMEISPMCD 0.662
530 KHNASVEKS 0.981
534 SVEKSQVGF 0.529
579 TIPQSPSPA 0.983
580 PQSPSPAPD 0.927
610 EDGESDTEK 0.991
616 TEKDSGSQV 0.949
617 KDSGSQVEE 0.994
625 EEDTSCSDS 0.995
639 QDSESTEIP 0.992
Table 4.2. Probability of residue phosphorylation using NetPhos. The sequence of the 
Rat PDE4D3 isoform was submitted to the NetPhos prediction form, online {see section 
4.5.l.L ), and the probability that a residue was phosphorylated was calculated. The 
sequences in bold are those later identified as being phosphorylated by kinases from 
mitotic lysates {see section 4.7.).
2 2 0
Kinase Phosphorylated
residue
Motif Kinase Phosphorylated
residue
Motif
CaMII S-13 RRHSWIC GSK3 S-24 NGTSAGRS
S-54
S-61
RRESFLY
RSDSDYD C-terminal
T-34
S-71
DPMTSPGS
KSMSRNSS
S-75 RNSS(AS +4 S must S-165 HSVSEMAS
S-116 RAPSKRS be S-194 NQVSEYIS
T-181
S-226
RELTHLS
RPMSQIS
prephosph
orylated
S-239
S-530
HSSSLTNS
HNASVEKS
T-285 RPLTVIM T-575 YQSTIPQS
T-499 RQWTDRI T-612
S-625
ESDTEKDS
EDTSCSDS
CKI S-28 SAGRSPLD CKH S-28 AGRSPLD
N-terminal
S-38
S-69
TSPGSGLl
SPKSMSR
S-59
T-131
LYRSDSD
NKATITE
T/S must S-75 SRNSSIAS T-144 ASETLEE
be T-99 SLRTVRN S-163 TRHSVSE
phosphory
lated
S-119
T-160
SKRSPMC
TLQTRHS
T-200
T-214
ISNTFLD
PSPTQKE
S-169 SEMASNKF T-252 GVKTEQE
S-184 THLSEMS T-314 YLMTLED
S-198 SEYISNTF T-352 AVFTDLE
S-229 SQISGVK T-381 LINTNSE
T-241 SSSLTNSC S-393 NDSSVLE
T-310 TLITYLM T-451 DLKTMVE
S-440 TDMSKHM T-549 LWETWAD
T-455 TMVETKKV T-564 ILDTLED
T-489 SNPTKPL T-603 FELTLEE
S-534 SVEKSQVG S-610 DGESDTE
S-579 TIPQSPSP S-618 DSGSQVE
S-616 TEKDSGSQ S-62 EDTSCSD
S-627 TSCSDSK
T-634 TLCTQDS
T-640 SESTEIP
MLCK S-226 KKRPMSQIS P70s6k S-226 KRPMSQIS
PKA S-13 RRHSWIC PKC S-49 FVHSQRR
S-54 RRESFLY S-66 YDLSPKS
S-61 RSDSDYD S-96 VLASLRT
S-75 RNSSIAS S-116 RAPSKRS
S-116 RAPSKRS S-169 EMASNKF
S-163 RHSVSE T-214 PSPTQKE
T-181 RELTHLS T-300 LLKTFKI
S-226 RPMSQIS T-419 QNLTKKQ
T-285 RPLTVIM S-425 QRQSLRK
S-425 RQSLRK T-455 MVETKKV
T-499 RQWTDRI S-470
T-499
T-595
T-612
DNYSDRI
RQWTDRI
QGQTEKF
ESDTEKD
Z Z l
PKG s-13 RRHSWIC C dkl No identified
S-54 RRESFLY residues
T-459 KKVTSSG
Table 4.3. Predicted phosphorylation sites of PDE4D3 using PhosphoBase. The Rat
sequence of PDE4D3 was inserted into the prediction submission form on the 
PhosphoBase programme {see section 4.5.1.1.) and the predicted phosphorylation sites 
within the protein were given. The sequences in red conespond to those later identified as 
being targeted for phosphorylation by kinases active in mitotic lysates {see section 4.7.).
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Molecular Weight 
(Daltons)
Peptide Sequence
16662.365 CDKHNASVEKSQVGFIDYIVHPLWETWA
DLVHPDAQDILDTLEDNREWYQSTIPQSP
SPAPDDQEDGRQGQTEKFQFELTLEEDGE
SDTEKDSGSQVEEDTSCSDSKTLCTQDSE
STEIPLDEQVEEEAVAEEESQPQTGVADD
CCPDT
8111.52 TLEDHYHADVAYHNNIHAADVVQSTHVL
LSTPALEAVFTDLEILAAIFASAIHDVDHP
GVSNQFLINTNSELALM
5916.86 HSSSLTNSCIPRFGVKTEQEDVLAKELEDV
NKWGLHVFRIELSGNRPLTVIM
5502.895 SRNSSIASDIHGDDLIVTPFAQVLASLRTV
RNNFAALTNLQDRAPSKRSPM
5247.51 CNQPSINKATITEEAYQKLASETLEELDW
CLDQLETLQTRHSVSEM
4826.479 YNDSSVLENHHLAVGFKLLQEENCDIFQN
LTKKQRQSLRKM
4525.343 SRSGNQVSEYISNTFLDKQHEVEIPSPTQK
EKEKKKRPM
4141.37 TSPGSGLILQANFVHSQRRESFLYRSDSDY
DLSPKSM
351 1.671 HVNTFPFRRHSWICFDVDNGTSAGRSPLD
PM
3002.616 VETKKVTSSGVLLLDNYSDRIQVLQNM
2987.66 HTIFQERDLLKTFKIPVDTLITYLM
2837.452 VHCADLSNPTKPLQLYRQWT DRIM
1893.895 EEFFRQGDRERERGM
1294.675 LNRELTHLSEM
1042.625 SQISGVKKLM
1013.551 AIDIVLATDM
970.557 NLLADLKTM
933.526 ASNKFKRM
528.299 EISPM
Table 4.4. Predicted peptides generated upon cyanogen bromide cleavage of PDE4D3.
The molecular weights and sequences of the peptides generated by cleavage of PDE4D3 
with cyanogen bromide were calculated using the ExPASy-PeptideMass prediction web 
site at http://ca.expasy.org/cgi-bin/peptide-mass.pl. The highlighted peptides are those 
previously identified as being phosphorylated by PKA.
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Chapter 5
Characterisation of Phosphodiesterase 7 (PDE7)
Z Z 4
5.1 Introduction
T lymphocytes are activated by antigen bound to the major histo-compatability complex 
(MHC) on the antigen presenting cell interacting with the CD3 T cell receptor complex on 
surface of T cell (Geppert and Lipsky, 1986). This interaction alone induces expression of 
low levels of interleukin 2 (IL-2, June et al., 1989), an effect that is enhanced 
synergistic ally upon the co-stimulation of the T cell CD28 receptor by the antigen- 
presenting cell (Thompson et al., 1989). The co-stimulation of the two receptors causes the 
levels of cAMP to decrease, an affect brought about by an increase in PDE activity in the T 
cells (Takemoto et al., 1978). It is this decrease in cAMP that initiates the induction of high 
levels of IL-2 (Mary et al., 1987; Skalhegg et al., 1994). IL-2 acts in an autocrine fashion 
to stimulate T cell proliferation (Giembycz et al., 1996; Lingk et al., 1990) and to increase 
the expression of cytokines such as TNFa (Shames et al., 2001), IL-13 (Kanda and 
Watanabe, 2001) and IL-4 (Borger et al., 1996) and to stimulate their exocytosis 
(Shahinian et al., 1993) when bound to its cognate receptor. T cell activation is associated 
with inflammatory diseases (Kay, 2000) and PDE4 inhibitors have been identified as 
viable targets for therapeutic intervention (Rogers and Giembycz, 1998). Side effects such 
as emesis were associated with first generation PDE4 inhibitors and thus the next 
generation of more selective PDE4 inhibitors are required to target inflammatory diseases. 
This prompted the study of PDE profiles and function within T lymphocytes to identify 
new therapeutic targets.
Upon inhibition of PDE4 and PDE3 in T lymphocytes it was noted that there was a 25% 
residual cAMP specific hydrolytic activity in the cytosolic fraction of the cell (Robicsek et 
al., 1991; Tenor et al., 1995). This was referred to as the cAMP specific, IBMX-insensitive 
activity in the cell and has been attributed to PDE7 (Ichimura and Kase, 1993); to which 
there were no specific inhibitors. PDE7 activity has been suggested to be involved in 
signalling cascades that initiate proliferation and stimulate IL-2 release from T cells 
inducing their full activation (Giembycz et al., 1996). Both CD4^ and CD8^T cells express 
PDE7 (Giembycz et al., 1996; Glavas et al., 2001). Levels of PDE7 activity are low in 
peripheral T lymphocytes, but when they are activated there is a rapid increase in PDE7A1 
and PDE7A3 mRNA and protein levels (Glavas et al., 2001). Inhibition of PDE7, by 
down-regulating expression of the protein using anti-sense oligonucleotides, decreases the 
amount of IL-2 (Li et al., 1999) and IL-13 (Kanda and Watanabe, 2001) cytokine 
expression in activated T lymphocytes and inhibits the proliferation of T cells (Li et al.,
1999). With PDE7 contributing significantly to mechanisms involved in the full activation
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of T cells it could provide a potential therapeutic target. Specific inhibitors might be 
expected to decrease IL-2 production and thus, prevent excessive cellular proliferation 
perhaps without the side effects associated with PDE4 inhibition (Barnes et al., 2001).
The first synthetic inhibitors which targeted PDE7 activity were benzyl derivatives of 2,1,3 
-Benzo-and benzothienol [3,2-a]-thiadiazine2,2-dioxides (Fig. 5.1.). These showed 
inhibition of recombinant PDE7 expressed in Saccharomyces cerevisiae, with IC50 values 
of around 10 |iM. However, these compounds exhibited high cross-reactivity with PDE3 
and PDE4 isoforms and so were not suitable for explicit selectivity (Martinez et al., 2000). 
The next generation of PDE7 inhibitors were designed around a guanine based structure 
(Fig 5.1.) with 8  -bromo-9 -substitution (Barnes et al., 2001). These proved to be potent 
PDE7 inhibitors, the most selective having an IC50 of 1 |xM for PDE7, while only very 
weakly (-10 %) inhibiting PDE3 and PDE4 activity at a concentration of 10 juM (Barnes et 
al., 2001).
Four PDE7 isoforms have been identified, three originating from the PDE7A gene and one 
from the PDE7B gene. The PDE7A protein was initially identified by complementation 
analysis in cAMP-specific PDE-deficient Saccharomyces cerevisiae (Michaeli et al., 
1993). Further identification of this protein from both T cell lines and skeletal muscle 
uncovered two splice variants, PDE7A1 (accession number AAA35644) and PDE7A2 
(accession number AAB65772, Bloom and Beavo, 1996; Han et al., 1997). These two 
proteins have mobilities of 57 kDa and 50 kDa, respectively, and differ from one another 
in their extreme N-termini (Fig. 5.2., Panel A). The N-terminus of PDE7A2 encompasses a 
hydrophobic region that localises the protein to particulate cell fractions, whereas the 
PDE7A1 N-terminus is much more hydrophilic and a more even distribution of the protein 
between cytosolic and membrane fractions is found (Han et al., 1997). A third PDE7A 
splice variant has recently been identified in T-cells, PDE7A3 (accession number 
AAK57640, Glavas et al., 2001). It has the same N-terminus as PDE7A1 but differs at the 
C-terminus. It has an apparent molecular weight of 50 kDa (Fig. 5.2., Panel B).
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Results 
5.2. Expression of PDE7A isoforms in ceiis
5.2.1 Screening cell lines for endogenous PDE7A protein
PDE7A1 is the most abundant PDE7 isoform expressed in T cell lines (Glavas et al., 2001; 
Bloom and Beavo, 1996). In order to establish which cell lines would be appropriate to 
study the activity and sub-cellular distribution of PDE7A, a series of cell lines were 
screened with PDE7A specific polyclonal rabbit antisera, provided by Celltech Pic. The 
antiserum was raised against a synthetic peptide, ELNSQLLPQENRLS, which equates to a 
sequence located at the extreme C-termini of the PDE7A1 and PDE7A2 splice variants, but 
not PDE7A3. The cell lines screened ranged from T cells (Molt-3, Jurkat 16 and HuT-78), 
B cells and monocytes (U-937) to kidney (HEK-293, COS-1 and COS-7) and fibroblast 
cell lines (F442A, Fig. 5.3.). A  summary of the expression of the PDE7A isoforms in the 
different cell lines is presented in Table 5.1. In agreement with previously published 
observations (Glavas et al., 2001; Bloom and Beavo, 1996), PDE7A was only expressed at 
high levels in T cell lines where the most abundant isoform was PDE7A1 (57 kDa). No 
cell lines studied expressed PDE7A2 (50 kDa) at high levels, but immunoreactive bands 
were evident in COS-1, COS-7 and Jurkat J6 cells.
5.2.2. Expression of recombinant PDE7A protein In a mammalian system
I was supplied with several DNA plasmid constructs generated by Dr. Ray Owens at 
Celltech Pic. The first of these constructs, referred to as pSM2, contained the human 
PDE7A1 cDNA sequence cloned into the BamHI/Xbal sites of the polylinker region of the 
pcDNA3.1 expression vector (Invitrogen), with a FLAG sequence fused to the N-terminus 
of the protein. The second construct supplied, referred to as pBMC, contained the human 
PDE7A2 cDNA cloned into the BamHI site within the polylinker region of the pVL1392 
baculovirus transfer vector (Pharmingen). Celltech Pic had previously characterised these 
PDE7A isoforms as proteins expressed in insect cells. However, when they attempted to 
express the PDE7A proteins in COS-1 and Chinese hamster ovary (CHO) cells, no 
expression was detected by activity studies or by western blotting (personal 
communication, R Owens). PDE7A mRNA transcripts were detected in the transfected 
COS-1 and CHO cells by RT-PCR, which led the investigators to believe that PDE7A 
protein translation required a cofactor and this might be absent in these cell lines (personal 
communication, R. Owens). This suggestion of selective translation of PDE7 in cells
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containing the mRNA transcripts had previously been proposed by Bloom and Beavo, 
since they also observed PDE7A mRNA, but detected no PDE7A protein in skeletal 
muscle and B cell lines (Bloom and Beavo, 1996).
5.2.2.1. Cloning PDE7A2 into the pcDNA3.
As the human PDE7A2 cDNA was supplied in the baculovirus transfer vector pVL1392, 
the PDE7A2 cDNA had to be subcloned into a mammalian expression vector, to allow 
expression of the protein in mammalian cell lines.
The PDE7A2 open reading frame (ORE) cDNA was excised from the pVL1392 vector 
using the BamHI endonuclease (Materials and methods 2.5.3.1). The PDE7A2 cDNA 
fragment was isolated by agarose gel electrophoresis, purified from the gel (Materials and 
methods 2.5.3.1 and 2.5.3.3) and ligated into purified, BamHI digested, pcDNA3 vector 
(Materials and methods 2.5.4), giving rise to the plasmid pCSl. To confirm the subcloning 
of the PDE7A2 cDNA into pcDNA3 had occurred in the correct orientation the pCSl 
construct was sequenced (Materials and methods 2.5.8) and was found to be correct (data 
not shown).
5.2.2.2. Transfection of COS-7 cells with PDE7A constructs
To characterise the PDE7A proteins, the PDE7A1 containing construct, pSM2, and the 
PDE7A2 containing construct, pCSl, were transfected into COS-7 cells using the DEAE- 
Dextran method (Materials and methods 2.1.3.1). Transfected cells were incubated for 24 -  
48 h, to allow for expression of the protein, before being harvested and processed for 
immunoblotting. As can be seen in Fig. 5.4., COS-1 cells transfected with the PDE7A1 
construct expressed the protein well when compared to mock transfected cells. The 
PDE7A2 construct, however, did not produce any detectable immunoreactive protein (Fig. 
5.4,).
In an attempt to express the PDE7A2 construct in COS-7 cells, different transfection 
methods were utilised, including calcium phosphate mediated transfection (Materials and 
methods 2.3,1.2.) and several commercially available lipid based transfections procedures, 
including lipofectAMINE^^, Dotap™ and Superfect™ reagents (Materials and methods 
2.3.1.3 and manufacturer’s instructions). When the transfected cell lysates were analysed 
by immunoblotting (Materials and methods 2.3.5.) none of the methods of transfection 
allowed the expression of PDE7A2 (Fig. 5.5.).
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5.2.2.3. PDE7A mRNA is detected in COS-7 cells
As Celltech Pic. had previously confirmed the expression of PDE7A mRNA from the 
pSM2 plasmid by RT-PCR analysis, I endeavoured to perform similar analysis of COS-1 
cells transfected with pCSl, using primers specific for PDE7A isoforms, to check whether 
expression at the mRNA level could be observed. The RT-PCR reactions from pCSl 
transfected COS-7 total RNA, using specific PDE7A primers (W1075 and W1070, see Fig.
5.6., Panel A), supplied by Cellteeh Pic, were carried out. PCR products of approximately 
600 bases were amplified from RNA extracted from both mock and transfected COS-7 
cells (Fig. 5.6., Panel B). This indicated that transcripts of PDE7A were endogenously 
present in COS-7 cells and it was therefore impossible to determine whether the PDE7A2 
construct was functional.
5.2.2.4. Attempt to transfect T-cell lines with PDE7A1
T cells are known to express PDE7A1 (Ichimura and Kase, 1993; Bloom and Beavo, 1996) 
and as the levels of PDE7A1 protein had previously been shown to be increased upon the 
activation of T cells (Glavas et al., 2001) I endeavoured to study the effects of 
overexpression of PDE7A1 in T cell lines. I attempted to introduce the pSM2 construct 
into Jurkat J6 and Hut-78 T-cell lines. However, these cells proved difficult to transfect 
using many different transfection methods including calcium phosphate-mediated 
transfection (Materials and methods 2.3.1.2.) and several commercially available lipid 
based transfections procedures, which included lipofectAMINE'^^, Dotap' '^  ^ and Superfecf^'^ 
reagents (Materials and methods 2.3.1.3 and manufacturer’s instructions). The levels of 
PDE7A1 protein in these cells utilising these transfection methods never increased above 
that of the endogenously expressed protein (Fig. 5.7.). Therefore, COS-1 and COS-7 cell 
lines were used to study expression and characterisation of PDE7A1.
5.2.2.5. Subcellular localisation of PDE7A1 in mammalian cells
PDE7A1 has previously been shown to be distributed between the particulate and cytosolic 
fraction of a cell when analysed in brain, kidney, lung and skeletal muscle (Han et al., 
1997). To confirm that PDE7A1, when overexpressed in the COS-1 cells, was localising to 
similar cellular compartments as the endogenous protein in primary cells crude subcellular 
fractionations of COS-1 cells transfected with the pSM2 construct (Materials and methods 
2.3.1.2) were probed with the PDE7 specific antiserum (Fig. 5.8.). These results indicate
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that the majority of the PDE7A1 protein was localised to the cytosolic fraction of the cell, 
with a small proportion localising to the low speed PI and high speed P2 fraction.
5.3. Analysis of PDE7A1 Protein Activity
As the transient overexpression of PDE7A2 proved fruitless, further work was carried out 
on the characterisation of the PDE7A1 protein. In order to elucidate which effectors 
control and regulate the activity of PDE7A1 within mammalian cells it is necessary to be 
able to determine the activity of the PDE7A1 enzyme. There are no commercially available 
inhibitors of PDE7, so its activity has been determined as the cAMP, specific IBMX- 
insensitive activity within the cell, as it has been described by others (Michaeli et al., 
1993). However, in light of the characterisation of the ‘new’ PDE families (PDE8, PDE9, 
PDE 10 and PD E ll) it has become apparent that PDE8, PDE9 and PD E ll are all 
insensitive to IB MX inhibition therefore anaylsis of PDE activity under these conditions 
does not allow detection of PDE7 activity specifically. Only very recently have inhibitors 
been synthesised that exhibit PDE7 specificity (Barnes et al., 2001), but unfortunately 
these were not available for use at this stage of my study. The activities of PDE7A1 were 
therefore determined on isolated protein.
5.3.1. Modification of PDE assay to optimise the detection of PDE7 activity
Our laboratory has an established assay method for determining the activity of PDE4 from 
cellular lysates, as described in section 2.3.9. of the Materials and Methods. However, the 
concentration of cAMP used was closer to the Km values for PDE4, namely 2 pM 
(Materials and methods 2.3.9.) than that of PDE7. As both COS-1 and COS-7 cells appear 
to have high levels of endogenous PDE4 protein (Fig, 5.9.), this assay would pick up 
alterations in PDE4 activities as well as those of PDE7. Therefore, it was necessary to 
modify the standard PDE assay used in the laboratory to maximise the sensitivity of the 
assay to detect PDE7 activity. PDE7A has a Km value of 0.2 pM for cAMP (Michaeli et 
al., 1993) and PDE4 proteins have Km values for cAMP in the ranges of 1.5 -8  pM (Bolger 
et al., 1997; Huston et al., 1997; McPhee et al., 1995). A range of cAMP concentrations 
was utilised in the PDE assay to maximise detection of PDE7 and minimise detection of 
PDE4 activities (Fig, 5.10.). The activity of PDE7 was detected to a greater extent than the 
activity of PDE4 when a concentration of 0.05 pM cAMP was used in the PDE assay. This 
concentration of cAMP was therefore utilised in further PDE assays.
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5.4. Characterisation of PDE7 specific inhibitors
After optimisation of the PDE assay for the specific detection of PDE7, presumed selective 
inhibitors for PDE7 were made available from Celltech Pic, Therefore full characterisation 
of the specificities of the PDE7 selective inhibitors for different PDE families was 
performed.
5.4.1. Production of PDE7 specific inhibitors.
The PDE7 inhibitors CT6351 and CT6236 supplied by Celltech Pic. were different to the 
compounds that had been previously published by the Celltech group (Barnes et al., 2001). 
The structures of the CT6251 and CT6236 compounds are shown in Figure 5.11. I would 
have liked to have discussed the chemistry behind the synthesis of these inhibitor 
compounds and the IC50 values obtained by Celltech Pic for them, but due to 
confidentiality agreements, these details have not been provided to our group.
5.4.2. Characterisation of PDE7 inhibitors in mammaiian ceils
The PDE7 inhibitors CT6351 and CT6236 had previously been characterised by Celltech 
Pic on insect cell-expressed cAMP specific PDE proteins (personal communication, R- 
Owens). Studies of recombinant PDE proteins from insect cells only allow characterisation 
of the protein in isolation. In mammalian cells there are profiles of PDE isoforms 
expressed, therefore the cross reactivities of the inhibitor compounds can be analysed. The 
IC50 values obtained by Celltech for the PDE7 inhibitors, CT6251 and CT6236, on the 
PDE7 and PDE4 isoforms are shown in Table 5.2. I analysed the IC50 values of the 
CT6351 and CT6236 inhibitor compounds for PDE7A1 and PDE4D3 recombinant protein 
expressed in mammalian cells. The values obtained for PDE7A1 and PDE4D3 were 0.1 
|LiM ± 0.02 and 1.3 |liM respectively for the CT6251 compound (Fig. 5.12.,Panel A &
5.12., Panel B) and for CT6236 were 0.65 p,M and >50 pM for PDE7A1 and PDE4D3 
respectively (Fig. 5.13., Panel A & 5.13., Panel B). The CT6251 compound was not 
selective enough to inhibit PDE7 activity in cells specifically, whereas the CT6236 
compound had enough specificity for PDE7 to allow determination of the PDE7 activity in 
a cell in isolation from PDE4.
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5.5. Modification of PDE7 within ceiis
As the increases of PDE7A1 activity has only been associated with its increased expression 
upon T cell activation an investigation was carried out in an attempt to identify any post- 
translational modification PDE7A1 might be subjected to. Phosphodiesterase activities are 
altered by phosphorylation (see section 1.2.5 and those within section 1.3.), by binding to 
adapter proteins such as AKAPs (see section 1.3.4.2) and by binding phospholipids (see 
section 1.3.4.5.), so these were all taken into consideration.
5.5. f. Prediction of phosphoryiation sites within PDE7A1
Phosphorylation of PDEs has been the most extensively studied post-translational 
mechanism by which these enzyme activities are modulated (Beavo, 1995; Shibata et al., 
1991; Sette and Conti, 1996; Tetsuka et al., 1995; Paglia et al., 2001; Rybalkin et al., 2001; 
Ahmad et al., 2000; Hoffmann et al., 1999; MacKenzie et al., 2000). Therefore, the 
potential phosphorylation sites within PDE7 were analysed using the web-based analysis 
package, PhosphoBase v2.0 to determine whether there are potential target sites for 
phosphorylation. This is a database of phosphorylation sites provided by the Center for 
Biological Sequence Analysis (Kreegipuu et al., 1999). It is a service which implements a 
prediction algorithm based on substrate consensus sequences of some of the more 
commonly known protein kinases. As mentioned in chapter 4, the results from these 
predicted protein phosphorylation sequence sites have to be interpreted with caution as 
many sequences that do not coirespond to a consensus motif can be phosphorylated and 
not all consensus phosphorylation sequences aie indeed phosphorylated. The sites on 
PDE7A1 identified by these services were, therefore, only used as tentative guidelines for 
the potential phosphorylation sites of the protein. As can been seen in Table 5.3., there are 
several candidate kinases which have been identified as potentially being able to 
phosphorylated sites in PDE7A1, these include PKA, PKC, Calmodulin dependent kinase 
II (CaMII), Casein kinase I and II (CKI and CKII) and GSK-3.
5.5,2. Stimuiation of ceiis in an attempt to phosphoryiate PDE7A1
As described in the introduction and as demonstrated in chapter 4 several modifications of 
phosphodiesterases including phosphorylation can alter the activity of the enzyme (Ahmad 
et al., 2000; Rybalkin et al., 2001).
Cells expressing PDE7A1 were stimulated with agonists of kinase signalling cascades and 
alterations in the activity of PDE7 in cells was detected by isolation of PDE7A1 by 
immunoprécipitation and the activity of the immunoprecipitate was assayed {Fig, 5.14.). 
Forskolin treatment of cells led to a 1.5 fold stimulation of PDE7A1 activity. Whereas the 
stimulation of cells with other agonists such as ionomycin, EGF and PMA showed no 
change in PDE7A1 activity {Fig. 5.14.).
5.5.3, Attempted\x\ vitro phosphorylation of PDE7A1
Work in our laboratory and others has shown that PDE4 isofoims are phosphorylated by 
PKA (Hoffmann et al., 1998; Sette and Conti, 1996) and more recently it has been shown 
that one of the PDE7B splice variants, PDE7B2 can potentially be phosphorylated by PKA 
(Sasaki et al., 2002). There are 12 predicted sites for PKA phosphorylation of PDE7A1 
{Table 5.3.) and challenge of cells with forskolin did appear to increase PDE7 activity (see 
section 5.5.2.2.). This in vitro phosphorylation of PDE7A1 with PKA was attempted. Some 
method development was required to ensure PDE7A1 isolation was optimal for 
phosphorylation.
5.5.3.1. Efficacy of the PDE7A antibody in the isolation of PDE7A from cell 
lysates
PDE7A protein needed to be isolated from cell lysate at levels high enough to provide an 
adequate target for phosphorylation of the protein in an in vitro system. Therefore the 
efficacy of the PDE7A antibody for immunoprécipitation of the PDE7A1 protein from 
transfected cells was assessed (Materials and methods 2.3.10). As the protein migrated 
similarly to the IgG heavy chains, it was necessary to use a mouse monoclonal anti-FLAG 
antibody directed against the epitope tag at the N-terminus of the protein. As can be seen in 
Fig. 5.15., PDE7A1 was successfully immunoprecipitated from cells over-expressing it.
5.5.3.2. In v itro  phosphorylation of PDE7A1
PDE7A1 was isolated from transfected COS-1 cells and both endogenous PDE7A1 and 
PDE7A2 were isolated from Molt-3 cells by immunoprécipitation using the PDE7A 
antiserum. These proteins were subjected to an in vitro kinase assay using the purified 
PKA catalytic sub-unit (Materials and methods 2.4.5.1). The reaction incorporated ^^ P into 
the PDE7A1 and PDE7A2 protein in the presence and absence of the PKA catalytic 
subunit {Fig. 5.16.). This suggested that a kinase was co-immunoprecipitating with the
PDE7A1 protein and phosphorylating the protein even in the absence of the PKA. 
Therefore the phosphorylation of PDE7A isoforms could not be attributed conclusively to 
a PKA dependent mechanism.
5.5.4. In vivo phosphorylation of PDE7A1
Recently, PDE7B isoforms have been reported to be phosphorylated in vivo (Sasaki et al., 
2002). In order to determine whether PDE7A1 was targeted for phosphorylation in vivo, 
COS-7 cells were transfected with the pSM2 construct and subjected to whole cell 
labelling (Materials and methods 2.4.4.). Phosphorylation of the transfected protein was 
observed, well above that observed in mock-transfected cells (Fig. 5.17.), suggesting that 
PDE7A1 can indeed be potentially phosphorylated under physiological conditions.
5.5.5. Attempted identification of kinase which co-immunoprecipitates with 
PDE7A antibody.
As PDE7A1 was subjected to phosphorylation in vitro, in the absence of a recombinant 
kinase an investigation as to which kinase might be co-immunoprecipitating with PDE7A1 
was carried out.
5.5.5.1. Immunoprobe of the PDE7A1 immunoprecipitate
The polyclonal anti-PDE7A antibody used to immunoprecipitate PDE7A1 protein and the 
monoclonal anti-FLAG antibody used in the isolation of the FLAG-tagged PDE7A1 
protein from cells appeared to bind non-specifically to many proteins within the cell lysate 
(Fig. 5.18.). Therefore, to reduce the amount of non-specific proteins bound these 
antibodies during immunoprécipitation a series of stringent washes of the 
immunoprecipitates were carried out {Fig. 5.18.). It was found that even with high 
concentrations of salt and SDS in the final washes lots of protein remained bound to the 
PDE7Al/beads/antibody, suggesting that these proteins might be binding specifically to 
PDE7A1.
I set out to determine whether any of these proteins, which appeared to bind specifically to 
FDE7A1, could be a kinase able to phosphoryiate PDE7A1 in the in vitro phosphorylation 
reactions. In the first instance, PDE7A1 immunoprecipitates were immunoprobed with a 
goat pan-PKC antibody. This identified a protein that migrated at around 90 kDa in the
immunoprecipitates {Fig. 5.19.), suggesting that PKC isofoims could be binding 
specifically to PDE7A1.
5.5.5.2. Colmmunopreclpitatlon of RACK1 with PDE7A1
Our laboratory has previously reported a potential effect of the activation of PKC causing 
an alteration in the activity of the IBMX-insensitive fraction of PDE activity in CHO cells 
(Spence et al., 1995). We have also shown that the PKC adaptor protein, RACKl (receptor 
for activated C-Mnase) can interact with the PDE4D5 isoform (Yarwood et al., 1999). 
Therefore, further studies were carried out to investigate whether PKC was targeting 
PDE7A1 for phosphorylation and, more specifically, whether RACK-1 interacted with 
PDE7A1.
PDE7A1 was isolated from cells by immunoprécipitation using the PDE7A anti serum and 
the proteins were probed with an anti-RACKl monoclonal antibody. RACKl appeared to 
co-immunoprecipite with the PDE7A1 protein from the pSM2 transfected COS-1 cells 
{Fig. 5.20.), suggesting that an interaction between PDE7A1 and RACKl occurs within 
cells. There was a small amount of RACKl protein detected in the immunoprecipitate from 
mock transfected cells, suggesting either a small amount of endogenous PDE7A was being 
immunoprecipitated from the COSl cells and the RACKl was co-immunoprecipitating 
with it or else a small amount of RACKl binds non-specifically to the PDE7 specific 
anti serum.
5.5.5.3. RACK 1 -GST pulldown of in v itro  expressed PDE7A1
To remove the possibility of endogenous PDE7A protein interfering with the 
immunoprécipitation reaction and in an attempt to determine whether there was a specific 
interaction between PDE7A1 and RACKl, an in vitro pulldown reaction between PDE7A1 
and RACKl was carried out. PDE7A1 protein was generated by an in vitro expression 
system that incorporated into the protein. This labelled protein was then used in a 
pulldown experiment with a recombinant RACKl-GST fusion protein (Materials and 
methods 2.4.7.). Although RACKl-GST did bind to the PDE7A1 protein {Fig. 5.21.), the 
control pull-down reaction in which GST alone was used to bind PDE7A1, also appeared 
to interact with PDE7A1. This suggests that the PDE7A1 in this reaction did not bind to 
RACKl specifically and that the interaction seen to occur between PDE7A1 and RACKl 
was due to a non-specific protein interaction. Therefore no conclusions can be drawn about 
the ability of RACKl to interact with PDE7A1.
5.6. Conclusions
The PDE7 family of phosphodiesterases is generated from two genes, PDE7A and PDE7B. 
There are three PDE7A splice variants two of which, PDE7A1 and PDE7A3, have been 
associated with the activation of T cells (Li et al., 1999; Glavas et al., 2001; Bloom and 
Beavo, 1996) and the third splice variant, PDE7A2, is relatively uncharacterised (Han et 
al., 1997; Wang et al., 2000). Screening a variety of cell lines confirmed that PDE7A1 was 
expressed endogenously in T cells, as PDE7A1 protein was detected in HuT-78, Jurkat J6  
and Molt-3 cells, all of which are derived from T cells (Ichimura and Kase, 1993). 
PDE7A2 is not expressed at high levels in many cell lines, although it has been detected in 
skeletal muscle, heart, embryo and kidney primary cells (Wang et al., 2000). There were 
low levels of PDE7A2 protein detected in COS-1, COS-7 and HEK-293 cells, all of which 
are kidney derived cell lines and there were also low levels of immunoreactive PDE7A2 
detected in HuT-78, Jurkat J6  and Molt-3 cell lines.
At the outset of this investigation, relatively little was known about the PDE7 isoforms. I 
wished to perform characterisation studies of PDE7A in mammalian cells, which required 
isolation of high levels of PDE7 protein from these cells. Previous attempts by workers at 
Celltech Pic to over-express both PDE7A1 and PDE7A2 in mammalian cells had failed. 
Utilising several methods of transfection and recloning the PDE7A2 cDNA into a 
mammalian expression vector I was also unable to overexpress PDE7A2. However, over­
expression of PDE7A1 protein was achieved in all but the immune cell lines as they were 
difficult to transfect. The distribution of the over-expressed PDE7A1 suggested similar 
compartmentalisation as had been detected previously in primary cells by the Beavo group 
(Bloom and Beavo, 1996). Therefore further characterisation of the protein was attempted.
With PDE7 isoforms identified as a relatively novel phosphodiesterase various groups are 
attempting to assess the functions of PDE7A within cells. It has been shown that PDE7A 
isoforms contribute to the activation of T cells (Bloom and Beavo, 1996), although the 
mechanisms of their activation have been linked only to alterations in their expression 
levels (Glavas et al., 2001). It was hoped, therefore, that this study would elucidate 
mechanisms of control of enzymatic activity brought about by post-translational 
modifications of PDE7A isoforms. This might then lead to further understanding of the 
involvement of PDE7 in the activation of T lymphocytes (Li et al., 1999). The effect of 
subjecting COS-1 cells overexpressing PDE7A1, to different chemical stimuli on the 
phosphorylation state and activity of PDE7A1 were studied.
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PDE7A is phosphorylated in vivo in cells and a kinase that co-immunoprecipitates with 
PDE7A1 phosphorylates the protein in vitro. However, the kinase responsible for this 
phosphorylation modification, within the limits of this study at the time it was carried out, 
was not identified. To determine whether phosphorylation of PDE7A1 affected the 
enzymatic activity of the protein the standard PDE assay was modified to maximise the 
detection of PDE7 activity. This required reduction of the concentration of cAMP within 
the assay from levels which were close to the V m a x  of the PDE7 isoforms (2 jxM) to 
amounts nearer to their Km values (0.05 jiiM). Previously, PDE7 activity had been 
characterised as the cAMP specific IBMX-insensitive PDE activity within a cell (Ichimura 
and Kase, 1993; Michaeli et al., 1993). As an increasing number of PDE families, such as 
PDE8 , PDE9 and PD E ll, are being identified which have reduced sensitivities to the 
general PDE inhibitor IB MX (Hayashi et al., 1998; Fisher et al., 1998; Fawcett et al., 
2000), it is becoming apparent that the initial observations regarding the IBMX-insensitive 
fraction of T lymphocytes (Ichimura and Kase, 1993) are unlikely to be due to just one 
family of PDE. Currently there are no commercially available PDE7 inhibitors, however, 
inhibitor compounds were made available by Celltech Pic. and one of these, CT6236, was 
deteimined to be highly selective for PDE7 over other cAMP specific phosphodiesterases.
In forskolin stimulated cells isolated PDE7A1 was found to have slightly elevated activity, 
when compared to the activity of PDE7A1 from unstimulated cells. This suggests that 
PKA could potentially be regulating the activity of PDE7A1, as it does members of the 
PDE4 family (Sette and Conti, 1996; Hoffmann et al., 1998).
PDE7A isoforms aid the full activation of T cells (Glavas et al., 2001) through stimulating 
the induction of IL-2 expression and increasing cellular proliferation (Li et al., 1999). 
Incubation of T cells with phorbol esters also stimulates expression of IL-2 (Klein et al., 
1983; Sander et al., 1991; Reem et al., 1984), induces DNA synthesis (Di Pauli and Rassat, 
1983) and increase T cell proliferation (Gause et al., 1988). It was speculated that a PKC 
dependent mechanism could induce the alterations in PDE7A1 activity in T cell activation 
as our laboratory have shown PMA stimulation of CHO cells alters the IBMX insensitive 
fraction of PDE activity (Spence et al., 1995). Further investigations of PKC dependent 
effects on PDE7A1 activity were carried out. A kinase of approximately 90 kDa, detected 
with a pan-PKC antibody, apparently co-immunoprecipitated with PDE7A1, leading to 
further consideration that PKC could be phosphorylating the protein in the in vitro 
phosphorylation reactions. A direct interaction between the receptor for activated C-kinase, 
RACKl and a PDE4D isoform has been reported linking the PDE isoform into a complex 
with active PKC (Yarwood et al., 1999). However, the investigation as to whether
PDE7A1 could form an interaction with the RACKl/ PKC complex, showed no apparent 
interaction of PDE7A1 with the scaffolding protein. From these investigations it can only 
be concluded that the initial interaction apparent between RACKl and PDE7A1 was due to 
either non-specific interactions with antibodies or a non-specific binding of PDE7A1 to the 
GST protein tag, and no direct interaction of the proteins was ever shown. Therefore, 
although PDE7A1 is subjected to phosphorylation in cells under physiological conditions 
identification of the candidate kinase was not achieved.
Due to problems related to the availability of selective inhibitors and difficulties 
experienced in obtaining high levels of expression of the PDE7A2 isoform at the end of 
my first year I changed to working on the PDE4 enzymes. However, with the current 
technology available in proteomics and, in particular, in light of the work I have 
consequently carried out and presented in Chapters 3 and 4 on the analysis of 
phosphorylation sites, it would be possible to set out to identify the co-immunoprecipitated 
protein and phosphorylation sites on PDE7A1. These are likely to be important processes 
to making novel insights into PDE7 activation.
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Figure 5.1. Synthetic selective inhibitors of PDE7. Although the benzyl 
derivatives of 2,1,3-benzo (A) and benzothienol[3,2-a]thiadiazine 2,2-dioxides 
(B) target PDE7 activity with high potency, they also cross react with the other 
cAMP specific phosphodiesterase families, PDE4 and PDE3 (Martinez et al.,
2000). The IC50 values are indicated for PDE7, PDE3 and PDE4 . Guanine based 
analogues were synthesised by the Celltech group producing the final compound 
with high potency and selectivity for PDE7 (C) (Barnes et al., 2001). The IC50 
value for PDE7 is indicated, as is the percentage of PDE3 and PDE4 inhibited 
with 10 fiM  of the same compound.
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Figure 5.2. Alignment of PDE7A1, PDE7A2 and PDE7A3 peptide sequences. Panel A. 
The peptide sequence of PDE7A1 (accession number A A A35644) and PDE7A2 (accession 
number AAB65772) are aligned with one another using the GeneJockey v2.2H software. 
Panel B. The C-terminal peptide sequences of PDE7A1 and PDE7A3 (accession number 
AAK57640) are aligned with one another using the GeneJockey v2.2II software. The N- 
terminal sequences of the proteins up to residue 415 are identical, the extreme C-terminal 
residues of PDE7A3 differ from those in PDE7A1 and the protein is truncated at residue 
244.
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Figure 5.3. Screening cell lines for PDE7A isoforms. 50 ju-g
cell lysates from multiple cell lines, as indicated, and 5 fig 
standard PDE7A1 and PDE7A2 proteins were separated by SDS- 
PAGE on a 10 % gel. The proteins were transferred to 
nitrocellulose and immunoprobed with PDE7A specific 
antiserum. The migration of PDE7A1 (57 kDa) and PDE7A2 (50 
kDa) isoforms on each blot are indicated. A summary of the cell 
lines and their origins are presented in table 5.1..
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Figure 5.4. Transfection of COS-1 cells with PDE7A1 and PDE7A2 
cDNA constructs. COS-1 cells were transfected with constucts containing 
PDE7A1 or PDE7A2 cDNA, or were subjected to a mock transfection 
using the DEAE-Dextran method {see section 2.1.2.). The cells were left to 
express the proteins for 48 h and were then harvested in KHEM. 25 fig of 
protein from the cell lysate and 5 fig of the PDE7A1 and PDE7A2 protein 
standards (Stds), expressed in insect cells, were separated by SDS-PAGE 
on a 10 % gel and transferred to nitrocellulose. The proteins were then 
immunoprobed using PDE7A specific antiserum. The positions of the 
PDE7A1 (57 kDa) and PDE7A2 (50 kDa) proteins are indicated.
PDE7A1 
PDE7A2
Figure 5.5. Attempted lipid-based transfection of COS-7 cells with 
pC Sl. COS-7 cells were left untransfected {lane 1) or transfected with the 
pCSl construct using LipofectAMINE^^ {lane 2), Dotap ™ {lane 3) or 
Superfect {lane 4) reagents as described in section 2.1.3. and according 
to manufacturer’s instructions. The cells were harvested in 3T3 lysis buffer 
and 100 fig protein from these lysates were separated by SDS-PAGE on a 
10 % gel, along with the protein standards {lane 5). The upper protein 
standard migrated with a molecular weight of 8 6  kDa, and the lower marker 
migrated at 47.5 kDa. 5 fig of PDE7A1 (57 kDa) and PDE7A2 (50 kDa) 
recombinant protein were also separated on the same gel {lanes 6 & 7 
respectively). The proteins were transferred onto nitrocellulose and then 
immunoprobed using the PDE7A specific anti serum.
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Figure 5.6. RT-PCR analysis of pCSl transfected COS-7 cells. Panel 
A. The forward primer W1075 and the reverse primer W1070, both 
indicated above, were used for RT-PCR analysis of mRNA transcripts of 
PDE7A. The DNA fragment produced by RT-PCR had a predicted 
weight of 600 base pairs (bp). Panel B. Total RNA was extracted from 
COS-7 cells transfected with the construct containing PDE7A2 (pCSl) or 
subjected to a mock transfection (mock) (see section 2.5.10.1.). First 
strand cDNA synthesis was carried out (see section 2.5.10.2.) and the 
W1075 and W1070 primers were used to amplify PDE7A cDNA. A 
reaction containing no cDNA was also carried out (blank). The DNA 
fragments produced were separated on a 1.5 % agarose gel, alongside a 1 
kilobase DNA ladder. The sizes of the markers are indicated in base- 
pairs.
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Figure 5.7. Attempted transfection of Jurkat J6  and HuT-78 cells 
with PDE7A1 containing construct. Jurkat J6  and HuT-78 cells were 
transfected with the pSM2 constuct, which contains the PDE7A1 cDNA 
(7A1), or subjected to a mock transfection without a vector (Mock), 
using the lipofectAMINE^^ lipid based transfection reagent (see section
2.1.3.). The cells were allowed to express the protein for 36 h and then 
harvested in 3T3 lysis buffer. Then 50 fig of protein from the cell lysate 
and 5 fig of the PDE7A1 and PDE7A2 recombinant protein standards 
were separated by SDS-PAGE on a 10 % gel. The proteins were 
transferred to nitrocellulose and immunoprobed using the PDE7A 
specific antiserum. The position of PDE7A1 (57 kDa) and PDE7A2 (50 
kDa) migration are indicated.
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Figure 5.8. Subceilular localisation of PDE7A1 in COS-1 ceils. COS-1 
cells transfected with the pSM2 construct, which contains the PDE7A1 
cDNA, were harvested in KHEM buffer and subjected to crude 
subceilular fractionation (see section 2.3.1.2.). 50 /rg protein from the 
low speed (2000 g, fixed angle rotor, 15 min) cell pellet (PI), the high 
speed (75000 g fixed angle rotor, 45 min) cell pellet (P2) and the residual 
cytosolic fraction (S) together with 5 fxg recombinant protein standards 
(Stds.) were separated by SDS-PAGE on a 10 % gel. The proteins were 
transferred to nitrocellulose and immunoprobed with a PDE7A specific 
anti serum. The positions of PDE7A1 (57 kDa) and PDE7A2 (50 kDa) are 
indicated.
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Figure 5.9. Expression of endogenous PDE4 isoforms in COS cell lines.
COS-1 and COS-7 cells were harvested in 3T3 lysis buffer and 100 fig 
protein from the cell lysates were separated by SDS-PAGE on a 10 % gel. 
The proteins were transferred to nitrocellulose and were then 
immunoprobed with a PDE4D specific antibody (see section 3.2.4.), the 
positions of the PDE4D5 (105 kDa) and PDE4D3 (95 kDa) proteins are 
indicated, as are the molecular weights of the protein standard markers.
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Figure 5.10. Detection of PDE7 and PDE4 enzymatic activity in the 
presence of varying cAMP concentrations. Constructs containing 
PDE7A1 (□) or PDE4D3 (O) cDNA were transfected into COS-1 cells and 
expressed in the cells for 24 h. The cells were then harvested in KHEM 
buffer and the lysates used for PDE assay analysis {see section 2.3.9.). 
Increasing concentrations of cAMP were used in the PDE assay, as 
indicated. The results are expressed as the means ± SE o f 5 independent 
experiments.
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Figure 5.11, Chemical structures of CT6251 and CT6236. The chemical 
structures of the PDE7 selective inhibitor compounds CT6251 and CT6236 were 
supplied by Celltech Pic. However, the basis of these inhibitor compounds cannot 
be discussed due to confidentiality agreements.
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Figure 5.12. IC5 0  values of CT6251 for PDE4 and PDE7. Panel A, Cell 
lysate from COS-1 cells overexpressing PDE4D3, was used in PDE assays 
(see section 2.3.9,) in the presence of increasing concentrations of the 
inhibitor compound, CT6251, as indicated. The percentage of the total 
PDE4D3 activity suppressed by CT6251 was calculated and from the 
equation of the line of best fit for these points the IC50 value was 
calculated. The IC50 value (in jttM) for CT6251 on PDE4D3 and the SE of 
this value, from 3 independent experiments is indicated. Panel B, Cell 
lysate from COS-1 cells over-expressing PDE7A1 was used in the same 
IC50 analysis for the CT6251 compound and the IC50 values (in (jlM)  were 
calculated from the line of best fit from 4 independent experiments
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Figure 5.13. ICgg values of CT6236 for PDE4 and PDE7. Panel A, Cell 
lysate from COS-1 cells overexpressing PDE4D3, was used in PDE assays 
{see section 2.3.9.) in the presence of increasing concentrations of the 
inhibitor compound, CT6236, as indicated. The percentage of the total 
PDE4D3 activity suppressed by CT6236 was calculated and from the 
equation of the line of best fit for these points the IC50 value was 
calculated. The IC50 value (in juM) for CT6236 on PDE4D3 and the SE of 
this value, from two independent experiments is indicated. Panel B, Cell 
lysate from COS-1 cells overexpressing PDE7A1 was used in the same 
IC50 analysis for the CT6236 compound and the IC50 values (in /xM) were 
calculated from the line of best fit from two independent experiments
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Figure 5.14. Activity changes of PDE7A1 upon stimulation of cells 
with agonists of kinase signalling cascades. COS-1 cells were transfected 
with pSM2, the construct containing the cDNA for PDE7A1, and 
stimulated with agonists of kinase signalling cascades, such as 100 nM 
PMA, 10 fxM forskolin, 10 fxM ionomycin and 50ng/ml EGF, as indicated, 
for 20 min. The cells were then harvested in KHEM and PDE7A1 was 
isolated from 1 mg protein from these cell lysates by immunoprécipitation 
using PDE7 specific antiserum (see section 2,3.10.). The enzymatic 
activity of the isolated protein was then determined by PDE assay (see 
section 2.3.9.). The results are expressed as the means ± SE of three 
independent experiments.
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Figure 5.15. Rabbit anti-PDE7A antibody successfully 
immunoprecipitates PDE7A1 from COS-1 cell lysate. COS-1 cells 
transfected with the PDE7A1 plasmid, pSM2 (see section 2.1.2.), were 
allowed to express the protein for 24 h and were then harvested in KHEM 
buffer. The PDE7A1 protein was isolated by immunoprécipitation from 1 
mg of the cell lysate, using the PDE7A specific anti serum (aPDE7 IP). 
The proteins were separated by SDS-PAGE on a 10 % gel alongside 50 /tg 
protein from pSM2 transfected COS-1 whole cell lysate. The protein were 
transferred to nitrocellulose and immunoprobed with the monoclonal anti- 
FLAG antibody, the migration of the PDE7A1 protein (57 kDa) and the 
molecular weight standards are indicated.
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Figure 5.16. In vitro phosphorylation of PDE7A1 and PDE7A2. Molt-3 
cells and COS-1 cells, transfected with pSM2 (Transfect), were harvested in 
3T3 lysis buffer and the PDE7A isoforms were isolated by 
immunoprécipitation (see section 2.3.10.), from 1 mg of protein from these 
lysates, using PDE7A specific anti serum. The proteins were subjected to an 
in vitro phosphorylation reaction using y[^^P]ATP in the presence or absence 
of the purified catalytic sub-unit of PKA (see section 2.4.5.1.). The 
phosphorylated proteins and 1 0  ^1 of the radiolabelled protein standards 
(Stds.) were separated by SDS-PAGE on a 10 % gel and then transferred to 
nitrocellulose. The nitrocellulose was exposed to a phosphorimage screen 
for 2 days, and the proteins visualised using the BioRad system (see section 
2.4.5.4.). The migration of the molecular weight standards and the PDE7A1 
(57 kDa) and PDE7A2 (50 kDa) isoforms are indicated.
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Figure 5.17. Whole cell labelling of COS-7 cells transfected with the 
pSM2 construct. COS-7 cells were either transfected with the PDE7A1 
containing construct, pSM2 (7A1), or subjected to a mock transfection 
(Mock). The cells were allowed to express the protein for 24 h and were 
then labelled with 300 p,Ci/ml ^^ P- orthophosphate overnight (see section
2.4.4.). The cells were harvested in 3T3 lysis buffer and the PDE7A1 
protein was isolated from 1 mg of protein from these cell lysates by 
immunoprécipitation using the anti-FLAG antibody. The 
immunoprecipitated proteins were separated by SDS-PAGE on a 10 % gel, 
transferred to nitrocellulose and exposed to a phosphorimage screen 
overnight (see section 2.4.4.). The migration of the radiolabelled protein 
markers and PDE7A1 (57 kDa) are indicated.
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Figure 5.18. High salt and SDS washes remove none specific bound 
protein from immunoprecipitates of PDE7A1. PDE7A1 protein was 
isolated from 1 mg COS-1 cell lysate transfected with the pSM2 
construct, using the monoclonal anti-FLAG antibody (aFLAG) or 
PDE7A specific antiserum (aPDE7). The protein bound beads were then 
subjected either to a stringent wash, which include a 0.5M NaCl, 0.1% 
SDS and a 0.01% NaPa wash (High) or subjected to the original wash 
procedure with lysis buffer (Low). The proteins bound to the beads were 
separated by SDS-PAGE on a 10 % gel and the gel was silver stained ( 
see section 2.3.7.). The migration of the molecular weights standards and 
the PDE7A1 protein (57 kDa) is indicated.
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Figure 5.19. A protein which cross reacts with the pan-PKC 
antibody co-immunoprecipitates with PDE7A1 protein. PDE7A1 
protein was isolated by immunoprécipitation using the PDE7 specific 
antiserum (aPDE7) from 1 mg COS-1 cell lysate transfected with the 
PDE7A1 containing construct, pSM2, or from mock transfected cells 
or pre-immune sera from rabbit (IgG). The isolated protein was 
subjected to SDS-PAGE on a 10 % gel, transferred to nitrocellulose 
and probed with the goat polyclonal Pan-PKC antibody. 100 fxg Whole 
cell lysate was used as a standard to determine where the PKC 
isoforms from COS-1 cells migrated. The migration of the molecular 
weight standards are also indicated.
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Figure 5.20. RACK-1 appears to coimmunoprecipitate with PDE7A1.
PDE7A1 was isolated from 1 mg COS-1 cell lysates which were 
transfected with the pSM2 construct (pSM2), or mock transfected (Mock) 
by immunoprécipitation using the PDE7 anti serum (aPDE7) or rabbit 
preimmune sera (IgG) (as described in section 2.3.10.). The isolated 
proteins were separated by SDS-PAGE on a 10 % gel, transferred to 
nitrocellulose and immunoprobed using monoclonal antibody raised 
against RACK-1. Whole cell lysate from COS-1 cells was used as a 
control to confirm RACK-1 was expressed in these cells (lysate). The 
migration of the RACK-1 protein (36 kDa) and the 35 kDa molecular 
weight marker is indicated.
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Figure 5.21. GST-RACK-1 pulldown of in vitro synthesised PDE7A1 
protein. Recombinant RACK-1-GST protein was incubated with in vitro 
synthesised PDE7A1 protein, for 1 h at 4 °C, prior to the addition of GSH- 
sepharose beads for a further 1 h {see section 2.4.7.). The beads were then 
washed and boiled in laemllis sample buffer before the proteins were 
subjected to SDS-PAGE on a 10 % gel. The proteins were transferred to 
nitrocellulose and exposed to a phosphorimage screen for 3 days. Lane 1 
contains the in vitro synthesised PDE7A1 protein products. Lane 2 
contains the GSH-sepharose beads alone. Lane 3 contains the PDE7A1 
protein bound to GST/GSH beads alone. Lane 4 contains RACK-1-GST 
bound to the GSH beads. Lane 5 contains the in vitro synthesised PDE7A1 
bound to RACK-l-GST/GSH beads. Lane 6  contains the radiolabelled 
molecular weight markers. The migration of the molecular weight markers 
and the migration of PDE7A1 (57 kDa) are indicated.
Cell Line Cell Origin PDE7A1
Detected
PDE7A2
Detected
B-cell Human atopic B cells NO NO
COS-1 & cos-7 
ATCC: CRL 1650 & 
CRL 1651
African green monkey 
kidney
NO Low levels
F442A Fibroblast, preadipocyte NO NO
FTC133
ECACC 94060901
Human thyroid folicular 
carcinoma
NO NO
HEK-293 
ATCC: CRL 1573
Human embryo kidney NO Low levels
HuT-78
ATCC: TIB 161
Human peripheral blood 
cutaneous lymphoma T-cell
Yes Low levels
Jurkat J6
ATCC BS TC LllO
human leukaemia T-cell Low levels Low levels
Molt-3
ECACC 90021901
Human leukemia, acute 
lymphoblastic T-cell
Yes Low levels
U118
ATCC HTB-15
Human glioblastoma 
astrocytoma
NO NO
U397
CRL-1593.2
Human monocyte NO NO
Table 5.1. Summary of the expression of PDE7A1 and PDE7A2 protein in different 
cell lines. The indicated cell lines were harvested in 3T3 lysis buffer and 100 \xg of protein 
from the cell lysates were separated by SDS-PAGE on a 10 % gel. The proteins were then 
transferred onto nitrocellulose and immunoprobed with PDE7A specific antiserum {see 
Fig, 5.3.). The table indicates the name and origin of the cell line analysed and it also 
specifies whether PDE7A1 and/or PDE7A2 was detected by immunoblotting in each cell 
line.
Isoform PDE3 PDE4 PDE7
CT6251 IC50 >1.3 pM N/A 0.014 jiiM
CT6236 IC50 >1.3 |iM >1.3 pM 0.117 pM
Table 5.2. The ÏC50 values of the PDE7 selective inhibitors CT6251 and CT6236. The
above table details the IC50 values obtained by Celltech Pic for the inhibitor compounds, 
CT6251 and CT6236. These IC50 values were calculated on recombinant proteins 
expressed in insect cells. The IC50 value for the CT6251 compound on PDE4 was not given 
(N/A) due to contractual commitments to which Celltech Pic were bound.
Kinase Phosphorylated
residue
Motif Kinase Phosphorylated
residue
Motif
CaMII S-45 RQLSQRR GSK3 S-28 GAISFSSS
S-73
S-84
RVRSRAG
RRGSHPY C-terminal
S-52
T-165
GAISYDSS
DRLTNGNS
S-113 RLLSFQR 4-4 S must S-296 LRESGLFS
S-459 REQSSSE be
prephosph-
orylated
S-331
T-369
S-373
EYLSLFRS
PCRTWELS
WELSKQWS
CKI S-32 SFSSSSAL CKII S-95 IFHSQSE
N-terminal
S-56
S-130
SYDSSDQT
TAVSNSL
T-238
S-279
NSVTPWD
KNTSVLB
T/S must S-169 TNGNSLVS S-335 LFRSHLD
be S-300 SGLFSHLP S-459 REQSSSE
S-324
S-335
S-373
TDISRQN
SLFRSHLD
TWELSKQW
phosphory
-lated Cdkl No identified 
Residues
T-381 SEKVTEEF
S-437 TRLSQTM PKG S-84 RRGSHPY
T-464 SSEDTDAA
MLCK No identified 
residues
P70s6k No identified 
residues
PKA s-45 RQLSQRR PKC S-22 HVLSRRG
S-73 RVRSRAG S-45 RQLSQRR
S-84 RRGSHPY S-79 GFBSERR
S-113 RLLSFQR S-104 VSVSARN
S-121 RSSRFF S-120 YLRSSRF
T-127 RGTAVS S-377 KQWSEKV
T-165 RLTNGN S-450 NKASWKG
S-296 RESGLF
T-406 RHTESI
S-432 RFSNTR
S-437 RLSQTM
S-459 REQSSSE
Table 5.3. Predicted phosphorylation sites of PDE7A1 using PhosphoBase. The
sequence of PDE7A1 was inserted into the prediction submission form on the 
PhosphoBase programme and the predicted phosphorylation sites within the protein were 
given.
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Chapter 6
General discussion and future directions
Phosphodiesterases make up a large family of key enzymes involved in the regulation of 
intracellular concentration of cAMP, which is central to many physiological processes 
including cell differentiation, survival, inflammatory processes and lipolysis.
It has been known for many years that cAMP and its downstream signal transducing 
kinase, PKA are involved in influencing cell proliferation. Increases in PKA activity, in 
particular, have been associated with the arrest of cells in the cell cycle prior to the G l/S  
transition. Fluctuations of PKA activity have also been associated with processes involved 
in the onset, progression through and exit from mitosis. PDFs antagonise PKA activity 
since they degrade cAMP. Thus, an intimate relationship exists between PDE isoforms and 
PKA, which involves multiple positive and negative feedback loops and common binding 
proteins.
As with many systems, most studies of PDE isoforms in mammalian somatic cells have 
focussed on asynchronous populations of cells, with little attention having been paid to the 
possibility that PDEs might be regulated during the cell cycle. Given that cAMP and PKA 
have established important roles in progression through the cell cycle, I set out to 
determine whether specific PDEs could play a regulatory role. This notion initiated the 
majority of the work of this thesis, namely that described in chapter 3 and chapter 4, in 
which a study of phosphodiesterase activity through the cell cycle was undertaken.
The initial conclusion drawn from the work presented here indicates that the activity of 
certain cAMP-specific PDEs do indeed fluctuate through the cell cycle in Rat-1 fibroblasts. 
Particularly interesting was the finding that there was an increase in total PDE activity 
during nocodazole-induced mitosis. This was shown to be essentially attributable to 
alterations in PDE4 isoform reactivity, in studies that were initially based on rolipram 
sensitivity. More detailed analysis of the enzymatic activities of PDE4 family members 
revealed that it was alterations in the PDE4D3 isoform that underpinned such changes in 
PDE4 activity. This increase in PDE4D3 activity was especially interesting because it 
coincided with the lowest PKA activity observed throughout the cell cycle, suggesting that 
the increased PDE4D3 activity might be responsible for this decreased PKA activity. In 
support of this hypothesis, inhibition of PDE4 enzymes, using rolipram, was shown to 
drastically increase PKA activity during mitosis.
Further work identified that this activation of PDE4D3 was brought about by the 
phosphorylation of the protein. Concomitant with this elevation of activity, 
phosphorylation of PDE4D3 induced a change in its electrophoretic mobility when
analysed by SDS-PAGE. Initial observations suggested that these two events were 
manifestations of the same or related phosphorylation events for several reasons. Firstly, 
they were both sensitive to the general kinase inhibitor, staurosporine, but insensitive to a 
whole range of other more specific kinase inhibitors, including ones to PKA and the ERK 
pathway, the only two kinases previously known to phosphorylate PDE4D3. Secondly, 
both the band-shifts and the increased activity can be prolonged over a comparable time- 
course by high concentrations of okadaic acid, following a release from a mitotic block. 
Thirdly, they could both be reversed using calf intestinal alkaline phosphatase.
However, the in vivo phosphorylation of PDE4D3 provided the first indication that the 
activatory phosphorylation of PDE4D3 occurs independently of the phosphorylation of 
PDE4D3 that altered its electrophoretic mobility. From metabolic labelling of cells with 
^^ P it appears that, although PDE4D3 was phosphorylated in mitosis the incorporation of 
^^ P into the stage 1 and stage 2 species of PDE4D3 occurred at such low levels that it was 
not detectable by phosphorimage analysis. As the activation of PDE4D3 was also brought 
about by a phosphorylation event, this suggests that the phosphorylation of ‘native’ 
PDE4D3 observed by in vivo phosphorylation was related to the activatory 
phosphorylation.
Forskolin stimulation of mitotic cells led to further indication that the mitotic activation 
and ‘band-shifts’ of PDE4D3 were not manifestations of the same phosphorylation event. 
When mitotic cells were stimulated with forskolin the increase in the amount of 
immunoreactive PDE4D3 migrating with lower electrophoretic mobility was a much 
higher proportion than the small increase in the activity of PDE4D3 observed. In contrast 
to this, the challenge of asynchronous cells with forskolin caused an increase in the activity 
of PDE4D3 that was proportional to the amount of PDE4D3 with altered electrophoretic 
mobility.
The HPLC analysis of the residues of PDE4D3 phosphorylated by kinases in mitotic 
lysates also suggested that incorporation of ^^ P occurs to different extents, depending on 
the serine residue. This analysis also provided the initial evidence as to the identity of the 
residues phosphorylated in mitosis that were responsible for the increase the activity of 
PDE4D3 and those that alter the migration of PDE4D3 by SDS-PAGE.
HPLC analysis of PDE4D3 peptides phosphorylated by mitotic lysates identified four 
serine residues, Ser^\ Ser^ ,^ Ser^ ^^  and Ser^ ^^  as incorporating ^^ P. Three of these sites 
(Ser^\ Ser^  ^ and Ser^ ^^ ) are residues of PDE4D3 that have never previously been shown to
^ o o
be phosphorylated. With the HPLC analysis there was, presumably similar amounts of 
peptides but the levels of ^^ P incorporated into each site were variable. It was shown that 
Ser*^  ^ and Ser^  ^ both incorporated lower levels of ^^ P than the Ser^ ^^  and Ser^ ^^  residues. 
This indicated that the kinases that target Ser^  ^ and Ser^  ^ were less active that the kinases 
that target Ser^ ^^  and Ser^ ^^ . Alternatively, the lower levels of ^^ P incorporation could be 
due to the fact that Ser*^  ^ and Ser^  ^ do not lie within ideal consensus motifs for the 
candidate kinases or that dephosphorylation of these sites was very active.
It is likely that high levels of phosphorylation were responsible for confering the activated 
state of PDE4D3 as, in mitotic cells PDE4D3 activity was only slightly increased when 
treated with forskolin. This suggests that the auto-inhibition of PDE4D3, exhibited in the 
unmodified protein was almost entirely ablated when PDE4D3 was subjected to mitotic 
phosphorylation. This leads to the suggestion that it could be the Ser^ ^^  and/or Ser^ ^^ , 
which via HPLC analysis were shown to incorporate the highest levels of ^^ P, that are 
phosphorylated in order to activate PDE4D3. Phosphorylation of Ser^ ^^  has previously 
been shown by our group to be the site that is phosphorylated by ERK (Hoffmann et al., 
1999), leading to a decrease in PDE4D3 activity. The occurrence of this inhibitory 
phosphorylation is due to an effect mediated by the UCRl and UCR2 domains of 
PDE4D3. Thus it is unlikely that phosphorylation of Ser^ ^^  is responsible for PDE4D3 
activation. Therefore, I propose that the phosphorylation of Ser^ ^^ , located within the N- 
terminus of the catalytic domain by a kinase activated in mitosis, confers activation upon 
PDE4D3. Increasingly this region of the catalytic domain has been suggested to interact 
with the auto-inhibitory UCR2. Thus if this ‘model’ was valid, it utilises the same route to 
PDE4D3 activation as PKA. However, with PKA it is phosphorylation of UCRl that 
appears to disrupt the UCR2/catalytic inhibitory coupling. Thus the proposal for mitotic 
phosphorylation of Ser^ ^^  would achieve the same ends, but by disrupting the target for 
UCR2 interaction in the catalytic unit. Hence, this model also explains why the mitotic and 
PKA phosphorylations do not give additive effects.
Mitotic phosphorylation led to the change in electrophoretic mobility of PDE4D3. 
However, only a small amount of PDE4D3 was modified. This was evident because only 
35 % of the immunoreactive PDE4D3 migrated with the stage 1 and stage 2 forms of the 
protein, which both have reduced electrophoretic mobilities when analysed by SDS-PAGE, 
compared to ‘native’ PDE4D3. These shifted forms of PDE4D3 were not detected by in 
vivo phosphorylation of the protein, although both stage 1 and stage 2 forms of PDE4D3 
are present in the mitotic cell. It is proposed that the phosphorylations that induce changes 
in the electrophoretic mobility of PDE4D3 are brought about by kinases for which
PDE4D3 is a poor substrate or kinases that have low activity in mitotic lysate. Relating this 
to the identification, by HPLC, of the serine residues phosphorylated to a lesser extent than 
Ser^ ^^  and Ser^ ^^  by the mitotic kinases would suggest that Ser^  ^ and Ser^  ^ are the residues 
in PDE4D3 that are phosphorylated and bring about the shift in the electrophoretic 
mobility of PDE4D3. The proposed model for the phosphorylation of PDE4D3 during 
mitosis is presented in Figure 6.1.
Important work that needs attention in the short term clearly includes the in-depth 
characterisation of each of the three novel phosphorylation sites, Ser*’  ^Ser^  ^and Ser^ ^^  and 
further studies of the phosphorylation of Ser^ ^^ . This could be carried out through the 
generation of phospho-specific antibodies that detect phosphorylation of these sites in 
isolation of each other. This would enable analysis of the kinetics of phosphorylation of 
these sites as cells accumulate and leave mitosis. These antibodies could also be used to 
monitor the phosphorylation of the serine residues in in vitro kinase reactions. Where they 
could aid the identification of the kinase which target these sites. The phospho-specific 
antibodies would also confirm the identification of the residues phosphorylated in the stage 
1 and stage 2 foims of PDE4D3.
Mutational analysis of the serine residues at positions 61, 75 and 239 of the PDE4D3 
amino acid sequence would enable conformation of the identity of the residues required to 
be phosphorylated in order to activate PDE4D3. It would also provide distinction between 
these residues and those involved the alteration in the electrophoretic mobility of PDE4D3. 
The serine residues need to be mutated both singly and in combination with each other and 
also with the previously identified PKA and ERK phosphorylation sites. These should 
ideally be produced as both alanine substitutions that would be predicted to mimic the 
unphosphorylated states, and as aspartate substitutions that may behave more as 
phosphomimetic mutants. As well as allowing the effects of each residue on PDE4D3 
activity and its electrophoretic mobility need to be assessed and will also enable functional 
analyses of PDE4D3 activity to be performed. In this respect, it would be interesting to see 
what effect these mutations have on various parameters such as the distribution of cells in 
the cell cycle, the rate of exit of the cells from mitosis and the activity of PKA at different 
stages of the cell cycle. It has already been shown within this study that rolipram-mediated 
inhibition of PDE4 leads to an increase in PKA activity in mitosis and an increase in the 
rate at which cells leave mitosis. However, due to the lack of PDE4 isoform-specific 
inhibitors these observations can not be associated definitively with the mitotic increase in 
PDE4D3 activity.
Also of crucial importance, although possibly more challenging, is the elucidation of the 
mitotic kinases phosphorylating these novel sites on PDE4D3. This could then shed much 
more light on the physiological role of these novel phosphorylation events and how 
PDE4D3 activity might be controlled through the cell cycle. The identification of the 
residues in PDE4D3 phosphorylated during mitosis has enabled us to analyse the 
consensus sequences in which they lie enabling us to predict the candidate kinases. 
However, using this as a starting point the key experiments would now involve the 
utilisation of a panel of recombinant protein kinases for in vitro phosphorylation of 
PDE4D3, to determine if the Ser^\ Ser^  ^ or Ser^ ^^  were the substrate residues. Upon 
identification of the candidate kinases further investigations would then need to be carried 
out in order to ascertain whether the kinases target PDE4D3 in vivo during the cell cycle.
Once the candidate kinases have been identified immuno-depletion of the mitotic lysates, 
using antibodies specific to the kinases, would provide lysate that could be used for in vitro 
phosphorylation of PDE4D3. With the lack of the kinase in the lysate it would enable 
determination as to whether the kinase altered the activity or the electrophoretic mobility 
ofPDE4D3.
Another important investigation that needs to be carried out involves the study of 
physiological processes that take place during mitosis and the effect that the inhibition of 
PDE4 has on these. One such mitotic process with which PKA has been associated is the 
control of the formation of the nuclear envelope. As I have already shown that the 
inhibition of PDE4 appears to increase the rate at which cells leave mitosis, it would be 
interesting to investigate why this occurs. Following work carried out by Steens et al. 
(Steen et al., 2000) and Lamb et al. (Lamb et al., 1991), the changes in nuclear lamin 
assembly should be investigated to assess whether it is the target for a PDE4-mediated 
control mechanism during mitosis. The kinetics of the rates of nuclear envelope 
reformation upon exit from mitosis and analysis of the cytoskeletal dynamics should also 
be visualised by conofocal microscopy. A currently proposed model of how the activity of 
PDE4D3 during mitosis affects the transition of cells from G2/M and into the next G1 are 
shown in Figure 6.2.
The body of work presented here is an important contribution to the field of cell cycle 
progression and the control of mitosis. It is the first demonstration of a mechanism by 
which PKA activity might be regulated as cells pass the G2 checkpoint and proceed into 
mitosis. On a more general level, the work contributes to the ever expanding larger picture 
of how a typical cell functions and divides: the picture that will ultimately allow us to
devise specific therapies for the treatment of human health conditions such as cancer, to 
name but one obvious example.
The work carried out on the characterisation of PDE7A1 as presented in this thesis in 
chapter 5 is too preliminary as yet to formulate any conclusions from. What can be gleaned 
from the study is that PDE7A1 appears to be phosphorylated by an as yet unidentified 
kinase. This observation is novel in the characterisation of PDE7A1 and with the 
technologies used in the characterisation of PDE4D3 phosphorylation during mitosis it 
would now be feasible to carry out a similar study in order to identify the residues of 
PDE7A1 which exhibit the potential to be phosphorylated.
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Figure 6.1. Proposed mechanism of PDE4D3 phosphorylation in mitosis. It is
proposed that ‘native’ PDE4D3 is phosphorylated by kinases activated in mitosis with 
high efficiency on residues Ser^ ^^  and Ser^ ’^. This leads to an increase in the enzymatic 
activity of PDE4D3. PDE4D3 is then subjected to phosphorylation by a less efficient 
kinase, in mitosis, at either residue Ser^ ' or Ser^ .^ This causes the protein to migrate with a 
slightly reduced electrophoretic mobility when analysed by SDS-PAGE, which has been 
termed the stage 1 form of PDE4D3. Another inefficient kinase also targets PDE4D3 
during mitosis, phosphorylating the protein at either Ser '^or Ser^ ,^ which changes the 
electrophoretic mobility of PDE4D3 further still. This final phosphorylation causes 
PDE4D3 to migrate with a mobility that has been termed stage 2.
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Figure 6.2. Involvement of PDE4D3 in the progression of cells through mitosis. The
mechanisms by which the activation of PDE4D3 controls the progression of cells 
through mitosis is governed by the influence it has on the levels of cAMP in the cell. In 
interphase cells PDE4D3 activity is low, consequently the levels of cAMP are high and 
PKA is active. PKA activity maintains the cell nucleus and an ordered cytoskeleton. 
PKA phosphorylates the regulatory subunits of the anaphase promoting complex 
(APC), which prevents the formation of the active APC, and also phosphorylates the 
maturation promoting factor (MPF), preventing its premature activation. Upon the 
G2/M transition, PDE4D3 is phosphorylated by an as yet unidentified kinase and the 
activity of the PDE increases. Cyclic AMP in the cell is hydrolysed, causing re­
association of the regulatory and catalytic subunits of PKA. The APC subunits are 
dephosphorylated by protein phosphatase 1 (PPl) and the active APC forms, this then 
targets multiple substrates for ubiquitinlyation, instigating their proteasome mediated 
degradation. Dephosphorylation of nuclear lamins and the cytoskeletal elements causes 
nuclear envelope breakdown, and cytoskeletal re-arrangements and the cells pass 
through mitosis. The kinase which phosphorylates PDE4D3 is then inactivated and 
PDE4D3 is dephosphorylated by PPl as cells make the M/Gl transition. The levels of 
cAMP increase, activating PKA and initiating the reformation of the cytoskeleton and 
the nuclear envelope.
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